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Outline ol !his thesis 
Type 1 diabetes mellitus or insulin dependent diabetes mellitus is a disease 
characterized by the selective destruction of insulin producing B-cells in the islets of 
Langerhans. The exact cause of this destruction is unknown, but is mediated by 
cells of the immune system. The immune system has a remarkable ability to rec-
ognize self from non-self, thereby providing a constant surveillance-mechanism 
that protects us for foreign invaders. This mechanism has failed in type 1 diabetes 
and attacks and destroys B-cells. The autoimmune basis of type 1 diabetes is de-
scribed in chapter 1. The central problem in autoimmunity is why and how the im-
mune system sometimes fails to distinguish between self and non-self. Re-instruct-
ing the immune system or blocking faulty immune reactions could result in primary-
or secondary prevention of type 1 Diabetes Mellitus. This requires however, the 
molecular dissection of the process, including the identification of B-cell proteins 
involved in the autoimmune reactions. This thesis aims to contribute to this by the 
identification and characterization of two humoral autoantigens in type 1 Diabetes 
Mellitus, a 64kD and a 38kD protein. These aims are specified as follows: 
1. Identification of the 64kD autoantigen in type 1 Diabetes Mellitus. 
2. Biochemical and Cell biological characterization of the 64kD protein. 
3. Identification of the 38kD autoantigen in type 1 Diabetes Mellitus. 
4. Biochemical and Cell biological characterization of the 38kD protein. 
5. Analysis of the frequencies of autoantibodies to the 64kD and the 38kD auto-
antigen at clinical diagnosis and in the prediabetic period. 
6. Assessment of the predictive value of these autoantibodies, in particular in 
relation to other markers of autoimmune B-cell destruction. 
In chapter 2 experimental work is presented that identified the 64kD auto-
antigen as the neurotransmitter y-amino butyric acid (GABA) synthesizing enzyme 
Glutamic Acid Decarboxylase (GAD). This identification was the result of the com-
bination of clinical and laboratory data. The 64kD/GAD autoantigen was found to 
be a target for humoral autoimmunity in both type 1 Diabetes Mellitus and in the 
neurological disease Stiff-man syndrome. Differences between the two diseases 
in antigenicity towards GAD were found. From biochemical and cell biological 
studies presented in chapter 2 it was concluded that the 2 forms of GAD, found in 
pancreatic islets of Langerhans were identical to the 2 forms found in brain. One 
form of GAD has a molecular weight of 67kD and is usually referred to as GADs?. 
This molecule is water soluble. The second form of GAD was originally described 
as the 64kD autoantigen. The calculated molecular weight is 65kD and hence this 
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molecule is now referred to as GAD65· GAD65 can be soluble and membrane 
bound. We found that membrane binding of GAD65 is a two-step process. The 
second step involves palmitoylation of the protein. The membrane binding allows 
the GAD65 molecule to combine with the membranes of synaptic vesicles in neu-
rons or microvesicles of endocrine cells. Taken together, these findings have im-
portant implications for the understanding of why and how this antigen becomes a 
target for the immune system and provide a basis to study the function of GAD and 
GABA in these cells in more detail. 
Autoantibodies are important markers for ongoing destruction of B-cells. The 
identification of 64kD as GAD allowed to develop recombinant expression systems 
producing GAD that can be used in autoantibody assays. In chapter 3, the 
development and use of an improved immunoprecipitation method for the detection 
of autoantibodies to GAD is described. In addition, this method was compared with 
the original 64kD autoantibody assay where human or rat islets were used. The 
new recombinant GAD bases assay yielded a more sensitive test. More important 
is the predictive value of autoantibodies for the clinical onset of type 1 Diabetes: In 
a population of schoolchildren the predictive value of GAD autoantibodies was 
analyzed, and was found to be better than prediction with a traditional method. In 
chapter 4, studies on a 38kD autoantigen are presented. Alter establishing the 
optimal conditions for the partial purification of this protein, sera were analyzed 
from patients and prediabetic individuals (individuals from whom serum samples 
were ava'ilable from the time preceding the clinical diagnosis). Although the 
frequency of autoantibodies to 38kD is low, the analysis contributed to the 
predictive value since individuals could be identified who were positive for 38kD 
autoantibodies, but negative for any other autoimmune marker used in prediction. 
Although the frequency of autoantibodies is low, this protein can still be considered 
a candidate primary autoantigen. Characteristics of the 38kD protein were studied 
and described, but the molecular identity has not been resolved yet. 
In summary, the experimental work helped to identify and characterize two 
autoantigens in type 1 diabetes. Until now, experiments on pathophysiology and 
assays on prediction lacked such a B-cell specific autoantigen. The findings 
described in this thesis can be applied in experiments where B-cell specific 
antigens are used. The hypothesis can be tested if these autoantigens are involved 
in the primary events leading to type 1 diabetes. Finally, this work will allow the 
development of prediction tests, which use B-cell specific autoantigens, are 
quantifyable and have an increased sensitivity and specificity. 
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Chapter 1 
GENERAL INTRODUCTION 
Introduction 14 
Introduction 15 
1 .1 Diabetes Mellitus 
1.1.1 The Diabetic Syndrome. 
Diabetes mellitus is a syndrome of a disturbed energy homeostasis caused 
by a deficient production or action of insulin. Insulin is a hormone involved in glu-
cose homeostasis and is produced by the B-cells in the islets of Langerhans in the 
pancreas. Diabetes mellitus encompasses a group of disorders with an inability to 
properly metabolize glucose, leading to the characteristic feature of hyperglycemia. 
Type 1 or insulin dependent diabetes mellitus, the focus of this thesis, is the most 
common endocrine disorder in childhood and adolescence and is, in frequency, 
the third most common chronic disease in children alter chronic obstructive pulmo-
nary diseases and epilepsy (1 ). With an annual incidence rate among people 
under the age of 20 years of roughly 10-20 (1 new case per 5000-7000 children 
per year) it is 3-4-fold more common than chronic childhood diseases as cystic fi-
brosis or leukemia and it is nearly 10-fold more common than nephrotic syndrome, 
muscular dystrophy or lymphomas in this age group (1). Whether frequent or not, 
all chronic diseases have important consequences on physical and emotional de-
velopment in children and adolescents affected. In addition, it has an impact on 
parents and sibs. Although symptomatic treatment is available, no cure exists. 
Long-term complications, which are frequent, put an additional burden on the pa-
tients. Taken together, type 1 diabetes mellitus is a disease with strong repercus-
sions on the lives of individuals affected, and it is a major health care problem. 
1.1.2 Classification of Diabetes Mellitus. 
The endocrine pancreas has been implicated since a long time in the 
pathogenesis of diabetes mellitus. Increasing clinical and pathophysiological 
knowledge of this organ resulted in the distinction of three major categories of the 
diabetic syndrome, type 1 d·1abetes, type 2 diabetes and a third group of several 
different diabetic syndromes. In addition gestational diabetes is recognized as a 
separate entity. This classification is based on clinical (phenotypic) characteristics 
(2). Analysis of the etiologies at the molecular level might lead to a different clas-
sification. 
Type 1 or insulin dependent diabetes mellitus (IDDM) is characterized by the 
inability of the body to produce insulin, due to the loss of insulin producing B-cells. 
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This lack of insulin results in dependence on exogenous insulin, which can be par-
tial, as is often the case shortly after diagnosis, but usually becomes complete 
within 2-7 years. The onset of type 1 diabetes is often insidious and can occur at 
any age. Without the administration of insulin, type 1 diabetes is fatal. It is predom-
inantly this form that affects children and adolescents. Type 1 diabetes accounts 
for 5-10% of all cases of diabetes mellitus in industrialized countries (3). 
Type 2 or non-insulin dependent diabetes (NIDDM) accounts for 90-95% of 
diabetes mellitus cases. Patients are generally, but not always, obese and may be 
non-symptomatic. This form has two components: 1) insulin resistance and 2) the 
failure of B-cells to compensate for the resistance. This disease starts usually after 
the age of 30 years. Although some people with NIDDM use insulin, this is mainly 
to achieve a better glucose homeostasis and is not of vital importance. Usually 
classified as a form of type 2 diabetes is Maturity Onset Diabetes in Youth (MODY) 
(4). Recent data showed a linkage of the glucokinase locus on chromosome 7p to 
this disease (5) or, in other families with the Adenosine Deaminase gene on chro-
mosome 20q (6). Nonsense mutations in the glucokinase gene have been re-
ported in non-insulin dependent patients (7). 
Some studies have suggested that the division between type 1 and type 2 
diabetes may be less clear than suggested. In particular in older individuals, the 
development of type 1 diabetes may mimic that of type 2. A number of type 2 pa-
tients fail to respond to treatment with oral hypoglycemic agents and show features 
of type 1 diabetes, such as islet cell antibodies (ICA's, see chapter 1.5) (8). It has 
been estimated that 1-2% of apparent non-insulin dependent diabetes patients be-
come insulin deficient (9). Although most NIDDM patients have a relative, rather 
than an absolute deficiency of insulin, some NIDDM patients develop an absolute 
insulin deficiency within a few years after instigation of oral therapy. This type of 
diabetes has been called type 11/2 and while the clinical features at first resembled 
much of those found in type 2 diabetes, these pat'1ents show several aspects of 
type 1 diabetes (1 0, 11) such as low C-peptide levels, low body weights, Islet cell 
autoantibodies, other organ specific autoantibodies and a high frequency of HLA 
DR haplotypes (12) (see chapter 1.5). 
The third group of diabetes mellitus includes a mixture of diabetic syn-
dromes including diabetes resulting from or associated with other specific syn-
dromes or conditions (sometimes referred to as secondary diabetes), such as dia-
betes in patients with cystic fibrosis (13), hemochromatosis (14) and some syn-
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dromes with known chromosomal defects with an increased frequency of diabetes. 
In Trisomy 21, (Down's syndrome) (15) this is primarily autoimmune (insulin de-
pendent) type 1 diabetes. In other syndromes such as Turner's syndrome (16) the 
association is with non-insulin dependent diabetes. A very rare cause of insulin 
dependent diabetes is due to pancreatic agenesis (17). In the 1980 and 1985 
World Health Organization (WHO) classification of diabetes mellitus included mal-
nutrition-related diabetes mellitus as a new entity of diabetes (18) of which the etio-
logy is unknown and both exocrine and endocrine tissue of the pancreas is in-
volved (19). A syndrome of transient diabetes mellitus of the newborn exists that 
seems to be due to a delay in maturation of the B-cell (20). 
The heterogeneity of clinical presentation in type 1 diabetes suggests the 
possibility of multiple mechanisms as etiologies. This was recently confirmed by 
the finding that mitochondrial DNA deletions are associated with familiar forms of 
insulin dependent d'1abetes (21 ). The disease started in the twenties and thirties. 
This indicates again that insulin dependent diabetes mellitus might not in all indi-
viduals be caused by autoimmunity and warrants further studies on etiology. 
No cure exists yet for type 1 diabetes mellitus, but the disease can be treated 
by frequent insulin injections. Although the daily applications of insulin might sug-
gest a relatively stable life, it is in fact a constant challenge, especially for children, 
parents and sibs. Insulin therapy is only a simple imitation of the body's superb 
fine-tuned mechanism of hormone secretion and glucose homeostasis. Insulin in-
jections will usually prevent the acute life threatening complications, but do not ex-
clude the development of acute and long-term complications. Other therapies used 
in type 1 diabetes mellitus, such as immunosuppression and transplantation are 
not causal and have several disadvantages such as their costs and complications. 
It is conce·lvable that only prevention will change this substantially . However, pr'l-
mary prevention requires adequate prediction. Useful strategies for prediction and 
prevention will only be developed if the pathophysiological mechanisms of type 1 
diabetes are dissected at the molecular level. The work described in this thesis 
aims to contribute to this. 
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1 . 2 Type 1 Diabetes Mellitus. 
1.2.1 Epidemiological Characteristics. 
Epidemiological surveys revealed that some features of type 1 diabetes 
have a striking similarity to infectious diseases, such as rheumatic fever I rheumatic 
heart disease, which occurs after streptococcal infections (22). This disease 
showed a dramatic decline in incidence when preventive approaches designed 
from epidemiological and microbiological data became available and applicable. 
Thus, proper analysis of the epidemiology of diabetes could help to identify risk 
factors involved in the etiology (23) and help to develop preventive strategies. 
Most of the studies describing the incidence or prevalence of type 1 d"1abetes 
are conducted in children and collection of epidemiological data has been difficult 
since only a few countries have complete population based registries available for 
the analysis of type 1 diabetes. A WHO project (DIAMOND) is initiated to collect 
epidemiological data on type 1 diabetes from around the world (24). The next para-
graphs outline some important epidemiological findings. 
Type 1 diabetes shows a specific age distribution. Although slightly different 
per country, roughly 40-50% of the cases occur before the age of 15 years, 30-40% 
occurs between 15 and 34 years of age and the remainder of the patients will de-
velop type 1 diabetes later in life (9). Several studies indicate a very low incidence 
before the age of 5 with a more or less linear increase until puberty, where the 
peak incidence is found (25). In a recent study from Finland however, the inci-
dence was extremely low under the age of 1 year but reached already almost its 
maximum in the 1-4 year old group (26). The puberty peak, also reported in earlier 
work from Finland (27), was lacking. This might reflect a trend that the onset of the 
disease is shifting towards the younger age group, but more research is needed to 
substantiate this hypothesis (25). It is also conceivable that the onset of diabetes in 
the very young children has a different etiology and therefore follows a different 
pattern. 
The incidence of type 1 diabetes varies enormously between dilferent areas 
of the world. The highest incidence is reported in Finland with 35.2 cases per 
100,000 children under 14 years of age (26). Other Nordic countries have similar 
high rates: Sweden 22.6, Norway 17.6, Denmark 13.7 (28). In other parts of the 
world a low incidence rate has been found, such as Israel (4.3) and France (3.7) 
Introduction 19 
and Japan that has the lowest reported incidence with 0.8 per 100,000 (28). The 
analys·,s of all the incidence data ·,n several areas of the world is suggestive for a 
gradient in North-South direction. High incidences are found in countries closer to 
the earth's poles and lower incidences in countries close to the equator (29). The 
increasing number of diabetes registries, established in recent years show, how-
ever, that it is not just a simple gradient: 'Hot-spots' with high incidence rates can 
be found in areas with an overall low incidence of type 1 diabetes. An example of 
this is Sardinia, which has an extreme high incidence of 30.01100,000 (31) .. The 
incidence rate in the mainland of Italy ranges between 4-10 (30). Another spot with 
a very high incidence was found in Poland (32). 
The incidence of type 1 diabetes shows an increase in several countries 
over the last decades (25, 33-37). A mostly linear increase in type 1 diabetes risk 
was found over the past 20 years in children under 15 years of age (25). This in-
crease has, however, not been reported from all areas (38, 39). A recent cohort 
study in Dutch army conscripts found cumulative incidences of 1.85 per 1000 in 
1960, slowly increasing to 2.12 per 1000 in 1970. The overall increase was calcu-
lated as 4.4% per year (40). These data were confirmed and extended by a recent 
national survey on the epidemiology of type 1 diabetes in the Netherlands (41 ). 
This increased incidence over time in the Netherlands is similar to that in other 
European countries. 
In chapter 1.5 the strong association between genetic factors and type 1 
diabetes will be discussed, originally based on epidemiological data showing that 
the disease tends to cluster in families. However, in a large prospective nation-
wide, Finnish study, it was shown that of all the new cases of type 1 diabetes, only 
11.2% were multiple cases, affecting first degree family members (26). Similar re-
sults were suggested earlier (42). Thus, although a determinant for the disease, 
the predictive power of a family history is limited and most cases of type 1 diabetes 
occur sporadically in the population. 
A seasonal pattern was observed in the incidence of type 1 diabetes in older 
children and adolescents. A significant lower incidence was found in spring and 
summer. This seasonal dependence has been found for populations both north 
and south of the equator (34, 43, 44). It is also suggestive for an environmental 
factor. This will be discussed in detail in chapter 1.5. 
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In conclusion, type i diabetes has specific epidemiological characteristics. 
They indicate that genetic and environmental factors contribute to the disease. 
Further and detailed analysis of these features may help to unravel the etiology of 
type i diabetes in a similar way as has been done for rheumatic fever and other 
infectious diseases. 
1.2.2 Impact on Health Care. 
The diagnosis of type i diabetes has. without doubt, a tremendous impact 
on somebody's life. Morbidity and mortality of acute and chronic complications are 
high and this puts an additional burden on both personal life as well as on the 
health care system. Type i diabetes is disproportional associated with premature 
mortality and with high morbidity. Death rates are 8 - 10 times that of the general 
populat'ron (45). More than 2% of affected individuals die each year (46). Already 
at the age of 25 years, individuals with type i diabetes have an increased fre-
quency of hospitalizations compared to non-diabetic controls for ophthalmic (5 x 
more frequent), neurological (9 x more frequent), renal (14 x more frequent) and 
cardiovascular complications (3). Hospital stays of type i diabetic patients are 
longer (47). The total cost increases with the age of the patients and is almost 3 
times higher for patients over the age of 65 years compared to patients under 20 
years of age. 
Type 1 diabetes has an additional impact on health care. The necessary 
control of food intake, sleep, injections, daily activities and other things, results in 
additional stress and psychosocial problems. Especially in adolescents, these 
problems often need extra medical attention. Moreover, living with diabetes has 
implications for employment, travel, and life insurance. 
These facts implicate that type i diabetes absorbs a substantial part of 
health care budgets, especially since the incidence increases. In sum, the morbid-
ity and mortality statistics urge for careful planning of both medical care and re-
search intended to reduction of complications and in particular aimed at primary 
prevention of the disease. 
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1.2.3 Natural Course and Complications. 
After diagnosis and treatment of the acute metabolic derangement. the life 
expectancy of diabetes is mainly determined by the occurrence of secondary (long· 
term) complications. These can be divided into consequences of macrovascular 
and microvascular disease. Macrovascular disease results in coronary heart dis-
ease (CHD), cerebrovascular accidents (CVA's) and gangrenous disease of the 
extremities. Microvascular disease includes retinopathy, nephropathy and neuro-
pathy. Both groups of complications occur very frequent Where most studies 
describe features of only one of these complications, only a few have examined the 
epidemiology, interrelationships and correlates of these complications. In the large 
follow-up study from Pittsburgh (48) 657 type 1 diabetic patients were studied with 
a mean duration of diabetes of 20 years. Table 1.1 summarizes this study, showing 
that complications are very frequent. The sex-differences suggest that hormonal 
changes may have some influence. The severity of these complications as well as 
the speed with which they develop varies widely (49, 50). II ranges from minor 
retinopathy without the need for intervention to kidney dialysis or amputations of 
extremities. The fact that the same clinical complications occur in both type 1 and 
type 2 diabetes strongly supports the idea that metabolic (glycemic) control is a 
major factor. 
Several studies indicate that duration of diabetes and the cumulative effect 
of prolonged metabolic aberrations are the main determinants of this risk, espe-
cially in microvascular complications (51-53). Glycemic control may be important, 
but large prospective studies are needed to prove that light control results in fewer 
complications and have not been performed. One large collaborative study, origi-
nally intended as a long term study (54). has recently been stopped prematurely. 
Although not yet published, the results indicate that good glycemic control was 
beneficial to reduce long-term complications (DCCT study; data presented at the 
1993 American Diabetes Association meeting, Las Vegas). Two groups of patients 
were studied. Those with good glycemic control showed a lower incidence of 
complications over a 10 year study period. Although this study is the first that 
clearly shows that glycemic control is likely to have an effect on the occurrence of 
complications, this issue is still open. More data are needed from patients who de-
veloped the disease at young age: in children, the goals of glycemic control aimed 
for in this study are almost impossible to reach. Moreover, even with strict 
metabolic control, complications can occur as is illustrated in descriptions of pa-
tients with type 1 diabetes of less than 3 years duration, with good 
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TABLE 1.1 
Study of Complications Alter Various Years of 
Type I Diabetes Mellitus ( 48). 
MACROVASCULAR DISEASE 
Cardiovascular disease 10% of men after 30 years of type 1 
diabetes 
30% of women after 30 years of type 
1 diabetes 
MICROVASCULAR DISEASE 
Background retinopathy 99% after 20 years of type 1 diabetes 
Proliferate retinopathy 70% after 30 years of type 1 diabetes 
Kidney disease (from mi- 84% of men after 30 years of type 1 
croalbuminuria to dialysis I diabetes 
insufficiency) 
59% of women after 30 years of type 
1 diabetes 
Polyneuropathy 72% after 30 years of type 1 diabetes 
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to extremely good metabolic control, but already with complications such as neuro-
pathy and retinopathy. This suggests that additional factors are involved, a fact that 
is supported by the differences in incidence and severity of complications observed 
in monozygotic diabetic twins (55). 
The pathological hallmark of diabetic microvascular disease is thickening of 
the capillary basement membrane (56). This process is found in all affected or-
gans, resulting however in a wide variety of clinical symptoms in the three target 
organs: retina, kidney and peripheral nerves. The mechanisms involved are not 
clear. Insulin does not seem to play an important role, since the tissues affected 
are not dependent on insulin for their glucose uptake, suggesting that hyper-
glycemia itself plays a major role. Several mechanisms for the effect of hyper-
glycemia on the development of diabetic complications have been suggested, but 
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no definitive consensus has been reached. Hyperglycemia is likely to interfere with 
several enzymatic systems in the cell, either by direct inhibition (57), by osmotic 
effects of intermediate accumulations like sorbitol (58), glycosylation of the protein 
(59), inhibition of oxygen free radical scavenger mechanisms (60) or by combina-
tions of these factors. Autoimmunity, the mechanism by which type 1 diabetes de-
velops, has been implicated in the etiology of peripheral neuropathy in type 1 pa-
tients (61 ). The identification of neuronal enzymes in this autoimmune mechanism 
of diabetes (62) urges for further evaluation. 
In summary, diabetic complications are a frequent cause of morbidity and 
mortality in type 1 diabetes. They are likely to be caused by the interaction of multi-
ple metabolic and other factors. Epidemiologic data support a common back-
ground lor the different forms of microvascular complications. Hyperglycemia plays 
a major role and probably initiates changes in the capillary basement membrane 
that results in a cascade of effects, influenced by other factors. Diabetic patients, 
with a detected microvascular complication, are 5-10 times more likely to develop 
another complication as well, compared with patients free of complications (48, 63). 
The high mortality and morbidity associated with diabetic complications is another 
justification for the development of preventive measures. 
1 . 3 The Islets of Langer hans 
1. 3.1 Anatomy of the Islets 
In type 1 diabetes, the pathological hallmark is the infiltration by mononu-
clear cells of the islets of Langerhans in the pancreas. Before discussing this pro-
cess, called lnsulitis, and its implications for further studies on the pathogenesis. 
the normal islet anatomy and physiological implications will be outlined in this sec-
tion. 
The human adult pancreas contains 1 o5 to 1 o6 islets (64). They are scat-
tered through the parenchyma (exocrine tissue) of the pancreas, vary in size and 
cell number with a mean of 140 f'm and about 1000 cells per islet (65). In the adult, 
the endocrine cell mass occupies 1% of the total organ (66), but in the embryo-
logical phase this might be up to 10%. In fish, one endocrine pancreatic organ 
called the Brockmann body (67) can be found. The advantage of having the endo-
crine cells scattered in islets throughout the pancreas, as is seen in higher animals, 
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is not clear. It is suggested that the interaction between acinar (exocrine) cells and 
islet cells (66) and intra-islet regulation are more effective in the case of dispersed 
islets. Four major endocrine cell types can be found in the islets and table 1.2 
summarizes some characteristics. 
TABLE 1.2 
Characteristics ol the lour endocrine cell types of the endocrine pan-
creas (islets of Langerhans) 
Cell hormone se- % of islet cell localization in 
type creted mass islet 
a-cell glucagon 15-20 cortex 
B-cell insulin 60-80 core 
5-cell somatostatin 5-10 cortex 
PP-cell pancreatic 15-25 cortex 
polypeptide 
The islets of Langerhans have a typical architecture where B-cells are pre-
dominantly found in the core of the islet and a-, b-and PP-cells occupy the cortical 
(periphery) areas. This is most outspoken in the rat, where the a-cells can be out-
lined as a ring around a core. In other animals and humans ·,tis less outspoken. 
1.3.2. The Micro Society in the Islets ol Langerhans 
Islets are innervated by different neuronal systems. Claude Bernard (1813-
1878) already demonstrated that innervation is very important for glucose homeo-
stasis: lesions in the medulla resulted in hyperglycemia (Piqure diabetique) (68). 
Both parasympathetic (cholinergic) as well as sympathetic (adrenergic) nerves 
enter the islets. An additional innervation by .other systems such as GABA-ergic 
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(69) as well as peptidergic neurons (70) has been described. The role of these 
nerves in the regulation and their exact target cell are unknown. 
Islets contain a dense capillary network. Afferent arterioles enter the islet in 
the periphery but do not have contacts with endocrine cells until they branch in the 
B-cell core of the islet. This branching results in a dense capillary network, re-
sembling that of the kidney glomerulus. This makes the endocrine pancreas a well 
supplied organ. With 1% of the organ volume it receives 10% of the pancreatic 
blood flow (66). The capillaries are lined with fenestrated endothelial cells, allow-
ing a rapid exchange of metabolites and products. The typical anatomical pattern 
of the arterioles and capillaries results in a blood flow that is directed from B-cell 
towards the periphery, with direct consequences for the regulation of hormone se-
cretion (71 ). The B-cells are in close contact with these capillaries and show a po-
larized morphology. In the rat, 8-10 B-cells form a tube-like structure around a 
capillary. Most of the insulin granules are grouped in proximity of this capillary 
(apical) side of the cell. The other side of the B-cell also faces a capillary (72). The 
close relationships between B-cells and capillaries were concluded from studies in 
rodents where the three dimensional structure of islets was reconstructed as well 
as from physiological studies that measured hormone responses upon injections of 
the counter hormones in different areas of the islet (73). B-cells therefore can influ-
ence a- and 6-cells by the release of substances into the capillaries. The situation 
in human islets is less clear and the capillary network seems to be even more 
complicated (64). 
The islet cells are furthermore characterized by intensive cell-to-cell contacts 
that allows paracrine signaling. B-cells can depolarize and have a synchronized 
electrical activity, providing an alternative way of cell-cell signaling (74). The 
neurotransmitter GABA is present in B-cells (75) and GABAA receptors have been 
identified on a-cells (76). This provides a mechanism for paracrine signaling. 
Some recent findings and implications of the GABA-ergic mechanism in B-cells are 
discussed in chapter 3. A link between the autoimmunity and the GABA-ergic sys-
tem in the B-cell has been made (62). In addition to these communication systems, 
the islet cells have gap junctions, specializations between homologous and 
heterologous cells that allow passage of molecules up to Mw 1200 Dalton (64). 
Finally, to form and maintain this specific construction, islet cells must express ad-
hesion molecules. Non-B-cells predominantly express the 135kD isoform of the 
neural cell adhesion molecule (NCAM)(77), while E-cadherin (Uvomorulin) is in-
volved in the B-cell core interactions (78). Expression of adhesion molecules in 
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islet cells is dependent on the developmental stage of the islet cells (79). The ad-
vances in adhesion molecule research including studies on cell-cell interactions 
that play a role in autoimmunity (80), urge for further studies. Recent work de-
scribes prevention of an autoimmune disease by blocking a specific integrin recep-
tor (81) and the use of antibodies to two adhesion molecules (ICAM-1 and LFA) in 
blocking cardiac allograft rejection (82). The autoimmune disease pemphigus 
vulgaris is caused by an autoimmune reaction towards an adhesion molecule (83). 
Such data clearly exemplify the importance of adhesion molecules. 
The anatomical organization of islets results in a micro society of interacting 
cells. There is evidence supporting the idea that the organization of this micro so-
ciety is of physiological importance. This is illustrated by experiments where islets 
were dissociated, resulting in a loss of regulated function. Spontaneous reaggre-
gation results both in the restoration of the typical anatomy (with B-cells in the core 
and the other endocrine cells in the cortex of the islet) as well as a return of the 
normal physiological pattern of basal and glucose stimulated insulin secretion (84-
86). Not only do differences exist between the islet cells, also within the population 
of B-cells there is anatomical and functional heterogeneity (69) . 
In summary, the islet is a micro society of cells with abundant possibilities for 
interaction. The central role of the B-cell is striking. Heterogeneity within the B-
cells is important when considering the pathology of type 1 diabetes, where some 
islets and B-cells seem much more vulnerable than others in the same pancreas. 
1.3.3 Islet Development and the Relations Between Neurons and 
B-cells 
Since the structure of the islets has implications for its function, it is con-
ceivable that the embryo-fetal development of the human islets is of paramount im-
portance for its structure, function and pathology. Some considerations on this 
point are given in this section. First, the islet is formed from single endocrine cells, 
that are able to differentiate and divide and thereby eventually form a cluster of 
cells called the islet of Langerhans. Second, embryological development of cells 
and tissues takes place during a certain time-frame. Although learning of the im-
mune system continues throughout life, the embryo-fetal period is crucial. 
Expression of antigen during that period teaches the immune system to recognize 
them as self antigens or non-self 'invaders'. It should be noted that the term 
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'antigen' implies an immunological reaction. In fact antigens are normal cellular 
components, that only by virtue of an immunological reaction become 'antigen' in a 
strict sense. Third, knowledge of the development of B-cells will result in the un-
raveling of the process of proliferation and differentiation of these cells. Such 
knowledge is pertinent for the development of strategies that will facilitate regen-
eration B-cells after an attack, a situation that does occur naturally after partial pan-
createctomy. In addition, the selective destruction of B-cells seems to be a process 
that spreads out over a long period of time. The rapid onset of diabetes in some 
children under the age of 1 year and the finding of persistent neonatal diabetes not 
due to agenesis of islets (Bruining, Aanstoot, unpublished observations), urge for 
studies that analyze the role of developmental factors in B-cell heterogeneity and 
this destruction. Finally, endocrine cells have several features in common with 
neurons. Most autoimmune diseases involve neuroendocrine tissue illustrated by 
the enzyme Glutamic Acid Decarboxylase, which is a target tor studies in this thesis 
and which is present in neurons and B-cells. Some of the shared features be-
tween these cells are especially outspoken during the embryo-fetal development of 
the islets. 
The human pancreas develops from two diverticulae of the embryological 
gut during the 4th week of gestation in the human embryo. A ventral and dorsal 
primordium grow out and fuse at 7-8 weeks. At this stage all four major hormones 
can already been found. Glucagon is the earliest hormone detected by 
immunohistochemistry at 6 weeks of gestation (87). Islets are not present at that 
stage and the endocrine cells are scattered through the exocrine tissue, as single 
cells, especially in the area of ducts, or as small groups of cells (islet-like clusters) 
(88). Although endocrine cells have several features in common with neurons, 
they are believed to origin from endodermal precursors. However, several 
polypeptide hormone producing cells are suggested to develop from a neural crest 
precursor cell. Their similar characteristics lead to the concept of APUD cells 
(Amine E'_recursor 1!_ptake and Q_ecarboxylat'1on (89)). While cell-tracing methods 
demonstrated the neuroectodermal origin of several APUD cells, a similar origin for 
endocrine cells of the pancreas could never be proven (90). Moreover, other 
studies supported an endodermal origin of the endocrine pancreas (91-93). 
Recently, using sensitive PCR combined with microsurgery techniques, Gittes and 
Rutter were able to identify mRNA for the islet hormones in the mouse embryo at 
very early stages (at somite stage 10, day 8) (94). They showed that at 20 somite 
stage (day 8.5-9) hormonal mRNA's were present in foregut cells that would later 
form the pancreas anlage. Areas that are located outside this zone were negative 
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lor these mRNA's. The same study showed that cell-specific gene expression in 
the endocrine pancreas anlage began at a premorphogenetic phase i.e. before the 
organ itself started to form. It is conceivable that some of the foregut cells are 
pluripotent precursors of the endocrine lineage. Evidence lor a common endocrine 
pancreatic precursor cell comes from studies in transgenic mice harboring hybrid 
genes containing the rat insulin II promoter gene linked to the coding sequence of 
SV40 large T antigen (Tag). Tag is primarily a nuclear, nonsecreted antigen. 
Pancreatic B-cells in transgenic animals coexpressed the endogenous insulin 
gene and the transgene suggesting a common precursor lor these cells. 
Subsequent work in the rat-insulin promoter-Tag (RIP-Tag) transgenes (95) 
showed that a period of coexpression of neuroectodermal markers and hormones 
takes place. Early endocrine pancreatic precursor cell express glucagon. Some 
cells will continue to express only glucagon dur'1ng their entire life span and will 
give rise to a-cells. Other glucagon expressing cells will start coexpression of 
insulin. These cells will become committed to become insulin producing beta cells 
after loosing their glucagon expression. A fraction of these insulin/glucagon cells 
stop expressing glucagon and start to coexpress PP or somatostatin next to insulin. 
They are committed to become PP- or a-cells. Interestingly, those early stages of 
differentiation show coexpression of neuronal markers such as tyrosine 
hydroxylase (TH) and phenylethanolamine N-methyltransferase (PNMT, the final 
enzyme in the catecholamine synthesis) (96). In the final stages of differentiation 
TH expression was lost (97). In the developing human endocrine pancreas, cells 
expressing simultaneously two or three hormones have also been identified (88). 
This coexpression in the human endocrine pancreas was confined to the second 
trimester of gestation, although data from the first trimester are incomplete (88). 
Coexpression of endocr'lne hormonal and neuronal markers can also be found in 
developing sympathetic neurons and chromaffin cells (98). Although expression of 
a hormone might indicate an end-stage of differentiation. it has been shown in 
experimental animals that some differentiated cells (defined by insulin expression) 
have proliferative capacity (as determined by 3H-thymidine incorporation) in situa-
tions such as partial pancreatectomy (99). Such cells were furthermore char-
acterized by (re-)expression of Tyrosine hydroxylase. Earlier studies suggested 
that (both fetal and adult) endocrine hormone containing cells can proliferate in 
vitro, but only under stimulating conditions (1 00, 101 ). 
During the formation of islets, it is conceivable that, parallel to neuronal de-
velopment, more cells are formed than eventually needed. This is more or less il-
lustrated by the relative large amount of islets in the neonatal pancreas. The most 
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extreme example of this are newborn calves. They show such an extreme amount 
of islets that they become visible on the outside of the pancreas as small red dots 
('blutinseln') (66). In pregnant animals and humans, an absolute and relative in-
crease in B-cells can be observed (66). Not all cells formed are needed to function 
as an organ and a special gene-controlled mechanism of cell death is used to 
adapt the number of cells to the situation. Organ formation and organ sculpturing is 
fully dependent on this process of programmed cell death (PCD). This process of 
cell death is different from necrosis. Special gene products are needed to induce 
apoptosis, which takes place without induction of scarring (102-104). This process 
is most extreme in lower animals such as the nematode C. elegans. Some cells 
are formed in this organism that only live a completely predictable period of time. 
They solely function as a 'message' or 'organizer' for other cells. In higher animals 
and humans similar processes take place. Genes and gene products are identified 
which are required in this process. The gene product Bcl-2, which encoding gene 
is localized within the human MHC, is a protein that stops programmed cell death 
and prolongs the life of cells. Except for these gene products, other molecules 
such as Tumor Necrosis Factor-a (TN F-a) and MOiler Inhibiting Substance (MIS) 
are known to induce apoptosis (1 05). The role of apoptosis both in autoreactive T-
cells as well as in islet formation is not clear. The formation of islets, also involves 
cells that are present in higher numbers during formation than after birth (Krijger, 
RR de, Bruining, GJ, Aanstoot, HJ, unpublished observations). This is in particular 
true for cells expressing somatostatin. These observations suggest that becoming 
a single hormone secreting pancreatic islet cell depends on the temporal expres-
sion of several genes during a certain time frame in the islet development. The im-
portance of timed expression for the development of immunological tolerance, 
which may play a role in the pathophysiology of diabetes, will be discussed in 
Chapter 1.5 . 
Despite the endodermal origin endocrine cells and neurons do share 
several features. In addition to the already mentioned TH and PNMT, other neu-
roectodermal antigens are expressed in B-cells, for example PGP 9.5 (106), 
Neuron Specific Enolase (NSE) (1 07), Synaptophysin (1 08), Tyrosine Hydroxylase 
(TH) (109), and Glutamic Acid Decarboxylase (GAD) (110, 111). Moreover, B-cells 
also show functional characteristics of neurons. They are excitable cells, respond-
ing to chemical signals with depolarization (74) An other example of identical sys-
tems is a similar dual pathway of regulated secretion. All cells have a constitutive 
pathway of secretion. This includes •Jhe formation and transportation of small 
vesicles from the trans-golgi region to the plasmamembrane, responsible for the 
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delivery of membrane components to the cell surtace (112). In addition to this sys-
tem some cells specialize in regulated secretion. Endocrine cells and neurons 
therefore have a regulated secretion mechanism consisting of two additional path-
ways. The first system consists of small vesicles: neurons possess small synaptic 
vesicles (SSV's) that contain neurotransmitters, which are released at the synaptic 
cleft upon depolarization (113). SSV's are 20-40 nm in diameter. Endocrine cells 
have a similar vesicle population, which is slightly larger (30-40 nm) and are usu-
ally referred to as synaptic vesicle like microvesicles (SLMV's). They are believed 
to contain non-peptide messengers that are involved in paracrine regulation (for 
review see (114)). Next to this SSV!SLMV system, neurons harbor larger vesicles 
that contain peptide messengers such as enkephalines. The peptide contents re-
sults in a dense image of these vesicles in electron microscopy, hence their name 
Large Dense Core Vesicles (LDCV's) (114). Although it was thOught initially that 
neurons were committed to the secretion of one type of neurotransmitter (i.e. GABA 
or acetylcholine or adrenaline), it has been shown that one neuron can release 
more than one transmitter simultaneously (113). Peptidergic transmitters, such as 
enkephalines, are stored and released by LDCV's. The counterpart of LDCV's in 
the endocrine cells is the secretory granule (SG). They contain peptide hormones. 
Thus, both cell types have two pathways for regulated secretion, the SSV/SLMV 
pathway and the LDCV/SG pathway. SSV's are characterized by specific marker 
proteins such as synaptophysin, synaptobrevin, synapsins and p65 (113). SLMV's 
contain (at least in some cell types) marker proteins identical to those in SSV's. For 
synaptophysin however, there seems to be an overlap in localization. This marker 
is reported to be found in both SLMV's and the secretory granules of a- and B-cells 
(115). A comparable situation was found for the neuronal SSV marker protein Rab 
3A, which was believed to be a selective marker for SSV's (116), but was also 
found in the secretory granules (chromaffin granules) of bovine adrenal cells (117). 
The GABA-synthesizing hormone Glutamic Ac"1d Decarboxylase (GAD) is another 
example of a protein expressed in both neuronal and endocrine lineages. The 
role, function and localization of GAD is further discussed in chapter 2. 
In conclusion, endocrine pancreatic cells originate from endodermal 
(foregut) cells, albeit that they possess several neuronal markers. The development 
and formation of, eventually, 4 endocrine cell types producing one hormone each, 
is still largely unknown, but they are likely to develop from one precursor cell. Islet 
formation is dependent on specific and probably timed expression of proteins such 
as neuroendocrine markers and adhesion molecules. The result of islet formation 
is a micro society of cells with several anatomical and functional interactions. 
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These features might have d'~rect implications for the pathophysiological mecha-
nisms that lead to type 1 diabetes as is illustrated by the role of a neuronal enzyme 
in the autoimmune process as described in the experimental work of this thesis. 
1.4 
1.4.1 
The Pathology of the Pancreas in Type 1 Diabetes Mellitus 
Studies in Post-mortem Pancreas Tissues of Diabetic 
Patients 
The pathology of type 1 diabetes is characterized by a selective deplef1on of 
the B-cells in the islets of Langerhans. However, the process of destruction can be 
very heterogeneous. This depletion is almost complete after more than 1 year of 
diabetes in most patients, but even after 20 years of type 1 diabetes, B-cells can be 
found (118). In a pancreas of a patient with type 1 diabetes, Glucagon-, 
Somatostatin- and PP-cells are present in normal numbers and are distributed 
normally in the remainder of the islets (119). Earlier studies suggested a hypertro-
phy and hyperplasia of somatostatin producing o-cells (120) and PP-cells (121), 
but quantitative ·,mmunohistochem·lcal studies showed that this was related to atro-
phy of the exocrine pancreas (119, 122). The exocrine tissue shows atrophy which 
is reflected in a lower, but clinically not significant, level of serum amylase in dia-
betic patients (118). 
Pathological analysis during the first period after clinical onset has been 
limited to patients who died in the acute phase or in the first year after onset (123-
126). One report from Japan described histologic features of pancreas biopsies 
performed in the first 2-4 months after diagnosis (127). Although the pathological 
findings only provide us with a static view of the process, the studies indicate the 
existence of three types of islets in recent onset diabetes: 
1) Most islets (approximately 70%) are B-cell deficient (as defined by the lack of 
insulin immunostaining) and are identical to those seen in long-standing diabetes; 
2) Some islets still contain B-cells and appear normal; 
3) A portion of those islets with remaining B-cells show the characteristics of 
'insulitis', an infiltration with inflammatory cells; 
This indicates that the infiltration is a variable process in place and time. lnsulitis 
can be found in about 80% of the studied post mortem pancreases. (128). One 
study d'1d not find any s·lgn of insulitis ·,n recent onset diabetic pancreases (129). 
Although the pathogenetic importance of insulitis and type 1 diabetes was first 
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stressed by Gepts (123), other reports described insulitis years earlier (130, 131). 
The cells in the infiltrate are mainly lymphocytes and macrophages. The factors 
that trigger the invasion of these cells are unknown. The histology of insulitis can 
be very different between adjacent lobules of the pancreas (128). Although insuli-
tis is the pathological hallmark of type 1 diabetes mellitus, a striking heterogeneity 
of the islet pathology is seen within one affected pancreas. 
1.4.2 The Concept ol Autoimmunity in Type 1 Diabetes Mellitus. 
The observations of insulitis and the selective depletion of B-cells made 
Gepts to suggest (123) that the process of B-cell destruction is slow and that it may 
take years to eventually destroy enough B-cells to result in clinical symptoms. This 
is in keeping with observations that B-cell dysfunction can be demonstrated up to 
(at least) 3 years before the clinical presentation (132), and the fact that after the 
onset of the disease, a residual B-cell function may persist for several years. 
Furthermore, it was found that type 1 diabetes occurred more frequently in patients 
with autoimmune diseases and that diabetic patients often had organ specific anti-
bodies (133). The identification of islet cell autoantibodies (134), association of 
type 1 diabetes with certain haplotypes of the human leukocyte antigen (HLA) sys-
tem and the lymphocyte and macrophage infiltration of the islets, made it likely that 
type 1 diabetes was an autoimmune disease. The suggestion of Gepts of a chronic 
rather than an acute process was strengthened by the finding that circulating auto-
antibodies in relatives of patients with type 1 diabetes could be present long before 
clinical onset of the disease (135). 
These observations suggested type 1 diabetes to be an autoimmune dis-
ease caused by a multifactorial complex of genetic, environmental and ·Immuno-
logical factors. Once initiated the process is insidious, and it is conceivable that a 
considerable time can elapse before the clinical manifestations. Onset in very 
young children may indicate that the process can however be fast. The model 
shown in figure 1.1 was proposed by Bruining (136) and shows B-cell mass plotted 
against time. Two phases of preclinical diabetes precede a third clinical phase (I, II 
and Ill). In phase I there is no evidence ol B-cell destruction and only genetic pre-
disposition is present. Due to, presumably, environmental or other unknown lac-
tors, a selective attack towards the B-cells starts. The duration ol this second phase 
(II) is unknown and may span several years. l.t is conceivable that in some individ-
uals this process might come to a halt ('), or that even some form ol (persistent or 
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FIGURE 1.1: 
Schematic representation of B-cell mass during an autoimmune attack with increasing B-cell destruc--
tion. X-axis represents time, Y-axis represents 13-cell mass (Adapted from (136), with permission). For 
details see text. 
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temporal) regeneration of B·cells is possible (#). In general, the destruction will 
continue and eventually surpass a threshold of B-cell loss that leads to the symp-
toms of diabetes (@). From animal studies it was suggested that after a 70-80% 
loss of B-cell mass, diabetes ensues (137). This final phase might be triggered by 
a second insult, that leads to a relative fast loss in a short period of time (11) . Very 
often the onset of type 1 diabetes is preceded by a period of physical or psychoso-
cial stress. 
Insulin therapy is started, which results in 75% of children with newly onset 
diabetes in a short period of high endogenous insulin secretion called the honey-
moon period. Exogenous insulin needs drop sharply, and in some children exo-
genous insulin administration can be stopped temporarily. However, this is of 
limited duration and eventually all B-cells will be killed although this can take con-
siderable t'tme as shown by Rahier who identified B-cells in a person after 20 years 
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of insulin dependency (118). The honeymoon period seems to be a feature 
especially found in children and young adolescents (138). 
1.5 Studies on Etiology and Pathogenesis in Type 1 Diabetes 
Mellitus. 
The studies on the pathology of newly onset type 1 diabetes strongly sug-
gest that the selective depletion of B-cells is due to an attack by mononuclear cells 
of the immune system. This observation was the basis for the concept of auto-
immunity as the cause of type 1 diabetes mellitus (139, 140). This concept was 
based on the observations of infiltration in the islets and the occurrence of auto-
antibodies directed against ·,slet cell ant'1gens in the sera of patients with type 1 
diabetes. Additionally, genes of the Major Histocompatibility Complex (MHC) 
showed to confer susceptibility for the disease, first shown by Singal and 
Blajchman (141). This suggested an autoimmune basis, since MHC products play 
a major role in the immune response. Moreover, type 1 diabetes is associated with 
other diseases that have an autoimmune basis such as thyroid disease 
(Hashimoto's and Grave's thyroiditis) and adrenal disease (Addison's disease). 
Other findings contributed to the concept, such as the response of newly diagnosed 
diabetes on treatment with immunosuppressives (142). This chapter will discuss 
the pathophysiology of autoimmunity. Since several studies use animal models of 
diabetes, some characteristics of these models will be introduced. 
1.5.1 Animal Models of type 1 Diabetes Mellitus 
Animal models of type 1 diabetes have been an important tool to study the 
pathogenetic processes since they facilitate to address questions that can not be 
answered in humans. The most widely used models are the NOD-mouse (Non 
Obese Diabetic mouse) (143) and the BB-rat (BioBreeding), (144), both having 
cellular and humoral autoimmune and genetic features of B-cell destruction. 
Inbreeding resulted in a genetic background that coincides with a high incidence of 
autoimmune diabetes. NOD-mice have a unique MHC class II molecule, not pre-
sent in other strains (145). Whatever drawbacks animal models may have for the 
study of a human disease, they clearly show that the process of autoimmunity is 
dependent on both genetic and environmental factors. Although genetically identi-
cal, not all BB-rats or NOD-mice develop diabetes. Moreover, in some animals in-
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sulitis does develop, but it does not result in diabetes. BB-rats develop auto-
immune diabetes ·,n 40-90% depending on the colony (146). The diabetic prone 
rats have a lymphopenia and diabetes usually starts before they are 120 days old. 
The diabetes of BB- rats has been associated with an infection with Kilham's Rat 
virus, a parvovirus (147). In addition, diabetes in the NOD-mouse has been related 
to the presence of retroviral genes in the mouse genome (148) . Such findings 
clearly illustrates that environmental factors play a role in the animal models as 
well. In male NOD-mice, only a minority develops diabetes, while between 40 and 
90% of the females develop the disease (149). The disease develops after 12-30 
weeks. Several factors are known to influence the frequencies of insulitis and dia-
betes such as diet (150). The gender differences observed seem partly due to ef-
fects of sex-hormones (151) These two animal models, together with others (152), 
have had great influence on the research of type 1 diabetes and are mentioned in 
the next sections. Genetic, environmental and immunological factors have helped 
to provide evidence for the autoimmune nature of the disease. 
1.5.2 Genetic Factors in Type 1 Diabetes Mellitus 
1.5.2.1 The Major Histocompatibility Complex (MHC). 
Two functions of class I and II Major Histocompatibility Complex (MHC). in 
humans called HLA (Human Leukocyte Antigen) complex. have been mentioned in 
earlier sections. First, HLA molecules are involved in the shaping of the immuno-
logical make-up of self and non-self. Second, HLA-molecules are involved in sub-
cellular peptide transport. As discussed in the epidemiology chapter, they confer 
susceptibility to type 1 diabetes mellitus. The genes encoding the human MHC are 
located on the short arm of chromosome 6. A simplified map of the MHC is given in 
figure 1.2. A detailed description can be found in (153) 
Three major areas exist within the MHC, coding for Class I, Class II and 
Class Ill gene products. Class Ill products are complement factors and are not dis-
cussed here. HLA genes are highly polymorphic. Three groups of Class I genes 
were described: A, B, C, later followed by three other groups: E, F, G, the latter do 
not show polymorphism. Class I gene products are glycoproteins consisting of an 
a-chain with 3 extracellular domains, a transmembrane region and an intracellular 
cytoplasmic tail and are associated with ~2-microglobulin. HLA-G gene products 
are only expressed in extra embryonic tissues (154). HLA-E is ex-
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FIGURE 1.2 
Map of the short arm of chromosome 6 (human). Not all localized genes are shown 
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pressed in several tissues and plays an additional role in embryological tissues. 
The function and structure of these molecules remain putative (155. 156). Class II 
molecules are heterodimers composed of an noncovalently bound a- and B-glyco-
protein chain. The chains have two extracellular domains of which the proximal 
(a2,B2) form an immunoglobulin-like structure. The class II genes are clustered in 
3 regions (HLA DR, -DQ and DP) intermingled with other genes. During biosyn-
thesis of class II molecules a third chain, y- or invariant chain associates tem-
porarily with the class II a/p dimer. They-chain is responsible for the targetting the 
ap dimers into the endocy1ic pathway and for preventing premature peptide 
binding The structure of Class II molecules resembles that of class 1. The poly-
morphic areas of the HLA molecules line the protein binding groove and are ex-
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tremely important for the HLA-peptide interactions. Class II molecules however, 
b·lnd peptides of a slightly larger size than Class I("' t4 aminoacids) (t 57). Class I 
molecules contain peptides of 8-10 aminoacids in a real cleft , while in class II 
molecules, larger peptides bulge out on both sides ((158, 159) for review). 
The HLA DR region has 6 loci, the non polymorphic ORA 1 locus (encoding 
the a-chain) and five ORB loci of which DRB1 is the most polymorphic. The HLA-
DO subregion consists of two a- and two B-chain loci: DOA1, DOA2, DQB1 and 
DQB2. DQA 1 and DQB1 are polymorphic with 8 variants of DQA 1 and 14 for DQB1. 
These genes correspond to nine serological recognizable specificity's of DOa~ 
heterodimers which are called D0w1 - DQw9. 
The HLA loci are in close linkage. This results in inheritance 'en bloc', which 
is called a haplotype. The consequence of this is a strong linkage disequilibrium 
between certain alleles, which means that some alleles occur together more often 
than expected on basis of their gene frequencies. Certain haplotypes are therefore 
often maintained in the population. An example is the haplotype HLA-A1-B8-DR3-
DOw2. The importance of HLA molecules in prediction and pathogenesis of type 1 
diabetes is discussed in the next paragraph. 
1.5.2.2 Genetics of Type 1 Diabetes Mellitus. 
It was noticed in epidemiological and genetic studies that a pattern of inheri-
tance existed for type 1 diabetes. Diabetes 'runs' in families, but the complexity of 
the inheritance resulted in the nick name the 'geneticists nightmare'. Also popular 
belief, such as 'it skips every other generation', indicates this problem. Studies in 
twins proved helpful in complex genetics and showed two important findings. 
Comparing the phenotypic similarity (concordance) in monozygotic and dizygotic 
twins it became clear that in type 1 diabetes the susceptibility and not the disease 
itself is inherited: monozygotic twins are concordant in only 30-55% of the pairs, 
when one child of a dizygotic twins has type 1 diabetes, the chances for the other 
are still high (55, 160, 161) The low concordance rate indicates that additional 
factors must come into play. This is further supported by the finding that the longer 
the time from diagnosis in the first (monozygotic) twin, the smaller the possibility for 
the other to get diabetes. Recurrence risks have been established and are given in 
table 1.3 (162). Several genetic markers have been evaluated as 'diabetes gene', 
but only the HLA system showed linkage to type 1 diabetes. After initial linkage 
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was described lor the class I HLA loci HLA B-15 (141) and HLA BS (163) (with the 
strongest association with heterozygosity oi B8/B15), a stronger 
TABLE 1.3 
Estimated recurrence risk (%) lor relatives ol type 1 DM probands 
Relative: Percentage: 
Monozygotic Twins 30-55 
Dizygotic Twins 15 
Siblings 3-6.2 
Children 3.4- 5.4 
Nephews and Nieces 1.5 
General Population 0.15- 0.4 
association was found with MHC class II gene products oi HLA DR3 and DR4 
(164). About 90-95% of Caucasian patients with type 1 diabetes are either DR3 
and/or DR4 positive compared to 40-60% of controls. The strongest association 
was found for HLA DR3/4 heterozygosity and in Sweden, with a high incidence of 
type 1 diabetes, 30-40% of the patients have this haplotype, compared to 3-8% of 
controls (165, 166). The haplotype HLA DR2 showed is associated with a very low 
risk of type 1 diabetes. Since most of the work was performed in Caucasian 
people it was an interesting observation to find that in other races different haplo-
types are linked to type 1 diabetes. In the Chinese population the highest risk was 
in HLA DR3/9 individuals, while in the Japanese the highest risk was confined to 
individuals with HLA DR4/9. Numerous studies indicated that HLA DR4, DR3, DR1 
and DRS are associated with type 1 diabetes in a descending order. 
The importance of genes in the DO region was first described by Owerbach 
and colleagues, using restriction fragment length polymorphism (167). A BamHI 
3.7 kb fragment was found more frequent in DR4 patients than in controls. Cloning 
of this fragment revealed, that it flanks the coding region of the first and second 
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domain of an HLA DOB-chain. The stronger association with diabetes indicates 
that the DO locus is closer linked to a presumable diabetes susceptibility locus(28, 
168). Further work showed that the DOp-chains of haplotypes associated with type 
1 diabetes (such as DR4-D0w8, DR3-DOw2, DR1-DOw5) were different at 
aminoacid position 57 when compared with haplotypes negatively associated with 
type 1 diabetes (such as DR4-DOw7, DR2-DOw1.2, DR2-DOw1.12) (169). This 
position is located in the groove of the MHC molecule, thus interfering with peptide 
binding. Alleles encoding aspartic acid (asp) at position 57 of the DQp chain were 
suggested to confer resistance to type 1 diabetes, while alanine, serine or valine in 
this position coded for susceptibility (169-171 ). Subsequent work showed that 
arginine (arg) at position 52 of the DOa-chain was associated with susceptibility, 
whereas an other (non-arg) residue at this position conferred resistance to type 1 
diabetes (172). It is however, unlikely that only these two residues confer the risk 
for diabetes, since not all persons with haplotypes coding for both susceptible 
aminoacids develop the disease. Furthermore, Japanese patients do not show the 
association with the asp at position 57 of the DOp chain (173, 174). The two DO 
loci do however, provide a way to assess such HLA data in prediction. Simple 
assessment of ARG and ASP in the two DO chains can be done with relative fast 
and cheap methods and provide an important risk marker for type 1 diabetes. In a 
study where different ethnic groups were compared, Giphart and colleagues found 
that the risk for diabetes increases from homozygote non-susceptible haplotypes 
via heterozygote susceptible to a group with the highest risk, the homozygotes with 
a susceptible haplotype for both the ASP and the ARG position (175). Although 
assessment of these aminoacid residues helps to determine the risk for the dis-
ease, it should be stated that, although may be important marker for type 1 dia-
betes susceptibility, they are not the only determinants (9). 
The linkage of MHC class II markers with type 1 diabetes risk is not absolute, 
and suggests that further analysis of genes in the region may result in the identifi-
cation of 'the' susceptibility gene and that all other described associations are 
simply linkages to this gene. A number of genes coding for proteins involved in 
peptide processing and transport can be considered as a candidate. Antigen pro-
cessing involves first the generation of peptides from cellular proteins, a process 
that takes place by the LMP complex, a distinct subset of the cellular pool of pro-
teasomes. Subsequently, such peptides are transported into the endoplasmic 
reticulum and combine with HLA class I molecules. The TAP-1 and TAP-2 
molecules, formerly in humans referred to as RING 4 and RING 11 respectively 
(176-179) are involved in the transport into the endoplasmic reticulum (ER). Inside 
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the ER, binding to the class I molecules includes conformational changes that may 
facilitate their export to the cell surface. The TAP genes are characterized by a 
polymorphism comparable to other MHC genes. The recent observations that a 
defect in antigen binding and presentation by class I molecules might be involved 
in type 1 diabetes (180) could indicate that these gene products might play a role. 
In addition, the gene product Bcl-2, a protein that prevents programmed cell death 
(apoptosis) of lymphocytes (during the selection process) and other cells (B-cells?) 
is also located within the MHC (153). Such a gene could play an additional role in 
autoimmunity, but no definite evidence has yet been found. 
Other genes outside the MHC region have been found to add.ltionally influ-
ence the susceptibility of type 1 diabetes. Using congenic strains of mice (NOD's 
back crossed with other strains with particular haplotypes) Todd and coworkers 
identified 11 additional loci on different mouse chromosomes that were associated 
with the inheritance of insulitis and/or diabetes. Two of these genes in NOD-mice, 
idd-3 and idd-4, located on chromosomes 3 and 11 respectively, are strongly as-
sociated although less than MHC genes (referred to as idd-1 by Todd and cowork-
ers) (181 ). ldd-3 is associated with insulitis. It is located on mouse chromosome 3. 
An important factor associated with idd-3 is the gene that codes for the high affinity 
lgG2 receptor (FcGR1). A pathophysiologic role for this gene product in auto-
immune diabetes is unclear. ldd-4 is associated with the disease in the youngest 
age group of NOD-mice and not in older mice. The observations argue for a com-
plex polygenic regulation, where different stages of the disease are under control 
of different genes. Homologues of these genes in humans are only partly ·Identified 
and their role in (human) type 1 diabetes is still unknown. Studies in humans have 
only involved multiplex families (more than one sib or parent has the disease), 
which contribute to only about 5% of the cases (26). It is conceivable that the dis-
ease in these multiplex families represents a different subtype of type 1 diabetes, 
than what is found in the 95% remaining cases without a family history. 
Until now, the analysis of the contribution of other genes is limited in hu-
mans. The polymorphic TCR genes were studied, but no correlation with the dis-
ease has been established, although this is still subject to controversy both in type 
1 diabetes (182-184) as well as in autoimmunity in general (185, 186). 
In summary, a strong association between genetic factors and type 1 dia-
betes exists for HLA genes, but they can only explain (a part of) the susceptibility to 
develop the disease. The HLA molecules have two important functions that could 
contribute to the disease. First, they are involved in the selection process ofT-cells. 
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Second, their role is to present peptides to the immune system. No 'diabetogenic 
gene' has yet been described. The disease is polygenic and the inheritance ·,sex-
tremely complex. Although not conclusive, the data from all these observations do 
help in determining the risk for diabetes. The presence of predisposing or protec-
tive haplotypes can contribute in establishing the risk. Regarding other non-HLA 
genes within the MHC and non-MHC genes, more data are needed before conclu-
sions can be drawn. Genetic analysis is extremely important in the prediction of 
type 1 diabetes and the study of its pathophysiology .. 
1.5.3 Environmental Factors in Type 1 Diabetes Mellitus. 
The previous chapters suggest that type 1 diabetes is an autoimmune dis-
ease. Three phases could be recognized in the development of the disease (figure 
1.1 ). Genetic factors determine susceptibility, indicated by phase I. Phase II is be-
lieved to start after the initiation by an environmental trigger. The nature of this trig-
ger (or triggers) is unknown. Strong evidence that environmental factors play a 
role comes from studies in monozygotic twins, where the identical genetic back-
ground does not result in a 100% concordance. Moreover, the longer the time after 
the start of diabetes in one of the twin members. the lower the chances for the other 
one to develop the disease. In addition, only about 6-12% of the cases of type 1 
diabetes occur in families with an affected parent or sib with the disease. Together 
with the epidemiological observations of increased incidence associated with epi-
demic-like outbreaks, seasonal variation and a general pattern that resembles in-
fectious diseases, an environmental influences are very likely. Migration from an 
area with a low- to an area with a high incidence coincides with increased fre-
quency of the disease, even without ethnic mixing. The identification of environ-
mental factors is d'1fficult. The long lag period between initiation of B-cell destruc-
tion and clinical onset of the disease makes it difficult to pinpoint on factors that 
might have played a role in the initial process. A number of observations, however, 
support a causative role of the environment, including viral infections, chemicals, 
toxins and dietary constituents. 
Introduction 42 
1.5.3.1 Viral Infections and Type 1 Diabetes Mellitus. 
The first publication of a link between type 1 diabetes and viral infections 
dates from 1899, when Harris described a case of diabetes that started alter a 
mumps infection (187). Evidence for a role of viruses include: 
1) The presence of viral antigens in islets of newly diagnosed patients; 
2) The presence of antibodies against viruses in the serum of newly diagnosed 
patients; 
3) Observed B-cell damage in children who died of overwhelming viral infec-
tions, and 
4) The isolation of virus from the pancreas of children who died in the initial 
phases of diabetes with demonstration that this virus could induce diabetes 
in animals (thereby, fulfilling Koch's postulates). 
Viruses linked to the pathophysiology of type 1 d'1abetes in man include 
mumps, coxsackie, rubella and cytomegalovirus (CMV) (188). The association 
with mumps comes from the prevaccination period, when mumps infection were 
found to result in type 1 diabetes in some cases (189-191). Islet cell autoanti-
bodies (ICA's, see 1.5.7.1) were found after a mumps epidemic, but were not re-
lated to later onset of type 1 diabetes (192). Mumps virus can infect cultured hu-
man B-cells and can up-regulate MHC class I expression in cultured human fetal 
islet cells (193) Coxsackie 84 virus was cultured from a newly diagnosed child 
who died from the complications of a diabetic ketoacidotic coma. This virus was 
propagated in B-cells and could induce diabetes in mice. Coxsackie is normally 
tropic for exocrine tissue, but some strains seem to prefer endocrine cells of the 
pancreas (194). A large analysis of autopsy specimen from persons who died in 
initial periods of diabetes revealed no evidence for coxsackie B capsid protein 
(195). The responses ofT-cells from diabetic individuals towards (in vitro) mumps 
and coxsackie infections seem to be HLA DR4 restricted (188). Congenital rubella 
infections are in 10-20% of the cases complicated by type 1 diabetes mellitus 
(196). A majority of the patients are HLA-DR3 (197).Since postnatal rubella is not 
associated with type 1 diabetes, the embryo-fetal period is of importance in trigger-
ing the disease. Cytomegalovirus infection often complicates treatments that result 
in a diminished function of the immune system (chemotherapy, transplantations). 
One case of CMV particles in B-cells was described, and a subsequent analysis of 
45 children who died of disseminated CMV infections revealed 20 with similar in-
clusion bodies (198, 199). These children did not have any evidence of B-cell 
dysfunction. A monoclonal mouse antibody raised against CMV, reacted with a Mr. 
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38,000 islet antigen in humans and BB-rats (200). Recent, CMV was found to block 
the intracellular transport of peptide loaded HLA molecules, thereby interfering with 
immune surveillance (201). In NOD-mice a role for retroviral proteins was sug-
gested (148). In BB-rats a relation with the Kilham virus (parvovirus) was made 
(147). The interpretation of such studies is, however difficult. 
The mechanisms by which viruses can destroy B-cells are: 
a) direct B-cell destruction due to infection followed by B-cell lysis; 
b) molecular mimicry, where a viral component produced in the B-cell or else-
where looks very similar, but not identical, to a B-cell antigen and the im-
mune reaction directed against the viral intruder also attacks the self anti-
gen; 
c) disturbance of the B-cell metabolism and function, resulting in an increased 
or aberrant expression of a normally non (=sequestered) or almost non ex-
posed B-cell antigen; 
d) A virus can interfere with immune cells as exemplified by CMV; 
It should be realized that the infection and destruction process might take 
place shortly after the infection but also many years later. In a large population 
study 339 recently diagnosed children were evaluated for the effect of vaccinations 
on onset of type 1 diabetes. None of the vaccines (tuberculosis, smallpox, tetanus, 
whooping cough, rubella and mumps) appeared to be protective (202). 
1.5.3.2 Chemicals, Food Components and Type 1 Diabetes 
Mellitus. 
A striking example of environmental agents involved in type 1 diabetes 
came from accidents with the rodenticide Vacor® (N-3-pyridylmethyi-N'-p-nitro-
phenylurea). This substance is a nitrosurea compound. Accidental ingestion in 
humans lead to a syndrome of diabetes and severe neurological dysfunction (203). 
In vitro, the drug is toxic to human islets (204). Except for its presumed direct B-cell 
cytotoxic effects, patients showed a secondary autoimmune reaction after ingestion 
of Vacor (205). Similar observations of cytotoxicity and autoimmune phenomena 
were found for the nitrosamine compound Streptozotocin. Moderate and high 
doses of this drug have a direct cytotoxic effect on B-cells. Repeated low dose in-
toxications result in an MHC dependent attack on B-cells. This autoimmune-like 
destruction was transferable by injecting the lymphocytes from animals treated like 
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this into healthy controls. In addition, anti-lymphocyte serum and total body irradia-
tion prevented the occurrence of diabetes (206), also suggesting its autoimmune 
nature. N'1trosamine compounds are often produced in the human body from ni-
trites that are often used in food preservatives. One report suggested that ingestion 
of nitrites in food (Icelandic cured mutton) increased the incidence of type 1 dia-
betes (207) Epidemiological data are needed to support this hypothesis, which is 
largely based on animal experiments. Alloxan and pentamidine are other compo-
nents causing B-cell toxicity. Pentamidine is a anti protozoal drug reducing the re-
sponse of B-cells on glucose and arginine. Direct B-cell destruction was also seen 
after longer exposure to this drug (208). 
Food components linked to type 1 diabetes include coffee and cow's milk. 
Epidemiological data show a parallel between coffee consumption per capita and 
type 1 diabetes (209). Breast-feeding during infancy, or late introduction of cow's 
milk is suggested to be protective (21 0, 211 ). Studies from Finland and Canada 
showed that newly diagnosed children had a high frequency of antibodies to a 
fragment of bovine serum albumin (BSA). The epitope responsible for specific dia-
betes related antibodies is called the ABBOS (6_1Q_umin Bovine ~erum) fragment 
(212). The antibodies do not precipitate a protein in immunoprecipitations, but the 
authors were able to, indirectly, identify a protein of 69kD on western blot. Mimicry 
between the BSA and the 69k0 protein is the mechanism suggested of auto-
immunity in type 1 diabetes. Currently, other labs try to set up assays for ABBOS 
directed autoantibodies, but until now without success (Atkinson, personal com-
munication). Since the epidemiological studies are retrospective, a causal role for 
the disease nor a protective effect can easily be drawn. The ABBOS data triggered 
a nationwide blind study in Finland, where babies will be ted BSA free- or BSA-
containing formula. Apart from the ethical aspects of such studies, the presence of 
BSA in several foods and the possible transfer of BSA from the mother into the 
breast milk will make this study difficult to perform and analyze. In Sweden, where 
a national registry exists for type 1 diabetes, no evidence of a relation between cow 
milk and diabetes was found. However, a relation was found between the occur-
rence of type 1 diabetes and birth weight and weight gain in the first 6 months of life 
(J. Ludvigsson, personal communication). 
Effects of chemicals and food components can have an effect by cumulative 
damage. Both a repeated dose or chronic exposure to a diabetogenic agent can 
result in enough triggers to start a sequence of events, eventually resulting in auto-
immune diabetes. 
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Although a genetic susceptibility is a requirement for the development of 
type 1 diabetes, an additional environmental factor seems necessary. Since such 
factors could operate only over a brief period or could be repetitive, they are difficult 
to trace. Moreover, exposure does not necessarily result in diabetes, probably not 
even in those with a susceptible HLA-haplotype. The additional make-up of the 
immune system (see next section) is important. Viruses and toxins may function as 
environmental triggers, but it remains unclear which of these environmental factors 
contributes to (most of the cases of) type 1 diabetes. 
1.5.4 The Immune System: Components and Mechanisms of 
Tolerance. 
The major function of the immune system is to respond to foreign molecules 
(antigens), while avoiding reactions against molecules of the host itself (self-anti-
gens). Autoimmunity implies a faulty reaction of the immune system. Every un-
known molecule must be eliminated, which implies that a mechanism exists that is 
capable of distinguishing self from non-self. Tolerance to self is a prerequisite for 
survival. Earlier work (213, 214) suggested a clear and relatively simple mecha-
nism for this: upon the entry of a foreign antigen, the body would react by producing 
antibody and by developing a cellular response, thus showing non-tolerance. In 
this scenario, autoimmunity was the result of a loss of tolerance to an antigen that 
was originally tolerated. Toleration was thought to occur entirely in fetal life. At that 
stage, cells that were reactive to self-antigens would be eliminated, but in some 
cases, forbidden clones of self-reactive cells could await the moment to attack. 
Although several aspects of this concept still hold, the mechanisms of tolerance are 
more complex. 
The immune system recognizes antigens using three major recognition 
structures: immunoglobulin (lg) receptors on B-lymphocytes, T-lymphocyte recep-
tors (TCR's) on lymphocytes and cell surtace molecules of the class I and II major 
histocompatibility complex (MHC class I , MHC class II). MHC Class I molecules 
can be found on most nucleated cells of the body, including adult B-cells. They 
have a primary function in peptide transport. Fragments of proteins will bind to 
class I molecules, be transported and eventually presented at the cell surtace. 
MHC class II molecules are only found on specialized cells of the immune system 
that take up, process and present antigen (antigen presenting cell, APC) to T-lym-
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phocytes, B-lymphocytes and macrophages I dendritic cells. For both the lg-recep-
tors (215) and TCR's (216) a large repertoire is possible by programmed rear-
rangement and random assortment of the lg- and TCR-genes. TCR's are phyloge-
netically linked to lg-molecules, but have some different properties. T-lymphocytes 
recognize antigen fragments of S-12 aminoacids, independent from their spatial 
configuration (primary epitopes), whereas B-lymphocytes recognize conformational 
epitopes and thus, require an intact three dimensional structure of the antigen. 
MHC molecules possess a binding cleft or groove for antigens (217) and T-lym-
phocyte activation is achieved upon presentation of an antigen at the surface of a 
cell in this cleft with subsequent recognition by the TCR. In order to result in activa-
tion of the T-lymphocyte, spatial interactions between MHC molecule, antigen and 
TCR must be optimal. Additional molecules are necessary for the function of the 
trimeric complex of MHC, antigen and TCR, such as adhesion molecules. 
Moreover, APC's do not only present antigen toT-cells, they also provide a so-
called second signal, needed to obtain a proliferative response of the T-cells (21S) 
(219). 
Two classes of T -lymphocytes can be distinguished. One group consists of 
T-helper (Th) cells. They express CD4 cell surface molecules (CD4+) and can in-
teract with MHC class II expressing APC's. The others are cytotoxic T -cells (T c). 
They have the ability to express the surface molecule CDS (Cos+) and to kill other 
cells. CDS positive cells can interact with MHC class I expressing cells. CD4+ (Th) 
cells are regulators and orchestrators of the immune system. Upon activation they 
can start to secrete factors (cytokines) that recruit and activate other cells: 
macrophages, T c-cells, natural killer (NK) cells and B-cells. The activated cells are 
attracted to the site of the immune response which results in an infiltrate. This 
combined action results to the secretion of additional cytokines (lymphokines) that 
triggers the expansion of certain clones of B- and T-cells. Eventually, regulatory 
and suppressive mechanisms will limit and terminate the immune response. 
CD4+ cells can be divided into two functionally distinct groups on the basis of their 
cytokine production. Th1 cells produce predominantly lnterleukin 2 and interferon-
y, Th2 subsets produce lnterleukin 4 and 6. There is still controversy on this subdi-
vision. Phenotypic markers can also subdivide CD4+ cells. The CD45 molecule 
exists in low (CD45RO) and high (CD45RA, 8 or C) molecular weight forms which 
are the result of alternative splicing. The CD45RA+ cells were found to be predom-
inantly present in insulitis lesions in NOD-mice and seem to be the most important 
subgroup (220). It has been suggested that suppressor CD4+ T-cells do express 
CD45RA (220). 
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The result of all these components is a system that is diverse, able to en-
counter unknown antigens and to respond fast after a second encounter. However, 
tolerance to self antigens is required. Burnett suggested in 1959 that tolerance de-
pended on clonal deletion of self-reactive cells, a process he proposed to take 
place in the thymus (214). We now know that selection processes indeed take 
place in the thymus for both B-and T-cells. Immature T-cell precursors derived 
from the bone marrow start expressing both CD4 and CDS and arrive in the thymic 
cortex. They have the capacity to express TCR's for any antigenic determinant, but 
only those cells that actually do encounter self-MHC (presented by the thymic epi-
dermal stromal cells) will continue the process of differentiation. This means that 
they become committed to express either CD4 or CDS. Cells that do not continue 
differentiation (and keep expressing both CD4 and CDS) will undergo programmed 
cell death (apoptosis) (221 ). Programmed cell death is gene regulated. One of the 
genes involved is the BCL-2 locus in the HLA region. Cells that continue the pro-
cess of differentiation can encounter self-antigens in the thymic medulla, presented 
by dendritic cells. Dendritic cells are originally derived from the bone marrow. An 
initially, positively selected (on basis of its self-MHC recognition) cell that reacts 
with a very high-affinity to a self-peptide/MHC complex is eliminated. This process 
is referred to as negative selection. The theoretical result is that only T-cells that 
recognize foreign antigens in conjunction with self-MHC will survive. Autoreactive 
T-cells are however, present in many individuals as is illustrated by multiple scle-
rosis, where the frequency of auto reactive T -cells against the presumed trigger 
myelin basic protein is almost equal in controls and in patients. 
Thymic mechanisms of selection can thus explain the achievement of tol-
erance to antigens that are present in the thymus. However, not every antigen will 
reach the thymus. Some antigens are only expressed in a certain time frame of 
development, others are situated (sequestered) in anatomical privileged sites. In 
addition, some antigens may be expressed by cells that have a low or absent MHC 
class I expression or express MHC that is incapable of presenting antigen in a 
proper way to the immune system. In view of this, mechanisms of peripheral toler-
ance were considered and supported by experimental evidence (222). Work in 
transgenic mice clearly showed the existence of clonal anergy in vivo as reviewed 
in (223, 224). This is defined as silencing of a lymphocyte without its actual de-
struction (225). Anergic lymphocytes are capable of binding the self-antigen-MHC 
structure with their TCR, but incapable of proliferating in response to this (223, 
226). It is suggested that this anergy is due to the absence of a second signal, 
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needed to activate T -cells (218, 219). The mechanisms proposed for peripheral 
tolerance are however still open for debate and anergy may be more dependent on 
the thymus (227). Mice transgenic for an MHC molecule (Kb), targeted to the B-cell 
by linking it to the insulin promotor, do express this MHC in their B-cells, do not get 
infiltration of islets after immunization with Kb and become tolerant at the T -cell 
level. Crossing these mice with transgenes for the anti-Kb TCR, produces double 
transgenics. These double transgenics expressed, however, only small amounts of 
T-cells with the Kb TCR. This suggested that a few molecules of Kb must have 
been present in the thymus and were able to initiate deletion ol T-cells with high Kb 
TCR's. Although conventional techniques such as immunohistochemical staining 
and northern blotting could not reveal Kb in the thymus, it was possible, by PCR, to 
show Kb in the thymus. Triple transgenes, in which the double transgenes were 
crossed with mice transgenic for interleukin-2 (IL-2) expressed in B-cells, develop 
insulitis and no diabetes very fast. The autoimmunity did not seem to be related to 
Kb, but the expression of IL-2 in the context at antigen (Kb) and specific T-cells did 
stimulate Kb reactive T-cells in the double (Kb and anti-Kb TCR) transgenics. IL-2 
may have overcome the anergy and activated the 'ignorant' T -cells. When single 
transgenic Kb (expressed in the B-cells) mice were thymectomized (to prevent Kb 
expression in the thymus), irradiated, reconstituted with bone marrow from Kb TCR 
transgenes, and transplanted with a normal thymus, an immune response to Kb 
developed (228-231 ). This indicates that in this model, no anergy of Kb TCR cells 
develops actually, but that the system is more or less ignorant until a rather non-
specific trigger appears. While, in strict sense, anergy can be regarded as there-
sult of a lack of a secondary signal within the silent T-cell, ignorance could include 
the presence of other cells that suppress the T-cell. The mechanisms by which T-
cell suppression works in achieving tolerance, are poorly understood. The exis-
tence of suppressor T -cells was largely based on indirect experimental evidence 
without a clear view of the characteristics of this cell type. Since no direct evidence 
for their existence could be found, but since regulatory effects upon more aggres-
sive T-cells were found, they are also referred to as 'regulatory T-cells'. New data 
however, support the concept ot suppressor T-cells (232, 233) and indicate that 
they can be partly identified on the basis of their cytokine production (234). 
Suppressor T-cells could therefore have important functions in limiting the reac-
tions of autoreactive cells. In summary several mechanisms can induce or interfere 
with tolerance. At least four major groups can be outlined: 1) positive and 2) nega-
tive selection (both in the thymus) result in 'central' or thymic tolerance, 3) mecha-
nisms such as anergy result in peripheral tolerance and 4) suppressor mecha-
nisms can render T-cells ignorant and limit autoimmune reactions. 
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1.5.5 Tolerance and Autoimmunity. 
Positive and negative selection is a first filter system to autoreactive T-cells. 
If cells escape these mechanisms. peripheral mechanisms such as anergy, igno-
rance and suppression reduce the dangers of autoreactive T-cells. Recent work 
emphasizes the fact that autoreactive T-cells can escape the self-censorship and 
play a role in the onset of autoimmune disease (235). Additional evidence that not 
all autoreactive T-cells are eliminated comes from experiments where T-cell re-
sponses are induced using pancreatic islets. All NOD-mice, irrespective of age, 
sex, and disease progression possess islet specific CD4+ and MHC class II re-
stricted T-cells. These T-cells were specific by virtue of the absence of reactions 
with other cell types. Such autoreactive T-cells were however, also found in other 
non-diabetic mouse strains indicating a normal occurrence of islet cell reactive T-
cells (236). Similar findings were found in rats (237). Such data support that toler-
ance to some B-cell antigens is not established. Failure of thym·lc tolerance is one 
mechanism of aberrant tolerance. Other mechanisms include anergy and sup-
pression, but except lor T-cell mechanisms. also antigen and APC related causes 
lor tolerance ablation exist. Table 1.4 summarizes some mechanisms that could 
result in either autoreactive T-cells or the inability to induce tolerance (modified af-
ter (225)). 
Antigen sequestration in place is the situation where an antigen is not 
shown to the immune system, due to its privileged anatomical localization. The 
antigen cannot travel to the thymus and the privileged site may include the inability 
of peripheral lymphocytes to reach it. Thus, sequestration can result in non-visi-
bility and therefore intolerance. An example are the autoantigens against sperm 
found after vasectomy in men. The testis is an immunological privileged site. 
Following vasectomy, a striking accumulation of macrophages can be found 
around the obliterated vas deferens, not infrequently resulting in granulomas (238). 
Sperm components are absorbed into the body and such autoantibodies to sperm 
antigens can be found in 50-80% of men after vasectomy. 
Sequestration in time means that, dependent on the timing of presentation of 
an antigen to the immune system, tolerance may or may not ensue. It is evident 
that the process of maintaining tolerance to peripheral self proteins has to be con-
tinued throughout life. However, the period during development seems to be of 
crucial importance for the induction of tolerance. Studies in twin calves showed al-
ready in 1945 that exposure of the immune· system to foreign antigens in utero is 
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TABLE 1.4 
Mechanisms involved in change of tolerance and autoimmunity 
(T-cells) 
Lymphocyte related: 
failure of positive selection. 
failure of negative selection. 
failure of suppression mechanisms. 
failure of peripheral tolerance (anergyfignorance). 
Antigen related: 
sequestration in place or f1me 
molecular mimicry 
50 
alterations of self antigens (different processing or different 
post-translational modification) 
combination of self antigen wiih a foreign determinant 
APC related: 
aberrant M HC class II expression 
aberrant processing and presentation of antigen 
sufficient to permit the development of long-term immunological tolerance (239). 
Moreover, studies in transgenic mice strengthened the importance of expression of 
an antigen during ontogeny to ensure the development of tolerance (240). By tar-
geting expression of SV40 virus large T-antigen (Tag) to B-cells in mice, and by 
using different promoter lengths of the insulin promoter, animal strains with both 
early embryonic as well as animals with late post-natal expression of Tag were ob-
tained. Early embryonic expression resulted in life long tolerance, animals with 
late expression showed non-tolerance for Tag. Since Tag was selectively 
expressed in B-cells, the animals developed autoimmunity towards the B-cell. 
However, the animals did not die of diabetes. This was due to the oncogenic 
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properties of Tag, resulting in lethal insulinomas. Similar findings of the acquisition 
of self-tolerance to foreign genes came from other mouse lines transgenic for MHC 
II molecules (232, 241). 
An other example of sequestration is found in paraneoplastic diseases. 
Tumors are able to express several genes that are normally not encountered in 
certain tissues. This may include sequestered antigens or antigens that are nor-
mally only present in low concentrations. In patients with paraneoplastic cerebellar 
degeneration, it was found that the tumor (ovarian, breast or endometrial in origin) 
was able to produce large amounts of a protein normally only present in Purkinje 
cells. The presumed sequestration of this antigen resulted in autoimmunity to-
wards this antigen upon release of large quantities from the tumor, and subsequent 
cerebellar dysfunction (242, 243). 
Molecular mimicry is a mechanism whereby viruses and other infectious 
agents can cause autoimmunity (244). They possess this function by sharing anti-
genic determinants with self antigens of the host. The foreign antigen should not 
be completely identical. In that case, tolerance should already have been estab-
lished by the host, unless a second mechanism such as sequestration coincides. 
Depending on the antigenic differences or antigenic distance between the two 
components, the foreign antigen is able to 'fool' the immune system: the response 
to the foreign antigen coincides with a response to the self-antigen. A typical ex-
ample of molecular mimicry is the epitope shar'lng between streptococcal antigens 
and endocardial structures in rheumatic fever (245). 
Alterations of antigens can result in autoimmunity. A typical example is 
thyreoglobulin. After treatment with papain, that will break up the molecule, frag-
ments appear that are able to induce autoimmunity. Injection of the (rabbit) hor-
mone fragments without adjuvans in rabbits can result in both antibody production 
and thyroiditis in normally tolerant animals (246). Alterations can also include a 
different processing of a protein or a modified post-translational modification. 
Recently, it was shown that Cytomegalo virus (CMV) infections are able to modify 
the process of protein degeneration, which resulted in different peptides than nor-
mally encountered by the immune system (201). Such mechanism could be envis-
aged in diabetes and autoimmune diseases as well. 
Combinations of foreign determinants and antigens are exemplified by the 
drug-induced hemolytic anemia's such as alter a-methyl-dopa (247). The complex 
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evokes an immune response. Due to its binding to erythrocytes. these cells will be 
lysed as innocent bystanders. Chemicals and drugs could have additional influ-
ences on posttranslational modification or processing of an antigen. They could 
decrease, increase or otherwise alter the amount of antigen presented to the im-
mune system, thus interfering with tolerance. 
Aberrant expression of MHC class II antigens has been extensively studied 
in type 1 diabetes alter Bottazzo and colleagues suggested that aberrant expres-
sion of MHC class II (HLA-DR) by B-cells was the basis lor antigen expression by 
the B-cell and subsequent autoimmunity (126, 248). Class II expression has been 
described in target cells of other autoimmune diseases. Expression of MHC class 
II by the B-cell could directly present a B-cell autoantigen and stimulate auto-
reactive CD4 T-cells. Foulis and coworkers reported findings in post-mortem tissue 
of newly diagnosed type 1 diabetic patients (249). The immunohistochemical 
staining for MHC class II was seen on B-cells in islets that were not yet infiltrated by 
the insulitis, suggesting it was an early step in the destruction process and not due 
to secondary phenomena. The same type of islets showed hyperexpression of 
MHC class I molecules (96), but hyper expression of class I was also found on 
other endocrine cells in the islets. The concept of aberrant MHC expression by B-
cells was attractive. It would be a direct way to present a B-cell autoantigen to CD4 
positive T -cells, thus starting a cascade of reactions resulting in B-cell destruction. 
It initiated studies using MHC transgenic mice. Lo and colleagues and Sarvetnick 
and colleagues targeted MHC class II expression towards B-cells by using con-
structs of the MHC gene hooked to the insulin promoter (241, 250). Although the 
animals became diabetic, this was not due to an autoimmune disease. as was illus-
trated by the absence of insulitis. It was suggested that the aberrant expression of 
the MHC molecules interfered with the insulin secretion (251 ). The differences 
found between Bottazzo' s model and the flnd·,ngs in the transgenes could be due 
to differences between these models and the natural situation. The hypothesis of 
Bottazzo describes newly induced class II expression. The transgenic models, in 
contrast, have constant (from early embryological life on) class II expression on B-
cells and this timing of class II expression might be critical. In addition, T-cells 
need a 'second signal'. As indicated before, recent work shows that both an ap-
propriate presentation of the antigen as well as this second stimulating signal 
needs to come from a cell. In the absence of this second signal, unresponsive-
ness or anergy is likely to occur. It is unlikely that this second signal can be pro-
duced by the B-cell. Large numbers of dendritic cells added to in vitro experiments 
can mimic such a second signal. However, dosages used lor this, are far over 
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physiological levels. Other experiments also weakened the hypothesis. In NOD-
mice, no expression of MHC class II on B-cells was found. The cells in the islets 
that express class II were CD45 positive (bone marrow derived ) immune cells. 
There was increased expression of class I molecules on B-cells (252). In another 
study it was found that, at the electron microscopic level, some of the insulin positi-
ve, MHC class II expressing cells were in fact macrophages that had engulfed B-
cells and therefore stained for insulin. Experiments by Markmann and colleagues 
(253) showed that B-cells were poor antigen presenting cells in vitro and, by lack-
ing a second signal, induced anergy of T-cells instead of autoimmunity. Finally, it 
should be emphasized that class II - peptide associations usually involve exoge-
nous peptides that are endocytosed and processed in a different way than en-
dogenous peptides, of which the processing and presentation involves class I 
molecules. In order to function properly, it is important that the peptide meets the 
MHC molecule in the correct subcellular compartment. A number of newly identi-
fied gene products involved in this (176, 178, 179) is localized in proximity of the 
DO locus of the MHC. Equally important is the fact that T-ceii-APC interaction re-
quires additional adhesion molecules. In conclusion, the expression of class II 
molecules by B-cells is unlikely. If present, it does not necessarily result in correct 
presentation toT -cells, since the accessory system may be absent. 
In sum, the unique features of the immune system to discriminate self from 
non-self implies a system of tolerance. It seems, however, tolerance is not always 
established and that tolerance may also be broken. Selection processes of lym-
phocytes as well as aberrations in antigen may be important. Factors of the anti-
gen presenting cells play an additional role. The mechanisms involved in self-
and non-self recognition work surprisingly well, considering the wealth of antigens 
in and around us and the relative low frequency of autoimmune disease. Probably 
the 'cost' of maintaining this system is autoimmunity. If any of the suggested mech-
anisms applies for type 1 diabetes is at present unknown. Genetic susceptibility, 
characteristics of the immune system and specific features of the B-cell (such as 
sequestration in time and/or place of B-cell antigens, mimicry of a B-cell antigen 
with foreign molecules, post-translational processing and aberrations in this pro-
cess) are cooperating factors in the pathogenesis of type t diabetes. 
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1.5.6 Cellular Autoimmunity in Type 1 Diabetes Mellitus: 
T -lymphocytes. 
The current concept on the pathogenesis of type 1 diabetes is to regard this 
disease as aT-cell dependent and T-cell mediated disease. Evidence lor a major 
role of T-cells in B-cell destruction comes from several lines of research both in 
humans and in animal models ( (254, 255) lor review): 
The observations of insulitis were followed by analysis of the infiltrate which 
was found to contain T -cells and macrophages; 
Immunosuppressive drugs such as ciclosporine (= Cyclosporine A) and 
azathioprine. that are known to affect T-cells, delayed the onset of diabetes 
in NOD-mice and BB-rats and had a delaying effect on the last stages of B-
cell destruction in humans (256-258). In humans the benefits of such thera-
pies are still controversial; 
The disease can be transferred in laboratory animals with purified T-cells 
(259) 
Diabetes can be prevented in vitro, using antibodies specific forT-cells or T-
cell subsets 8(260, 261, 262) 
Diabetes can be prevented in susceptible animals by neonatal thymectomy 
(263). 
Islet cell specific T-cell clones can be isolated from NOD spleens (264-266) 
and islet cell specific T -cell clones can be isolated from inflamed pancreatic 
islets of Langerhans. 
C 04 + and B-cell reactive T -cells can be isolated from peripheral blood 
mononuclear cells (PBMC's) of newly diagnosed patients (267) and predia-
betic individuals (268). Moreover, T-cell responses can be obtained from T-
cells of newly diagnosed diabetic patients against specific antigens, such as 
GAD (269). 
T -cell clones reactive with an insulin secretory membrane protein of Mr 38kD 
can be isolated from newly diagnosed diabetic patients (270, 271 ). 
Together with the specific T-cell clones for 38kD, the transfer experiments 
(and T-cell deletion or inhibition experiments) are important both as proof lor the 
role ofT-cells as well as lor further analysis of the pathogenesis of the autoimmune 
process. Both CD4+ and cos+ T-cell subsets are required for the initiation of the 
disease in laboratory animals 8(259, 272, 273). Several experiments however, 
show that the process is primarily CD4+ T-cell dependent and not MHC (Class I) 
restricted. CD4+ cells therefcre orchestrate the autoimmune response (272, 274). 
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cos+ cells are cytotoxic T-cells. Such cos+ cytotoxic cells might be triggered to 
migrate to the islets after an initial effect ('help') by CD4+ cells . However, in one 
study (274) it was shown that in syngenic islet transplants in NOD-mice, the 
destruction was completely CD4+ dependent. In other models however, a clear 
differential effect was seen: CD4+ cells were found earlier and around the islets, 
while cos+ cells actually infiltrated the islets (275) (276). Recently, some clarifica-
tion of these controversial results on the role and necessity of CD4+ and cos+ 
cells was provided. Adoptive transfer studies in neonatal NOD-mice indicated that 
homing of cos+ cells to islets is CD4+ cell dependent (277). The models do how-
ever not allow tracking of adoptive transferred T -cells. Furthermore, none of the 
models document the B-cell specificity of the islet destruction i.e. that somatostatin 
and glucagon cells are not destroyed. Christianson and colleagues used an NOD-
mouse with SCID (Severe Combined Immune Deficiency) background (NOD-
scid/scid) to analyze the role of different T-cell subsets (27S). They used specific 
donor animals (NON-Thy-ta) to isolate T-cells (from the Thy-t.t+ thymic precur-
sor) from spleen or islets that could be traced with monoclonal antibodies since the 
NOD-scidlscid recipients are Thy 1.2+ in phenotype. However the scid mutation 
does not allow functional T and B cells. The NOD-scid/scid thymocytes are Thy 
1.2+ and all CD3 (TCR) and IL-2 receptor negative (279). CD4+ cells from young 
prediabetic animals were not able to induce diabetes when transferred without 
cos+ cells (depleted using an anti-COS antibody). CD4+ cells from diabetic(= 
older) animals could do this however, alter the CDS depletion. This suggests that 
older CD4+ cells are likely to have been activated and amplified. cos+ cells 
alone did not transfer the disease. This study confirms the requirements of cos+ 
cells in early insulitis lesions. This is also illustrated in a study by Roep and col-
leagues, showing that B-cell specific CD4+ cells from patients at onset are capable 
of lysing macrophages that are pulsed with B-cell antigen (280). In summary, the 
experiments do show that both cell types are needed for disease development. 
One of the key questions in T -cell autoimmunity of type 1 diabetes however 
is, which antigen is responsible for T -cell activation. The first studies that ad-
dressed this question analyzed responses to insulin or insulin fragments. This was 
initiated by the B-cell specificity of insulin and by the finding that autoantibodies to 
insulin are present in type 1 diabetes, thus suggesting that autoimmunity was most 
likely to be caused by breakdown of tolerance to insulin. No specific responses 
were found however, in newly diagnosed patients (2S1, 2S2). Subsequently, islet 
specific T-cells were generated from BB-rat spleens and pancreases after stimula-
tion with rat insulinoma protein fractions (2S3). The target antigen of these CD4+ T-
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cells has not been identified. Studies in humans have been hampered by the lack 
of sufficient amount of B-cell protein. The first identification of diabetes associated 
T-cell responses and their B-cell target came from Roep and colleagues, who 
identified aT-cell clone reactive with a 38kD insulin secretory membrane protein 
(270). The 38kD specific T -cells were established in more diabetic patients (271 ). 
Current efforts are directed to identify the 38kD target molecule. 
It was found that mycobacterial heat shock protein 65 (Hsp65) cross reacts 
with a B-cell target antigen in NOD-mice (284). Specific T-cells were found, as well 
as autoantibodies. A specific peptide of Hsp65 was identified. T -cell clones 
recognizing this peptide mediate insulitis and hyperglycemia. Moreover, adminis-
tration of the peptide itself to NOD-mice can down-regulate immunity to the 65kD 
heat shock protein and prevent the development of diabetes. Hsp65 (the human 
homologue is now referred to as Hsp60) is a ubiquitous protein and the mecha-
nism of this effect is not clear. Hsp is expressed in virtually all cells and a limited 
immune response to one cell type is unlikely. Other mechanisms must play a role, 
one of them the similarity of Hsp with HLA DQ. Hsp 60 has similar'1ties with several 
autoantigens in autoimmune diseases, but similarity scores rarely exceed 60, and 
similarity stretches are limited to 3 identical amino acids plus some flanking regions 
with similarities (285). No clear pathogenetic mechanism is known for a role of 
Hsp's in autoimmunity. The role of Hsp's as chaperones could result in a binding 
of potential antigens to these Hsp's, with aberrant processing and aberrant presen-
tation to the immune system. 
While antigens will be discussed in more detail in chapter 1.5.9, the third 
partner ol the trim eric complex, the TCR, needs to be discussed. TCR's are highly 
polymorphic. Random selection and pairing of gene segments of the variable parts 
of the molecule, allows the development of a large number of T -cell clones, each 
with a unique TCR. Despite their extreme variability, these TCR's can be grouped 
into families that each use a single VB gene segment. Such VB'S can be identified 
by monoclonal antibodies or oligonucleotides. In a model of multiple sclerosis, ex-
perimental allergic encephalomyelitis (EAE), T-cells that recognize the autoantigen 
of this disease (Myelin Basic Protein, MBP) are homogeneous in their VB usage. In 
this model, most MBP reactive T-eall clones have the TCR subtype VB8.2. (182, 
286). Specific monoclonal antibody therapy against this TCR prevents the disease 
(182). In diabetes of the NOD-mouse, both VB5 and VB8 TCR's have been sug-
gested to be implicated in the disease (287, 288). However, McDuffie found in 
non-manipulated NOD-mice that lacked the VB5 and VB8 TCR's, that neither of 
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these VB's is required for the onset of tlhe disease (289). Other groups found that 
VB usage of the first infiltrating T-cells was diverse (183, 290). Thus. no specific 
TCR is related to type 1 diabetes. If an antigen that triggers this disease is identi-
fied however, it is likely that specific TCR's will induce the strongest responses in 
the corresponding T-cells. 
In summary, type 1 diabetes is both T -cell mediated and T -cell dependent. 
However, other components of the immune system have to be taken into account 
as well. The key issue in dissecting the mechanism of autoimmunity is to obtain 
candidate autoantigens that serve as primary triggers of the autoimmune reaction. 
Which mechanism changes tolerance or ignorance can only be solved when 
models become available that pinpoint to such antigens. The identification of pro-
teins that are involved in the autoimmune T-cell reactions is therefore of paramount 
importance. 
1.5.7 Other Cells of the Immune System. 
Macrophages have been implicated in the development of type 1 diabetes. 
They are among the first immune cells found in the islets (291) and can function as 
an antigen presenting cell (APC) and a cytotoxic effector by releasing cytokines 
that attract other immune cells. In particular, dendritic cells of this macrophage/ 
monocyte lineage, present in the islets (292), can function as excellent antigen 
presenting cells. It is possible that such cells are indeed processing B-cell antigens 
in such a way that autoreactive T-cells become activated. However, which factors 
are responsible for this are unknown. Even if these cells are the first present in the 
islets and are activating T -cells, unknown factors must initiate this. Among the 
possible mechanisms are increased cytokine levels and virus induced direct B-cell 
lysis. A low-dose streptozotocin induced diabetes models showed similar charac-
teristics of so called 'single cell insulitis' (293). Moreover. the function of 
macrophages can be impaired with silica particles, which resulted in prevention of 
diabetes (294, 295). Experiments from the group of Yoon suggested that 
macrophages were essential in the initiating phases of insulitis in NOD-mice and 
BB-rats (296, 297). Other evidence for a role of macrophages came from studies 
where blocking of adhesion molecules, involved in macrophage migration, also re-
sulted in disease prevention (80). There is also evidence lor a role of 
macrophages in B-cell destruction. Macrophages can be found in the insulitis le-
sions, that engulfed B-cells as seen by the presence of insulin crystals (298, 299). 
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Recently, it was reported from the NOD-scidlscid model, that chronic silica treat-
ment in animals that received pathogenic T-cells, did not prevent diabetes (278). 
Chronic silica treatment did increase the number of macrophages in the islets and 
resulted even in granulomas without preventing insulitis. Thus, a primary role for 
macro phages is not yet established although their toxic eifects may add to the de-
struction of B-cells (see 1.5.8). 
Several studies in BB-rats suggest a role for Natural Killer (NK)-cells may in 
B-cell destruction. Treatment of BB-rats with antibodies specific for NK-cells, deple-
tes these cells from the animal, and significantly reduced the incidence of diabetes 
(252). However, there is no direct evidence for the involvement of NK-cells in the 
B-cell destruction in NOD-mice and in human lOOM patients (255, 300). The actual 
specificity of NK mediated B-cell lysis and the mechanism by which NK cells could 
cause B-cell destruction are unknown. It has been hypothesized that the metabolic 
state of the B-cell may influence its susceptibility to NK mediated injury, presumably 
by inhibiting membrane repair mechanisms and/or effector-target cell binding 
(301 ). NK cells also produce lymphokines, which could add to their B-cell cytotoxic 
action. 
1.5.8 Cytokines. 
Cytokines are produced by cells of the immune system. They are mediators 
of cell interactions and cytotoxicity. lnterleukin 1 (IL-1) is one of the best studied 
cytokines in type 1 diabetes (302). Nerup and co-workers developed a model of 
type 1 diabetes based upon the action of cytokines (303-305). 11-1 receptors have 
been reported to be present on B-cells (306). Macrophages can produce TNF-a, 
which can potentate the effects of IL-1. After initiation of cytotoxic effect and cyto-
kines, free radicals are formed. The B-cell has a reduced capacity for scavenging 
these compounds, thus further increasing their effects (307, 308). Moreover, IL-1 
has an effect on insulin secretion (309). The model describing a role of cytokines 
requires the concomitant presence of T -cells, antigen presenting cells 
(macrophages) and triggers for cytokine release. In particular dendritic cells, with 
high numbers of cytokine receptors would be very active in presenting antigen to 
(autoreactive) T-cells. Release of B-cell antigen(s), processed and presented by 
macrophages toT-cells initiates a self-perpetuating and self-limiting circuit of cyto-
kine production, of which IL-1 is cytotoxic forB-cells (310). 
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TN F-a and interferon-y can up regulate expression of class I and class II 
MHC molecules on islets. but, as discussed, the role of aberrant class II is un-
known. Induction of class I could help to increase expression of B-cell antigens 
thereby surpassing minimal level to induce aT-cell response. In a transgenic 
model, where interleron was placed under the control of the insulin promotor in 
mice that were already transgenic for MHC class II expression (which results in 
non-autoimmune diabetes, see 1.5.4.1 ). and thus expressed in B-cells, do develop 
an immune type of diabetes. 
In summary, cytokine production, one of the results ofT -cell activation does 
play a role in type 1 diabetes. If and which cytokines are involved in initial pro-
cesses is unclear, but a modulating role in the disease process is very likely. 
1.5.9 Humoral Autoimmunity and Type 1 Diabetes Mellitus. 
Among the best studied abnormalities in type 1 diabetes is the presence of 
autoantibodies, both at clinical onset of the disease as well as in the preceding 
period of B-cell destruction. The current model of autoimmune diseases suggests 
that tolerance to a self antigen is broken with the result ofT-helper cell activation 
and a subsequent attack of a specific cell or tissue. In some autoimmune diseases 
the T-helper induction results solely in activation of cells of the B lymphocyte lin-
eage followed by autoantibody production and such antibodies can be pathogenic 
as exemplified by pemphigus vulgaris. In this disease, a cell adhesion molecule, 
needed for a normal skin structure becomes a target of pathogenic autoantibodies 
(83). There is no cytotoxic T-cell infiltration. In other autoimmune diseases, such 
as type 1 diabetes, there is a predominant action ofT-cells. As described, the dis-
ease is characterized by infiltration of lymphocytes and macrophages into the islets 
of Langerhans, followed by specific destruction of the B-cell. Although autoanti-
bodies are produced in type 1 diabetes, they do not play an evident role in the 
pathophysiology of the disease. Transfer of B lymphocytes into diabetes prone 
animals does not result in the disease (278, 311 ). 
Additional evidence comes from pregnant diabetic mothers. Their babies do 
not develop diabetes although maternal lgG is present in their circulation. In addi-
tion, serum from newly diagnosed patients do not induce complement mediated 
lysis of B-cells. However, one group reported an inhibitory effect of diabetic sera on 
insulin secretion, due to antibodies to the GLUT-2 glucose transporter (312). 
Although not pathogenic in nature, such antibodies could further deteriorate the 
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glucose homeostasis in patients. Others described antibodies that stimulate insulin 
secretion (313). 
Analysis, identification and characterization of autoantibodies in type 1 dia-
betes has two major functions. First, autoantibodies were found to be predictive for 
the future clinical onset of type 1 diabetes. During the ongoing B-cell destruction of 
phase II in figure 1.1, autoantibodies can be detected. Second, antibodies may be 
closely related toT-cell responses against an antigen. In aT-cell mediated dis-
ease, it is obvious that the T-cell triggering antigen is of paramount importance, but 
T-cells can induce B-cell proliferation. Autoantibodies to such a trigger may reflect 
the antigen that initiated T -cell activation. Thus, identification, characterization and 
epitope mapping of candidate antigens of humoral responses may help to identify 
the primary T -cell antigens. 
Like autoreactive T -cells can be found in normal ind·lviduals, a similar situa-
tion exists for auto reactive B-cells. Low levels of autoantibodies are described to 
be present in normal individuals (314). Such 'natural autoantibodies' are in 
general non-organ specific and of the lgM isotype. They are believed to be coded 
for by germ line genes (315). Origin and function may be identical to natural anti-
bodies and may involve clearance of naturally occurring cell debris, participation in 
tissue regeneration, and regulation of immune-responses (316). However, it is 
clear, that natural autoantibodies are not associated with any pathological autoim-
mune processes, instead they may actually prevent the development of autoim-
mune disease (317). 
In contrast to the lgM natural autoantibodies, those found in disease are 
generally of the lgG isotype and form a spectrum of organ specificity (318). One 
end of the spectrum consists of non-organ-specific autoimmune diseases such as 
systemic lupus erythematosus, and are associated with a wide range of non-organ-
specific autoantibodies. The other end of the spectrum shows organ-specific auto-
immune diseases such as myasthenia gravis. multiple sclerosis and type 1 dia-
betes mellitus. These diseases are characterized by antibodies that are organ re-
stricted and highly specific for certain tissue antigens. There is definitely overlap in 
the spectrum. 
Autoantibodies in type 1 diabetes were first described by Bottazzo and col-
leagues, who found that sera from patients with multiple endocrine abnormalities, 
including type 1 diabetes, could stain islets of Langerhans in an indirect 
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fluorescence assay, using donor pancreatic tissue as a substrate (134). After this, 
other antigens were identified, which will also be discussed in the next paragraphs. 
1.5.9.1 Islet Cell Cytoplasmic Antibodies. 
Bottazzo and colleagues described in 1974 that in sera from patients with 
poly-endocrine diseases (including diabetes) antibodies to islets could be detected 
using indirect immunofluorescence (134). The technique involves immuno-histo-
chemistry on non-fixed human donor pancreas (Blood group 0). Additional work 
showed that sera from a majority of type 1 diabetic patients has these islet cell 
cy1oplasmic antibodies (319) (ICCA, usually referred to as ICA). Studies differ in 
percentage of positive patients at onset and range from 50-90% (320-322). The 
wide variation and bioassay character urged for standardization of the method. 
This was initiated by the Juvenile Diabetes Foundation International (JDF) by 
defining a standard serum. End-point titers are compared with the standard serum 
and values are expressed in JDF units, but even in these workshops the variation 
between participating labs is substantial (323, 324). 
Although ICA's or autoantibodies in general, can help to discriminate be-
tween different types of diabetes, this is usually not needed. One of the most 
important application of autoantibodies is to use them to detect ongoing B-cell 
destruction, thus to detect individuals on their way to clinical diabetes. This implies 
that normal populations must be screened for incidence of ICA's. Bruining and col-
leagues showed in a study of schoolcl1ildren that a single determination of ICA only 
predicts half of the diabetes cases over a period of 10 years (325). Similar findings 
were reported from other groups (326-328). Although the Bruining study showed a 
very low incidence of ICA's in the schoolchildren population (probably due to their 
excellent pancreas substrate), the prevalence of ICA in the normal schoolchildren 
population is mostly reported between 2 and 4%(321 ). A tenfold higher incidence 
was found in first degree relatives of patients with type 1 diabetes (132, 322, 327, 
329, 132). In these studies, the presence of ICA was associated with an increased 
risk of subsequent clinical lOOM. High titer ICA's (> 80 JDF units) confers a higher 
risk than low titer ICA (< 20 JDF) (324, 330). Furthermore, persistent ICA values 
are more predictive than intermittently positive (331). ICA's tend to disappear after 
onset of diabetes, reflecting the disappearance of the antigen from B-cells that 
initiated their existence. Patients with poly-endocrine disease (332) have persis-
tent ICA's long after onset of type 1 diabetes . 
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ICA's are not unique for type 1 diabetes (126) and as their name implies, 
ICA's recognize the whole islet of Langerhans and the target(s) for ICA's are not 
known. It is conceivable that several antigens which play a role in primary or 
secondary B-cell immune responses will be visualized by this technique. It has 
been proposed that the target of ICA is a mono sialoganglioside (333). This was 
based on studies where several solvents and proteolytic enzymes were used on 
pancreatic sections. Such experiments suggested that ICA's bind to a sialic acid 
containing glycolipid moiety (334). and a B-cell specific ganglioside GM2-1 has 
been proposed as the candidate. Others could not confirm this. 
While normal ICA staining shows fluorescence of all islet cells (a-, ~-, y-
and PP), a B-cell restricted staining pattern was described recently. Sera from 
some ICA positive individuals only stain B-cells (335-338) .This 'restricted' ICA 
staining was due to Glutamic Acid Decarboxylase( GAD) staining. Thus those sera 
strongly stained GAD in the indirect immunofluorescence technique. It was sug-
gested that this restricted ICA staining pattern is associated with a protective haplo-
type (DOB ·o602). Patients with this haplotype and restricted ICA pattern do not 
progress to overt diabetes, but do have strong GAD titers (339). Further studies are 
needed to analyze this interesting observation. 
In summary, ICA's are present in a majority of diabetic patients at onset of 
the disease and they are present before the clinical diagnosis thereby providing a 
method to predict ongoing B-cell destruction. They help to determine the risk for the 
development of type 1 diabetes in first degree relatives, but the predictive value of 
only ICA determinations in the population is not strong enough. High titers and 
repetitive positive titers are related to a short lag period before the clinical symp-
toms appear. ICA's generally show a decrease in titer alter clinical onset. The lack 
of knowledge on their target(s) does not allow further characterization and analysis 
of the role of these targets in the immune process. 
A spec·lal group of islet cell antibodies are the islet cell surface antibodies 
(I GSA's). They are characterized by their ability to bind to antigens on the surface 
of the B-cell (340, 341 ). They are difficult to assay. However, the finding that the 
glucose transporter GLUT 2, located on the plasmamembrane, may be a target for 
autoimmunity in type 1 diabetes, urges for additional studies (312). 
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1.5.9.2 Insulin Autoantibodies. 
Insulin antibodies were described in diabetes for the first time in 1963 (342). 
Insulin autoantibodies (IAA's) were described first in the insulin autoimmune syn-
drome (343). Insulin autoantibodies are defined as antibodies that bind insulin and 
occur in exogenous insulin naive subjects. The first association with diabetes in 
1963 was largely ignored until 1983, when Palmer and colleagues found IAA's in 
18% of newly diagnosed untreated patients (344). With standardization of the 
methods, IAA's can be found in up to 50% of newly diagnosed patients with type 1 
diabetes (345). They are more frequently in young children. In the prediabetic in-
dividuals, IAA are often coinciding with ICA and may increase the risk for diabetes 
development (346). More recent data indicate that IAA's do not contribute strongly 
to the risk of diabetes in first degree relatives (347). In the Swedish Childhood 
Diabetes study data are available on the predictive values of IAA and ICA (348). 
ICA's are present in 84% of newly diagnosed subjects and 3% of controls. IAA's 
were present in respectively 43% and 1%. In the newly diagnosed patients, 40% 
were double-positive. No controls were double-positive and none has developed 
diabetes in the 3-5 years follow-up. With a sensitivity of 88% and a specificity of 
96%, the predictive value for diabetes was only 3%. Moreover, in double positive 
patients the predictive value (at onset I) was 100% with 100% specificity and 40% 
sensitivity. Such data indicate that combination of ICA and IAA can add to the pre-
diction, but that predictive values of each assay alone are relatively low in a popu-
lation based setting. 
Like with ICA's, IAA assays are standardized by JDF workshops. Until now 
the epitope responsible for the diabetic antibody recognition has not been found. 
This hampers the analysis in a standardized way, since other anti-insulin anti-
bodies, not related to type 1 diabetes can be found. Only when using a radio 
immunoassay (RIA), the results are specific and sensitive enough (345). Some of 
the assays have incubation times of 7 days which indicates that the affinity of the 
antibodies for insulin is low, and might even reflect that they are actually not 
specific. A role of insulin in the pathogenic mechanisms of type 1 diabetes has not 
been elucidated. It is possible that these antibodies form as a result of insulin se-
cretion in a damaged environment. Insulin is stored in granules in crystal forms 
and is therefore relatively immunogenic when release takes place outside the nor-
mal secretory pathway. This is somewhat supported by the observation that also 
antibodies to proinsulin are present in type 1 diabetes (349). The reason for the 
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high incidence of autoantibodies in children is unknown. IAA's at onset of the dis-
ease are not predictive for the formation of antibodies to exogenous insulin. 
In summary, IAA's, when measured by RIA, are markers of autoimmunity in 
type 1 diabetes. Their analysis can help to improve the predictive power of anti-
body testing in type 1 diabetes. A primary role in the pathogenesis of insulin itself 
or of the IAA's is not likely. 
1.5.9.3 Autoantibodies to a 64kD Autoantigen. 
One of the major goals of this thesis was the identification of the 64kD anti-
gen in type 1 diabetes. At the beginning of the experimental work described in this 
thesis the following data were available on this antigen. 
Autoantibodies to a 64kD antigen were first described in 1982 by 
Brekkeskov and colleagues (350). Sera from type 1 diabetic patients were able to 
immunoprecipitate proteins from metabolically labeled (35S-methionine) human 
islets of Langerhans. Using SDS-PAGE analysis, followed by _fluorography, two 
proteins can be detected that were specifically immunoprecipitated by diabetic 
sera, a 38kD - and a 64kD protein (Figure 1.3). The immunoprecipitation assay is 
however technically demanding and time consuming, limiting ·its applicability for 
large series. Similar results were obtained when rat islets, which are less difficult 
to obtain, were used. The 64kD protein is not an abundant protein. It has been 
estimated that it represents at most 0.01% o"f total membrane bound proteins in the 
islet cells (351 ). This is in line with data obtained from two dimensional gel 
electrophoresis. Taking advantage of the fact that the molecule is partly membrane 
bound, Triton X-114 solubilization and temperature induced phase separation 
allowed to achieve a 1000 fold purification (352). The 64kD autoantibodies are of 
the lgG isotype (353). 
The 64kD protein was found to be present in several animal species (350, 
353, 354). In an analysis of rat tissues it was found to be islet specific (355), but the 
analysis did not include brain tissue, since neurons are difficult to label meta-
bolically by 35s-methionine. Islets were digested to single cells and using FAGS 
sorting of these cells, what yields separate B-cell and non-B-cell populations, it was 
possible to show B-cell specificity of the 64kD protein(355). The protein was found 
to be present in 2 forms, a membrane bound and a hydrophilic form (352). Which 
Introduction 
FIGURE 1.3: Sera from Diabetes Patients Precipitate a 641<0 
and a 38kD protein. 
Fluorogram of SDS-PAGE after immunoprecipitation of 35s-methionine labeled 
rat islet hydrophilic (S) and amphiphilic (P) protein fractions with control sera 
(lane 1 ,5) and sera from newly diagnosed diabetes patients (lanes 2,3,4,6,7,8). 
Some diabetic sera precipitate only the 64kD protein (visible in both S and P 
fractions in lanes 2,6), some precipitate both the 64kD and 38kD protein (lane 3) 
and some precipitate only the 38kD protein (lane 8), which is primarily pre-
sent in the P fraction. 
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subcellular membrane or organelle bound the 64kD protein was not clear (355, 
356). Glucose concentrations were found to stimulate 64kD expression (357). In 
addition, Coxsackie 84 infections in mice increased the B-cell expression of 64kD 
(358). 
The prevalence of 64kD antibodies at onset of the disease was tested in 3 
labs (351, 354, 359, 360). Cumulative data on 134 newly diagnosed patients 
showed 108 (81 %) positives. In this first series 2 of 111 controls (2%) were found 
positive. ICA's were available in 74 of these sera, of which 59 (80%) were positive. 
Sera from patients with other autoimmune diseases were tested (351) indicating 
the specificity for type 1 diabetes. 
Of even more importance is the possibility of detecting 64kD antibodies in 
prediabetic individuals. In the first study on prediabetic individuals, 64kD autoanti-
bodies were detected up to 8 years before clinical diagnosis in 11/14 individuals 
followed from 4-91 months prior to diagnosis. The 64kD antibodies were some-
times detected prior to ICA, but never later (361 ). In an other study, 23 of 28 pre-
diabetic individuals, also primarily from a family study, had 64kD autoantibodies 2 -
75 months before diagnosis. Ten of the 23 were IAA negative and 5 ICA negative 
(359). It should be noted that prior to onset, the response to the 64kD antigen (or a 
diabetic antigen in general), may already have been diminished and patients 
negative at onset might still have experienced 64kD directed humoral autoimmu-
nity (362). The few studies performed before 1990 were hampered by limited 
samples per individual and a relative short period before the clinical manifestation 
of the disease. A high incidence of 64kD autoantibodies has also been docu-
mented in the BB--rat (363) and the NOD-mouse (364). 
After an antigenic trigger fades out, the immune response will usually limit it-
self. Antibodies will gradually disappear and only low, often undetectable levels 
rema·ln. The decline in 64kD antibody titers has been reported to be present but 
was slow. Christie and colleagues detected 64kD autoantibodies 6-7 years after 
clinical onset in patients where B-cell depletion was complete as judged from 
undetectable basal and stimulated C-peptide levels (365). No explanation for this 
has been provided yet. Continuation of humoral autoimmun"ity to GAD in these 
cases is likely to be maintained by a source of GAD other than B-cells. 
In sum, the 64kD autoantibodies were the earliest detected signs of humoral 
autoimmunity in type 1 diabetes. Autoantibodies against 64kD can be used to de-
tect ongoing B-cell destruction. The protein is B-cell specific, but is a minor, mem-
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brane bound or soluble, constituent of B-cells The 64kD antigen was found to be 
present in several species, including animal models of type 1 diabetes. 
1.5.9.4 Autoantibodies to a 38kD Protein. 
BEekkeskov and colleagues described immunoprecipitation of a 38kD pro-
teins, from islets of DR3 positive donors, with sera from newly diagnosed diabetic 
patients (350). lmmunoprecipitation experiments provide stringent conditions for 
antigen recognition. The antigen is present in its native form. Antibodies that 
recognize conformational epitopes on a molecule can not be detected in Western 
blots, but can by immunoprecipitation. Using these conditions in one and two di-
mensional gel electrophoresis, virtually no other proteins were precipitated by dia-
betic sera than the 64kD and the 38kD as shown in figure 1.3. Both proteins could 
not be detected in Western blots of islet cell proteins stained with diabetic sera. 
The 38kD protein was recognized in about 20% of newly diagnosed diabetic sera 
and seemed to be completely distinct from the 64kD autoantibody reactivity. No 
38kD antibodies were found in controls. A few patient sera only recognized the 
38kD, while several others recognized both the 38kD and 64kD molecules (351 ). 
Other groups also reported activ.ity against a 38k0 target molecule. Yoon 
and colleagues found 38kD autoantibodies after an infection of human islets with 
Cy1omegalo virus (200). In BB-rats, autoantibodies to a 38kD islet cell protein pre-
cede the onset of diabetes. These antibodies were detectable in a Western blot 
method, but only after the blots were renaturated (366). The antibodies were pre-
sent before clinical onset and predictive for diabetes development. Finally, Roep 
and colleagues found (human) T -cell reactivity against a 38kD islet protein in newly 
diagnosed patients (270, 271 ). It is not known if the 38kD proteins mentioned in 
these studies are identical and further analysis is required. 
1.5.9.5 Other Autoantibodies in Type 1 Diabetes Mellitus. 
A number of other targets for autoantibodies have been identified, primarily 
in newly diagnosed patients. The numbers of patients studied is still small in most 
cases. 
By screening a eDNA library of islets with diabetic sera, Castano and col-
leagues isolated several clones of potential antigens. One clone was found to 
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represent carboxypeptidase H, an insulin processing enzyme (367). Another 
molecule, presumably B-cell specific was identified by similar techniques (368). 
This protein is 69kD in size and presumably B-cell specific. No large studies on T-
cell proliferative capacity or autoantibodies to this p69 have been performed yet. A 
portion of the 69kD peptide, shows resemblance to a fragment of bovine albumin. 
Autoantibodies to bovine serum albumin (BSA) have been implicated in the 
etiology of type 1 diabetes. Epidemiological evidence was reported, that early in-
troduction of cow's milk as well as early introduction of solid food was related to a 
higher incidence of type 1 diabetes ((369, 370) and references therein). Although 
the data do support some linkage, no proof can be provided from such studies. A 
(PCFIA) particle concentration fluorescence immunoassay showed that children 
with type 1 diabetes have autoantibodies against BSA. The diabetic children dis-
tinguished themselves from other children with BSA antibodies by the fact that their 
antibodies recognized a particular 17 amino acid epitope of the BSA, called 
ABBOS. Some evidence was provided that a Mw 69,000 islet cell protein showed 
mimicry with the ABBOS fragment (371). NoT-cell involvement has been shown 
yet. The assay has not yet been reproduced by other labs. Thus, a role for ABBOS 
and BSA in the pathogenesis of type 1 diat•etes remains to be established (211) 
One report describes that the 64kD autoantigen is the heat shock protein 
HSP65. Using recombinant mycobacterial Hsp65 and the human counterpart 
Hsp60, it was shown that the 64kD is a different protein with a lower mobility (372). 
In NOD-mice, autoantibodies to a 58kD protein were detected. This protein 
was identified as peripherin, a structural, intermediate filament, protein present in 
mouse and rat B-cells, neurons and human neuroblastoma cells. The NOD-mice 
were the only species so far to develop au·loantibodies to peripherin. Peripherin is 
cross-reactive with NOD class II molecules, suggesting that it may contribute to 
defective self-tolerance of islet B-cells in the NOD-mouse (373). 
Diabetic patients often develop autoantibodies to other endocrine organs, 
such as adrenal and thyroid. Moreover, antibodies to parietal cells as well as non-
organ specific antibodies can be found. Although in some cases this is related to 
polyendocrine diseases, several patients have these autoantibodies w·lthout further 
clinical problems (374). It seems that the susceptibility lor an autoimmune disease 
is linked to diminished tolerance for other antigens. A similar observation can be 
made in NOD-mice, where besides the islet infiltration several additional auto-
immune effects can be observed (375). 
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Type 1 Diabetes Mellitus has an autoimmune basis. Although this introduc-
tion has discussed different mechanisms and hypotheses, no evidence is at pre-
sent available to explain the disease at the molecular level. None of the antigens 
discovered is found to be causal in the early events where the immune system 
loses tolerance of recognizes a B-cell component as a non-self molecule. In the 
next chapters, the experimental work of this thesis, aimed at two antigens is pre-
sented and discussed. 
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Chapter 2 
THE 64kD AUTOANTIGEN IN TYPE 1 DIABETES 
IS THE GABA SYNTHESIZING ENZYME 
GLUTAMIC ACID DECARBOXYLASE (GAD): 
Identification, Characterization and Implications of GAD in type 1 
Diabetes Mellitus and Stili-man Syndrome. 
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2.1 
Identification of the 64K autoantigen in insulin dependent diabetes as 
the GABA synthesizing enzyme glutamic acid decarboxylase. 
Nature 199(); 347: 151-156. 
(with permission) 
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GABA-synthesi:zing enzyme 
glutamic acid decarboxylase 
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The pancreatic islet ,B-cell autoantigen of relative 
molecular mass 64,000 (64K), which is a major 
target of autoantibodies associated with the 
development of insulin-dependent diabetes mel-
litus (IDDM) has been identified as glutamic acid 
decarboxylase, the biosynthesizing enzyme of the 
inhibitory neurotransmitter GABA ( y-aminobutyric 
acid). Pancreatic /3 cells and a subpopulation of 
central nervous system neurons express high 
levels of this enzyme. Autoantibodies agains~: 
glutamic acid decarboxylase with a higher titre and 
increased epitope recognition compared with those 
usually associated with lOOM are found in stiff -man 
syndrome, a rare neurological disorder character-
ized by a high coincidence with IDDM. 
THE cell-specific destruction of pancreatic {3 cells, which pre-
cedes the clinical onset of insulin-dependent diabetes mellitus 
is believed to be mediated by autoimmune mechanisms 1• The 
autoimmune phenomena associated with the disease include 
massive lymphocytic infiltration of islets2 and circulating 
autoantibodies to j3 cells3 . A 64K /3-cell autoantigen is a target 
of autoantibodies in this disease4 . The 64K autoantibodies are 
present in ;;.SO% of newly diagnosed IDDM patients and have 
been detected up to several years before clinical onset of IDDM 
concomitant with a gradual loss of j3 cells5- 7 . The 64K antigen 
was found to be j3 cell-specific in an analysis of several tissues 
which did not include the brain'. The 64K autoantigen in f3 
cells is detected as a hydrophilic soluble 65K form and a 64K 
hydrophobic form which can be both membrane bound and 
soluble (H. Schierbeck, L. Aagaard and S.B., manuscriptsubmil:-
ted). The 64K forms can be resolved into two cpmponents, a 
and j3 (ref. 9). The function of the 64K protein in the j3 cell 
has remained elusive. 
Most patients with a rare but severe neurological disease 
called stiff-man syndrome (SMS) have autoantibodies to GABA-
secreting neurons. Glutamic acid decarboxylase (GAD), the 
enzyme that synthesizes GABA from glutamic acid, is the pre-
dominant autoantigen 10•1 1• Surprisingly, almost all patients posi-
tive for the autoantibody to GABA-secreting neurons are also 
positive for islet cell cytoplasmic antibodies, as demonstrated 
by immunofluorescence of pancreatic sections, and a significant 
fraction have IDOM11 • GAD is selectively expressed in GABA-
secreting neurons in the central nervous system ( CNS) 12 . Outside 
neurons, GAD is found at high levels in pancreatic j3 cells 13 - 15• 
There are at least two isomers of GAD in brain, which are 
resolved by differences in their mobility on SDS-polyacrylamide 
gel electrophoresis; their molecular weights have been described 
as 59-66K (ref. 16). 
Because IDDM is the autoimmune disease that is most often 
associated with SMS and because some of the characteristics 
of GAD and the 64K autoantigen are similar, we hypothesized 
that they were the same protein. Here we demonstrate that the 
64K autoantigen in IDDM is the same as GAO in pancreatic 
f3 cells. 
lmmunoprecipitation of 64K autoantigen 
We first assessed whether serum S3, a sheep antiserum raised 
against purified rat brain GAD 17 , and sera from SMS patients 
positive for GAD antibodies 10•11 , could immunoprecipitate the 
64K autoantigen from rat islets. We used e's]methionine-
labelled rat islet cell fractions partially enriched for the 64K 
antigen (S-100 DP. Fig. 1). The sera positive for GAD antibody 
(anti-GAD sera) imrnunoprecipitated a doublet of [35 S]methion-
ine-labelled proteins, which on SDS-PAGE have the same 
mobility as the 64K a/ j3 autoantigen immunoprecipitated by 
IDDM sera7 (Fig. la, lanes 4-9). 
To assess whether the proteins recognized by the anti-64K-sera 
and by anti-GAD sera were the same, supernatants resulting 
from immunoprecipitation with anti-GAD sera were sub-
sequently reprecipitated with anti-64K IDDM sera. Similarly, 
supernatants resulting from immunoprecipitation with anti-64K 
IDDM sera were reprecipitated with anti-GAD sera. Results 
from those experiments showed that anti-GAD sera, and 
anti-64K sera each quantitatively removed the protein 
recognized by the other group of sera, demonstrating complete 
cross-reactivity between ami-GAD sera and anti-64K sera, 
and strongly suggesting that the 64K protein is the same as 
GAD in rat islets (Fig. la, lanes 10-20). 
Trypsin digestion of [~'S]methionine-labelled islet cell 
extracts followed by immunoprecipitation showed that a 55K 
immunoreactive fragment was formed from both the 64K protein 
and GAD, further verifying their common identity (Fig. lb). 
Furthermore, two-dimensional analyses of GAD immune-
precipitated from ('5S]methionine-labelled islets with the S3 
antiserum revealed an identical pattern to that described for the 
64K protein (H. Schierbeck, L. Aagaard and S.B., manuscript 
submitted; and ref. 9) (results not shown). This pattern was also 
the same as the two-dimensional pattern of pancreatic and brain 
GAD shown by western blotting of two-dimensional gels with 
the S3 serum (see Fig. 5a). 
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FIG. 1 Anti-GAD sera and anti-64K IDDM sera recogn-
ize the same protein in rat islets. a. Fluorogram of an 
SDS-PAGE showing immunoprecipitation of Triton X-
114 detergent phase cytosolic fraction from 
P5S]methionine-labelled rat islets (S-100 DP) w1th 
anti-GAO sera. ant'I-64K IDDM sera and control sera. 
lanes 2-9, samples from a single immunopreciPita-
tion with sera indicated at the top of each lane: lanes 
10-20. samples from a second ·,mmunoprec'lpltation 
of supernatants remaining after a first immunopreCIPI-
tation. Sera used for the first and second 
immunoprecip1tations are indicated at the top of each 
lane. Sera used for the immunoprec1pitation were: C. 
sera from healthy individuals: SMS, sera of SMS 
patients previously shown to be GAD antibody posi-
tivell: I. sera from newly diagnosed anti-64K-positive 
IDDM patients' (numbers Indicate patient code); 53. 
a sheep antiserum raised to punfied rat brain GAD, 7 
Relative molecular mass marl<ers are shown in lane 
1 {M,x1Q-3 ). The anti-GAO sera lmmunoprecipitate 
GAD from supernatants after immunoprec1p1tation 
with control serum IIanes 10 and 19). but not from 
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supernatants after immunopreclpitation with anti-64K sera (lanes 11 and 
18). The anti-64K sera immunoprecipitate the 64K protein from super-
natants after immunoprecipitatiOn with control serum {lane 16). but not from 
supernatants after immunoprecipitation with anti-GAD sera {lanes 13-15). 
The triple band represents the 65K form and 64K a and {3 forms of the 
64K autoant1gen (H. Sch1erbeck. L. Aagaard and 5.8 .. manuscript submitted). 
b, Fluorogram showing immunoprecipitation of the 64K protein and GAD 
from S-100 DP of [35S]methionine-labelled rat islets before (lanes 2-4) and 
after (lanes 4-10) tl)'psin digestion. Serum codes are as in legend for a. 
NSS is a preimmune sheep serum. Trypsin digestion results 1n a 55K 
immunoreactive fragment that is recognized by both anti-64K sera and the 
anti-GAD serum S3. 
METHODS. Neonatal rat ·Islets were isolated and labelled with (35S)methio-
nine as described9• Islets were swollen on ice for 10 min in 10 mM HEPES, 
pH 7.4, 1 mM MgCI2 and 1 mM EGTA {HVIE buffer) and then homogenized 
by 20 strokes in a glass homogenr.oer. The homogenate was centr'1fuged at 
2.000g to remove cell debns and the postnuclear supernatant centrifuged 
at 100,000g for 1 h to obtain a cytosol {S-100) and a particulate (P-100) 
lmmunoprecipitation of GAD 
We next analysed whether anti-64K sera could immunoprecipi-
tate GAD from brain and islets. Membrane and soluble fractions 
were prepared from brain and islets and immunoprecipitated 
with serum S3, anti-GAD SMS sera, anti-64K IDDM sera, and 
control sera. Presence of GAD in the immunoprecipitates was 
analysed by western blotting. The blots were probed with serum 
S3 or serum 7673, a rabbit serum raised to a synthetic 17-amino-
acid peptide corresponding to the carboxyl terminus of the larger 
rat brain GAD isofonn (ref. 18; and D. Gottlieb, personal 
communication) (M.S. and A.R., unpublished data). Both sera 
gave identical results. Figure 2 shows a western blot containing 
some of such immunoprecipitates probed with serum S3. As 
expected, an immunoreactive band with the electrophoretic 
mobility of GAD was detected in immunoprecipitates obtained 
with anti-GAD sera (Fig. 2, lanes 11, 12, 16). A band of identical 
BRAIN ISLETS 
GAD-
IgG- lk1!f~k.i~)Thl\lil+.i\liliikilliikilliikiliill!ll"* i, ,;~&110"' 
fraction. Amphiphilic proteins were punfied from the S-100 fraction by a 
modification of the method descnbed by Bordier29 for Triton X-114 (TX-114) 
phase separation. S-100 fract'1on was made 1% in TX-114, warmed at 37 oc 
for 2 min to induce TX-114 phase transition. and centrifuged at 15.000g 
for 2 min to separate the aqueous and detergent phases. The detergent 
phase was diluted in 20rrM Tris buffer, pH 7.4, 150mM NaCI (TBS) and 
immunoprecip1tated as describedg using DP from 300 islets for each 
immunoprecipitate. lmmunoprecipitates were anal:)tsed by SOS-PAGE (10%) 
and processed for fluorography24 For the trypsin digestion. S-100 DP from 
4.000 islets was diluted to 200 IJ.i in TBS. Trypsin (0.74 units) was added 
and the sample was incubated for 1 h at 25 'C. The reaction was stopped 
by addition of 10 1-J.I 10 mM HEPES. 5 mM EDTA, 5 mM pyrophosphate. 5 mM 
benzamidine-HCI. pH 7.5 Digested and undigested material was 
immunoprecipitated and the immunoprecipitates analysed by SDS-PAGE 
(15%). Anti-64K sera were from three newly diagnosed IDDM patients7 , 
comrol sera were from two healthy individuals. SMS sera were from 
three anti-GAO-positive indivldualsll The S3 antiserum was a gift from 
I. J. Kopm. 
mobility was visualized in all immunoprecipitates obtained with 
anti-64K sera (7/7) (Fig. 2, lanes l-7, 14), but not in those 
obtained with control sera (Fig. 2, lanes 8-10, 13, 15, 17). These 
results demonstrate that the protein immunoprecipitated 
from brain and islets by anti-64K sera is indistinguishable 
from GAD. 
S4K protein has GAD enzyme activity 
If the 64K autoantigen is GAD, then the 64K protein should 
have the enzymatic properties of GAD. We therefore investi-
gated whether GAD enzyme activity could be removed from 
islet and brain cell lysates by immunoprecipitation with an 
anti-64K IDDM serum, and whether GAD activity could then 
be measured in the immunoprecipitates. Brain and islet cell 
fractions were immunoprecipitated with increasing amounts of 
an anti-64K JDDM serum, and the GAD enzyme activity 
FIG. 2 Anti-64K antibodies immunoprecip1tate GAD from brain and islets. 
Western blot of immunoprecipitates of rat brain (5-100 DP) and islet cell 
(P-100 DP) fractions obtained with anti-64K sera and anti-GAD sera. The 
blot was probed with the 53 serum. Sera used for the immunoprecipitation 
are indicated at the top of each lane by the same codes as in Fig. 1. The 
64K prote'1n immunoprecipitated from both brain and islets is immunostalned 
by anti-GAD antibodies. In the gel shown GAD migrated as a single band. 
METHODS. Neonatal rat brain was homogenized at 4 "C in seven volumes 
of HME buffer followed by centr'1fugat'1on at 100,000g for 1 h to obtain 
S-100 and P-100 fractions. S-100 DP was prepared and aliquots (1/13 brain 
per lane) immunoprec1pitated as described in the legend to Fig. 1. P-100 
was prepared from neonatal rat islets and extracted ·In 200 ml TBS with 
1% Triton X-114 for 2 hat 4 oc (ref. 9). P-100 DP was prepared as described 
for S-100 OP and aliquots (1,500 islets per lane) immunoprecipitated. 
lmmunoprec1pitates were subjected to SDS-PAGE followed by electroblotting 
to a PVDF membrane {lmmobilonl30, probing with the 53 serum and visualizing 
by alkaline phosphatase-conjugated rabbit anti-sheep lgG. 
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measured after immunoprecipitation in both supernatants and 
pellets (Fig. 3a, b). Immunoprecipitation with increasing 
amounts of anti-64K serum but not with control serum removed 
the GAD activity from both brain and islet cell lysates in a 
dose-dependent manner, and, in parallel, increasing amounts 
of GAD activity appeared in the immunoprecipitates. The GAD 
activity recovered in the immunoprecipitates did not account 
for all the activity lost from the supernatants, probably owing 
to an inhibiting effect of antibodies on enzyme activity. For islet 
cell extracts from [35 S]methionine-labeiled islets, SDS-PAGE 
revealed that the only islet cell protein specifically detected in 
the immunoprecipitates obtained with the anti-64K IDDM 
serum was the 64K autoantigen (see Fig. 1). Thus the GAD 
enzyme activity measured in immunoprecipitates obtained with 
the anti-64K IDDM serum is a propeny of the 64K autoantigen. 
Brain and ,B-cell GAD 
Analysis of GAD enzyme activity in neonatal and adult rat 
tissues showed that the expression of GAD is high in brain and 
islet cells and is either absent or low in a variety of other tissues 
(results not shown), confirming previous reports19• In islets, 
double immunostaining with a monoclonal antibody to GAD 
and either glucagon or somatostatin confirmed the localization 
of GAD to the t!-ce!l core, and the absence of GAD in the other 
endocrine cells, which are localized to the islet periphery (Fig. 
4).GAD in brain and islets was found to have identical mobility 
on SDS-PAGE (Fig. 2) and by two-dimensional gel elec-
trophoresis using isoelectric focusing/SDS-PAGE (Fig. 5a). We 
compared the immunoreactive trypsin fragments generated from 
brain and islet GAD. Trypsin generated a 55K immunoreactive 
fragment from both islet and brain GAD (Fig. Sb; see also Fig. 
1). In both tissues GAD was found in a soluble hydrophobic 
form as well as a membrane-bound hydrophobic form (Fig. 5b) 
as described for the 64K islet cell autoantigen (H. Schierbeck, 
L Aagaard and S.B., manuscript submitted). The 65K com-
ponent of the 64K protein in islets (H. Schierbeck, L Aagaard 
and S.B., manuscript submitted) was detected in brain and islet 
ceils in some (Figs I a, 5A, b, c, 5B and 6A) but not in other 
analyses (Figs lb, 2). Furthermore, the 64K aft! doublet was 
detected in some analyses (Figs la, 6A). The immunochemical 
and biochemical properties of the brain and islet GAD therefore 
indicate that they are very similar. 
Antibodies to GAD in SMS and IDDM sera 
The GAD reactivity in SMS sera has been demonstrated by 
western blotting and by immunocytochemical staining of fixed 
tissue sections 10 · 11 • that is, assays that involve complete or partial 
denaturation of the antigen. The standard assay for 64K anti-
bodies in IDDM sera has been immunoprecipitation from islet 
cell lysates prepared in nondenaturing conditions4 - 9 . We selec-
ted sera from the individuals who had the highest immunoreac-
tivity to the 64K autoantigen in immunoprecipitation experi-
ments in a survey of 112 IDDM patients and prediabetic 
individuals without SMS7 and tested them for immunoreactivity 
to the brain GAD protein on western blots (five sera) and for 
immunostaining of GABA-secreting neurons (7 sera). The 
results were compared with those for SMS sera. In contrast to 
the SMS sera, none of the IDDM sera detected the denatured 
GAD protein on western blots (Fig. 6A), and only one was able 
to weakly immunostain GABA-secreting neurons (Fig. 6B, c). 
Titration of IDDM and SMS' sera in immunoprecipitation 
experiments funhennore showed that the titre of anti-GAD 
antibodies in SMS sera was 10-200 times that in IDDM sera 
(results not shown). In another survey of 74 IDDM patients, 
only three were positive for antibodies to GABA-secreting 
neurons (Fig. 6B, b) including the only two which were positive 
by western blotting (ref. 11, and results not shown). By contrast, 
all SMS sera that were positive by immunocytochemistry and/or 
western blotting were also positive by immunoprecipitation 
(results not shown). So anti-GAD antibodies in SMS patients 
are generally present at higher titres and recognize more distinct 
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FIG. 3 Precipitation of GAD activity from brain and islets with anti-64K 
autoantibodies. a. Aliquots (700 islets per sample) of S-100 DPfrom neonatal 
rat islets were immunoprecipitated with increasing amounts of the anti-64K 
lOOM serum 1-1 {closed symbols) or the control serum C-1 (open symbols). 
GAD activity was measured in supernatants after immunoprecipitation 
(squares) and in peljets {circles). The activity in the supernatants was 
calculated as percentage of the activity in non-immunoprecipitated samples 
incubated with the same amount of control serum. The activity in the 
immunoprecipitates was calculated as percentage of the activity in samples 
incubated without serum. Values are mean of three experiments± s.d. b, 
As a. except that aliquots of S-100 DP from neonatal rat brain were used 
instead of is!et cell material. 
METHODS. S-100 DP was prepared from islets and brain as described in 
the legends to Figs 1 and 2, except that buffers were supplemented with 
1 mM aminoethylisott"liouronium bromide hydrobromide (AETl and 0.2 mM 
pyridoxal 5'-phosphate (PLP). S-100 DP was diluted 10 times in 50 mM 
potassium phosphate pH 6.8.1 mM AET. 0.2 mM PLP (buffer A) and incubated 
with the indicated amounts of sera in a total volume of 150 ml for 7 h at 
4 "C. lmmunocomplexes were absorbed to 150 f.!-l protein A-Sepharose 
beads (PAS Pharmacial and isolated by centrifugation. The supernatants 
were collected and centrifuged three times to remove traces of PAS. PAS 
pellets were washed five times by centrifugation in buffer A. Enzyme activity 
in the PAS pellets and the supernatants was measured using a modified 
version of the assay first described by Albers and O'Brady:u. Both PAS 
pellets and supernatants were transferred to 1.5-ml screw cap tubes; 20 f.!-l 
5 mM L-glutamate in buffer A and 0.4 ~.~-Ci [1-"'4 C]L-glutamate (59 mCi m-
mol-l, Amersham) were added. The tubes were closed immediately with a 
cap containing Whatman filter paper socked in 50 f.'-11 M hyamine hydroxide 
in methanol and incubated for 2 hat 37 "C. The filter paper was then removed 
and the absorbed 14C02 measured in a scintillation counter. The specific 
activity of GAD in homogenates of neonatal brain and islet cell material was 
similar (-40-70mU per g protein). 
epitopes than anti-GAD antibodies in IDDM patients. However, 
in rare cases, anti-GAD antibodies in IDDM patients can 
recognize denatured GAD. Whereas the 7673 and S3 antisera 
recognize both the 65K form and the 64K a: and {3 isofonns on 
western blots (Fig. 6A, lanes 2, 4, 5), human GAD autoantibodies 
as well as the monoclonal antibody GAD6 preferentially recogn-
ize the smaller 64K a and {3 isoforms (Fig. 2, lanes 7-11). The 
GAD6 antibody is specific for the smaller GAD isoform in 
brain16• 
Discussion 
The 64K autoantigen is the enzyme glutamic acid decarboxylase, 
We have demonstrated that the 64K autoantigen in lOOM is 
the enzyme GAD in pancreatic {3 cells. GAD. its product GABA, 
and the GABA-metabolizing enzyme GABA transaminase are 
present at high levels in pancreatic {3 cells as well as in GABA-
secreting neurons 19. GABA may act as an 'endocrine transmitter' 
in islets~ 0 - 23 and this may explain why GAD is expressed in {3 
cells. The {3 cell-specific expression of GAD in islets is consistent 
with its being an autoantigen associated with the selective 
destruction of pancreatic {3 cells in IDDM. GAD is a major 
auto antigen in SMS, a disease in which GABA-secreting neurons 
are thought to be affected 10 ' 11 . Thus pancreatic {3 cells and 
GABA-secreting neurons share a protein that is unusually sus-
ceptible to becoming an autoantigen, an observation that will 
surely motivate studies not only into the pathogenesis of IDDM 
and SMS, but also into the mechanisms of generation of self-
tOlerance by the immune system, and its failures. 
Differences in humoral autoimmunity to GAD in SMS and IDDM. 
The humoral autoimmunity towards GAD in the two diseases 
in which GAD-expressing cells are either destroyed (IDDM) 
FIG. 5 GAD •n bram and islets have 
stmilar properties. A. Two-
dimenSIOnal gel electrophoresis of 
neonatal rat and 1slet cell GAD/64K 
antigen. a. b. Western blots of two-
dimensional gels of a neonatal islet 
part1culate fraction (a) and abram 
fractiOn (b) probed wrth the GAD anti-
serum 53. c. d. Fluorograms of two-
dimensional gels of lmmunoprecrpl-
tates of a [35S]methionrne-labelled 
rat islets extract IS-100 DP) with the 
anti-64K IDDM serum 1-1 (c) and a 
wrth a control serum C-1 {d). The 
soluble fractions of bram and islets 
(band c) contain both the 65K pi 7,1 
component and the 64K 6,7 " com-
ponent. whereas the partiCulate frac-
tion contains only the 64K pi 6.7 a 
component (H. Sdlieroeck. L. Aagaard 
and s.B .. manuscript submrtted). Both 
the 65K and the 64K component diS-
A 
'" 
" '{ '( SDS-PAGE j 
play charge heterogeneity previously described for tile 64K autoantigen in 
isletss. The panels both demonstrate the Identical behaviour of the 64K 
protem (c) and GAD (a and b), further prov1ng they are the same protein. 
and show the srmilarities of bram and islet GAD with regard to both charge 
and size. B. western blot of soluble and particulate GAO from neonatal rat 
brarn and islets before and after tryps1n digestion. Lanes 1-8. probing with 
S3 serum: lanes 9-16. prob1ng with normal (preimmune) sheet serum. Trypsin 
cl"lgestron of both brain and islet GAD results in a 55K immunoreactive GAD 
fragment 
METHODS. A particulate fraction was prepared from neonatal rat ISlet 
homogenates by centr"1fugat"1on at 36.000g (aJ. A low-speed synaptosomal 
supernatant was prepared from brain as oescnbed~~ (b). S-100 DP was 
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FIG. 4 Immunofluorescence staining of pancreatic islets w1th GAD. glucagon 
a:"~d somatostatin antibodies. Immunofluorescence micrograph showmg pan-
creatic islets. The islet in a and c was double-labelled for GAD and glucagon. 
T1e islet in band d was double-labelled for GAD and somatostatin. Arrows 
point to corresponding cells in the two pairs of panels. The f3 cells in the 
central core of the islet are brightly stained with the GAO antibody, whereas 
the cells positive for glucagon and somatostatin do not stain with the same 
antibody. 
METHODS. Formaldehyde-fixed frozen sections of rat pancreas were first 
rhodamme-labelled for GAD using a mouse monoclonal GAD6, raised against 
purrf1ed rat brain GAri6 and then fluorescein-labelled for glucagon or 
somatostatin using rabbit polyclonal antibodies to either hormone and using 
methods described32. GAD6 was a grft from D. I. Gottlieb. University of 
Washington. Scale bar, 25 mm. 
or thought to be affected (SMS), suggests a direct relationship 
between GAD autoantibodies and the diseases. Not all SMS 
patients with GAD antibodies develop IDDM, and only a small 
proponion of IDDM patients develop SMS, in spite of their 
having GAD autoantibodies for several years. This suggests that 
there are other components to both diseases. The development 
of SMS seems to involve a stronger antibody response to GAD 
and includes epitope recognition which is usually absent in 
IDDM, perhaps as a result of different characteristics of pan-
creatic f3 cells and GABA-secreting neurons. For example, the 
microenvironment of the CNS is protected by the blood-brain 
barrier and the antigenic requirements to initiate an autoimmune 
response across this barrier may be distinct. Pancreatic f3 cells 
express major histocompatibility complex (MHC) class I 
molecules24 which are thought to present self-peptides to the 
immune system, whereas CNS neurons normally do not25 . 
Subcellular localization of GAD in brain and islets and its role as 
an autoantigen. Synaptic-like vesicles have recently been iden-
tified in endocrine cells26 and may be the storage sites of GABA 
in {3 cells, similar to synaptic vesicles in brain. Immunofluores-
cence studies have shown colocalization of GAD and membrane 
markers of these synaptic-like microvesicles (A.R., M.S. and 
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prepared from neonatal rat islets and immunoprecipitated as described in 
the legend to Fig. 1 (c and d). Two-dimensional gel electrophoresis was 
performed as described by O'Farrell34 and modified by Ames and Nikaido35. 
lmmunoblotting was accortflng to Towbin et a/.00 . GAD in a and b was 
visualized by probmg with the anti-GAD serum S3. followed by rabbit anti· 
s"eep lgG serum and ~~ 51.1abelled protein A and autoradiography. For B. 
S-100 DP and P·100 DP from islets and brain were prepared as described 
in legends to Figs 1 and 2 and digested with trypsin as described in legend 
to Fig. 1. Brain and islet cell fractions were subjected tc SDS-PAGE using 
15% polyacrylamide gel. Western blotting and staining procedures were as 
described in legend to Fig. 2. 
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P.D.C., unpublished results). We found that GAD in both brain 
and islets behave similarly with regard to hydrophobicity and 
compartmentalization, that is, both were detected in a soluble 
hydrophobic and a membrane-bound hydrophobic form. 
Although it cannot be excluded that GAD is expressed at the 
surface of f3 cells, it is more likely that the protein remains 
confined to the cytoplasmic space. Thus autoantibodies to GAD 
are unlikely to see the intact antigen on the surface of normal 
{3 cells. But peptides derived from the GAD molecule may be 
expressed at the cell sutfacein the cleft of MHC class I antigens, 
and so be recognized by pathogenic T cells (ref. 27, and refs 
therein). 
The identification of the 64K antigen as the enzyme GAD is 
of relevance in elucidating the role of this antigen in the develop-
ment of IDDM. If the GAD autoamigen is shown to be critical 
for the initiation of ti-cell destruction, then an approach to 
therapy might be to develop ways of preventing or reversing 
the autoimmune response towards GAD in {3 cells of 
susceptible individuals. This would be similar to the successflll 
prevention of autoimmune disease in experimental allergic 
encephalomyelitis28 . :J 
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Since the first description of stiff-man syndrome (SMS) in 1956, researchers 
have noted an association between this disease and type 1 or insulin-depen-
dent diabetes mellitus (IDDM) (!). In particular, roughly 30% of SMS pa-
tients also develop IDDM. In 1966, Young suggested that autoimmune pro-
cesses may be involved in the etiology of SMS. Subsequent research efforts 
revealed a link between SMS and some additional autoimmune diseases, and 
organ-specific autoantibodies were found in SMS patients (2,3). The recent 
discovery that the biosynthesizing enzyme for the inhibitory neurotransmit-
ter "Y-aminobutyric acid (GABA), glutamic acid decarboxylase (GAD), is the 
major target of autoantibodies in both SMS (4) and IDDM (5) shows that 
both diseases are characterized by a breakdown of tolerance to this antigen 
and suggests that they share some important etiological features. The two 
major sites of GAD expression are pancreatic !3-cells, which are destroyed 
in IDDM, and GABAergic neurons, which are believed to be affected in 
SMS (5). 
Despite the fact that SMS and !DDM share a common autoantigen, the 
clinical presentation of patients with these diseases is dramatically different. 
Furthermore, the prevalence of diabetes among SMS patients is markedly 
higher than the prevalence of SMS in diabetics. This chapter evaluates the 
specific features of autoimmunity to GAD in SMS and IDDM. Although GAD 
autoantibodies appear in both SMS and IDDM, there are major differences in 
the titer and epitope recognition between the two diseases. Moreover, the 
microenvironment of the sites of GAD expression in brain and pancreas may 
provide significantly different conditions for autoimmune reactions. On the 
basis of analysis of autoimmune features in SMS and !DDM, we propose 
that SMS is essentially an antibody-mediated disease whereas IDDM mainly 
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results from T-cell-mediated autoimmunity. Further elucidation of the auto-
immune mechanisms involved in the etiology of SMS and IDDM will guide 
the development of diagnostic and possibly preventative and therapeutic 
strategies in managing these conditions. 
AUTOIMMUNE MECHANISMS IN STIFF-MAN SYNDROME 
Autoimmune Phenomena in SMS 
Most case histories describing SMS patients have reported the presence 
of autoantibodies and autoimmune diseases, particularly islet-cell antibodies 
(!CA) and IDDM. McEvoy (6) reviewed 98 patients who fulfilled most or 
all of the diagnostic criteria for SMS. Approximately 30% of these patients 
had IDDM and 40% were diagnosed with an additional organ-specific autoim-
mune disease, including Hashimoto's thyroiditis, Graves' disease, myas-
thenia gravis, adrenal or ovarian failure, and/or pernicious anemia (6). In 
another survey of 33 SMS patients, 24 (73%) had organ-specific autoanti-
bodies and 9 of these (27%) had clinical signs of autoimmune disease (4). 
Thus, although the majority of SMS patients have signs of autoimmune disor-
ders, a significant fraction do not present these characteristics. 
GABAergic Neurons and SMS 
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Clinical observations and neurophysiologic studies indicate that SMS is a 
disease of the CNS (7). In addition, neuropharmacologic investigations sug-
gest that the disorder is associated with a dysfunction of the GABAergic 
system (8). Benzodiazepines and other agonists of GABAergic neurotrans-
mission significantly relieve the muscle spasms and stiffness in SMS patients 
(9). These observations have focused attention on the GABAergic neurons 
as the site of dysfunction in SMS. 
GAD Is an Autoantigen in a Subgroup of SMS Patients 
Two studies by Solimena and colleagues (3,4) suggested a link between 
autoimmunity and pathology of GABAergic neurons in SMS. In a 1988 case 
report (3), the authors described a SMS patient who developed !DDM and 
had antibodies in serum and cerebrospinal fluid (CSF) that intensely stained 
GABAergic neurons in sections of rat cerebellum. The staining patterns were 
identical to that of an antiserum raised against GAD. Furthermore, Western 
blotting suggested that the serum and CSF contained antibodies to GAD. In 
subsequent work, it was found that 20 of 33 SMS patients tested positive 
for antibodies to GABAergic neurons (4). In these 20 subjects, GAD was 
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identified by Western blotting as the principal autoantigen. Interestingly, 18 
of 19 GABAergic antibody-positive patients tested also bad islet-cell cyto-
plasmic antibodies (ICCA) as measured by indirect immunofluorescence on 
frozen pancreas sections. Furthermore, 6 of the 20 GABAergic antibody-
positive patients had IDDM. In contrast, in the 13 SMS patients negative 
for antibodies against GABAergic neurons, neither !CCA nor IDDM was 
reported (4). 
Interestingly, when Solimena and colleagues tested 57 newly diagnosed 
IDDM patients without SMS for GAD antibodies, only 1 was found to be 
positive. However, the GAD antibody-positive diabetic patient was unusual 
in also having cerebellar ataxia. As discussed below, the reason for the nega-
tive results in this group of diabetic patients is that GAD antibodies associ-
ated with IDDM, in contrast to SMS, usually recognize only conformational 
epitopes in the molecule and were therefore not detected in the assays of 
Solimena and colleagues, which used partly or fully denatured protein for 
their analysis (4). 
The results of autoantibody analysis in the SMS patients (4) appear to 
indicate that at least two groups of patients can be distinguished. One group 
has autoantibodies against GAD, often shows signs of organ-specific autoim-
munity, and has a high incidence of IDDM. The second group does not have 
GAD autoantibodies or other signs of autoimmunity and has no increased 
risk for diabetes. It is possible that the lack of autoantibodies reflects the 
depletion of the autoantigen over time. Alternatively, SMS could represent 
at least two distinct etiologic processes. Analogous to IDDM, we propose 
to designate the autoimmune-associated group as type I SMS and the appar-
ently non-autoimmune-associated group as type 2 SMS. Table 1 lists some 
observed differences that require further characterization to establish the two 
groups as separate entities. An additional example of SMS is the dominantly 
inherited congenital SMS described by Klein et at. (10) and Sander et al. 
(11). The two families described in these studies, as well as sporadic juvenile-
onset SMS (12-14), require further analysis for autoimmune phenomena to 
determine whether they can be classified as either type 1 SMS or type 2 
TABLE 1. Possible differences between type 1 and type 2 stiff-man syndrome 
Clinical differences 
Prodromal symptoms? 
Objective differences in clinical examination? 
Differences in age of onset? 
Laboratory differences 
No GAD- or organ-specific antibodies in type 2? 
Time course of antibodies in type 1? 
HLA haplotype differences? 
Electrophysiological differences? 
Pharmacological differences 
Differences in response to drugs used in the treatment of SMS 
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SMS. Therefore, the pathophysiology of the GABAergic system and the 
identification of GAD as a principal autoantigen support the hypothesis that 
autoimmune processes are involved in the pathogenesis of at least a subgroup 
of SMS patients. The etiology of type 2 SMS, however, remains obscure. 
AUTOIMMUNE MECHANISMS IN IDDM 
IDDM Is an Autoimmune Disease 
The most common autoimmune disease associated with SMS is IDDM. 
The components of the autoimmune processes in IDDM are fairly well estab-
lished and involve both cellular and humoral immunity (15). Because GAD is 
an autoantigen in both type ISMS and IDDM, elucidation of the autoimmune 
mechanisms involved in pancreatic 13-cell destruction may also lead to a 
clearer understanding of the etiology of SMS. In IDDM. the pancreatic 13-
cells are destroyed by an autoimmune process that extends over a period of 
time. The clinical symptoms develop only when :o:SO% of the 13-cells have 
been eradicated (16). 
Genetic Susceptibility in IDDM 
Several autoimmune diseases are associated with particular human major 
histocompatibility complex (MHC) (HLA) haplotypes. Examples of 
MHC-disease associations include HLA-DQw6 in pemphigus vulgaris (17), 
HLA-DR2 in multiple sclerosis (!8), and HLA-DR3 and -DR4 in IDDM (19). 
Among Caucasian individuals with IDDM, 95% express HLA-DR3 and/or 
-DR4, compared with 40% of the general population (20). Furthermore, anti-
gens expressed by the HLA-DQ locus demonstrate an even stronger associa-
tion to either IDDM susceptibility or protection than HLA-DR (21). 
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Two mechanisms can be suggested to explain the strong association be-
tween IDDM and certain HLA types. In the first, T-lymphocyte receptors 
(TCR) recognize antigens in conjunction with HLA molecules. Therefore, 
certain HLA molecules may present an antigenic peptide toT-cells in such 
a way that an autoimmune reaction results (22). In contrast, the presentation 
of the antigen by other protective HLA molecules may result in deletion of 
autoimmune clones (23,24). An alternative explanation is that other genes 
closely linked to HLA genes may be the actual genes that predispose for 
IDDM. Candidate genes include the proteasome and peptide transporter 
genes recently located in the HLA class II region (25 ,26). These genes encode 
proteins that are likely to be involved in antigen processing and translocation 
of peptides into the endoplasmic reticulum, where they associate with HLA 
class l molecules (25,26). 
Although specific HLA haplotypes are essential for the development of 
64kD GAD. Tvpe 1 Diabetes and Stiff-man Svndrome 
IDDM, they are not in themselves sufficient. The most striking evidence 
comes from twin studies demonstrating a concordance rate of only 36% in 
monozygotic twins (27). 
Environmental Factors In IDDM 
Several lines of evidence suggest that environmental factors are important 
in the etiology of IDDM. There are differences in disease incidence between 
several countries that cannot be attributed solely to genetic factors (28). 
Thus, for example, studies in migrant populations show differences in inci-
dence between the immigrant group and the native country (29). In addition, 
several areas in the world show a linear increase of IDDM over the past 15 
to 20 years without major genetic drifts (30). Furthermore, seasonal variation 
strengthens the idea that environmental factors are important (31). The long 
preclinical phase of IDDM makes it difficult, however, to identify which 
environmental factors are critical in the initial events. 
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Viral infections, such as rubella and coxsackie B virus, are the strongest 
examples of environmental factors contributing to the etiology of IDDM. 
Diabetes is found in 20% of patients with congenital rubella syndrome, with 
a median onset age of 13 years. There is a strong association with the HLA 
haplotype (32). Evidence also argues for a possible role of coxsackie B vi-
ruses (33). The mechanisms involved are not clear. Molecular mimicry be-
tween a viral antigen and an autoantigen has been suggested as a possible 
mechanism initiating 13-cell destruction and resulting in IDDM. A viral anti-
gen with a homology to a self-antigen can stimulate T- and B-cells that cross-
rea...:t and ltvme to the site of expression of the autoantigen. For example) 
in a transgenic mouse model the targeting of a LCMV viral transgene to 
pancreatic ~-cells did not result in autoimmunity and 13-cell destruction de-
spite low levels of tolerance to this protein. However, infection with the 
LCMV virus resulted in 13-cell autoimmunity and destruction and the devel-
opment ofiDDM (34,35). The results of these transgenic experiments demon-
strate that viral infections can recruit components of the immune system 
(e.g., cytotoxic T-cells) that can react with an otherwise ignored self-protein. 
In conclusion, current evidence suggests that environmental events are 
involved in the etiology of IDDM. Despite a strong association between 
IDDM and several viral infections, specific mechanisms have not yet been 
identified. 
Autoantibodies in IDDM and Identification of the 64-kDa Autoantigen 
Among the most thoroughly studied autoimmune abnormalities associated 
with IDDM is the high incidence of circulating islet-specific autoantibodies. 
Autoantibodies can be identified at the time of onset but also years before 
64kD. GAD. Tvpe 1 Diabetes and Stiff-man Svndrome 100 
the clinical diagnosis of the disease. Autoantibody titers can be used as a 
predictive marker, but the specificity and sensitivity of most tests are not 
yet optimal. 
In 1974, Bottazzo et a!. (36) first described (ICCA) in IDDM using an 
indirect immunofluorescence assay and frozen sections of human pancreas. 
Insulin autoantibodies (lAA) have been identified in patients with IDDM 
both during the preclinical phase and at diagnosis (37 ,38). The frequency of 
IAA is age-dependent. In young children frequencies up to 40% can be found 
in newly diagnosed patients (39). In contrast, the incidence is less than 10% 
in older patients (40). ICCA are often present in sera from SMS patients (6), 
but no data are available on IAA in this disease. 
In 1982, Baekkeskov and colleagues (41) identified autoantibodies to a 64-
kDa protein by immunoprecipitation of detergent lysates of [35S] methionine-
labeled human islets. The 64-kDa antigen was found to be 13-cell-speciflc in 
an analysis of several tissues in which neurons could not be included because 
of their poor biosynthetic labelling in vitro (42). The antigen was shown to 
have tbe properties of an amphiphilic membrane protein and to have an 
isoelectric point (pi) of 6.7 (43). Autoantibodies to the 64-kDa protein are 
present in 82 to 90% of newly diagnosed IDDM patients and in a majority 
of prediabetic individuals (see 44-47 for review). The presence of 64-kDa 
autoantibodies has a higher predictive value than ICCA or IAA (Aanstoot 
et al., unpublished results). Moreover, 64-kDa autoantibodies have been de-
tected earlier but never later than ICCA or IAA in the preclinical phase of 
IDDM (45,46). The high incidence and very early appearance of 64-kDa 
autoantibodies suggest that the protein may represent the primary target 
protein of the initial autoimmune reaction against 13-cells. The exact role of 
the 64-kDa protein in the 13-cell destruction is, however, still unclear. 
The characterization of the 64-kDa protein finally led to its identification 
as the enzyme GAD (5). Using the sensitive techniques developed for immu-
noprecipitation of the 64-kDa protein in its native configuration, we showed 
that there was complete immunological crossreactivity between the 64-kDa 
protein and GAD. The unequivocal identification of the 64-kDa protein as 
GAD furthermore involved demonstration of identical size and pl (6. 7-6.9) 
of GAD forms in brain and the 64-kDa antigen forms in islets, identical 
trypsin-generated fragments of tbe two proteins, and finally, and perhaps 
most important, that the 64-kDa protein had GAD enzyme activity (5). 
GAD AS A COMMON AUTOANTIGEN IN SMS AND IDDM 
GAD in Neurons and fi-Cells 
GAD is the synthesizing enzyme for the inhibitory neurotransmitter 
GABA. Two distinct GAD genes located on different chromosomes have 
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been identified in neurons (48). One gene encodes a 67-kDa protein, GAD67 , 
while the other gene encodes a slightly smaller form, GAD65 (48). Immuno-
histochemical analyses of GAD in neurons suggest that GAD67 is predomi-
nantly present in the cell body of the neuron, whereas GAD65 is more concen-
trated in nerve endings ( 49). Immunoelectron microscopy (EM) has localized 
GAD in nerve endings in close proximity to the synaptic vesicles (50,51). 
Recent work with postembedding immuno-EM suggests that GAD is local-
ized to the membrane of small synaptic vesicles (SSV) (52). 
GAD in 13-cells is expressed at levels comparable to those of GAD in the 
CNS (53). Pancreatic 13-cells express two forms of GAD (5,54). The larger 
protein, which is expressed at low levels in rat islets, is hydrophilic and 
soluble throughout its lifetime and was shown to be identical to GAD61 in 
neurons (54). The major GAD protein in 13-cells, alias the 64-kDa antigen, 
has been shown to be identical to GAD65 in neurons with regard to antigenic 
epitopes, size, and charge (54). A comparison of the primary structure of 
GAD., in islets (55) and brain (56) shows that they are identical. GAD65 is 
also synthesized as a hydrophilic and soluble molecule but matures into a 
firmly membrane-anchored protein in a process that seems to involve two 
steps (54). The first step results in a hydrophobic molecule which is soluble or 
has a low membrane avidity. The second step results in a firmly membrane-
anchored molecule. The exact subcellular localization of the membrane-an-
chored GAD6s in 13-cells is not known, but EM analysis suggests that GAD65 
is localized in the membrane of synaptic-like microvesicles (SLMV) contain-
ing GABA (52). Similar to neurons, 13-cells contain other components of the 
GABAergic system, including GABA and the GABA-metabolizing enzyme 
GABA transaminase (GABA-T) (57). Although the function of GABA in 
islets is unclear, the identification of GABAA receptors on glucagon-secreting 
u-cells suggests that GABA has a paracrine role in islets (58). 
Presentation of GAD to the Immune System 
There are at least two mechanisms by which GAD could become visible 
to the immune system as a target for autoimmunity. First, peptide fragments 
generated from the GAD molecule during its natural turnover can be ex-
pressed at the cell surface in conjunction with MHC class I antigens and can 
thus be recognized by cytotoxic T -lymphocytes. Second, if membrane-bound 
GAD6s protrudes into the lumen of the SLMV the antigen may become ex-
posed at the cell surface after fusion of the SLMV with the plasma membrane 
during GABA secretion and be recognized by GAD autoantibodies. The first 
mechanism would be applicable to both the GAD6s and GAD67 proteins, 
whereas the second mechanism would be applicable only to the membrane-
bound form of GAD65 (54). 
64kD GAD Tvoe 1 Diabetes and Stiff-man Svndrome 
DIFFERENCES IN AUTOIMMUNE REACTIONS IN 
TYPE 1 SMS AND IDDM 
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The identification of a common antigen in type I SMS and IDDM suggests 
that the diseases may share common features. However, if GAD is a major 
target antigen in both type I SMS and IDDM, why do not all SMS patients 
with GAD antibodies develop IDDM and why do IDDM patients almost 
never develop SMS? Also, why in type I SMS patients do the clinical symp-
toms of diabetes usually develop after the onset of the SMS symptoms (6)? 
It can be suggested that differences between the forms of GAD in brain 
and [3-cells could account for differences in the etiology of SMS and IDDM. 
As described above, this possibility seems to have been excluded, although 
differences in posttranslational modifications of GAD proteins in brain and 
[3-cells may still exist. There are some striking differences, however, in the 
character of GAD autoantibodies and in the target cell environment in the 
two diseases. These factors require further consideration and may play a 
significant role in disease etiology. 
Differences in Antibody Reactions 
Two major differences have been observed between GAD autoantibodies 
in type 1 SMS and IDDM (5). First, GAD autoantibodies in SMS are usually 
of a significantly higher titer than antibodies in IDDM. Second, autoanti-
bodies in IDDM recognize only conformational and not primary epitopes on 
both GAD6, and GAD67. In type 1 SMS, autoantibodies to GAD also recog-
nize conformation epitopes in both GAD6s and GAD67. However, in contrast 
to IDDM, SMS antibodies also recognize a primary epitope (or epitopes) in 
GAD65 which is absent in GAD67 (5). 
Although our analyses suggest that type 1 SMS sera usually recognize 
denatured GAD6s, one report (59) describes serum from an SMS patient that 
recognized only conformational epitopes and not denatured forms of GAD 
in brain. Therefore, primary GAD6s epitope recognition may not be charac-
teristic of all SMS patients. Serum from this individual stained GABAergic 
neurons and [3-cells. The characterization of autoantibodies in type I SMS 
and IDDM is summarized in Table 2. 
Differences in Target Cells 
Neurons and [3-cells differ significantly in their visibility to the immune 
system. First, the blood-brain barrier protects the microenvironment of the 
CNS. In addition, i)-cells express MHC class I molecules (60) which can 
present GAD epitopes to cytotoxic T-cells. Under normal conditions, neu-
rons do not express MHC class I antigens (61). 
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TABLE 2. Comparison of GAD antibodies in IDDM and in type 1 and type 2 SMS 
Titers 
Primary epitope recognition (4,5) 
Conformational epitope recognition (5) 
Frequency of GAD antibodies at onset 
(4,41 ,44,47) 
Before onset (45-47) 
Antibodies to GAD involved in pathogenesis 
Other organ-specific autoantibodies 
s Arbitrary units. 
IDDM 
1-1oa 
No 
Yes 
80-90% 
79-82% 
Probably not 
Yes 
b Recognition is restricted to primary epitopes in GAD65 . 
c N/D, not detected. 
d N/A, not available. 
Type 1 SMS Type 2 SMS 
10-1 DO" N/Dc 
Yes" N/Dc 
Yes N/Dc 
90-100% N/Dc 
N/Ad N/Ad 
Probably No 
Yes No 
The destruction of 13-cells in IDDM is believed to beT-cell-mediated (62). 
In SMS, few reports are available that describe the pathologic features of 
the neurons involved. Most studies found no histologic abnormalities and, 
in particular, there was no evidence of mononuclear cell infiltration (63,64), 
Nakamura and colleagues (65) have described an SMS patient with gliosis 
of the spinal cord, a feature that could be the result of a chronic inflammation. 
Unfortunately, histology of the brain was not interpretable. Complete de-
struction of GABAergic neurons due to an infiltration of mononuclear cells 
would be extremely devastating for several brain functions and would most 
likely be incompatible with life. Although the symptoms in SMS can be 
extremely severe and debilitating, the damage to GABAergic neurons seems 
to be more or less limited to a subgroup of GABAergic neurons in the motor 
neuron system. SMS symptoms can be influenced pharmacologically, sug-
gesting a functional impairment rather than a complete destruction of 
GABAergic neurons, 
HYPOTHESIS 
If GAD is the primary target of pathogenic autoimmune processes in both 
diseases, we propose the following hypothesis for the distinct etiologies of 
type l SMS and IDDM based on differences in autoantigen presentation, 
characteristics of autoantibodies, and microenvironments of target cells. In 
IDDM, cytotoxic T-lymphocytes directed to or cross-reacting with GAD 
recognize GAD fragments in conjunction with MHC class l on the surface 
of !3-cells and mediate J:l-cell destruction, resulting in disease. Antibodies to 
GAD, although a marker of the disease, play only a secondary role in the 
pathogenesis. Neurons are not affected because they are protected by the 
blood-brain barrier and do not express MHC class I antigens. Furthermore, 
the regulation of the immune response in the CNS is complex. Necessary 
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costimulatory mechanisms forT-cells may be lacking (66), and resistance or 
susceptibility to autoimmune processes may be related to the ability of brain 
endothelial and glial cells to express sufficient levels of MHC molecules to 
induce autoreactive T-cells (67). In type 1 SMS, however, autoantibodies of 
high titer develop which somehow pass the blood-brain barrier and recognize 
specific GAD epitopes on the surface ofGABAergic neurons. These antibod-
ies may mediate functional impairment of GABAergic neurons, perhaps by 
blocking the membrane-associated GAD6s form at the surface after exo-
cytosis of GABA. Other examples of autoimmune diseases in which autoanti-
bodies inhibit function of their target molecules include pernicious anemia 
(68), pemphigus vulgaris (69), and systemic autoimmune diseases such as 
scleroderma (70). The antibodies involved usually recognize antigenic epi-
topes that are highly conserved in evolution and often represent functionally 
important domains of the antigen (70). A pathogenic role of the antibodies 
in SMS cannot explain the high coincidence of IDDM. Ratber, it can be 
proposed that diabetes develops in SMS patients when the antibody response 
is accompanied by cytotoxic T -cells to GAD which can home to the pancreas 
and destroy 13-cells (71). In summary, we propose that if GAD is the primary 
target antigen in both type I SMS and IDDM, the first disease may be primar-
ily mediated by humoral response to the protein, whereas cytotoxic T -cells 
predominate in tbe pathology of the second disease. 
MOLECULAR MECHANISMS AND ROLE OF GAD AUTOIMMUNITY 
IN TYPE 1 SMS AND IDDM 
Although GAD is identified as a major target of autoantibodies associated 
with 13-cell loss and impairment of GABAergic neurons, some major ques-
tions remain to be answered. The first question is whether type I SMS is 
an autoimmune disease and, if so, whether it is associated with the same 
MHC haplotypes as IDDM. Although neurons lack MHC class I antigen 
expression under normal conditions, MHC class I antigen expression by neu-
rons in vivo is induced during viral and bacterial infections of the CNS (72). 
Furthermore, the initial presentation of GAD to aT-helper cell would still in-
volve MHC class II molecules. In the CNS, MHC class II antigens are ex-
pressed in astrocytes and perivascular microglial cells which, for example, can 
present myelin basic protein, the primary target autoantigen in the animal 
model of multiple sclerosis experimental autoimmune encephalomyelitis (73). 
A few reports are available that describe the HLA typing of SMS patients 
(3,74,75). The DR3/DR4 haplotype has been found in some patients, and 
others are described as positive for the HLA-B44 allele which is in linkage 
disequilibrium with DR4. Thus, the limited data presently available suggest 
that the MHC haplotypes associated with IDDM may also be found in SMS 
patients. 
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A correlation between autoimmunity and infectious disease is established 
in some cases and serves as an example of environmental factors involved 
in disease. For example, in rheumatic fever, molecular mimicry between a 
streptococcal antigen and heart valve components results in an autoimmune 
destruction of the valves (76). The low incidence of SMS makes it difficult 
to assess the role of predisposing environmental faCtors such as infection. 
One report has described the development of a partial SMS after bacterial 
infection with Borrelia burgdorferi, the causative agent of Lyme disease (77). 
B. burgdorferi is associated with chronic neurologic dysfunction (78) but has 
been related to SMS only in this one case. Its role in SMS therefore remains 
obscure. Associations with viral infections have not been described for SMS. 
If GAD autoantibodies in type l SMS are pathogenic, it can be expected 
that therapies that lower antibody levels will prove beneficial. One such 
method, plasmapheresis, has been tried with variable success in SMS pa-
tients (74,79). Brashear and Phillips. (80) described one patient with progres-
sive SMS who was treated with plasmapheresis. Serum antibody titers 
against GABAergic neurons were decreased by this treatment, and the pa-
tient improved. It is of note that this patient did not have GAD antibodies 
in the CSF. It is likely that high titers of GAD antibodies in the CSF are 
less amenable to plasmapheresis and that the benefit of this treatment is 
limited to patients with antibodies restricted to the blood circulation. 
A second major question is whether the autoimmune responses to GAD 
are the consequence rather than the cause of 13-cell destruction and neuronal 
degeneration. It is of note that in several neurologic diseases, neurons die 
and their contents become exposed to the immune system without initiating 
an autoimmune response to GAD (4,71). Furthermore, it can be argued that 
the release of the rare protein GAD from damaged 13-cells or neurons is 
accompanied by the release of all other cell components, including both rare 
and abundant proteins. The appearance of lgG antibodies of a very high 
specificity and affinity to GAD but not those other components therefore 
strongly suggests that the immune system has been specifically triggered into 
activity towards GAD and that GAD autoimmunity plays a role in disease 
pathogenesis rather than being merely a consequence of cell death. 
Animal models of GAD autoimmunity are presently being developed and 
will allow studies of the role of GAD in both 13-cell destruction and impair-
ment of GABAergic neurons. 
CONCLUSIONS 
The identification of GAD as the major target for humoral autoimmunity 
in type I SMS and IDDM allows a number of questions to be addressed for 
the first time. In IDDM, the development of rapid and accurate tests for 
GAD antibodies will help in prediction and diagnosis. In SMS, the analysis 
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of GAD antibodies will help in the diagnosis and further definition of different 
groups of patients. 
The pathogenic mechanisms of both SMS and diabetes remain to be eluci-
dated. The evaluation of the role·of GAD in T-cell-mediated immunity in 
both diseases is a major goal. The differences in autoantigenic epitopes de-
tected in type I SMS and IDDM are important and form the basis for further 
studies aimed at elucidation of the molecular mechanisms of 13-cell destruc-
tion and impairment of GABAergic neurons. It is believed that the accumula-
tion of knowledge in this area will eventually open up avenues for preventing 
or blocking the autoimmune responses to both 13-cells and neurons. 
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2.3. 
Studies on the characterization ol GAD in B-cells and neurons. 
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2.3.1 
Pancreatic B-cells Express Two Autoantigenic Forms ol Glutamic Acid 
Decarboxylase, a 65-kDa Hydrophilic Form and a 64kDa Amphiphilic 
Form Which Can Be Both Membrane-bound and Soluble. 
Journal ol Biological Chemistry 1991; 266: 21257-21264. 
(with permission) 
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Pancreatic {3 Cells Express Two Autoantigenic Forms of Glutamic Acid 
Decarboxylase, a 65-kDa Hydrophilic Form and a 64-kDa Amphiphilic 
Form Which Can Be Both Membrane-bound and Soluble* 
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The 64~kDa pancreatic ,8-cell autoantigen, which is 
a target of autoantibodies associated with early as well 
as progressive stages of ,8-cell destruction, resulting in 
insulin·dependent diabetes (IDDM) in humans, has 
been identified as the ')'·aminobutyric acid-synthesiz-
ing enzyme glutamic acid decarboxylase. We have 
identified two autoantigenic forms of this protein in 
rat pancreatic f3·cells, aMr 65,000 (GADs~) hydrophiliic 
and soluble form of pl 6.9-7.1 and a Mr 64,000 
(GADs.t) component of pl6.7. GADs4 is more abundant 
than GADs~ and has three distinct forms with regard 
to cellular compartment and hydrophobicity. A major 
portion of GADs.t is hydrophobic and firmly mem-
brane-anchored and can only be released from mem-
brane fractions by detergent. A second portion is hy-
drophobic but soluble or of a low membrane avidity, 
and a third minor portion is soluble and hydrophilic. 
All the GADs.t forms have identical pi and mobility l()n 
sodium dodecyl sulfate-polyacrylamide gel electropho-
resis. Results of pulse-chase labeling with (315S]methi-
onine are consistent with GAD6 4 being synthesized as 
a soluble protein that is processed into a firmly mem-
brane-anchored form in a process which involves in-
creases in hydrophobicity but no detectable changes in 
size or charge. All the GADs4 forms can be resolved 
into two isoforms, a and (3, which differ by approxi-
mately 1 kDa in mobility on sodium dodecyl sulfa1te-
polyacrylamide gel electrophoresis but are identical 
with regard to all other parameters analyzed in this 
study. GADs5 has a shorter half-life than the GADs4 
forms, remains hydrophilic and soluble, and does not 
resolve iiato isomers. Comparative analysis of the brain 
and (3-cell forms of GAD show that GADsl5 and GAD6 4 
in pancreatic (3~ceHs correspond to the larger and 
smaller forms of GAD in brain, respectively. The 
expression of different forms and the flexibility in 
subcellular localization of the GAD autoantigen in f3· 
cells may have implications for both its function and 
autoantigenicity. 
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charges. This article must therefore be hereby marked "advertise-
ment" in accordance with 18 U.S.C. Section 1734 solely to indicate 
this fact. 
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Insulin dependent diabetes mellitus (IDDM) 1 is character-
ized by a selective loss of the insulin producing I)-cells in a 
process which can span several years, and is characterized by 
clear indications of an autoimmune response, that includes 
circulating islet cell antibodies (Castano and Eisenbarth, 
1990). We have used the circulating antibodies present in 
IDDM sera to identify aM, 64,000 (64 kD) target human islet 
cell autoantigen by immunoprecipitation of [35S]methionine-
labeled human islets (Baekkeskov et al., 1982). Antibodies to 
the human islet cell 64· kD protein and its rat islet counterpart 
are present in approximately 80% of newly diagnosed IDDM 
patients and have been detected up to several years before the 
clinical onset of the disease, concomitantly with a decrease of 
/3-cell function (Sigurdsson and Baekkeskov, 1990 for review}. 
The 64-kD protein was recently identified as the GABA-
synthesizing enzyme glutamic acid decarboxylase (GAD) in 
pancreatic $-cells (Baekkeskov et al., 1990). The presence of 
GAD and its product GABA in islet (3-cells (Garry et al., 1986) 
and the presence of GABAA receptors on islet o:- and 0-cells 
(Rorsman et al., 1989; Reusens-Billen et al., 1984) suggests a 
role of GABA in paracrine signalling between the I)-cell and 
the other endocrine islet cells. GAD is expressed in high 
concentrations in GABA·ergic neurons in the central nervous 
system (Mugnaini and Oertel, 1985) and in the oviduct (Erdo 
et al., 1989). Two major forms of GAD have been detected in 
the brain and their molecular masses have been described as 
59-67 kDa {Kaufman et al., 1991; Legay et al., 1987; Chang 
and Gottlieb, 1988). The larger brain form has been cloned 
and sequenced from cat (Kaufman et al., 1986; Kobayashi et 
al., 1987), rat (Julien et al., 1990; Wyborski et al., 1990), and 
mouse (Katarova et al., 1990). The smaller GAD form in rat 
brain has recently been cloned, sequenced, and shown to be a 
product of a different gene (Erlander et al., 1991). 
Both the human (Baekkeskov et al., 1987; Baekkeskov et 
al., 1989) and rat (Christie et al., 1988, 1990) I)-cell 64-kD 
GAD autoantigen have been shown to have amphiphilic mem· 
brane protein properties, and this characteristic has been used 
in most analyses to partially purify the protein. The amphi· 
philic human f3·cell 64-kD GAD autoantigen (GAD64 ) was 
detected as two i.somers a and /3, which were identical in 
charge but differed in molecular mass by approximately 1 
kDa (Baekkeskov et aL, 1989). In the present study, we have 
'The abbreviations used are: IDDM, insulin-dependent diabetes 
mellitus; GABA, -y-aminobutyric acid; GAD. glutamic acid decarbox-
ylase: P-100, crude particulate fraction; 81-100, first cytosol fraction; 
82-100, second cytosol fraction; TX-100, Triton X-100; TX-114, 
Triton X-114; WP-100, washed particulate fraction; Hepes, 4-(2-
piperazine)-1-ethanesulfonic acid; 2D, two-dimensional; NEPHGE, 
nonequilibrium pH -gradient gel electrophoresis; IEF, isoelectric fo-
cusing; kb, kilobases. 
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analyzed autoantigenic forms of GAD in both soluble and 
membrane compartments of rat islets and characterized those 
with regard to size, charge, hydrophobicity, and half-life. We 
show that islets of Langerhans express a less abundant 65-
kDa soluble hydrophilic form of GAD (GADi>G) in addition to 
GAD54 a and [3, and provide evidence that only GAD&~ be-
comes membrane bound in a process which involves modifi-
cation with small nonchargedhyd.rophobic residue(s). We also 
show that GAD 65 and GAD64 are homologous to the larger 
and smaller brain forms of GAD, respectively. 
MATERIALS AND METHODS 
Isolation of Islets and Biosynthetic Labeling-Isolation of rat islets, 
maintenance in culture and radioactive labeling with [35S]methionine 
for 4 h was carried out as described (Baekkeskov et aL, 1989). In 
pulse-chase labeling elq)eriments, rat islets were starved in methio-
nine-free RPMI 1640 medium at 37 oC for 30 min and then given a 
pulse of [358)methionine (specific activity, >1000 Ci/mmol, Amer-
sham) for 30 or 40 min followed by chase periods in medium contain-
ing 5 X the normal content of nonradioactive methionine for 0-72 h 
before harvesting. Labeled islets were harvested by centrifugation, 
washed twice in nonradioactive medium and once in 20 mM Hepes, 
pH 7.4, 150 mM NaCI and 10 mM benzamidine/HCl, and then either 
immediately processed for homogenization and isolation of soluble 
and membrane compartments or snap frozen and stored in aliquots 
at -80 oc. 
Analysis of Compartmentalization of the GAD Autoantigen-Islets 
were homogenized in an isotonic sucrose buffer, 10 mM Hepes/NaOH, 
pH 7.4, 0.25 M sucrose, 10 mM benzarnidine/HCl, 0.1 mM p-chloro-
mercuribenzenesulfonic acid and 0.25% aprotinin (Novo-Nordisk, 
Bagsvaerd, Denmark) (homogenization buffer) at 4 oC and separated 
into crude particulate (P-100) and cytosol fractions (81-100) by 
ultracentrifugation at 100,000 X g for 1 h as described (Baekkeskov 
et al., 1989). The crude P-100 fraction was washed at 4 OC by resus-
pension in 10 mM Hepes/NaOH (pH 7.4), 150 mM NaCl, 10 mM 
benzamidine-HCI, 0.25% Trasylol, 0.1 mM p-chloromercuribenzene-
sulfonic acid and 0.1 mM Na,VO, (Hepes buffer A), fo!lowed by 
ultracentrifugation at 100,000 x g for 1 h resulting in a new 8100 
fraction {82-100) and a washed P-100 (WP-100) fraction. The WP-
100 fraction was e:o::tracted in Hepes buffer A containing 2% of either 
Triton X-100 (TX-100) or Triton X-114 (TX-114) (extraction buffer) 
at 4 OC for 2 h followed by ultracentrifugation as above. 
For quantitative analysis of GAD, the resulting pellet was subjected 
to repeated extractions and ultracentrifugations. Usually ail detergent 
releasable GAD was recovered in the two firSt extracts of the WP-
100 fraction. The Sl-100 and 82-100 fractions and the WP-100 
extracts were immunoprecipitated quantitatively with GAD antisera 
{Christie et aL, 1988) either directly or after preclearance with control 
sera as described (Baekkeskov et aL, 1987). In brief fractions were 
incubated with an excess of serum for 16 hat 4 OCto form immuno-
complexes, which were then isolated by adsorbti.on to excess amounts 
of protein A-Sepharose (Pharmacia LKB Technology Inc., Uppsalo., 
Sweden}. Analysis of supernatants after immunoprecipitation by 
reimmunoprecipitation with antisera and protein A-Sepharose re-
vealed that GAD was depleted quantitatively by the fust immunopre-
cipitation. Immunoprecipitates were analyzed by SDS-PAGE fol-
lowed by fluorography. Densitometric scanning of fluorograms was 
carried out as described {Christie et al., 1988), The results of density 
measurement of GAD in each fraction were expressed as percent of 
the sum of density values for GAD in ail three fractions. Distribution 
of total protein into the three fractions was expressed as a percentage 
of trichloroacetic acid-precipitable counts. WP-100 values were ex-
pressed as the sum of GAD recovered in repeated extracts of the WP-
100 fraction. 
For salt and EDT A washing elq)eri.ments identical aliquots of the 
WP-100 fraction were taken up in either Hepes buffer A or the same 
buffer supplemented with one of the following components: 0.5 M 
NaCI, 0.2 M Na2C03, 0.05 M Na.P2Q,, 0.2 M-MgCh, 0.05 M EDTA, or 
2% TX-100 and incubated at 4 oc for 1 h. The samples were then 
ultracentrifuged at 100,000 x g and the resulting supernatants im-
munoprecipitated and subjected to SDS-PAGE and fluorography. 
TX-114 Partitioning Assays-TX-114 detergent phase separations 
of detergent extracts of the WP-100 fraction or of soluble fractions 
following addition of TX-114 were performed as described (Baekkes-
kov etal., 1989). For comparative analysis ofTX-114 detergent phase 
partition of GAD in soluble and particulate fractions, 81-100, 82-100, 
and a WP-100 extract were each diluted with either extraction buffer 
or homogenization buffer, supplemented with TX-114 to obtain an 
identical buffer composition in each fraction during phase separation. 
Following TX-114 phase separation (Bordier, 1981; Baekkeskov et 
al., 1987) the aqueou.s (a) and detergent (d) phases of each fraction 
were immunoprecipitated and analyzed by SDS-PAGE and fluorog-
raphy. Distribution of GAD into a and din each fraction was meas-
ured by densitometric scanning of fluorograms and expressed as a 
percentage of the sum of the values in both fractions. 
Gel Electrophoretic Analysis-One-dimensional SDS-PAGE was 
performed u.sing uniform 8.5 or 10% 80S-polyacrylamide gels and 
either the buffer system of Laemmli (1970) (0.055 M Tris base, 0.192 
M glycine, and 0.1% SDS) or a modifiedLaemmli buffer system (0.025 
M Tris base, 0.192 M glycine, 0.05% SDS) (Fey et aL, 1984). The 
GAD.., a and p components usually only resolved in the latter buffer 
system. 
Two types oftwo-dimensional (2D) gel electrophoresis experiments 
were performed. The first involved NEPHGE (O'Farrell et aL, 1977) 
in the first dimension as described earlier (Baekkeskov et aL, 1989). 
This method has the advantage of applying the sample at the acidic 
end (anode) which results in less aggregates of GAD at the top of the 
gel than in the isoelectric focusing gels where proteins are applied at 
the basic end (cathode}. However, this method does not allow deter-
mination of true isoelectric points. For this purpose equilibrium IEF 
was carried out in the first dimension in tube gels (170 X 1.55 mm 
(id)) as described by O'Farrell (1975) consisting of 5.8% v/v ampho-
lines {pH 5-7} and 6.7% ampholines (pH 3.5-10) (Pharmacia}. Fol-
lowing prefocusing at 1200 V for 4 h, the samples were subjected to 
e-lectrophoresis for 20 h using 0.02 M NaOH at the anode and 0.01 M 
H3PO. at the cathode. The pH gradient was determined by elution of 
the ampholines from 1-cm slices of gel and measuring the pH. The 
second dimension for both the NEPHGE and IEF gels was 80S-
PAGE on 10% slab gels using modified Laemmli buffers (Fey et al., 
1984}. 
14C-Methylated }3-phosphorylase(molecular weight 94,000 and 
100,000) bovine serum albumin (M, 69,000), ovalbumin (M, 45,000) 
and carbonic anhydrase (M, 30,000) were used as M, markers in the 
gels. Gels were stained and processed for fluorography as described 
(Baekkeskov et aL, 1987). Fluorograms were prepared using Kodak 
XAR-5film. 
Protein Determinations-Protein quantification was carried out 
according to Bradford (l9'/6J. 
Immunoblotting-SDS gels were electroblotted to polyvinylidene 
difluoride membranes (Immobilon, Millipore). Unreacted binding 
sites were blocked by incubation for 60 min in 50 mM Tris-HCJ, pH 
7.4, 150 mM NaCl, 0.1% Tween 20 containing 3% skim milk. The 
blots were incubated for 2 h with the primary antibody diluted in the 
same buffer (sera 1266 and normal rabbit serum, 1:1000; K2, 1:2000; 
GAD6 ascites 1:500) followed by visualization with alkaline phospha-
tase-labeled second antibodies. 
Antisera-The antisera used in this study included three IDDM 
patient sera which were strongly positive for GAD autoantibodies 
and three control sera from healthy individuals; a polyclonal rabbit 
antiserum (1266) generated against a synthetic peptide prepared 
according to described methods (A tar et aL, 1989} and containing the 
C-terminal sequence of the larger rat brain form of GAD (Cys-Trp-
Ser-Ser-Arg-Thr-Gln-Leu-Leu-His·Ser-Pro-lle-Leu-Thr-Ser-Ser-
Ser·Arg-Arg) (Julien et al., 1990; Wyborski et al., 1990) coupled to 
keyhole limpet hemocyanin (a gift from Dr. J. 8. Petersen, Hagedorn 
Research Laboratory, Gentofte Denmark); GAD6, a mouse mono-
clonal antibody (ascites), which was raised against immunoaffinity 
purified rat brain GAD and which specifically recognizes the smaller 
GAD form in brain on Western blots {Chang and Gottlieb, 1988) (a 
gift from Dr. D. Gottlieb, Univ. of Washington, St. Louis), and K2, a 
rabbit antiserum raised to the larger form of cat GAD produced in a 
bacterial expression system and which almost exclusively reacts with 
the larger brain form on Western blots (Kaufman et al., 1991) (a gift 
f:rom Dr. Allan Tobin, UCLA). 
Transient Expression of the Larger Form of Brain GAD in COS 
Cells-The eukaryotic expression vector 910238 (Wong et aL, 1985) 
(a gift by Dr. Randall Kaufman, Genetics Institute, Boston) was 
modified at the EcoRI cloning site with synthetic linkers to produce 
a Spei site. This plasmid is called pEXP130. A plasmid containing a 
full-length eDNA clone encoding the larger rat brain form of GAD (a 
gift; from Dr. A. Tobin, UCLA) was digested with Xbai to isolate a 3-
kb fragment corresponding to nucleotides -250 to 2750. The 5' 200 
base pairs are intronic (an artifact in eDNA synthesis) but contain 
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no translational start sequence. The Xbal fragment was ligated t·J 
the Spel site of pEXP130 and transformed using standard methods. 
Sense and antisense conformations were screened and named 
pGAD17 and pGAD16, respectively. 
COS7 cells (American Type Culture Collection) were transfected 
using a lipofectin reagent (BRL) according to the manufacturer"s 
protocol. 60 11-g of lipofectin and .30 1'-g of either pGADl6 or pGADl7 
were added to lOO"mm dishes of COS7 cells at 80% confluency i~1 
GIBCO optimum medium supplemented with 20% FCS. Following 5· 
h incubation at 37 "C, an equal volume ofDulbecco's modined Eagle's 
medium with 20% fetal bovine serum was added. Cells were harvested 
after 48 h, snap frozen, and stored in aliquots at -SO" C. 
RESULTS 
Analysis of Amphiphilic GAD6, a and (3 in Membrane Frac-
tions of Rat Islets-We have previously identified an amphi-
philic 64-kD autoantigenic form of GAD (GAD64 ) in human 
islets and showed that this form can resolve into two isomers 
o: and i3 which have an identical pi of 6.7 and differ i::1 
molecular mass by about 1 kDa. The frequent inavailability 
of fresh human material has hampered further analyses and 
motivated the identification of alternative sources of islets for 
the characterization of this protein in pancreatic (3-cells. Rat 
islets have been shown to express amphiphilic GAD134 in 
particulate fractions {Christie et al., 1988, Baekkeskov et al., 
1989, 1990). To analyze this form in more detail we immu-
noprecipitated GAD64 from TX-114 detergent phase-purified 
extracts of crude particulate fraction (P-100) of a large num-
ber (n = 88) of rat islet preparations using GAD64 antibody-
positive IDDM sera. GAD64 in particulate rat islet fractions 
was also detected as two isoforms, a and {3, which differ in 
molecular mass by about 1 kDa (Fig. 1A) and have a pi of 6. 7 
(Fig. 1B), suggesting a significant homology between the 
human and rat GADr,, autoantigen. The a/(3 ratio differed 
among the preparations (Fig. 1C) and the i3 isoform was 
practically absent in approximately 25% of the preparations. 
The (3-isoform did not differ from the a isoform in any 
discernible properties, except mobility on 8DS-PAGE. Thus 
the a and f3 isoforms behaved identically with regard to 
subcellular distribution, hydrophobicity, membrane anchor-
ing, and turnover time (see below). The (3 isoform may be 
derived from the a isoform or vice versa, either de novo or 
during isolation of GAD. For this reason we refer to the 64-
kD pi 6.7 a/(3 doublet as one entity, GAD"'' unless otherwi~e 
indicated. 
Detection of Amphiphilic and Hydrophilic GAD64 but Only 
Hydrophilic GADoo in Soluble Fractions of Rat Islets-To 
analyze the distribution of the GAD autoantigen into soluble 
and membrane compartments, islets were homogenized and 
subjected to ultracentrifugation to prepare a primary cytosol 
(81-100) fraction. The crude particulate fraction (P-100) was 
resuspended in an isotonic Hepes buffer to remove cytosoli.c 
proteins and proteins loosely associated to membranes, fol-
lowed by ultracentrifugation to prepare a secondary cytosol 
fraction (82-100) and a washed particulate fraction (WP-
100). GAD was immunoprecipitated from the different frac-
tions using GAD antibody-positive IDDM sera and analyzed 
by 8D8-PAGE and fluorography. 
Analyses of the soluble fractions of 81-100 and 82-100 
showed that the expression of GAD in rat islets was not 
restricted to membrane bound compartments. Thus 8D8-
PAGE (Fig. 2, A and B) and 2D gel electrophoresis (Fig. 2C) 
showed the presence of the GAD64 form of pi 6.7 in both the 
81-100 and 82-100 cytosol fractions in addition to the partic-
ulate fractions. No difference was detected in the mobility of 
GADG4 in the different compartments (Fig. 1C; Fig. 2). The 
analysis of the soluble and particulate fractions furthermore 
revealed an additional form of GAD of M, 65,000 and pi 6.9-
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FIG. 1. Analysis of the amphiphilic GAD6., ~/(3. A SDS-PAGE 
analysis of particulate amphiphilic GADu, immunoprecipitated from 
rat islets by GAD antibody-positive sera from three IDDM patients 
(lanes 4~6). Immunoprecipitation with sera from three healthy con-
trol individuals is shown in lanes 1~3. ["''S]Methionine-labeled rat 
islets were homogenized in an isotonic Hepe~/sucrose buffer and the 
homogenate centrifuged at 100,000 x g for 1 h. The pellet (P-100) 
was extracted in Triton X-114 and the lysate subjected to tempera-
ture-induced phase separation. The detergent-enriched phase was 
predeared with normal human serum and then immunoprecipitated. 
In addition to the positions of GAD64 u./d, the positions of actin (a) 
and tubulin (t), which were present as background in all immunopre-
cipitates, are indicated. The sera used in lanes 4 and 5 were used in 
all subsequent analyses of GAD and sera in lanes 1 and 2 as control 
sera. B, ).'EPHGE/808-PAGE analysis of particulate amphiphilic 
GADo, prepared as in A. The pi of the u. and 6 components was 
determined by a separate analysis using IEF/SDS-PAGE (not 
shown}. C, 808-PAGE analysis of amphiphilic GADc.1 immunopre-
cipitated from either soluble (82-100) or particulate (WP-100) frac-
tions of three different rat islet cell preparations. The crude particu-
late fraction (P-100) from each islet preparation was washed by 
resuspension in Hepes buffer A, followed by centrifugation at 100.000 
x g for 1 h to prepare a supernatant (82-100) and a washed particulate 
fraction (WP-100). TX-114 detergent phase-purified material from 
each fraction was immunoprecipitated with either a control serum 
(C) or a GAD antibody-positive IDDM serum (1). The GAD 01 u./.B 
ratio varies between the three preparations shown in lanes I ~4, 5~8, 
and 9~12, respectively, but is similar for 82-100 and \VP-100 in each 
preparation. Note that samples from 82-100 (lanes 5 and 6) and WP-
100 (lanes 7 and 8) of one islet preparation were analyzed on two 
separate gels. 
7.1 (GAD65) in the 81-100 and 82-100 fractions (Fig. 2A, lane 
2; Fig. 2C, a and c). GADGr, was absent in the WP-100 fraction 
(Fig. 2C, d). Electron microscopic analysis of the 81-100 and 
82-100 fractions did not reveal the presence of small mem-
brane vesicles or fragments (data not shown), suggesting that 
the GAD6, and GAD65 forms detected in these fractions were 
indeed soluble. 
To analyze the hydrophobicity of GAD65 and GADM in the 
different fractions, the soluble fractions 81-100 and 82-100 
and the particulate fractions were subjected to TX-114 phase 
separation. The distribution of GAD65 and GAD61 into the 
detergent and aqueous phases was analyzed by immunopre-
cipitation. This analysis showed that GAD6.; was only present 
in the aqueous phase and never partitioned into the detergent 
phase demonstrating that this form is hydrophilic (Fig. 2, A 
and B). However, whereas GAD04 in both the 82-100, P-100, 
and WP-100 fractions partitioned into the TX-114 detergent 
phase (Fig. 2, A and B), GAD64 in the 81-100 fraction was 
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detected predominantly in the aqueous phase (see below), 
suggesting heterogeneity in hydrophilic/hydrophobic proper-
ties of GAD6, in the different compartments. 
We considered that the difference in mobility between the 
a and {3 components of GADG4 might represent the membrane 
anchor, and therefore that the distribution of those compo-
nents might differ between the soluble and particulate com-
partments. The cr./fJ ratio was however identical in each com-
partment (Fig. lC; Fig. 2B and results not shown). In the 
preparations where the fJ isoform was not evident, the a 
isoform was still found in the different compartments (Fig. 2, 
A and C). Thus the a and fJ isoforms of GAD64 show identical 
behavior with regard to compartmentalization. 
As described earlier (Baekkeskov et al., 1988, 1989) TX-114 
detergent phase purification of the amphiphilic form of GADs. 
efficiently eliminates background proteins in immunoprecip-
itates (Figs. 1 and 2). In contrast, several background proteins 
can be detected in immunoprecipitates of crude cellular frac-
tions and in particular in the aqueous phases using either 
IDDM or control sera (Fig. 2A, lanes 2-5; Fig. 2B, lanes 3,4, 
6, 7). As shown elsewhere (Baekkeskov et aL, 1989) the back-
ground proteins represent a minor fraction of abundant cel-
lular proteins carried nonspecifically through the immunopre-
cipitation procedure. Since GAD is a very rare protein in the 
crude extracts, a small fraction of an abundant cellular protein 
may be detected on a fluorogram similarly to the total amount 
of GAD present in tl:>is fraction, which is being specifically 
immunoprecipitated by IDDM sera. 
In addition to GADGo and GAD64, a component of M, 55,000 
was sometimes specifically detected in immunoprecipitates 
with IDDM sera (Fig. 2A, lanes 2 and 4~ Fig. 2B, lanes 3 and 
7). This component was only detected in the aqueous phases 
following phase separation. Mild proteolytic digestion of both 
GAD65 and GADs. with trypsin and other proteases results in 
a hydrophilic fragment of this size (Baekkeskov et aL, 1990).2 
Furthermore we have occasionally detected a 55-kDa GAD 
fragment in islet cell extracts which have not been treated 
with proteases. Thus GAD seems to be unusually susceptible 
to degradation resulting in a 55-kDa fragment.3 It is therefore 
likely that the 55-kDa component detected in some immu-
noprecipitates with IDDM sera in this study represents a 
hydrophilic fragment of either GAD65 or GAD64 generated by 
proteolytic cleavage either in vivo or during preparation of 
immunoprecipitates. 
GAD~>o~ and GAD65 were quantitatively immunoprecipitated 
from the 81-100, 82-100, and WP-100 fractions in six inde-
pendent experiments, and the relative distribution estimated 
by densitometric scanning of fluorograms and compared to 
the distribution of total proteins {Fig. 3). The fraction of 
GAD 64 detected in 81-100 (-10%) was 4.5-fold lower than the 
fraction of total rs"S]methionine-labeled proteins in this frac-
tion. In contrast, the fraction of GAD<>-l detected in the 82-
100 fraction (-30%) was about 1.7-fold higher than the frac-
tion of total [35S]methionine-labeled proteins. This difference 
in fractionation suggests that GADs. in the 82-100 fraction 
consisted not only of a truly soluble protein entrapped in 
membrane vesicles, but also of protein directly released from 
the membranes. The washed particulate CWP-100) fraction 
contained approximately 60% of the [3"S]methionine-labeled 
GAD~>o~, consistent with a membrane anchoring. Quantitative 
determination of GAD65 was more difficult due to an interfer-
ing background band in this area in some preparations of the 
particulate fraction. The values presented in Fig. 3, -55% in 
81-100, -40 in 82-100, and 5% in WP-100 are therefore a 
2 K Hejnaes and 8. Baekkeskov, unpublished results. 
0 8. Christgau and 8. Baekkeskov, unpublished observation. 
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FIG. 2. One- and two-dimensional gel electrophoretic 
analysis of GAD in membrane bound and soluble compart-
ments. A, 8D8-PAGE analysis of GAD immunoprecipitated from 
81·100 and P-100 fractions. Primary cytosol (81-100) and a crude 
particulate (P-100) fraction were prepared and detergent phase (d) 
and aqueous phase (a) derived from the P-100 e:x:tract as described in 
Fig. 1, followed by immunoprecipitation with control (C) and IDDM 
(!) sera, 8D8-PAGE analysis using modifi"'d LMmmli buffer, and 
fluorography. The immunoprecipit.ates in lanes 2 and 3 represent 81-
100 prepared from 3000 rat islets and the immunoprecipitates in lanes 
4-7 represent P-100 prepared from 1000 islets to obtain comparable 
signal intensities between the soluble 81-100 and particulate P-100 
fractions. In addition to GAD6, o, the IDDM serum specifically 
immunoprecipitates a 65-kDa band (GAD,;,) from 81·100 (lane 2). 
This band is also present in the aqueous phase of the P-100 fraction 
(lane 4), although it is not clearly distinguished from the background. 
Only GAD.,. a is present in the detergent phase of the particulate 
fraction (lane 6). M, markers at the positions indicated are shown in 
lane 1. TheM, marker with mobility between the GAD6o and GAD"' 
a: (indicated with an arrowhead in lane 1) and the background band 
i:11dicated with an arrowhead in lane 3, which has been shown to have 
mobility in between the GAD6, a and {1 components, were used 
together with the TX-114 phase distribution pattern to identify the 
two bands as GAD65 and GAD.,. a as opposed to GAD.., a and {3. 2D 
analyses confirmed that thi~ preparation of islets lacked the GAD.., 
(J' (not shown). The background bands in immunoprecipitates of 81-
100 and the aqueous phases represent a small fraction of major 
cellular proteins carried nonspecifically through the immunoprecipi-
t!ltion procedure. IDDM sera may, however, speciftcally recognize a 
weak 55-kDa band in lanes 2 and 4 (see legend to Fig. 2B); B, SDS-
p AGE analysis of GAD immunoprecipitated from aqueous and deter-
gent phases prepared from 82-100 and WP-100 fractions as described 
ll1 the legend to Fig. lB. M, markers are shown in W.ne 5. GAD<l.l is 
absent in WP-100 (W.nes 7 and 9) but present in 82-100 aqueous 
phase (W.ne 3). GAD85 does not partition into the TX-114 detergent 
phase (lane 2). In addition to GAD60 and GADQ<, the IDDM serum 
specifically immunoprecipitates a 55-k.Da band {open arrow) from 
6e aqueous phases (lanes 3 and 7). This protein may represent a 
proteolytic fragment of GAD65 or GAD..,. C, NEPHGE/SDS·PAGE 
analysis of immunoprecipitates of 81-100 with IDDM serum {a) and 
a control serum (b) and of 82-100 (c) and WP-100 (d) with IDDM 
serum. The e:&:act pis of the GAD<l.l and GAD.., a/(3 components were 
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FIG. 3, Quantitative analysis of the distribution of total 
cellular proteins, GAD6~, and GAD64 into soluble and mem~ 
brane-bound islet cell compartments. Portions of 2000 [358] 
methionine-labeled rat islets were subjected to homogenization fol-
lowed by ultracentrifugation at 100,000 x g to fractionate 81-100 {300 
1-dl and P-100 fractions. The crude P-100 was resuspended in 300 ,u;\ 
of HEPES buffer A and ultracentrifuged to yield 82-100 and WP-
100 fractions. WP-100 was extracted twice in 150 ;tl of extraction 
buffer containing 2% TX-100. 81-100, 82-100, and P-100 extracts 
were precleared twice by immunoprecipitation with normal serum 
and then divided in two aliquots and immunoprecipitated with GAD 
antibody·positive IDDM serum and a negative control serum, fol-
lowed by resolution on SDS-gels in modified Laemmli buffers and 
fluorography. The distribution of GAD60 (dark-shaded bars), GAD,. 
(shaded bars), and total cellular proteins (open bars) into the three 
fractions was assessed as described under "Materials and Methods" 
and mean ±S.D. calculated from six experiments. 
rough estimate. Nevertheless they demonstrate that GAD6s is 
soluble and not membrane-anchored. Thus rat islets express 
two forms of GAD recognized by autoantibodies in IDDM, a 
soluble and hydrophilic form, GADso, of pi 6.9-7.1 and a 
second form, GAD,., of pi 6. 7 which is heterogeneous with 
regard to both subcellular localization and hydrophobicity. 
A Major Portion of GAD,. Is Firmly Membrane-anchored-
The results described above demonstrate that a subpopulation 
of GAD,. behaves as a soluble protein during traditional cell 
fractionation, and suggested that membrane-bound GAD&~ 
might not be an integral membrane protein, but rather asso-
ciated with the periphery of the membrane, such that it can 
be released during washing of the particulate fraction. To 
address this possibility, compounds which release peripheral 
membrane proteins were tested for their ability to release 
GAD64- Aliquots ofWP-100 fractions were incubated in Hepes 
buffer A supplemented with one of the following compounds: 
0.5 M NaCl; 0.2 M NazCOs (pH 10.9); 0.5 M NB..!PzO,; 0.2 M 
MgCb; or 50 mM EDTA. In addition, the detergent TX-100 
was used to release integral membrane proteins. After ultra-
centrifugation to remove insoluble material, the supernatants 
were analyzed for released proteins by immunoprecipitation 
and SDS-PAGE (Fig. 4). GAD64 in the WP-100 fraction was 
only released from the membranes in a significant manner by 
detergent, but not by any of the agents known to release 
peripheral membrane proteins. This result indicates that the 
hydrophobic GAD&~ exists in two different forms with regard 
to cellular compartments. One form, found in the 82-100 
fraction, is soluble or has a low membrane avidity. The other 
form, found in the WP-100 fraction, is 6rmly membrane-
anchored and, in the presence of enzyme inhibitors (Hepes 
buffer A), can only be released from the membrane by deter-
gent. Time-dependent spontaneous release of membrane an-
chored GAD64 from the WP-100 fraction can, however, take 
place in buffer compositions without enzyme inhibitors and 
may signify an endogenous enzyme capable of removing the 
determined by IEF/SD&-PAGEanalysis in separate experiments (not 
shown). Background spots are labeled with small numerals to enable 
comparison between different panels. 
-200 
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FIG. 4. SDS-PAGE analysis of GAD6 4 released from mem-
brane fractions in different conditions. [30S]Methionine-labeled 
rat islets were homogenized in homogenization buffer and separated 
into Sl-100 and a crude P-100. The crude P-100 fraction was resus-
pended in Hepes washing buffer, aliquoted in seven equal portions 
and ultracentrifuged. Each WP-100 aliquot was extracted in Hepes 
washing buffer supplemented as indicated with salts, detergent, 
EDT A, or nothing, and the extracts were immunoprecipitated with 
GAD antibody-positive IDDM serum (1) and a negative control serum 
(C) followed by analysis of GAD.,. in immunoprecipitates by SDS-
PAGE in standard Laemmli buffers and fluorography. 
membrane anchor of GAD&< and resulting in the amphiphilic 
but soluble 82-100 form. 3 
Differential Hydrophobicity of the Membrane-bound and 
Soluble Forms of GAD64-A portion of GAD64 consistently 
remained in the aqueous phase even after repeated detergent 
extractions and phase separations. This distribution pattern 
might either be due to its size precluding quantitative parti-
tioning into the detergent phase (Bjerrum et al., 1983), or to 
a heterogeneity in the protein with regard to hydrophobic 
properties. As shown above, a large proportion of GAD64 in 
both the 82-100 and WP-100 fractions partitioned into the 
TX-114 detergent phase. To investigate whether the soluble 
and membrane-bound fractions of GAD64 differed in their 
amphiphilic properties, we analyzed their distribution be-
tween the two phases. The 81-100, 82-100, and WP-100 
fraction were each subjected to a phase separation using 
identical buffer compositions in the three fractions. The dis-
tribution of GAD54 in the aqueous phase and detergent phase 
was analyzed by quantitative immunoprecipitation and SDS-
PAGE. The relative quantity of GAD64 in the different phases 
was estimated by densitometric scanning of fluorograms from 
nine experiments and compared to the distribution of total 
cell proteins (Fig. 5). In all the experiments, no differences in 
the ratio between the a and {3 forms of GAD64 were detected 
between the aqueous and detergent phases. In the nine inde-
pendent experiments, total cellular proteins in the 81-100 and 
82-100 fractions behaved similarly, with -10% and -11% 
distributing into the detergent phase, respectively. As ex-
pected, a much higher proportion, -55% of the total cellular 
proteins in the WP-100 fraction separated into the detergent 
phase. The corresponding figures for GAD64 in the detergent 
phases, as assessed after immunoprecipitation, were -8% in 
the 81-100, and -60% in the WP-100 fractions, respectively. 
The results show that the membrane-anchored and 82-100 
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FIG. 5. Quantitative analysis of the hydrophobicity of 
GADu in soluble and membrane·bound islet cell compart-
ments by TX-114 partitioning. Sl-100. 82-100, and WP-100 
fractions were prepared from portions of 2000 ['0S]methionine-la-
beled rat islets and subjected to phase separation as described under 
"Materials and Methods." The aqueous (a) and detergent (d) phases 
were subjected to quantitative immunoprecipitation with a GAD 
amibody-positive IDDM serum and a control serum followed by 
resolution of immunoprecipitates by SDS-PAGE in modified Laem-
mli buffers and fluorography. The density of bands on fluorograms 
was measured by densitometry. The bars show the percentage distri-
bution of total cellular proteins (open bars) and the GAD,. autoanti-
gen (shaded bars) into the detergent phase of Sl-100, 82-100, and 
WP-100 fractions. Mean ±S.D. was calculated from the results of 
nine experiments. 
forms of GADs4 are more hydrophobic than GAD64 found in 
the 81-100 cytosol fraction. Furthermore, the membrane-
anchored GAD64 and the 81-100 GAD&~ each follow the gen-
eral pattern of TX-114 partition characteristics in their re-
spective compartments. The hydrophobic characteristics of 
GAD&~ in the 82-100 fraction were, however, anomalous for 
that fraction, in that -50% partitioned into the detergent 
phase. GAD&< residing in this fraction is either cytosolic or 
has been released from the membrane, and yet displays a TX-
114 binding pattern resembling that of the protein in the 
particulate fraction. The data are compatible with the exist-
ence of three populations of GAD&< which differ with regard 
to compartment and hydrophobicity. One form is localized to 
the 81-100 fraction and is mainly hydrophilic. The second 
form, which is most concentrated in 82-100, has a signifi-
cantly increased hydrophobicity compared to the 81-100 form 
and seems to have a low membrane avidity. The third form, 
which predominates in the WP-100 fraction, has similar hy-
drophobicity as the 82-100 form but differs in being tightly 
membrane-bound. 
PuLse-chase Analysis of GADas and GAD64-Islets were la-
beled for short periods and then subjected to chase periods of 
1-48 h to assess the half-life of GADGo and GAD64 in soluble 
and membrane-bound compartments. The results of one such 
experiment are shown in Fig. 6. Based on densitometric 
scanning of the autoradiogram shown in Fig. 6 and of three 
other experiments it was concluded that a and (3 of GAD64 
had the same rate of turnover in each individual fraction, 
with the maximum incorporation at 4 h of chase. In contrast, 
GADBo had a maximum incorporation at 0 h of chase, and had 
a shorter half-life (::::4 h) than the GAD&-~ a/{3 doublet. GAD65 
was hydrophilic throughout the time course in that it did not 
separate into the detergent phase (data not shown). The half-
life of GAD6. in the three different fractions 81-100, 82-100, 
and WP-100 was estimated to be about 6-10 h in the 81-100 
WP-100 $2-100 
Chase 0 04223544 42235440 4223544 
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FIG. 6. Turnover of GAD80 and GADs4 a/fJ in soluble and 
membrane-bound compartments. Portions of 2000 islets were 
starved for 30 min in 2-ml methionine-free medium, the medium was 
decreased to 600 >tl and the islets were labeled for 40 min with 1 mCi 
of [30S]methionine. Islets were chased in medium containing five 
times the normal methionine content for the indicated number of 
f:lours and then washed and fractionated. S-100, 82-100, and an 
extract of WP-100 were immunoprecipitated and then analyzed by 
SDS-PAGE in modified Laemmli buffers and fluorography. Larw I 
shows an immunoprecipitate with control serum, lanes 2-16 with 
:ODM serum. The gel was fluorographed for 1 month to obtain an 
exposure suitable for densitometric analysis of GAD in the WP-100 
fraction (top panel) and then refluorographed for 3.5 months to obtain 
an appropriate exposure of GAD in the 81-100 and 82-100 fractions. 
The WP-100 fraction in the long exposure is shown in the lower panel 
for comparison. 
fraction, about 22-28 h in the 82-100 fraction, and about 20-
30 h in the WP-100 fraction. TX-114 phase separation of 
pulse-chase-labeled material showed that GADs• in the 81-
:~oo and 82-100 fractions displayed the same amphilicity 
pattern as demonstrated in the 4-h-labeled islets, i.e. the form 
predominating in 81-100 being hydrophilic and the 82·100 
and WP-100 forms being amphiphilic (about 50% distributing 
into the detergent phase, data not shown). These results 
suggest that the GAD&< autoantigen in the (3-cells is synthe-
sized as a hydrophilic soluble form which predominates in the 
Sl-100 fraction and then is processed into the hydrophobic 
forms seen in the 82-100 and WP-100 fractions by a matu-
ration process that results in membrane anchoring for the 
WP-100 form. 
Comparative Analysis of Brain and {3-Cell Forms of GAD-
We have shown that brain and (3-cell forms of GAD have 
identical mobility by SD8-PAGE and identical patterns on 
two-dimensional gels (NEPHGE/SDS-PAGE) Baekkeskov et 
aL, 1990), suggesting that islets and brain express identical 
forms of GAD and that GADGS and GAD&~ in islets correspond 
to the larger and smaller forms of GAD in brain (Chang and 
Gottlieb, 1988), respectively. The smaller brain form has been 
cloned and sequenced recently and shown to be encoded by a 
different gene than the larger form (Erlander et aL, 1991). 
Thus in brain the two forms are clearly different and do not 
have a precursor-product relationship. To further assess the 
possible identity between the GAD forms in the two tissues, 
the brain and /3-cell forms of GAD, as well as the larger brain 
form transfected and expressed in COS cells, were analyzed 
in parallel by immunoblotting using a set of distinctive anti-
bodies: 1) An antibody (1266) raised against a C-terminal 
peptide in the larger brain form, which recognizes both forms 
of GAD in brain (Fig. 7, lane 5), in agreement with the 
homology between the two forms at the C terminus (Erlander 
et aL, 1991); 2) an antibody which preferably recognizes the 
larger brain form (the K2 antibody, Kaufman et al., 1991); or 
3) an antibody which is specific for the smaller brain form 
(the GAD6 antibody, Chang and Gottlieb, 1988). As shown 
previously (Baekkeskov et al., 1990) the mobility of GAD65 
and GADM in islet cells on 8D8-PAGE was identical to that 
of the larger and smaller brain forms of GAD respectively 
(Fig. 7). The 1266 antibody recognized both GADas and GAD64 
in {3-cells (Fig. 7, lane 6). The K2 antibody specifically stained 
GADss in islets (Fig. 7, lane 3) in analogy with its staining of 
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FIG. 7. Comparison of islet and brain forms of GAD. Western 
blot of a soluble fraction {81-100 + 82-100) prepared from COS cells 
expressing the larger brain form of GAD (lanes 1,4, 7, and 10, 15 J.Lg 
of protein per lane), from rat brain (lanes 2,5,8, and 11, 25 1'-g of 
protein per lane), and from rat islets (lanes 3,6,9, and 12, 25 _.g of 
protein per lane). Lanes I-3 were probed with the K2 antisel:'l~m. 
which recognizes almost exclusively the larger form of GAD in brain 
(Kaufman et al., 1991, lanes 1 and 2). This antibody specific.ally 
recognizes GAD65 and does not show detectable staining of GADM in 
islets (lane 3). Lanes 4-6 were probed with the 1266 antiserum, which 
recognizes both forms of GAD in brain (lanes 4 and 5) and in islets 
(lane 6) and furthermore stains some background bands. Lanes 7-9 
were probed with the GAD6 ascites, which only recognizes the smaller 
form of GAD in brain {Chang and Gottlieb, 1988, lane 8). This 
antibody speciftcally binds GAD"" and does not react with GAD"' in 
islets (lane 9). 
the larger brain form of GAD in both the COS expression 
system and brain tissue (Fig. 7, lanes 1 and 2). In contrast 
GADs4 and the smaller brain form were specifically recognized 
by the GAD6 antibody which did not stain GAD,;;; or the 
larger brain form (Fig. 7, lanes 7-9). Those results are con-
sistent with GAD,;;; and GAD64 representing two distinct forms 
of GAD in pancreatic P-cells which are identical in size and 
antigenicity to the larger and smaller brain forms of GAD, 
respectively. 
DISCUSSION 
The 64-kDa autoantigen, which is a major target of auto-
antibodies associated with insulin dependent diabetes has 
been identified as the GABA-synthesizing enzyme glutamic 
acid decarboxylase in pancreatic P-cells (Baekkeskov et aL, 
1990). In the present report we have used human autoanti-
bodies to identify and characterize the different autoantigenic 
forms of this enzyme in membrane-bound and soluble frac-
tions of pancreatic 13-cells in steady state and pulse-chase-
labeling experiments. Although GAD has been detected in 
both membrane bound and soluble compartments of brain 
(Chang and Gottlieb, 1988; Baekkeskov et al., 1990) and [3-
cells (Baekkeskov et al., 1990), this study represents the first 
detailed characterization of membrane bound and soluble 
forms of this enzyme. 
The results show that pancreatic [3-cells express two distinct 
forms of GAD, a larger form of Me. approximately 65,000 
(GADss), which is hydrophilic and soluble and has a pi of 6.9-
7.1, and a smaller form of M" approximately 64,000, and pi 
6.7 (GAD 64), which partitions between soluble and membrane 
bound compartments and is heterogeneous with regard to 
amphiphilicity. The pulse-chase analysis suggests that both 
GAD% and GADs• are synthesized as hydrophilic soluble 
molecules, which are predominantly found in the S1-100 
fraction, and that only GAD64 is posttranslationally modified 
to become an amphiphilic molecule which can either be solu-
ble or firmly membrane anchored. It is conceivable that GADs• 
is modified by hydrophobic residues in a two-step process, 
which results in first a hydrophobic form which is either 
soluble or of a low membrane avidity and which is predomi-
nantly found in the S2-100 fraction and second, a firmly 
membrane-anchored form found in the WP-100 fraction. The 
second step may be reversible.3 The modification of GADs4 is 
not accompanied by detectable changes in size or charge, 
suggesting that the modification is mediated by small hydro-
phobic noncharged residues. Based on those results we pro-
pose that the membrane anchoring is mediated by a small 
lipid or fatty acid(s). 
2D gel electrophoretic analysis of the GAD forms in rat 
brain and islets showed that both tissues have a larger and a 
smaller GAD form of similar size and pi (Baekkeskov et aL, 
1990). Based on the 2D gel electrophoretic analysis (Baekkes-
kov et aL, 1990) and the size and immunochemical compari-
sons of the brain and [3-cell forms presented here, we conclude 
that the 65- and the 64-kDa [3-cell form correspond to the 
larger and smaller brain forms of GAD, respectively. We have 
recently isolated eDNA spanning the entire amino acid coding 
region for GAD65 in rat islet cells. Sequencing of the cDNA4 
confirmed that the sequence of GAD66 in islets is identical to 
that of the larger GAD form in rat brain (Julien et al., 1990; 
Wyborski et al., 1990). The amino acid sequence of the GADs5 
form does not contain membrane anchoring domains (Julien 
et aL, 1990; Wyborski et al., 1990) in agreement with the 
soluble hydrophilic properties of GAD65 demonstrated in the 
present study. Similarly the amino acid sequence of the 
smaller rat brain form of GAD does not contain stretches of 
hydrophobic amino acids (Erlander et al., 1991), in agreement 
with our results that GAD64 in islets is also being synthesized 
as a hydrophilic soluble molecule. The amphiphilic properties 
of the more mature GAD64 and the ability of this form to 
become membrane anchored, however, clearly distinguishes it 
from GADGs, which remains hydrophilic and soluble through-
out its lifetime. 
What is the subcellular localization of GAD? In brain, 
electron microscopic studies suggest that GAD is present in 
proximity to or associated with the membrane of synaptic 
vesicles which contain GABA (Wood et al., 1976). Immuno-
gold electron microscopic analysis of pancreatic sections sug-
gest that GAD is localized to the membrane of small vesicles 
in .8-cells, which contain GABA and stain for the synaptic 
vesicle protein synaptophysin (Aanstoot et al., 1991; Reetz et 
al., 1991). It is thus conceivable that membrane bound GAD 
may become visible at the surface following fusion of GABA-
containing vesicles with the plasma membrane during secre-
tion. However the exact subcellular distribution of the two 
forms of GAD in brain and P-cells remains to be elucidated. 
The two forms of mammalian GAD are encoded by two 
distinct and unlinked genes (Erlander et aL, 1991). The reason 
why two different forms of GAD have evolved is unknown. It 
is conceivable that the differences in compartmentalization 
of the two GAD forms demonstrated in this study may affect 
their enzymatic functions and influence the intracellular 
routes of transport and secretion of their product, GABA. 
Furthermore the .ability of the smaller [3-cell form to be either 
membrane bound or soluble may reflect the possibility to 
control its amount in membrane compartments, a character~ 
istic which may influence the visibility of the protein to the 
immune system. 
Ackrwwledgment.s~We thank Dr. A. Tobin for donating the K2 
antiserum and a eDNA clone for the larger brain form of GAD, and 
for discussing the results of the sequencing of the smaller brain form 
'A. Covacci and S. Baekkeskov, unpublished results. 
64kD. GAD. Tvoe 1 Diabetes and Stiff-man Syndrome 122 
with us before publication; Dr. J. S. Petersen for donating the 1266 
antibody; Dr. D. Gottlieb for donating the GAD6 monoclonal anti-
body, and Dr. R. Kaufman for donating the 910238 vector. We thank 
L. M. Thousig, A. B. Andersen, and M. R. Williamsson for e:y;cellent 
technical help, H. Richter-Olesen, Dr. N. Zhan-Po, and the Hagedorn 
islet isolation group for isolation of rat islets, D. A. Crumrine for 
electron microscopic analysis, and D. Esson for manuscript prepara-
tion. 
REFERENCES 
Aanstoot, H.-J., Christgau, 8., Crumrine, D., and Baekkeskov, S. 
(1991) J. Cell. BiocMm. SuppL 15A, 306 (abstr.} 
Atar, D., Dyrberg, T.,,Michelsen, B., Karlsen. A., Kofod, H., M0lvig, 
J., and Lernmark, A. (1989} J. lmmunol. 143, 533-538 
Baekkeskov, S., Nielsen, J. H., Marner, B., Bilde, T., Ludvigsson, J., 
and Lernmark, A. (1982) Nature 298, 167-169 
Baekkeskov, S., Landin, M., Kristensen, J. K., Srikanta, S., Bruining, 
G. J., Mandrup-Poulsen, T., de Beaufort, C., Soeldner, J. S., Eisen-
barth, G., Lindgren, F., Sundquist, G., and Lernmark, A. (1987) J. 
Clin. I nuest. 79, 926-934 
Baekkeskov, S., Markholst, H., and Christie, M. (1988) in Lessons in 
Animal Diabetes (Shafrir, E., and Renold, A. E., eds} pp. 40-45, 
John Libbey & Co., London 
Baekkeskov, S., Warnock, G., Christie, M., Rajott, R. V., Yfose-
Larsen, P., and Fey, S. (1989} Diabetes 38, 1133-1141 
Baekkeskov, S., Aanstoot, H.-J., Christgau, S., Reetz, A., Soiimena, 
M., Cascalho, M., Folli, F., Richter-Olesen, H., and De Camilli, P. 
(1990) Nature 347, 151-156 
Bjerrum, 0. J., Larsen, K. P., and Wilken, M. (1983) in Modern 
Methods in Protein CMmistry (Tschesche, H., ed) pp. 79-124, 
Walter de Gruyter & Co., New York 
Bordier, C. (1981) J. Bioi. CMm. 256,1604-1607 
Bradford, C. (1976} AnaL Biachem. 72, 248-254 
Castano, L., and Eisenbarth, G. S. (1990} Annu. Reu. Immunol. 8, 
647-679 
Chang, Y.-C., and Gottlieb, D. I. (1988} J. Neurosci. 8, 2123-2130 
Christie, M., Landin-Olsson, M., Sundkvist, G., Dahlquist, G., Lern-
mark, A., and Baekkeskov, S. (1988) D!abetologia 31, 597-602 
Christie, M., Pipeleers, D., Lernmark, A., and Baekkeskov, S. (1990) 
J. Bioi. Chern. 265, 376-381 
ErdO, S. L., Joo, F., and Wolff, J. R. (1989} Cell Tissue Res. 255, 
431-434 
Erlander, M. G., Tillakaratne, N.J. K., Feldblum, S., Patel, N., and 
Tobin, A. J. (1991) Neuron 7, 91-100 
Fey, S., Mose Larsen, P., and Biskjaer, N. L. (1984) Ph.D. thesis 
Faculty of Natural Sciences, Aarhus University, Denmark 
Garry, D. J., Sorenson, R. L., Elde, R. P., Maley, B. E., and Madsen, 
A. (1986) Diabetes 35, 1090-1095 
Julien, J.-F., Samama, P., and Mallet, J. (1990) J. Neurochem. 54, 
703-705 
Katarova, Z., Szabo, G., Mugnaini, E., and Greenspan, R. J. (1990) 
Eur. J. Neurosci. 2, 190-202 
Kaufman, D. L., McGinnis, J. F., Krieger, N. R., and Tobin. A. J. 
(1986} Science 232, 1138~1140 
Kaufman, D. L., Houser, C. R., and Tobin, A. J. (1991) J. Neurochem. 
56, 720-723 
Kobayashi, Y .• Kaufman, D. L., and Tobin; A. J. (1987) J. Neurosci. 
7' 2768-2772 
Laemmli, U.K. (1970) Nature 227, 680-685 
Legay, F., Henry, S., and Tappaz, M. (1987) J. Neurochem. 48, 1022-
1026 
Mugnaini, E., and Oertel, W. H. (1985} in Handbook of Chemical 
Neuroanatomy GABA and Neuropeptides in the Central Neruous 
System (Bjorklund, A., and HOkfelt, T., eds} VoL 4, Part 1, pp. 
436~608, Elsevier, Amsterdam 
O'Farrell, P. H. (1975) J. Bioi. Chern. 250, 4007-4021 
O'Farrell, P. H., Goodman, H. M., and O'Farrell, P. Z. (1977) Cell 
12, 1133-1142 
Reetz, A., Solimena, M., Matteoli, M., Folli, F., Takei, K., and De 
Camilli, P. (1991) EMBOJ. 10, 1275-1284 
Reusens-B\llen, B., Pirlot, X., Remade, C., Iloet, J. J., and de Gas-
para, M. (1984} Cell Tissue Res. 235, 503-508 
Rorsman, P., Berggren, P.-O., Bokvist, K., Ericson, H., Mohler, H., 
Ostenson, C.-G., and Smith, P. A. (1989) Nature 341, 233-234 
Sigurdsson, E., and Baekkeskov, S. (1990) Curr. Top. Microbial. 
Immun.ol. 164, 143-167 
Wong, G. G., Witek, J. S., Temple, P. A., Wilkens, K. M., Leary, A. 
C., Luxenberg, D. P., Jones, S. S., Brown, E. L., Kay, R. M., Orr, 
E. C., Shoemaker, C. S .. Golde, D. W., Kaufman, R. J., Hewick, R. 
M., Wang, E. A., and Clark, S. C. (1985) Science 228, 810-815 
Wood, J. G., McLaughlin, B. J., and Vaughn, J. E. (1976} in GABA 
in Neruous System Function (RobertS, E., Chase, T. ;:-.J., and Tower, 
D. B., eels} pp. 133-148, Raven Press, New York 
Wyborski, R. J., Bond, R. W., and Gottlieb, D. I. (1990) Mol. Brain 
Res. 8, 193-198 
64kD. GAD Tvoe 1 Diabetes and Stiff-man Svndrome 123 
2.3.2 
Membrane Anchoring ol the Autoantigen GAD55 to Microvesicles in 
Pancreatic B-cells by Palmiloylalion in the NH2-Terminal Domain 
Journal ol Cell Biology 1992; 118: 309-320. 
(with permission) 
64kD. GAD. Tvoe 1 Diabetes and Stiff-man Svndrome 124 
64k0, GAO, Type 1 Diabetes and Stiff-man Syndrome 125 
Membrane Anchoring of the Autoantigen GAD65 to Microvesides in 
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Abstract. Pancreatic 13-cells and -y-aminobutyric acid 
(GABA)-secreting neurons both express the enzyme 
glutamic acid decarboxylase (GAD) which is a major 
target of autoantibodies associated with 13-cell destruc-
tion and impairment of GABA-ergic neurotransmitter 
pathways. The predominant form of GAD in pancreatic 
!3-cells, GADGs, is synthesized as a soluble hydrophilic 
molecule, which is modified to become firmly mem-
brane anchored. Here we show by immunogold elec-
tron microscopy that GAD6s is localized to the mem-
brane of small vesicles which are identical in size to 
small synaptic-like microvesicles in pancreatic 13-cells. 
THE )'-aminobutyric acid (GABA)!-synthesizing en-zyme glutamic acid decarboxylase (GAD) is ex-pressed at comparable levels in GABA-secreting neu-
rons and in pancreatic )3-cells in the islets of Langerhans 
(Okada et al., 1976). GABA is a major inhibitory neuro-
transmitter in the CNS, whereas its function in islets remains 
elusive. The expression of GABA,.. receptors on the glucagon 
producing a-cells in islets (Rorsman et al., 1989) suggests 
that GABA may play a role in paracrine signaling within the 
islet. GAD has been identified as the 64-kD autoantigen of 
the )3-cells (Baekkeskov et al., 1990), to which autoanti-
bodies arise concomitant with !3-cell destruction and the de-
velopment of insulin-dependent diabetes mellitus (IDD~\.1) 
(Baekkeskov et al., 1982, 1987; Atkinson et al., 1990). Fur-
thermore, GAD in neurons is an autoantigen in stiff-man 
syndrome, a rare neurological disease characterized by a 
high coincidence with IDDM (Solimena et al., 1990). The 
Steinunn Baekkeskov's current address is Hormone Research Institute and 
the Departments of Microbiology/Immunology and Medicine, University 
of California, San Francisco, CA 94143-0534. Correspondence should be 
addressed to Steinunn Baekkeskov. 
1. Abbr<'Vimions used in this paper: GABA, )'-aminobutyric acid; GAD, 
glutamic acid decarboxylase; IDDM, insulin dependent diabetes mellitus; 
PIG, phospatidyl inositol glycan; PIPLC, phosphatidyl inositol-specific 
phospholipase C; RP-HPLC, reverse phase high pressure liquid chromatog-
raphy; 51, First cytosol fraction; 52, second cytosol fraction; SMS, >tiff-
man syndrome; TX-114, Triton X-114; WP, washed panicle fraction. 
The NHrterminal domain of GAD6s is the site of a 
two-step modification, the last of which results in a 
firm membrane anchoring that involves posttranslational 
hydroxylamine sensitive palmitoylation. GAD6s can be 
released from the membrane by an apparent enzyme 
activity in islets, suggesting that the membrane an-
choring step is reversible and potentially regulated. 
The hydrophobic modifications and consequent mem-
brane anchoring of GAD6s to microvesicles that store 
its product GABA may be of functional importance 
and, moreover, significant for its selective role as an 
autoantigen. 
reasons for the unusual susceptibility of the GAD molecule 
to becoming an autoantigen are unclear, and their elucida-
tion is a major goal. Neurons express two GAD proteins en-
coded by two distinct genes. The proteins differ mainly in the 
first 100 amino acids, but share extensive homology in the 
remainder of the molecules (Erlander et al., 1991). 
We have identified two GAD proteins in pancreatic )3-cells 
(Baekkeskov et al., 1990; Christgau et al., 1991). The larger 
65-k.D protein, which is expressed at low levels in rat islets, 
is hydrophilic and soluble throughout its lifetime and was 
shown to be identical to the larger GAD protein in brain 
(Christgau eta!., 1991). This protein is now called GAD67 
(also called GAD-1 and previously GAD65). The smaller 
64-k.D protein, which is the major GAD protein in !3-cells, 
was shown to be identical to the smaller GAD protein in 
brain, with regard to antigenic epitopes, size and charge 
(Christgau et al., 1991). A comparison of the primary struc-
ture of the smaller GAD protein in islets (Karlsen et al., 
1991) and the smaller GAD protein in brain (Bu et al., 1992) 
shows that they are identical. This protein is now called 
GAD6s (also called GAD-2 and previously GAD64). GAD65 
is also synthesized as a hydrophilic and soluble molecule but 
matures into a fmnly membrane anchored protein in a pro-
cess that seems to involve two steps (Christgau et al., 1991). 
The first step results in a hydrophobic molecule which is 
soluble or has a low membrane avidity. The second step 
results in me1'1brane anchoring. Thus three distinct forms of 
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GAD65 can be detected in pancreatic !3-cells, a hydrophilic 
soluble form, a hydrophobic form that is soluble or has a low 
membrane avidity, and a finnly membrane-bound form that 
can only be released from membranes by detergent, and thus 
has the characteristics of an intrinsic membrane protein. The 
maturation of GAD65 does not involve detectable changes in 
size or charge, which suggests that membrane anchoring 
may be mediated by a small lipid (Christgau et al., 1991). 
Although antibodies in many diabetic and stiff-man syn-
drome patients recognize both GAD61 and GADos in their 
native configuration. the incidence of antibodies to GAD65 
is significantly higher than to GAD61 (our unpublished 
results). Furthermore, GADos, but not GAD07 , possesses a 
primary structure epitope or epitopes that are recognized by 
stiff-man syndrome antibodies but not by IDDM antibodies 
(Baekkeskov et al., 1990). Thus GAD65 has autoamigenic 
properties that clearly set it aside from GAD07 and that may 
be related to its subcellular targeting to membrane compart-
ments. GAD is an intracellular enzyme, but its exact subcel-
lular localization is not known. Immunohistochemical stain-
ing and confocal microscopy analysis of neurons and 13-cells 
showed colocalization of GAD with GABA and synaptophy-
sin, a marker protein for synaptic vesicles (Reetz et a!., 
1991). Such studies have also demonstrated the localization 
of GAD and GABA to a vesicular compartment, which is 
clearly distinct from the insulin secretory granules in 13-cells 
(Sorenson eta!., 1991: Reetz eta!., 1991) and which was ten-
tatively identified as synaptic vesicles in neurons and synap-
tic like microvesicles in 13-cells (Reetz et al., 1991). Im-
munoperoxidase EM of brain sections and immunogold EM 
of brain and islet cell homogenates using GAD antibodies 
however did not show GAD immunoreactivity in synaptic 
vesicles but rather localized GAD to the cytoplasm and in 
the proximity of synaptic vesicles in neurons and around 
membranes of pleomorphic microvesicles of tubular and 
cisternal elements, as well as throughout the cytoplasm in 
pancreatic 13-ce!ls (Wood eta!., 1976; Reetz et al., 1991). 
Furthermore, GAD could not be recovered on synaptic vesi-
cles or synaptic-like microvesicles nor in other membrane 
compartments after subcellular fractionation (Reetz et al.. 
1991). The EM analysis and the subcellular fractionation 
data are consistent with the localization of GAD61 in the 
cytoplasm, but raise questions about the subcellular local-
ization of the membrane bound GADo,. 
In this report we have analyzed the subcellular localization 
ofGAD6s in intact islets by immunogold EM. Furthermore, 
we have characterized the hydrophobic membrane anchoring 
domain in the GAD65 molecule and addressed the question 
of whether GADo1 is modified by one or more of the lipid 
moieties which are known to mediate membrane anchoring 
of proteins, i.e., phosphatidylinositolglycan (PIG) poly-
isoprenyl groups, and/or fatty acids (Sefton and Buss 1987; 
Hancock et al., 1989; Casey et al., 1989). We present evi-
dence that GADo5 is anchored to the membrane of vesicles, 
which are likely to be the synaptic-like microvesicles in 
13-cells, and that membrane anchoring is achieved by a post-
translational hydroxylamine-sensitive palmitoylation in the 
NHrterminal region of the molecule where GADos differs 
significantly from GAD67 • The membrane anchoring is re-
versible, which may reflect the possibility of controlling the 
amount of the protein in membrane compartments. 
Materials and Methods 
Antibodies 
53, a sheep antiserum raised to purified rat brain GAD (Oertel et al .. 1980), 
was a gift from I. Kopin (National Institutes of Health). The GAD6 mAb 
(Chang and Gottlieb, 1988) was a gift from D. Gottlieb (Washington 
University, St. Louis, MQ). A polydonal rabbit antibody (1266) raised 
against a synthetic peptide containing the carboxyl-tenninal sequence of rat 
GAD6; (Cys-Thr-Gln-Ser-Asp-Ile-Asp-Phe-Leu-Ile-Glu-Glu-Ile-Glu-Arg-
Leu-Gly-Gln-Asp-Leu) (Wyborski eta!.. 1990) was a gift from J. S. Peter-
sen (Hagedorn Research Laboratory, Gentofte. Denmark}. Sera from IDDM 
patients with high titers of GAD autoantibodies have been described earlier 
{Baekkeskov eta!., 1989). 
Isolation of Islets and Biosynthetic Labeling 
Rat islets were used in all experiments described in this >tudy except that 
biosymhetic labeling with 3H-fatty acids was also carried out using human 
islets. !solation of human and rat islets, maintenance in culture and radioac-
tive labeling with e5s]methionine for 4 h was carried out as described 
(Baekkeskov et al.. 1989). For biosymhetic labeling with fatty acids, islets 
were washed twice by centnfugation in DME containing 16 mM glucose 
and supplemented with 5 mM Na-pyruvate, 5 mglml fatty acid free BSA. 
100 U/ml penicillin, 100 ,_.glml streptomycin. and nonessential amino acids 
(FA medium). Islets were labeled for 4 hat 37°C in the same medium con-
t~.ining either (9, !Ol 1H-palmitic acid or (9, 10) 1H-myristic acid (50-60 
Cilmmol. Amersham Corp., Arlington Heights. ILl at 800 ~tCilml. In ex-
periments to analyze effect of emetine in labeling experiments, islets were 
preincubated with 10 ~tM emetine followed by [l'S]methionine labeling for 
4 h in the presence of 10 J.'M emetine. Similarly in experiments with 
mevinolin (a kind gift from Dr. A. W. Alberts, Merck, Sharp, and Dohme 
Research Laboratories, Rahway, NJ), islets were preincubated for 1 h with 
10, 20. 30. 40, or 50 J.<M mevinolin and then labeled for 4 h with [3'S]me-
thionine in the presence of the same concentrations oi mevinolin. For bio-
symhetic labeling with 3H-mevalooic acid, islets were preincubated for 1 h 
with 50 !J.M mevinolin in FA medium and labeled with 3H-mevalono lac-
tone (36 Cilmmol. New England Nuclear DuPont Co., Wilmington, DEl 
at 250 J.<Ci/ml for 4 h. Islets were also labeled with 3H-myoinositol (90.5 
Cilmmol. Amersham Corp.), 3H-ethanolamine (40 Cilmmol, Amersham 
Corp.) and 3H-g!ucosamine {32 Cilmmol, Amersham Corp.) for 6 h in 
RPM! 1640 containing 16 mM glucose and supplemented with 1% FCS. 
0.5% human serum. 100 Ulml penicillin, 100 ~J.glml streptomycin, and iso-
tope at 200 J.'Cilml. Labeled islets were harvested by centrifugation, washed 
twice in nonradioactive medium and once in 20 mM Hepes, pH 7.4, !50 
mM NaCl and 10 mM benzamidineiHCl, and then either immediately 
processed for homogenization and isolation of soluble and particulate frac-
tions or snap frozen and stored in aliquots at ~sooc. 
Expression ofGAD~s in Sf9lnsect Cells 
Recombinant GAD6s baculovirus vecwrs were constructed by ligating a 
2.4-kb EcoRl fragment of rat GAD6s eDNA clone pGAD-92 (a kind gift 
from Dr. A. Tobin, UCLA) into the EcoRl site of the baculovirus transfer 
vector pVLJ392 (Invitrogen. San Diego, CA). Clone pGAD-515 containing 
the sense orientation for GADos was used in a calcium phosphate cotrans-
fection with wild-type Autographa californica nuclear polyhedrosis virus. 
Recombinant viruses were then isolated as described (Summers and Smith, 
1987), For radiolabeling of GAD6s in insect cells. Spodopterofrugiperda 
Sf9 cells were infected with recombinant baculovirus. 48 h later the cells 
were labeled for 4 h with either 3H-palmitate, 'H-myristate, 1H-meva-
lonolactone at 800 1-'Ci/ml. or ' 55-methionine at 80 ~J.Cilml as described 
above for islets, except thai labeling was in Grace medium. 
Fractionation of Islets and Sf9 Cells 
Separation of soluble and membrane-bound fractions was carried out by two 
methods described in detail previously (Christgau et al., 1991; Baekk:eskov 
et al., 1990). The first method involves homogenization in an isotonic 
Hepes/sucrose buffer (10 mM HepesiNaOH, pH 7.4, 0.25 M sucrose. 10 
mM benzamidine/HCl. 0.1 mM p-chloromercuribenzene sulfonic acid and 
0.25% Trasylol) (Christgau et al., 1991) followed by ultracemrifuga~ion at 
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!00,000 g or higher for I h to separate a crude particulate and a cytosol 
{51) fraction. The crude particulate fraction is then resuspended in Hepes 
buffer A (]0 mM Hepes/NaOH, pH 7.4, 150 mM NaCl. 10 mM benzami-
dineiHCl. 0.25% Trasylol, 0.1 mM P-chloromercuribenzene sulfonic acid 
and 0.1 mM Na,V04) followed by llltracemrifugation at 100,000 g or 
higher for 1 h resulting in a new cytosol fraction. 52. and a washed particu-
late fraction, WP. The Sl fraction prepared by this method comains mainly 
GADo1 and the hydrophilic soluble form of GADo5. The crude particulate 
fraction contains both a hydrophobic firmly membrane anchored GAD65 
and hydrophobic GADo5 which is either soluble or has a low membrane 
avidity. The two hydrophobic GAD6s tOrms separate into the WP and S2 
fractions, respectively (Christgau et aL, 199\). The second method uses 
homogenization in a hypotonic Hepes buffer (10 mM HepesiNaOH, pH 7.4·. 
1 mM EGTA. l mM MgCh. 1 mM aminoethylisothiouronium bromide 
hydrobromide, and 0.2 mM pyridoxal5'-phosphate (Hepes buffer B) (Baek-
keskov eta! .. I 990). tbllowed by ultracentrifugation at 100,000 g or higher. 
The hypotonic conditions result in release of most of the hydrophobic. solu-
ble, or low membrane avidity GAD6o form into the cytosol and combir::e 
in one fraction the soluble forms of GAD65· The membrane fraction con-
tains the firmly membrane-anchored hydrophobic GAD6s form which can 
only be released by detergents. 
Proteins were extracted from the particulate fractions with l% Triton 
X-114 CTX-114} in either Hepes buffer A or B. as described (Baekkeskov 
et al.. 1990: Christgau et al., 199\). 
TX-114 Partitioning Assays 
TX-114 detergent phase separations of detergent extracts of particulate frac-
tions or of soli;ble fractions after addition of TX-114 were performed ac-
cording to Bordier (1981) (Baekkeskov et al.. 1989). For comparative analy-
ses of the amphiphilic properties of GADns in different fractions. buffer 
compositions were adjusted to obtain identical conditions in each fraction. 
Experiments with Phosphatidyl Inositol-specific 
Phospholipase C 
The phosphatidyl inositol-specific phospholipase C {PIPLC) used for these 
experiments was either from Bacillus lhuringiensis (a kind gift from Or. M. 
Low, The Rockefeller University. New York) or Bacillus cereus (Boehringer 
Mannheim Corp .. Indianapolis. IN). Islets were homogenized in isotonic 
Hepes buffer and the P~100 fraction washed twice by resuspension nd 
ultracentrifugation followed by resuspension and incubation for 30. 60. or 
120 min at 0. 13. 24. and 37°C in the presence or absence ofPIPLC at con-
centrations ranging from 125 mU/ml to 5 U!mi. Experiments were per-
formed using three different buffer compositions for washings of the P-100 
fraction and the incubations with and without PIPLC. Hepes buffer C ;vas 
10 mM Hepes/NaOH. pH 7.4. supplemented with 0.25% Trasylol. Hepes 
buffer D was 10 mM Hepes/NaOH. pH 7.4, supplemented with 10 1-'g/ml 
pepstatin A, 20 1-'giml leupeptin, 10 1-'g/ml antipain. and 0.01% TrasyloL 
Buffer E was 10 mM Tris/HCI, pH 7.5. 0.25 M sucrose. 5 mM PMSF. 5 
mM iodoacetate, I mM \eupeptin. and 100 I-'M N-a-p-tosyl-L·lysine chlo-
romethyl ketone. Hepes buffer A was used for control incubations. 
lmmunochemical Analysis and Gelelectrophoresis 
SDS-PAGE. immunoprecipitation, and immunoblolling were performed as 
described {Baekkeskov eta!., 1989, 1990: Christgau eta!.. 199!). 
Chemical Analysis of the Fatty Acid Group 
For reverse phase high pressure liquid chromowgraphy (RP-HPLC) analy-
sis of covalently bound fatty acids. 1 H-palmitate~labeled GADos was ex-
cised from SDS-gels and the gel pieces were incubated for 2 h at 30°C in 
L5 M NaOH in 20% methanol tO release fauy acids followed by pentane 
extraction to remove neutral lipids. The reaction mixture was acidified with 
HCl and fauy acids extracted into pentane. The free fatty acids isolated 
from GADo5 and cold standards were derivatized to their corresponding 
phenacyl esters according to Wood and Lee (1983), and analyzed on anAl-
tex C-\8 ultrasphere reverse phase HPLC column. Bound material ·.vas 
eluted with a linear gradient of 75-100% acetonitrile. Absorbance at 242 
nm and cpms were measured in the eluted fractions. For RP-HPLC analysis 
of total fatty acids in Sf9 cells, the membrane fraction was extracted with 
chloroform methanol. hydrolyzed. and analyzed as described above. Peaks 
were identified by comparison with the retention time for cold fatty acid 
smndards carried along through the denvatization procedure. 
Tryptic Cleavage of GAD 
TX-114 detergent phase purified particulate and soluble fractions prepared 
in hypotonic Hepes buffer were diluted to 1% TX-114 and incubated with 
and without trypsin as described (Baekkeskov et aL, 1990) followed by a 
renewed phase separation and analysis of aqueous and detergent phases by 
immunobloning. To analyze the ability of trypsin tO release GADM from 
membranes, aliquots of P-100 were prepared, washed two times in Hepes 
buffer B. resuspended in 200 Iii of the same buffer, and incubated for 1 h 
at 25oc in the presence or absence of 4.0 U trypsin (Sigma Chern. Co .. St. 
Louis, MO). The trypsin digestion was terminated by placing the samples 
on ice and adding 1/10 vol of 10 mM Hepes/NaOH. pH 7.5, 5 mM benzami-
dine/HCL 5 mM EDTA. 5 mM N!14Pc0c. and 1110 vol of 1 mg/ml soya 
bean trypsin inflibitor in water. Particulate material was sedimented by 
ultracentrifugation at 265.000 g. Released material and particulate extracts 
were subjected to TX-114 phase separation followed by Western blot analy-
sis of GAD in the different fractions. 
Spontaneous Release ofGAD65 from 
Membrane Fractions 
Islets were homogenized in 10 mM Hepes. 150 mM NaCl. pH 7.4 (Hepes 
buffer F). The P-100 particulate fraction was washed twice in the same 
buffer and separated into aliquots. Membrane aliquots were resuspended in 
either Hepes buffer F or in the same buffer supplemented with 0.1 mM 
PCMBS. 5 mM EDTA. 0.25% trasylol. 5 mM NaF. 10 mM benzami-
dine!HCl. 0.1 mM :-l"a3V04. pH 7.4. and incubated for 5, 15, 45. and 75 
min at 25°C, respectively. followed by centrifugation at 265.000 g for 30 
min and analysis of released material by Western blotting. 
Electron Microscopy 
Immunogold electronmicroscopy was performed on neonatal rat islets. 
which had been maimained in culture for 3-5 d. Islets were fixed for 6 h 
in 4% paraformaldehyde, 0.1% glutaraldehyde in 100 mM cacodylate buffer 
containing 0.2 mM CaCh, and 4% sucrose. Islets were postfixed for 15 
min in 1% Os04, 1.5% ferricyanide in 0.1 M 2,4.6-trimethylpyridine and 
for 30 min in 2% aqueous uranyl acetate. Dehydration and embedding in 
LR White resin (medium hardness: Polysciences Inc., Warrington, PA) was 
performed as described (Newman et aL. 1983). 50-nm sections were cut 
on a U\tracut E microtome (Reichard Jung, Deerfield, IL) and placed on 
grids. Antibody incubation was for 18 h with the GAD antiserom 1266 or 
53 (dilution 1:100) followed by incubation with appropriate 10-nm gold-
conjugated secondary antibodies (E-Y Labs., San Mate\J, CA). Control 
grids were stained with normal sheep or rabbit serum followed by the sec-
ondary antiserum or with secondary antiserum only. Grids were coated with 
formvar and viewed on a JECL-JOOC transmission electron microscope at 
60 kV. !3-cells as well as non-!3-cells (a-cells. exocrine cells) were viewed 
on each grid and subjected to quantitative analysis by counting the gold par-
ticles. u-cells and exo-crine cells did nm differ significantly in total gold par-
ticle counts and a-cells were selected as control cells for further subcellular 
analysis. Gold particles were counted in 19 !3-cells on \9 different grids 
representing 4 different islet isolations and in 7 adjacent 0'-cells stained with 
the 1266 anubody. 1821 gold particles were detected in the !3-cells, giving 
95.8 ± 17 (mean ± SO) particles per $-celL The 0'-cell counts revealed 
226 particles or 32.3 ± 4.7 particles per a-cell. As a control six !3-cells (227 
particles. 41.3 ± 2.5 per !3-cell) and five adjacent a-cells (165 particles. 33 
:!:: 4.7 per 0'-cell) were counted on six grids stained with normal rabbit se-
rum. Ceils were divided into the following subcellular areas during the 
quantitative analysis: small vesicles of diameter 30-60 nm (49.6 ± 17.6, 
mean ± SD). ER/Golgi, other membranes (including plasma membranes 
and unidentified membranes), cytoplasma, nuclei. large dense core vesicles 
(insulin or glucagon secretory vesicles), mitochondria/other (other = 
unidentified subcellular structures). The mean values for each fraction ob-
tained with the 1266 serum were corrected by subtraction of mean values 
obtained with the nonimmune serum and the pooled standard deviations 
calculated. 
Results 
GAD~s Is Localized to the Membrane of Small Vesicles 
To analyze the subcellular localization of GAD~s, sections 
of fixed and embedded rat islets were sectioned and sub~ 
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jeered to imrnunogold staining using both the S3 antiserum, 
which has a high immunoreactivity to GAD6s but reacts 
only weakly with GADo, in immunoprecipiration experi-
ments and on Western blots (results not shown), and the 1266 
antiserum, which recognizes both forms (Christgau eta!., 
1991). The specificity of EM·immunogold labeling of fixed 
and embedded tissue with both antisera was high and the sen-
sitivity low (Fig. 1). The predominant immunolabeling for 
GAD with either antiserum was in the membrane of small 
vesicles (30-60 om in diam) in !3-cells (Fig. 1, A-C). The 
F::gure 1. Electron micrographic analysis of GAD expression ·m 
pancreatic islet cells. (A and B) Micrographs of 13-cell areas show-
ing the localization of GAD by an immunogold labeling technique. 
The sections shown in A and B were stained with the S3 antiserum 
to GAD. Some microvesicles with a dear core (V) show GAD 
staining in the membrane. Insulin-containing secrewry granules (i) 
are characterized by a typical halo around a dense granule core. Mi. 
mitochondrion. (C) Quantitative analysis of the localization of 
GAD in different subcellular areas of 13 (black bars) and Q-cells 
(shaded bars) on electronmicrographs subjected to immunogold la-
beling using the 1266 antiserum to GAD. N0 p is the corrected 
nllmber of gold particles obtained by subtracting nonimmune se-
rum values from those produced with the GAD specific 1266 an-
tiserum as described in Materials and Methods. SO is indicated on 
the bars. SMLV. small vesicles 30-60 nm in diam; WCV. large 
dense core vesicles which secrete insulin or glucagon; ERIC, ER 
and Golgi membranes; 0/M. other nonidentified membranes and 
plasma membranes: Cyr. Cytoplasm: Nuc, Nuclei: Mir/0 Mito· 
chondria and nonidentified subcellular structures. Bars, 240 nm. 
specificity of this localization is illustrated by the number of 
gold particles detected in this compartment in i3·cells im· 
munolabeled with the 1266 antiserum (29.7 ± 6.6 parti-
cles/cell, mean ± SD) which was rv60-fold higher than the 
labeling of comparable small vesicles in a-cells (0.4 ± 0.7 
particles/cell), and 60-75-fold higher than nonspecific label-
ing of small vesicles in (3- and a-cells produced with a 
nonimmune serum (0.5 ± 0.8 particles/cell and 0.4 ± 0.5 
particles/cell, respectively). The gold particles in 13-cells la-
beled with nonimmune serum and in a-cells labeled with 
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either GAD antiserum or nonimmune serum were concen-
trated in the cytoplasm, mitochondria, and nuclear fractions. 
The results of a quantitative analysis of electronmicrographs 
immunolabeled with the 1266 antiserum and corrected for 
background immunolabeling with nonimmune serum (Fig. 
1 C) indicate that "-'50% of the specific immunolabeling for 
GAD in /3-cells is localized to the membrane of the small 
vesicles, 18% is found in insulin secretory granules, 14% in 
ER/Golgi membranes, 12% in other membranes (unidenti-
fied membranes and plasma membranes), and 6% in the cy-
toplasm. The low level of specific GAD immunolabeling in 
the cytoplasm of ,S-cells is consistent with the low level of 
cytosolic GAD67 protein in these cells and with the majority 
of the GAD6s protein being membrane associated (Chris,:-
gau et al., 1991). The specific GAD immunolabeling in in-
sulin granules was detected in the perigranular space but 
not in the dense insulin core. The gold particles sometimes 
formed characteristic circular structures of 30-60 run in di-
ameter just inside the insulin secretory granule membrane 
(results not shown) suggesting that they represent small vesi-
cles that have fused with the insulin granule. This result, 
which merits further investigation, suggests that the small 
GAD-positive vesicles can fuse with and perhaps release 
GABA into the insulin secretory granules. The specific GAD 
immunolabeling in all companments was restricted to 
/S~cells. Thus the number of gold particles in a~cells (Fig. 
1 C) and exocrine cells (results not shown) was not sig~ 
nificantly different from background immunolabeling with 
nonspecific serum, which is consistent with the IS-cell spe-
cific expression of GAD (Okada et al., 1976; Baekkeskov et 
al., 1990; Sorensen eta!., 1991). The results provide evi~ 
dence that GAD6s is predominantly localized to the mem-
brane of microvesicles in the pancreatic /S~cell. The small 
vesicles are clearly distinct from the insulin granules in those 
cells (Fig. 1) and are likely to be the synaptic~ like microvesi-
cles containing GABA which have been described in /S~cells 
(Reetz et al., 1991). This result raises questions of the mech~ 
anism by which this subcellular localization is achieved. The 
following sections characterize the membrane anchoring of 
GAD~s. 
Palmitoylation Distinguishes Membrane-bound and 
Soluble Forms of GAD6s 
Depending on the conditions by which islets of Langerhans 
are homogenized and separated into soluble and particulate 
fractions, hydrophilic soluble GAD6s (Sl-form) and hydro-
phobic soluble or low membrane avidity GAD6s (S2~form) 
can either be released simultaneously (in hypotonic Hepes 
homogenization buffer), or sequentially (in isotonic Hepes/ 
sucrose homogenization buffer followed by resuspension of 
a crude particulate fraction in an isotonic Hepes buffer and 
resedimentation of membranes to form WP). The hydropho~ 
hie membrane~anchored GAD65 (WP~form) can, in both 
conditions, only be released from the particulate fraction by 
detergent (Christgau et al., 1991 and results not shown). 
Two~dimensional gel electrophoretic analyses of the mem~ 
brane~anchored and soluble GADos forms has not revealed 
any differences in size or charge between the different forms 
(Christgau et al., 1991), suggesting that the hydrophobic 
modification and membrane anchoring is mediated by a fatty 
acid or a small neutral lipid. 
To assess the possibility that GADM contains fatty acids 
either covalently linked to the protein backbone or as a part 
of a larger lipid structure, human and rat islets were labeled 
for 4 h with either >H~palmitic acid or 3H-myristic acid at 
the same specific activity. Islets were homogenized in iso-
tonic conditions and the two cytosolic fractions, Sl and S2, 
and the washed WP were prepared. GAD6s was isolated by 
immunoprecipitation and analyzed by SDS-PAGE and fiuo-
rography (Fig. 2). The incorporation of radioactivity was de~ 
tected in GAD65 immunoprecipitated from detergent lysates 
of whole human islets (results not shown) and only in the 
washed membrane fractions but not the cytosolic Sl and S2 
fractions ofrat islets labeled with >H-palmitic acid (Fig. 2). 
Incorporation of radioactivity into GAD65 was not detected 
in experiments with 3H~myristic acid (results not shown). 
The absence of label in background bands and in soluble 
forms of GAD65 in the immunoprecipitates from 3H-pal-
mitic acid-labeled material (Fig. 2) suggested that the incor~ 
poration of tritium into membrane~bound GAD65 was not 
due to conversion of label to radioactive amino acids. Thus 
the results suggest that palmitic acid itself or a lipid deriva-
tive of palmitate is covalently linked to the membrane an~ 
chored but not the soluble forms of GAD.,~ and is involved 
in the membrane anchoring of the enzyme. 
Palmitoylation ofGAD6s Is a PosttranSlational Event 
Palmitoylation of some cellular proteins is greatly reduced 
when protein synthesis is inhibited, indicating that acylation 
in these cases is cotranslational (Magee and Counneidge, 
1985; Olson et al., 1985). In contrast, acylation of other pro-
teins, including p21 N~ras (Magee et al., 1987), GAP 43 
(Skene and Virag, 1989), and others (Olson and Spizz, 
1986), is unaffected by these inhibitors, showing that acyla-
tion of these proteins is posttranslational. To assess whether 
the incorporation of radioactivity into membrane-anchored 
GAD65 in the presence of 3H-palmitic acid is dependent on 
protein synthesis, we analyzed the effect of emetine, an in-
hibitOr of protein biosynthesis (Fig. 2 B). The presence of 
10 ~M emetine did not inhibit incorporation of radioactivity 
into rnembrane~anchored GAD6o in labeling experiments 
with 3H-palmitic acid (Fig. 2 B, compare lanes 4 and 7), 
despite inhibiting (3 5S)methionine incorporation >90%. 
This result shows that the labeling of the membrane-
anchored GADo5 in the presence of 3H-palmitic acid is a 
posttranslational event independent of protein synthesis and 
excludes the possibility that the protein is labeled by biosyn~ 
thetic incorporation of 3H amino acids derived from palmi-
tate. The data do not, however, exclude the possibility that 
GAD6s is modified posttranslationally by a lipid derivative 
of palmitate. 
GAD Is Palmitoylated in Sj9 Insect Cells 
Sf9 insect cells have been shown to correctly modify ex-
pressed proteins with both palmityl (Lanford, 1988), myris-
tyl (Gheysen et al., 1989), and isoprenyl moieties (Khosravi-
Far et al., 1991). Since GAD6s is a rare protein in pancreatic 
l3~cells (Baekkeskov et al., 1989), and since the autoradio-
graphic detection of 3H is very insensitive, we assessed 
whether recombinant GAD65 expressed at high levels in Sf9 
cells could be used to further characterize 3H~palmitate-la~ 
beled GAD6s. GAD65 was distributed in soluble and mem-
brane~bound fractions in Sf9 cells, much as in pancreatic 
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Figure 2. Posttranslational incorporation of palmitic acid into membrane-bound but not soluble forms of GAD65 . (A) Radioactive labeling 
of membrane bound GAD60 in the presence of 3H-palmitic acid. Rat islets were labeled in the presence of 3H-palmitic acid for 4 h and 
subjected to homogenization in isotonic conditions to prepare a cyw·solic (SJ) and a crude membrane fraction. The crude membrane frac-
tion was washed by resuspension and centrifugation resulting in a supernatant (S2) containing mainly cytosolic proteins and WP fractions. 
The Sl fraction (lanes 6 and 7), was concenm~ted fivefold and subjec'!ed to imrnunoprecipitation together with 2/3 of the S2 (lanes 4 and 
5) and 1/3 of the WP fraction (lanes 6 and 7) to obtain similar levels of GADM in each fraction. Immunoprecipitation was performed 
first with control serum (C) (lanes 3. 5 and 7) and then with IDDM serum(/) (lanes 2, 4, and 6). Immunoprecipitates were analyzed 
by SDS-PAGE in modified Laemmli buffers followed by fiuorography. A shan exposure to visualize (35S]methionine-labeled GAD67 and 
GAD65 components immunoprecipitated from the SI fraction of 1,000 islets is shown in lane 1. Note that GADM splits into two compo-
nents o: and {3, which have been shown to be identical with regard to all parameters analyzed except mobility on SDS-PAGE. (B) Effect 
of emetine on incorporation of radioactivity into membrane-bound GADM in the presence of palmitic acid. Rat islets were preincubated 
in FA medium either with or without 10 nM emetine for l hand then labeled with 3H-palmitic acid in the same medium for 4 h. Aliquots 
of rat islets were incubated in parallel with or without emetine and labeled with P'S)methionine. Sl, S2, and WP fractions were prepared, 
immunoprecipitated with IDDM serum (!), and analyzed by SDS-PAGE in modified Laemmli buffers and fiuorography. Fluorography 
shown for [3.lS]methionine-labeled proteins was for 14 d with emetine (lanes 1, 2, and 3), at which time lanes without emetine were com-
pletely black (not shown). Fluorography for 3H-labeled proteins witt. (lanes 4-6) and without emetine (lane 7) was for 3 mo. Note that 
in this experiment the GAD6s {3 component is more pronounced than o: in lanes 2. 3, 4, and 7. The position of molecular mass markers 
is indicated in kilodaltons. 
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Figure 3. Cellular localization and hydroxylamine sensitivity of 3H palmitate labeled GAD6s in Sf9 cells. S£9 cells were infected with bac-
ulovirus containing the rat GAD65 eDNA and grown in the presence of either [;5S]methionine or 3H-palmitic acid and separated into a 
cytosolic and a membrane fraction after homogenization in hypotonic conditions. Cytosol and membrane fractions from 'H-palmitic 
acid-labeled islets were immunoprecipitated with either the GAD6 rnAb or an irrelevant mAb (C). Immunoprecipitates were divided into 
three equal size aliquots and analyzed in triplicate by SDS-PAGE (lanes2-5, 10-13, and 18-21) in parallel with an aliquotofnonimmunopre-
cipitated cytosol and membrane fractions of 'H-palmitate-labeled material (lanes 7, 8, 15, 16, 23, and 24) and an immunoprecipitate of 
a ['5S]methionine-labeled membrane fraction (lanes 6, 14 and 22). The triplicate gels were either untreated or incubated in either 1 M 
hydroxylamine, pH 8, or 1 M Tris, pH 8, before processing for fiuorography. Molecular mass markers indicated in kilodaltons are shown 
in lanes 1, 9, 17, and 25. 
{3-cells. Again, as in {3-cells, membrane-bound GAD6s be-
haved like an intrinsic membrane protein, which could only 
be removed by detergent and not by salt, EDTA, or basic pH 
treatment (results not shown). Consistent with the results in 
{3-cells, incorporation of radioactivity from 1H-palmitate 
was detected in membrane-bound but not soluble GADos in 
Sf9 cells (Fig. 3). 
Palmitoylation ofGAD6J Is Hydroxylamine Sensitive 
Hydroxylamine at pH 8.0 is used as a method for a gentl·e 
removal of fatty acid from proteins (Omary and Trowbridge, 
1981; Magee et al., 1984) and can be used as a diagnostk: 
test of a thioester- or ester-linked fatty acid. Incubations of 
3H-palrnitic-labeled membrane-bound GAD65 on SDS-poly-
acrylamide gels with hydroxylamine efficiently removed the 
radioactivity (Fig. 3, lanes 13 and ](i) without loss of (35S]-
methionine-labeled GAD6s (Fig. 3, lane 14). 
The fatty acid composition of the 3H-palmitate-labeled 
St9 cells was analyzed to assess whether palmitate had been 
converted to other fatty acids during the labeling period. 
Fatty acids were extracted from a membrane fraction pre-
pared from the cells which contained 91% of the incorpo-
rated label. The fatty acids were derivatized and analyzed by 
reverse phase high performance liquid chromatography (RP-
HPLC). Fatty acid standards were cochromatographed to al-
low the identification of extracted fatty acids. 51% of the in~ 
corpora ted label in Sf9 cells was found as palmitic acid, 26% 
was found as myristic acid, 10% was found as stearic acid, 
and 13% was found as minor unidentified peaks. (Fig. 4 A}. 
The label incorporated into GADM was identified by excis-
ing radiolabeled GADM from gels, followed by hydrolysis 
under alkaline conditions. The released fatty acids were ana-
lyzed by RP-HPLC and identified by cochromatography with 
standards. Only palmitic acid was detected in GAD65 ex-
cised from gels (Fig. 4 B). Thus the incorporation of radio-
activity into membrane-bound GAD65 in the presence of 'H 
palmitic acid represents palmitoylation of the protein and not 
incorporation of a palmitate-derived fatty acid confirming 
that the acylation of GADM is specific for palmitic acid. 
The analyses of membrane-bound and soluble fonns of 
GAD65 suggested that the hydrophobic soluble and hydro-
phobic membrane-bound GAD65 represent differential stages 
of a two-step posttranslational modification with hydropho-
bic residues. Thus, attachment of the first hydrophobic resi-
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Figure 4. Identification of palmitic acid as the lipid attached to 
GAD6s. (A) Reverse phase HPLC analysis of 3H~labeled fatty 
acids isolated from 3H-palmitic acid-labeled Sf9 ceUs. The posi-
tions of myristate, palmitate, and stearate were identified by co-
chromatography with standards. (B) Analysis of 3H-Iabeled fatty 
acids isolated from GADos purified from 3H-palmitic acid-labeled 
Sf9 cells. The palmitate peak was identified by cochromatography 
with standards. The peak in the beginning of the chromatOgram is 
nonderivatized fatty acids. 
due would result in soluble hydrophobic GAD6s and then 
palmitoylation of this form would result in the membrane-
anchored form. 
To examine the possibility that the GADss autoantigen in 
!3-cells is polyisoprenylated and that this modification is re-
sponsible for the hydrophobicity of the S2 form, we tested 
whether 3H-mevalonate was incorporated into GAD65 in ei-
ther rat islet cells or Sf:9 cells. The results of those experi-
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ments were negative, suggesting that a polyisoprenyl moiety 
is not a part of the hydrophobic modification and membrane 
anchoring of GAD6S (data not shown). Mevinolin, an inhib-
itor of polyisoprenyl synthesis, also inhibited protein synthe-
sis in islet cells, but did not inhibit hydrophobic modification 
and membrane anchoring of GAD6s significantly. The re-
sults are consistent with the absence of the known COOH-
tenninal consensus sequences forpolyisoprenylation, CAAX, 
CC, or CXC (Hancock et al., 1989; Khosravi-Far et al., 
1991) in GADos (Erlander et al., 1991). 
Spontaneous and Time-dependent Release of GAD65 from Membranes 
In the initial phases of this study we had assessed whether 
GADos was membrane anchored by a PIG moiety (for re-
view see Ferguson and Williams, 1988). In this type of mem-
brane anchor, the diacylglycerol moiety of the PIG is in-
serted into the lipid bilayer of membranes, but can be 
removed by the action of exogenous or endogenous phos-
phatidyl inositol specific phospholipase C (PIPLC) (for re~ 
view see Ferguson and Williams, 1988). 
Several lines of evidence, however, led to the conclusion 
that GAD6s is not modified by a PIG residue. First, no in-
corporation of radioactivity into GAD6s was detected in the 
presence of 3H-inositol, 3H-ethanolamine, or 3H-glucos-
amine which are building blocks of the PIG anchor. Second, 
if the soluble and membrane-bound forms of GAD55 differed 
by a PIG moiety, they would be expected to have different 
isoelectric points, which is not the case (Christgau et al., 
1991). 
Finally, we analyzed the ability of PIPLC to release 
GAD6s from washed islet cell membranes in the presence of 
buffers with and without components which either inhibit or 
stimulate the activity or PIPLC. The standard Hepes buffer 
A, which contains a cocktail of proteolytic and other enzyme 
inhibitors, was used in control experiments. These experi-
ments revealed that GAD6s was released from the mem-
branes in all conditions except in buffer A, but equally with 
and without the addition of PIPLC. Taken together, the 
results suggest that an endogenous enzyme, which is in-
hibited in the conditions of Hepes buffer A, can cleave the 
membrane anchor and release GAD6s. Exogenously added 
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Figure 5. Time-dependent re-
lease of GAD65 from mem-
branes. Washed membrane 
fractions prepared from rat is-
lets homogenized in hypotonic 
conditions were resuspended 
and incubated in the presence 
or absence of protease inhibi-
tors for the indicated length of 
time and then repelleted by ul-
tracentrifugation at 265,000 g. 
The release of GAD6s was 
analyzed by imrnunoprecipi-
tation of supernatants, SDS-
PAGE, and immunoblotting 
with the 1266 COOH-tenninal 
peptide antibody. GADss released during a 60-min incubation without enzyme inhibitors was subjected to a TX-114 phase separation to 
analyze the distribution into detergent (d) and aqueous (a) phases (lanes 9 and 10). 
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Figure 6. Absence of hydrophobic and membrane anchoring moieties in a 55-kDC-terminal trypsin fragment of GAD65 . (A) Tx-114 deter-
gent phase was prepared from a cyto~ol and membrane fraction isolated from rat islets homogenized in hypotonic conditions. The detergent 
phases were incubated with and without trypsin followed by a new TX-114 phase separation. The detergent phase (d) and aqueous phase 
(a) from this last separation were analyzed by SDS-PAGE followed by Western blotring and immunostaining with the COOH-terminal 
peptide antiserum 1266. (B) Washed membranes were prepared from rat islets homogenized in hypotonic conditions resuspended and incu-
bated with and without trypsin followed by ultracentrifugation at 265.000 g. The supernatants and TX-114 extracts of residual membranes 
were subjected to phase separation and aqueous (a) and detergent (d) phases were analyzed by SDS-PAGE. Western blotting. and immune-
staining with the COOH-terminal peptide antiserum 1266. 
PIPLC does not. however. affect this release, consistent with 
the membrane anchor not having the properties of a PIG 
residue. 
To analyze the release of GAD 65 further, washed mem-
branes prepared from islets, were incubated with and with-
out enzyme inhibitors for different periods of time. No re-
lease of GADM from membranes was detected in the 
presence of enzyme inhibitors. In the absence of enzyme in-
hibitors, however, amphiphilic GAD65 was released from 
membranes in a time-dependent fashion (Fig. 5), suggesting 
that islets contain an enzyme activity which can cleave the 
GAD6s membrane anchor, but not the hydrophobic moiety 
of the soluble S2 form. GAD65 released from membranes of 
islet cells did partition into the TX-114 detergent phase (Fig. 
5, lanes 9 and 10, see also Fig. 6 B), suggesting that there-
lease represents a conversion of the firmly membrane an-
chored form to the soluble but still hydrophobic S2 form. In 
addition a 55-kD hydrophilic fragment of GAD6s was de-
tected in the fraction released from the membrane in some 
experiments (Fig. 5, lane 10), suggesting either that the pro-
tein can also be released from the membrane by proteolytic 
cleavage or that released GAD65 is susceptible to proteo-
lytic cleavage. 
Localization of the Hydrophobic 
Membrane Anchoring Region ofGAD65 to a Fragment 
at the NH2 Tenninal 
We addressed the localization of the hydrophobic residue(s;1 
and membrane anchor in the GADM protein by analyzing 
the hydrophobicity of fragment(s) generated by mild trypsin 
digestion of the hydrophobic soluble and membrane forms 
of GADo:;. Islets were homogenized in a hypotonic buffer 
and cytosol and membrane fractions prepared. The am-
phiphilic proteins in both fractions were purified into the de-
tergent phase of TX-114 and incubated with and without 
trypsin followed by a new TX-114 phase separation. The de-
tergent and aqueous phases from this last phase separation 
were analyzed by SDS-PAGE and immunoblotting using an 
antiserum raised against a 19-amino acid COOH-tenninal 
peptide of the larger brain form of GAD (GAD 51). Because 
of an extensive homology at the COOH terminus between 
GAD~7 and GAD~s (Erlander et al., 1991), this antiserum 
recognizes both forms equally well. The results are shown 
in Fig. 6 A. Trypsin digestion resulted in a 55-kD fragment 
in both the soluble and the particulate fraction, which was 
recognized by the COOH-terminal peptide antibody, and 
therefore contains the COOH-terminal part of the GAD mol~ 
ecule. 
In incubations without trypsin, GAD65 from both soluble 
and particulate fractions partitioned into the TX-114 deter-
gent phase. The 55-kD fragment from both fractions was, 
however. exclusively detected in the aqueous phase and had 
thus lost its hydrophobic moiety (Fig. 6 A). The results sug-
gest that the hydrophobic residue(s) in both the soluble and 
membrane anchored form reside in a 9-lO~kD fragment at 
the NHrterminus. 
We next analyzed whether trypsin was able to release 
membrane~bound GAD65 • The particulate fraction was 
resuspended and washed three times in TBS to remove 
loosely associated proteins. and then incubated with and 
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without trypsin for 1 h. Released proteins were analyzed by 
western blotting (Fig. 6 B). Although a minor fraction of 
full-length amphiphilic GAD65 is released spontaneously 
from the membranes in those conditions (Fig. 6 B. lanes 1 
and 2), the majority ofGAD65 remains membrane-anchored 
(Figure 6 B, lanes 5 and 6). In experiments containing tryp-
sin, GAD65 was released from the membranes as a 55-kD 
hydrophilic COOH-terminal fragment (Fig. 6 B), indicating 
that the membrane-anchoring moiety resides in a 9-10-kD 
fragment at the NHderminus. Attempts to detect the NH1-
terminal fragment following trypsin digestion by immuno-
blotting were unsuccessfuL Thus, a small (9-10 kD) fragment 
was not detected by immunostaining with the polyclonal an¥ 
tibody S3 nor with the monoclonal antibody GAD6. It is con¥ 
ceivable that neither antibody reacts with the NHrterminal 
fragment or that the fragment is further digested into small 
fragments by trypsin since it comains several basic residues 
(Erlander et aL, 1991). In attempts to detect the NHder-
minal fragment, the trypsin experiments described above 
and shown in Fig. 6 A and B were repeated using 3H¥pal¥ 
mitic acid-labeled Sf9 cells and analysis by SDS¥PAGE fol¥ 
lowed by both ftuorography of gels as well as immunostaining 
of Western blots using the COOH-terminal peptide antibody 
1266. In those experiments tOllowing trypsin treatment, as 
expected 3H-palmitic acid labeling was only detected in re¥ 
sidual particulate full¥length GADo;- but not in the 55 kD 
fragment (results not shown). A residual 9-10 kD fragment 
was detected in ftuorograms of total extracts of membranes 
treated with trypsin but not in membranes from control incu¥ 
bations and may represent the 3H¥palmitoylated NH1¥termi¥ 
nal fragment of GAD65 (not shown). Consistently this frag¥ 
ment did not stain with the 1266 antibody on Western blots. 
In sum the experiments with trypsin provide evidence that 
the hydrophobic modification and membrane anchoring of 
GAD65 takes place in the NH2-terminak 9-10-kD part of the 
protein. 
Discussion 
In pancreatic islets GADo;- undergoes membrane anchoring 
in a process that involves a two-step modification. The first 
step results in a hydrophobic molecule which is soluble or 
has a low membrane avidity. The second step results in a firm 
membrane anchoring. (Christgau et aL, 1991). The results 
described herein show that the second step involves a hy-
droxylamine-sensitive palmitoylation, and results in a mole-
cule with intrinsic membrane protein propenies. GAD65 can 
be released from islet cell membranes in a time-dependent 
manner, in a process in which enzyme activity is implicated, 
suggesting that the second step is reversible and that GAD6s 
may be flexible in its membrane-anchoring properties. Im-
munogold EM analysis with GAD antibodies show clear 
labeling of the membrane of small vesicles in pancreatic 
!3-cells. which are similar in size to synaptic-like microvesi-
cles (Reetz et al., 1991) and clearly distinct from the insulin-
containing secretory vesicles in those cells. The EM results 
shown here are consistent with data from immunohistochem-
ical analysis of GAD and GABA in !3-cells and neurons by 
confocal microscopy (Sorenson et al., 1991; Reetz et al., 
1991), which show localization of both to a vesicular com-
partment. This companment was shown to be concentrated 
in nerve terminals and in the distal portions of neurite-like 
extensions in /3-cells, and was tentatively identified as synap-
tic vesicles in neurons and synaptic-like microvesicles in 
!3-cells by colocalization with synaptophysin (Reetz et al., 
1991). Based on the confocal microscopy data (Sorenson et 
al., 1991; Reetz et al., 1991), on the electron microscopic 
analysis shown here, and on the demonstration of the intrin-
sic membrane protein propenies of GADos (Christgau et al., 
1991, this study, and unpublished results) we conclude that 
the membrane-anchored form of GAD6;- is localized to the 
membrane of synaptic-like microvesicles containing GABA 
in !3-cells and synaptic vesicles in neurons. A previous im-
munogold EM study using embedded brain and islet-cell 
homogenates (Reetz et al., 1991) has shown concentrations 
of GAD immunoreactivity in the proximity of synaptic vesi-
cles in brain and synaptic-like microvesicles containing 
GABA in pancreatic !3-cells. However this study did notre-
veal an association of GAD with those microvesicles. This 
previous failure to detect GAD in synaptic vesicle mem-
branes by immunogold EM of homogenized islets, and by 
subcellular fractionation (Reetz et al., 1991) is most likely 
because of the reversible nature of the membrane anchoring 
we have now documented. In fact, preparation of membranes 
in the absence of enzyme inhibitors and at elevated tempera-
tures or at weak alkaline pH can result in the majority of 
GAD65 being recovered as soluble (our unpublished results). 
Furthermore, even in the absence of trypsin a fraction of 
GAD is often recovered as a 55-kD soluble and hydrophilic 
COOH-terminal fragment (Christgau et al., 1991; and this 
study), suggesting that GAD may also be released from mem-
branes by proteolytic cleavage during homogenization and/ 
or further fractionation of cells. 
The characteristics of the posttranslational modifications 
and the subcellular and amphiphilic properties of the differ-
ent forms of GAD6, resemble in many ways those of the ras 
proteins (Hancock eta!., 1989) and the rab GTP-binding 
proteins (for review see Balch, 1990), all of which exist both 
in a soluble hydrophobic and a membrane-bound hydropho-
bic form, with intrinsic membrane protein propenies. The 
latter group includes the rab 3A and 38 proteins which are 
also found in the membrane of synaptic vesicles (for review 
see Siidhof and Jahn. 1991). The posttranslational modifica-
tion and membrane anchoring of the ras and the rab proteins, 
however, involves isoprenylation and carboxymethylation at 
the COOH terminus which contains either a CAAX, CXC, 
or CC motif(Hancock et al., 1989; Farnsworth et al., 1991; 
Kohsravi-Far et al., 1991). GADo;- does not contain an iso-
prenylation motif at the COOH terminus (Erlander et al., 
1991) and does not seem to undergo this modification. Rather, 
the first modification of GAD 65 appearS to involve a differ-
ent mechanism. The second modification of GAD65, how-
ever, does resemble that of some of the ras proteins in being 
a palmitoylation that results in firm membrane anchoring. 
Furthermore, as for ras proteins (Magee et al., 1987), the 
membrane anchoring is reversible. 
Interestingly, GADo5 can be posttranslationally modified, 
palmi toy lated, and membrane anchored in insect Sf9 cells 
and in cos cells (our unpublished results), which apparently 
do not contain synaptic-like microvesicles. This result sug-
gests that the posttranslational modification of GAD6, and 
its targeting to synaptic vesicles are separate events. Post-
translational modification and membrane anchoring may 
take place before budding of membrane vesicles from the 
64kD. GAD Tvoe 1 Diabetes and Stiff-man Svndrome 135 
Golgi complex. Then perhaps the final targeting of the 
membrane-anchored form to synaptic-like microvesicles in 
P'-cells and synaptic vesicles in neurons depends on interac-
tion with components of synaptic vesicles which are absent 
in Sf9 and cos cells. 
Relevance for Function 
In cerebral cortex, both GABA and glutamate have been 
shown to be stored in synaptic vesicles. It is however unclear 
whether those amino acids reside in the same or different 
vesicles (Burger et al., 1991). Membrane-anchored GAD0~ 
may therefore be localized so as to provide GABA directly 
to the vesicle that secretes it, thereby coordinating enzymatic 
activity and GABA secretion. An important question is 
whether GAD65 resides in the lumen or at the cytosolic face 
of the vesicles. In the first case the enzyme would be in the 
immediate proximity of glutamate and/or GABA. It is nota-
ble that GAD65 lacks a known signal sequence (Erlander et 
al., 1991) and thus would require a novel transport mecha-
nism to achieve a luminal localization. If GAD is anchored 
at the cytoplasmic face, which seems most likely, it could as-
sociate with its substrate glutamate and release its product 
GABA in coordination with their transporters in the mem-
brane of synaptic vesicles (Burger et a!., 1991 and references 
therein). 
In rat pancreatic 13-cells membrane attachment is the ex-
clusive property of the predominant GAD65 form and is not 
detected in the minor nonallelic protein, GAD 61, which re-
mains hydrophilic and soluble throughout its lifespan (Christ-
gao et al., 1991). GAD65 and GAD61 are most divergent in 
the first 100 amino acids but share in high degree of ho-
mology in the remainder of the molecules (Erlander et al., 
1991). Taking advantage of a trypsin sensitive hot spot, we 
have now shown evidence that the area of hydrophobic modi-
fication and membrane anchoring of GAD65 resides in the 
9-10-k.D fragment at the NH2 terminus where this protein 
differs most significantly from GADo1. 
The reason why two genes encoding distinct versions of 
this enzyme have developed and why /3-cells preferably ex-
press GADM is not known. GADo, binds the coenzyme 
pyridoxal phosphate more tightly and is less dependent on 
exogenous coenzyme than GAD65 , which is mainly found in 
the apoenzyme form (Martin et al., 1991). Accordingly 
GAD6s activity is more sensitive to pyridoxal phosphate 
levels than GAD67 (Kaufman et al., 1991). In neurons 
GAD6s has been shown to be predominantly localized to 
nerve endings (Henry and Tappaz 1991; Kaufman et al. 
1991) consistent with its localization in the membrane of syn-
aptic vesicles which concentrate proximal to the synaptic 
membrane. GAD67 is however predominantly localized in 
the cell bodies of neurons (Kaufman et al., 1991; Henry and 
Tappaz, 1991). It is conceivable that the localization of the 
pyridoxal phosphate inducible form. GAD65, to the mem-
brane of the vesicles that store and secrete its product GABA 
has a regulatory purpose and serves to accommodate sudden 
increases in GABA demand. Interestingly there are examples 
of other enzymes involved in the synthesis of transmitters 
that are anchored to the membrane of granules that store and 
secrete them. Thus tyrosine hydroxylase, the initial and rate-
limiting enzyme in the biosynthesis of the catecholamines. 
and dopamine /3-hydroxylase, the final enzyme in the synthe-
sis of norepinephrine, exist in both soluble and membrane-
bound forms and the latter have been localized to the mem-
brane of chromaffin granules in the adrenal medulla (Kuhn 
et al., 1990; Bonet a!., 1991). 
Relevance for Autoimmunity 
The correlation in autoimmunity toward pancreatic /3-cells 
and brain neurons is remarkable, especially as it is revealed 
in the development of autoantibodies which recognize the 
same antigen, the 64-kD form of glutamic acid decarboxy-
lase. A second nonallelic form of this enzyme encoded by 
a distinct gene, GAD67 , is apparently only of secondary im-
portance. GAD67 lacks the primary epi.topes which are anti-
genic in SMS (Baek.keskov et al., 1990), and evidences a 
lower incidence of specific autoantibodies in IDDM (our un-
published results). It is therefore provocative that these two 
proteins are clearly distinguished by an NH2-terminal re-
gion which determines hydrophobic modification. subse-
quent palmitoylation, and consequent membrane anchoring 
and subcellular localization. Only GADM has these two 
posttranslational modifications that confer hydrophobicity, 
membrane attachment, and association with microvesicles. 
It is of note that palmitoylated influenza peptides induce po-
tent cytotoxic T-cell responses in vivo whereas their non-
palmitoylated counterparts do not (Deres et al., 1989). Per-
haps one of the posttranslational modifications, or the 
selective localization of GAD6s into a membrane compart-
ment that is secretory in nature is instrumental for its role 
as an autoantigen in these two diverse but coinciding autoim-
mune diseases. 
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Summary 
Antibodies to the 64kD autoantigen in type 1 diabetes, now identified as the 
65kD form of the GABA synthesizing enzyme Glutamic Acid Decarboxylase (GAD), 
are markers of ongoing B-cell destruction. Analysis of these autoantibodies is 
usually performed by immunoprecipitation of islet protein fractions with patient 
sera. The identification of the 64kD autoantigen as Glutamic Acid Decarboxylase 
(GAD) allowed the development of recombinant expression systems lor GAD. It 
has been suggested that not all 64kD ·lmmuno-activity precipitated from islets is 
accounted lor by GAD65· We analyzed if recombinant GAD55 is suitable lor im-
munoprecipitation in 48 newly diagnosed diabetes patients and 135 controls. The 
same sera were tested using the original 64kD immunoprecipitation method with 
rat islets. Two eukaryotic expression systems, one in the Baculovirus infected SF9 
insect cells and one in translected COS-7 cells, were used. The SF9 expressed 
GAD55 showed aggregation of GAD55, resulting in false positive samples. The 
COS expressed GAD65 was suitable for immunoprecipitations and the assay was 
improved using pretreatment of the protein A Sepharose®. The sera analysis 
showed that from 48 newly diagnosed patients, 38 were ICA positive (79%). Using 
COS expressed GAD65, 39 patients were positive for GAD 55 autoantibodies 
(81 %). The comb'1nation of ICA and COS-GAD55 was detected 90% (43 of 48) of 
the patients. One control of 135 tested samples was positive (0.7%). Using the 
islet 64kD method 35 of the 48 patient sera were positive (73%) and 1 of the 135 
controls (0.7%). The 4 disparate patients which were negative in the rat islet assay 
were weakly posHive in the COS-7 cell assay. We conclude that 1) GAD ex-
pressed in Baculovirus infected SF9 cells is unsuitable for immunoprecipitations; 
2) Analysis of GAD antibodies using COS expressed GAD55 can be more sensi-
tive than immunoprecipitation of 64kD/GAD65 expressed in rat islets; 3) The 
GAD55 antibody positive sera include all 64kD antibody positive sera. Further 
simplification of the GAD-autoantibody assay will make these antibodies important 
markers in the prediction of type 1 diabetes. 
Introduction: 
Glutamic Acid Decarboxylase (GAD/ 64kD protein), the key enzyme in the 
synthesis of the neurotransmitter GABA, is a major target for humoral autoimmunity 
in type 1 diabetes mellitus (1). Two forms of GAD exist, for which two non-allelic 
genes code (2). GAD57 is a hydrophilic molecule and is present in human GABA-
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ergic neurons and in B-cells of rats (3, 4). The GADss isoform can be membrane 
bound (5), and is the only form expressed in human islets (6, 7). GAD antibodies 
are the first to appear in the preclinical stage of type 1 diabetes and can be found 
in up to 80% of the prediabetic individuals (8, 9). At clinical onset of the disease 
the antibodies are present in at least 80% of newly diagnosed patients (1 0). The 
high frequency and early appearance of the antibodies make them important 
parameters of beta cell destruction. Moreover, the study of GAD and GAD-
antibodies provides a model that can help to elucidate the pathogenesis of 
autoimmune B-cell destruction. Dissection of this process will enable to design 
strategies that aim at primary prevention of the disease. However, prevention will 
only be feasible and cost effective if adequate prediction is available. This is 
emphasized by the fact that in most countries only 5-10% of new cases of diabetes 
have a family history of the disease (11 ), ·,mplying that most cases occur in the 
general population. Thus, screening of populations will be needed to achieve 
prevention that is cost-effective. This will require extremely sensitive, specific and 
simple prediction tests. Autoantibodies to GAD are serious candidates for such a 
test. 
The identification of the 64kD autoimmune target in type 1 diabetes as 
GAD65 (1) allowed to produce both forms of GAD by eukaryotic expression 
systems (3,5). In earlier studies, isolated rat or human islet were used as a source 
for 64kD/GAD. Expression systems for GAD have, however, not yet resulted in fast 
ELISA- or RIA-type tests with comparable pertormance as the more laborious and 
expensive immunoprecipitation assays with islet material. Moreover, sera from 
diabetes patients mainly recognize conformational epitopes of the GADs 5 
molecule, primarily in the C-terminal and middle domains (12). Thus, the 
recombinant material must have the correct post-translat"1onal modifications and 
folding. Moreover, using recombinant GAD could result in a lower incidence in 
autoantibodies, since it has been suggested that not all 64kD immunoreactivity 
can be accounted for by GAD55 (13). 
In this study, we analyzed if recombinant GAD, produced by two different 
eukaryotic expression systems, is suitable for GAD autoantibody analysis. While 
GAD 55, produced in insect cells (SF9} showed to be unsuitable, the use of COS-7 
expressed GAD55 resulted in a sensitive and specific immunoprecipitation assay. 
The frequencies of GAD55 autoantibodies at onset and in the preclinical phase 
were determined and compared to Islet cell autoantibodies (ICA) and Insulin 
Autoantibodies (IAA). We compared the incidences of GAD55 autoantibodies in 
this assay with the original 64kD autoantibody analysis using rat islet material. All 
the 64kD activity could be contributed to GAD55 immunoreactivity. Using COS-7 
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expressed GAo65, more GAD antibody positive sera were identified than with the 
islet cell method. This study showed that COS-7 expressed GADs5 in 
immunoprecipitations results in a sensitive and specific tests for GAD 
autoantibodies. 
Methods: 
Patients Prediabetic Individuals and Controls. 
Sera were obtained after signed informed consent and with approval from 
the Hospital ethical committee from all individuals and, if needed from their 
parents. The sera were drawn between 1987 and 1992 and were stored at -8QOC. 
Forty-eight Dutch newly diagnosed diabetes patients were evaluated and 135 
controls. Characteristics of the patients tested are given in table 1. 
Islet cell antibody (!CAl determinations: 
ICA's were measured as described before (14). Briefly, coded slides of 
unfixed frozen thins of human donor pancreas (blood group 0) were incubated 
with 25 I-ll ol pure or diluted serum and evaluated after conjugation with a 
secondary FITC labeled antibody by two independent observers. Control sera 
included JDF standard serum and negative samples. End-point titers were 
defined as the h"1ghest detectable ICA staining. The levels were expressed in JDF 
units. 
Insulin Autoantibody Assay: 
Insulin autoantibodies (IAA) were tested using a radio binding assay as 
described (14). Cold insulin displacement was measured according to the 
international workshop on IAA standardization. The cut-off level between positive 
and negative values was defined as 3 x SD from the mean of normal control sera . 
Analysis of 64kD/GAD autoantibodies using rat islets. 
Soluble amphiphilic proteins were prepared from 35s-methionine labeled 
rat islets as described (8,15). Isolated immune complexes were analyzed by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 
10% uniform stab gels and a modified Laemmti buffer system to achieve 
resolution of the GADs5 a- and ~-chains (15). The gels were processed for lluo-
rography as described (8). Autoradiograms were analyzed and scored positive or 
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negative by three independent observers without knowledge of sample identity. 
Positive and negative controls were used in all gels. 
COS-7 Expressed Rat GADss,. 
a. Transient expression of GADe5 in COS-7 cells: 
The expression vector MT-2 was used to construct a vector containing the 
rat GAD55 eDNA as described before (3). COS-7 cells were transfected by 
lipofection (DOTAP, Boehringer Mannheim, Indianapolis, IN) according to the 
manufacturers instructions. DNA, mixed with DOTAP in HEPES buffered saline 
(10 mM HEPES, 150 mM NaCI, pH=7.4), was added to 60-70% confluent plates of 
COS after refreshing of the medium (Dulbecco modified Eagles medium (DMEM) 
with 10% Fetal calf serum (Hyclone, Logan, UT). After 12 hours of incubation with 
the DNMipofection agent, the medium was refreshed again and the cells cultured 
for an additional 48 hours. The cells were washed twice with 37oc Phosphate 
buffered Saline (PBS) followed by a 30 min. starvation period in DMEM without 
methionine and with 2% dialyzed fetal calf serum. After refreshing this medium, 
400 ~Ci of 35s-methionine (Amersham SJ-1515) was added per 10 em plate for 
4hrs. The labeled cells were washed 3 times in an ice-cold harvest buffer (150 
mM NaCI, 10 mM HEPES, 10 mM Benzamidine, 0.1 mM p-Chloromercuriphenyl 
sulfonic acid (PCMPS) and 0.1 mM Phenylmethylsulfonyl fluoride (PMSF), pH=7.4, 
all chemicals from Sigma, St. Louis, unless stated otherwise). All other 
procedures were performed at 4oc. The cells were collected with a cell scraper in 
1 ml of a hypotonic lysis buffer (HEMAP: 10 mM HEPES, 1 mM EGTA, 1 mM 
Magnesium Chloride, 1 mM aminoethylisothiouronium bromide hydrobromide 
(AET), 0.2 mM Pyridoxal 5'-Phosphate (PLP), 0.1 mM PCMPS, 0,1 mM PMSF and 
10 mM Benzamidine, pH=7.4) and 1% Triton X-1 14 (TX-114, Calbiochem, La 
Jolla, CA), incubated for 10 minutes, followed by repeated pi petting through a 
bended t'1p for 10 minutes. The solution was cleared by ultracentrifugation at 
400.000g for 1 hr in a Beckman TLA-1 00 ultracentrifuge with a TLA 100.3 rotor 
(Beckman, Fullerton, CA) resulting in an S-400 fraction. This supernatant was 
subjected to temperature induced phase separation (16). The detergent phase, 
containing the soluble amphiphilic GAD55, was collected and diluted in HEMAP. 
Aliquots, equivalent to 30 immunoprecipitations were frozen at -sooc. 
b. Analysis of 64k /GAD autoantibodies using recombinant COS-7 expressed 
GAD6s,_ 
Autoantibodies GADe5 were analyzed using immunoprecipitation of GAD55 
transiently expressed in COS-7 cells. For immunoprecipitations (IMP's), the semi 
purified GAD55 material was thawed on ice andre-spun for 30 minutes at 400.000 
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g to clear aggregates. An equivalent of 200.000 cpm of the semi-purified material 
was used for each IMP, diluted to 200 !'I in HEMAP, and precleared in one batch, 
using a normal serum. An equivalent of 20 !'I serum per 200.000 cpm was 
incubated for 2 hrs. Protein A sepharose {PAS, Pharmacia, Piscataway NJ) was 
preswollen in a large volume of an IMP washing buffer {150 mM NaCI, 10m M 
HEPES, 10 mM Benzamidine, 0.5 mM Methionine, 5 mg% BSA and 5 mM EDTA, 
pH=7.4) and washed 3 times in the same buller. We pretreated the PAS with an 
S-400 of GAD translected COS-7 cells which were not labeled, mixed 1 :1 with 
non-transfected COS-7-cell S400, based on the rationale that any non-specific 
binding of labeled GAD to PAS would be blocked by this non-radioactive material. 
No background precipitation in control sera was seen, including 3 month 
exposures {approx. one half-life of 35s) o·fthe gels. Precleared labeled COS-7-
GAD65 was incubated with test sera for 16 hours in a total volume of 220 !'1. 
Immune complexes were isolated using PAS, that was pretreated with cold 
material identically, in a 1 hr incubation. PAS with immune complexes was 
washed 5 times with IMP-washing buller and 1 time with water. Laemmli buffer 
was added and the samples were applied on 10% SDS-PAGE slab gels alter 
boiling. Gels were processed lor fluorography and analyzed and scored positive 
or negative by three independent observers without knowledge of sample identity. 
Baculovirus Infected SF-9 Cell Expressed GAD65. 
a. Transient expression of human GADs5 in SF-9 cells. 
Recombinant human GAD55 Baculovirus vectors were constructed and 
analyzed as described before (5). Spodoptera lrugiperda (SF9) cells were infected 
with recombinant -GAD55- containing viruses. Alter 48 hrs, the cells were labeled 
for 4 hrs with 35S-methionine at 80 ~Ci/ml as described lor COS-7 cells, except 
that labeling was in methionine free Grace medium (Gibco-BRL). 
b. Analysis of GAD autoantibodies using recombinant SF9 expressed GADs~ 
Infected and labeled SF9 cells were harvested identical as described for 
COS-7 cells. An S-400 was obtained as described for COS-7 cells and stored in 
frozen aliquots after temperature induced phase separation. lrnmunoprecipitations 
were performed as described lor COS-7 GADs5-
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Results. 
ICA and IAA analysis in the newly diagnosed patients and controls. 
Results of the ICA and IAA analysis are summarized in table 1. 79 percent 
(38/48) of the newly diagnosed patients were ICA positive as defined as > 20 JDF 
units. Only 5% (2/4 1) showed Insulin autoantibodies. In the control group, 3% 
showed ICA's and 1% IAA's. 
TABLE 1 
Data and results on 48 newly diagnosed diabetes patients and 139 
control individuals. 
n= age ±. SD M:F ICA· lA A· Islet Cos-
ratio posi- posi- 64kD GAD65 
tive tive DOSitive I nosi-tive 
Newly 48 12.1+ 9.7 0.82 79% 5% 73% 81% 
Diagnosed (38/48) (2/41) (35/48) (39/48) 
oatients 
Controls 139 14.0 ± 3.8 0.75 3% 0.7'% 0.7% 0.7% 
(4/139) (1/139) (1/139) (1/139) 
Analysis of 64kD/GAD autoantibodies using rat islets 
Using the islet cell method for 64kD/GAD autoantibodies, 35 patients and 
one control individual were identified with 64kD I GAD autoantibodies. The results 
are accumulated in table 1. An example of the rat islet analysis is given in figure 1. 
Analysis of GAD Autoantibodies using COS-7 Expressed GADss 
Cos-7 expressed GADs5 was produced as described and immunopre· 
cipitated with sera from the patient and control groups. Analysis by SDS·PAGE 
and fluorography showed the typical a· and ~-band of GAD65 in positive controls 
(figure 2). All gels of the 48 newly diagnosed diabetes patients and controls were 
exposed on film for a maximum period of 3 months to be able to identify weak 
GAD-autoantibody positive samples. An example of these sera can be seen in 
figure 2. 
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FIGURE 1 
lmmunoprecipitation of soluble amphiphilic proteins 1rom 35S methionine labelled rat islets whh sera from patients with newly 
diagnosed type 1 diabetes and controls. Fluorogram of an SOS-PAGE showing precipitation of the 64k0 I GAD doublet in most of the 
d"labetic paf1ents and not in control individuals. Nof1ce the differences in GAD titers between the patients 
FIGURE 2 
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The results of the GAD analysis in the Dutch newly diagnosed individuals and con-
trols are collected in table 1. No background signal was observed in the control 
individuals (figure 2). Forty eight newly diagnosed individuals were analyzed, to-
gether with 135 controls. Thirty nine (81%) of the newly diagnosed patients 
showed antibodies to GAD by using the COS-GAD65 material, four more than with 
the rat islet method. One control was positive for GAD65 autoantibodies, identical 
to the positive control in the rat islet experiment. This individual has not 
developed diabetes in the follow-up period. 
Analysis of GAD Autoantibodies using GADss Expressed in 
Baculovirus infected SF9 cells 
Thawing SF9 expressed semi-purified GAD55, showed a significant pellet 
after centrifugation. Analysis of this pellet by SDS-PAGE and western blot showed 
that this was GAD55 (results not shown). Cleared material was immunoprecipi-
tated and processed as described above. SDS-PAGE showed background GAD 
bands in all controls. These sera were known to be negative by both islet and 
COS-7 GAD55 analysis. In order to reduce this aggregation problem, higher dilu-
tions of the semi purified GAD were used without solving this problem. 
Pretreatment of the PAS, intended to eliminate non-specific binding of labeled 
GAD to the beads, did not solve the problem. The material was therefore not used 
for large scale serum analysis. 
Comparison of the ICA, IAA and GAD-antibody analysis. 
Table 1 shows the combined analyses for all autoantibodies tested. Thirty-
eight of 48 (79%) patients were ICA positive. Four of these did not have GAD anti-
bodies by either of the two GAD antibody methods used. Moreover, 5 GAD anti-
body positive patients were negative for ICA, and 5 patients were negative for both 
ICA and GAD autoantibodies. All IAA positive samples were also positive for ICA 
and GAD antibodies. When combining both GAD-autoantibodies and ICA, 43 of 48 
(90%) of the patients showed signs of humoral autoimmunity directed towards B-
cell antigens. 
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Discussion 
Autoantibodies to the 64kD autoantigen are important markers of au-
toimmune destruction . The identification of this protein as GADss (1) allowed to 
design recombinant expression systems. Until then, islets of Langerhans were 
needed for the analysis of 64kD/GAd autoantibodies. Islet isolation and labeling is 
time consuming and expensive. Reports describing the incidence of 64kD/ GAD 
autoantibodies at onset as well as in the prediabetic period using islet cell 
methods (8,9) result in higher percentages of positive samples than the more re-
cently described methods using enzymatic assays (18) and ELISA's (19) do. 
Possible discrepancies could be due to a better sensitivity and specificity for the 
64kD immunoprecipitation methods, the use of GAD from other sources such as 
pig brain in some new assays, the use of only peptides of GAD instead of the 
whole molecule (19) or the fact that not all 64kD immunoreactivity is precipitated 
by GAD55 reactivity (13). To analyze this, we compared immunoprecipitation of 
recombinant GAD65 with immunoprecipitations using the 64kD method with rat 
islets in a group of newly diagnosed patients and controls. 
COS-7 Expressed GAD55 is Suitable lor the Detection of GAD-Au-
toantibodies in Type 1 Diabetes Mellitus. 
We analyzed if GAD65 expressed in COS-7 cells could be used for the 
analysis of autoantibodies in newly diagnosed type 1 diabetes patients. The 
transfection yielded sufficient amounts of GAD65 to be visible in Coomassie 
brilliant blue staining of gels. To avoid non-specific binding of labeled GADes to 
Protein A Sepharose, we pretreated the PAS with non-labeled material. Gels 
were exposed on film up to 3 months. No background GAD55 was seen in the 
immunoprecipitations of control sera. Both the absence of overexpression in 
COS-7 as well as the pretreatment of PAS with cold proteins seem to be important 
factors in obtaining a high resolution and low background. No evidence lor 
aggregation or misfolding was seen. The COS-7 system results in GAD that can 
be recognized by the diabetic autoantibodies and is thus likely to have the correct 
three dimensional structure. We found lour more patients positive by this assay 
compared to the original rat islet method. No individuals were found positive by 
the rat-islet method and negative on immunoprecipitation with COS-GADss. thus, 
all precipitated 64kD could be accounted for by GADss. The low background 
levels seen with the COS-GAD55 method seem to result in a higher sensitivity. 
However, this method only contains the amphiphilic prote·1ns and treatment of the 
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preparation with Triton X-114 (in both methods) could have disturbed binding of 
GAD to an associated molecule. In our hands, no evidence for an other 
component of the 64kD complex was found. In summary, GAD 55 expressed by 
transiently transfected COS cells is suitable for GAD antibody 
immunoprecipitations. 
Incidence of 64kD and GADss Autoantibodies in Newly Diagnosed 
Type 1 Diabetes Patients and Controls Compared to other 
Autoantibodies. 
We analyzed the frequencies of GAD autoantibodies in newly diagnosed 
patients with diabetes and controls and compared it with other autoantibodies in 
type 1 diabetes mellitus. Using the islet cell 64kD method, autoantibodies were 
found in 73% of newly diagnosed patients. The COS-GAD65 method found more 
(81%) of the patients positive (Table 1). One control individual was found positive 
in both methods. This person did not develop diabetes in the subsequent 8 years. 
No approval for further analysis was given. 
ICA's were found in 79% of the patients and in 3% of the controls. These 
levels compare to other studies (20-24). The combination of GAD and ICA yielded 
the strongest evidence for B-cell directed autoimmunity with 90% of the patients 
having either or both autoantibodies present. Four o! the ICA positive newly 
diagnosed patients were negative for GAD autoantibodies while 5 GAD positive 
patients were negative for ICA. Among these 5, three had very strong titers of GAD 
antibodies. Strong titers to GAD were associated to non-progression of B-cell 
destruction and combined with a restricted ICA staining pattern (25). The islet 
staining pattern was not evaluated in our study. From our study, strongly positive 
GAD sera are not necessarily protective. 
It will be necessary to perform similar studies in prediabetic individuals. 
Although the percentages of positive individuals for ICA and GAD differ only 
slightly (79 vs. 81 %) the GAD assays will be easier to standardize since they use a 
defined antigen and are not dependent on tbe quality of a biological variables 
such as the donor pancreas in ICA assays. 
Inclusion of the IAA status did not change the prediction of B-cell 
autoimmunity since all IAA individuals were ICA and GAD antibody positive. 
In summary, the combination of GAD antibody with ICA analysis provides a 
strong marker for ongoing B-cell destruction. Combined with other predictive 
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markers such as the HLA haplotype, they are candidates for family- and population 
based studies on the prediction of type 1 diabetes. 
GAD 65 Autoantibodies Can be Measured Using COS Expressed 
GADss, While SF9 Expressed GADs5 Shows Aggregation. 
In the baculovirus expression system, Spodoptera Frugiperda (SF9) insect 
cells are infected with a virus-construct in which the polyhedrin gene, coding for a 
structural protein of the virus, is replaced by human GAD55 eDNA. The polyhedrin 
promoter drives the expression. The infected SF9 cells produce large quantities of 
the recombinant protein. This expression system resulted however in aggregation 
of GAD65- Aggregates formed easily in the GAD55 preparations at high con-
centrations. This might be a result of the overexpression of GAD55 in the SF9 
cells. For correct folding into the three dimensional conformation and to prevent 
aggregation of GAD55, other cellular (chaperone) proteins are needed. Overload 
of the peptide transport- and post-translational modification mechanisms may 
induce faulty or absent tertiary structures. GAD55 becomes membrane bound in 
SF9 cells, identical as it does in islets (5). However, the presence of this post-
translational process in the SF9 cells does not imply that the three-dimensional 
structure of the molecule will be correct. The correct three-dimensional structure 
is necessary for stability of the molecule and of paramount importance for the 
recognition by autoantibodies in type 1 diabetes patients, which mainly recognize 
conformational epitopes. lmmunoprecipitations of SF9 produced GAD55 with 
diabetic and control sera, using re-centrifuged material, showed false positive 
signals, most likely due to aggregation of GAD55 and probably non-specific 
binding to the protein A Sepharose. Attempts to clear the preparations from 
aggregates and to block non-specific binding places on PAS were not successful. 
Dilution of the material had no effect. Although it could be argued that natural 
autoantibodies could be due to the immunoprecipitates in controls, we never 
encountered similar signals in analyses using islet materials or using the COS-
GAD 55 assay. Although the Baculovirus expression system is able to produce 
large amounts of GAD, we choose the COS-7 expressed GAD55 for our analyses. 
This study provides evidence lor the high incidence of GAD autoantibodies 
at onset of type 1 diabetes. No evidence for an additional compound of the 64kD 
precipitate was found. The data presented here show that the requirements for a 
specific and sensitive GAD antibody assay are high. GAD antibody analysis by 
immunoprecipitation is still not easily applicable in large scale studies. The 
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analysis by SDS-PAGE and fluorography requires time, although the use of 
phosphor-imagers can shorten this. The immunoprecipitation method can still be 
regarded as the most sensitive method for the analysis for GAD autoantibodies, 
but simpler and cheaper methods need to be developed. 
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Submitted 
Autoantibodies to GAD 158 
Autoantibodies to GAD 159 
VALUE OF ANTIBODIES TO GAD65 COMBINED WITH ISLET CEll 
CYTOPLASMIC ANTIBODIES FOR PREDICTING TYPE 1 (INSULIN-
DEPENDENT) DIABETES MELLITUS 1111 A CHILDHOOD POPULATION 
Henk-Jan Aanstoot 1, Engilbert Sigurdsson2, Marc Jaffe 1, Yuguang Shi 1 ,Stephan 
Christgau 1 .2, Derek Grobbee3, G. Jan Bruining4, Jaques L. Molenaar5, Albert 
Hofman3 and Steinunn Baekkeskov1.2. 
1. Hormone Research Institute, Depts. of Microbiology I Immunology and 
Medicine, University of California San Francisco, CA 94143-0534, USA. 
2. Hagedorn Research Laboratory, Gentofte, Denmark. 
3. Dept. of Epidemiology, Erasmus University Medical School, Rotterdam, the 
Netherlands. 
4. Depts. of Pediatrics, Division of Congenital I Hereditary diseases, Erasmus 
University Medical School and Sophia Children's Hospital, Rotterdam, the 
Netherlands. 
5. Dept. of Immunology, Stichting Samenwerkende Delftse Ziekenhuizen, 
Delft, the Netherlands. 
Dr. H.-J. Aanstoot's current address is: Depts. of Pediatrics, Division of Congenital/ 
Hereditary Diseases, Erasmus University Medical School and Sophia Children's 
Hospital. Rotterdam, the Netherlands. 
Autoantibodies to GAD 160 
SUMMARY 
The value of a test for islet cell cytoplasmic antibodies together with a test for 
GAD55 antibodies to predict the subsequent development of diabetes over a 
period of 11.5 years was assessed in a childhood population comprising 2,805 
individuals. A single serum sample was obtained from each individual between 
1975 and 1977 and screened for complement fixing islet cell cytoplasmic 
antibodies. Eight individuals were positive (0.29%). During the average follow-up 
period of 11.5 years, 4/8 islet cell antibody positive and 3 islet cell antibody 
negative individuals developed clinical diabetes. Sera from all individuals, who 
were islet cell antibody positive and/or developed diabetes (total of eleven) and 
from 100 randomly selected controls were analyzed for GAD55 antibodies. Six of 
eight islet cell antibody positive individuals were GAD65 antibody positive 
including all 4 who subsequently developed Type 1 diabetes. Furthermore one of 
the three islet cell antibody negative individuals who developed Type 1 diabetes 
was GAD55 antibody positive both in 1976 and in 1989. Thus a positive test for 
GAD65 antibodies alone correctly predicted diabetes in 5 of 7 children, who 
developed the disease. Only one of the children, who developed diabetes was 
positive for insulin autoantibodies and this individual was also positive for islet cell 
cytoplasm·lc antibodies and GAD55 antibodies. One of the 100 control individuals 
was positive for GAD 55 antibodies (1 %). The results suggest that a single GAD55 
antibody test may have a higher sensitivity for predicting Type 1 diabetes than a 
test for islet cell cytoplasmic antibodies, but that a combined positive test for both 
antibodies increases the specificity for predicting Type 1 diabetes over a period of 
11.5 years. 
INTRODUCTION 
The destruction of pancreatic B-cells, which precedes the clinical onset of 
Type 1 (insulin-dependent) diabetes mellitus, is mediated by autoimmune 
mechanisms (1 ). The presence of islet specific autoantibodies in the prediabetic 
period (2-4) is likely to reflect the ongoing autoimmune process, one that eventually 
leads to critical B-cell depletion and insulin dependency. A major goal of diabetes 
research is to develop immune interventions that block or otherwise interfere with 
the destruction of 8-cells and the development of clinical diabetes. Concomitant 
with this goal is the necessity of methods for early accurate identification of 
susceptible individuals (5). Antibody assays that detect early signs of humoral 
autoimmunity associated with B-cell destruction are obvious candidates for this 
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purpose. Furthermore susceptibility to develop diabetes is associated with certain 
MHC-class II haplotypes (6) and analysis of both HLA haplotypes and 
autoantibodies provide a test of high predictive value in family members of Type 1 
diabetic patients (3, 7). Since most new cases of Type 1 diabetes involve 
individuals without a first degree relative with the disease (8,9), such methods are 
not easily applicable for prediction in the general population. 
The classical method to analyze islet cell autoantibodies is by 
immunohistology using frozen pancreatic sections. The ICA assay is however 
difficult to standardize (1 0). A better method for a standardized analyses of early 
humoral responses in Type 1 diabetes would involve a rapid and quantitative 
assay using a target antigen of humoral autoimmunity in type 1 diabetes like insulin 
(11 ), or the GAD65 autoantigen (12). 
Insulin autoantibodies (IAA's) are only detected in up to 50% of newly 
d·1agnosed patients and are most frequent in very young patients(< 5 yrs of age) 
(13). IAA's alone have a limited predictive value and are not suitable as a marker 
to replace ICA's (5). 
Incidence of 64kD or GAD65 autoantibodies in the prediabetic period and at 
clinical onset of type 1 diabetes measured by immunoprecipitation of 35-S 
methionine labeled human islet cell protein is 75-90% (4, 15). Following 
identificatiOn of the 64kD protein as the smaller form of the enzyme glutamic acid 
decarboxylase (12,16), now called GAD55, several assays have been developed 
and standardization is just beginning (1st GAD antibody workshop was held under 
the auspices of the 12th International Immunology of diabetes Workshop, Orlando, 
April 15-18, 1993). GAD55 antibodies precede Type 1 diabetes by several years 
and are detected concomitantly with, and sometimes before ICA and IAA (4, 15, 17). 
GAD65 is a cytoplasmic protein and is amongst the target antigens of ICA's 
(19). Purified GAD65 however does not block all ICA reactivity in some sera (19) 
and the ICA reactivity is likely to involve other targets molecules. Furthermore sera 
that immunoprecipitate GAD65 do not always react with the protein by 
immunohistology and are therefore negative in the ICA assay (15,20). In most 
Type 1 diabetic patients, ICAs only stain frozen and not fixed sections of human 
pancreas. Thus ICA epitopes are dependent on conformation of the relevant 
antigen (21 ). Similarly diabetes associated epitopes in the GAD65 molecule are 
predominantly conformational and only very few patients recognize a linear 
epitope in the protein (12, 18). 
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In addition to GAD55, GAD is expressed as a second non-allelic form, 
GAD57 in neurons (22) and in rat and mouse B-cells (23). Human islets only 
express the GAD55 protein (23, 24) and ·the incidence of GADs? antibodies in 
Type 1 diabetes is low (25, 26). GAD57 does not seem to have an independent 
role as an autoantigen in Type 1 diabetes. Rather this protein only seems to be 
recognized in cases where the immune response to GAD55 involves recognition of 
epitopes that crossreact in the two proteins (26). 
Previous studies have suggested that islet cell cytoplasmic antibodies (ICA) 
measured by immunohistology are of insufficient specificity to serve as a single 
marker of susceptibility (5, 27, 28). One study of the predictive value of ICA in a 
Dutch childhood population without emphasis on families of diabetes patients, 
found an incidence of 0.29%, which is close to the incidence of Type 1 diabetes in 
the Netherlands. In this study, all the ICA positive individuals had complement 
fixing ICA (CF-ICA) and the antibodies preceded the clinical onset non-familial 
diabetes in some individuals by several years (29). The predictive value of a 
positive CF-ICA test on a single occasion to predict the development of Type 1 
diabetes in a subsequent i 1.5 year follow-up period was 50%. The sensitivity of 
CF-ICA to predict Type 1 diabetes was 57%. 
The present study analyzed GAD55 autoantibodies in all individuals in this 
population which were either CF-ICA positive or developed Type i diabetes during 
the 11.5-year follow-up period, as well as in 100 randomly selected individuals that 
remained healthy during this period. Although it was not possible to analyze 
GAD55 autoantibodies in the whole population with the methodology currently 
available, we have calculated the potential of a combined test for CF-ICA followed 
by GAD55 antibody analysis to predict diabetes in a childhood population at large, 
based on a single serum drawing per child with a minimum follow-up of 10 years. 
The study shows that the combination of a positive test for CF-ICA and for GAD55 
antibodies yields a strong predictive value for subsequent development of Type 1 
diabetes in individuals who are not relatives of Type 1 d·iabetic patients and is more 
specific than a single positive test for either antibody. 
METHODS 
Description of the population 
The population studied has been described in detail (29). Approval was 
obtained from the local ethical committees. Briefly, 4860 schoolchildren aged 5-19 
years of age from one township in the Netherlands participated in a longitudinal 
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study on risk factors for cardiovascular and chronic diseases. The data collected 
included a history on Type 1 diabetes. Serum was collected from these children 
between 1975 and 1977. Serum samples of 3383 individuals were available for 
ICA analysis. In 1988, a questionnaire was sent to all subjects for who family data 
on diabetes were available. 2805 children fulfilled the three criteria of having a 
complete first-degree family history on Type 1 diabetes, a stored serum sample and 
an adequate response to the questionnaire by the end of an average follow-up 
time of 11.5 years CF-ICA's and IAA's were measured in this population and their 
predictive value analyzed (29). A second serum sample was obtained in 1989 from 
10 of the 11 individuals, who were ICA positive in 1975-1977 and/or who 
developed Type 1 diabetes in the interim period. 
Measurement of GAD55 antibodies• using rat islets. 
Autoantibodies to GAD55 expressed in rat islets were measured by 
immunoprecipitation of Triton X-114 detergent phase purified cytosolic protein 
fraction (12). Immune complexes were analyzed by SDS-PAGE using 10% slab 
gels and processed for fluorography (30). Fluorograms were analyzed visually by 
three independent observers, who did not know the sample identity and scored 
positive if the GAD 55 a/b doublet was visible. A quantitative estimate of GAD55 in 
positive immunoprecipitates was obtained by densitometric scanning of 
autoradiograms using a BioRad model 620 Video Densitometer with 1 D Analyst II 
and version 3.10 software (BioRad, Richmond, CA) and a control serum which is 
used as a positive standard for quantitative analyses of GAD55 autoantibodies and 
has an arbitrary value set at 10 (20). GAD55 antibody values in other sera were 
calculated from integrated peak areas by the formula: 10 x (value for unknown 
serum -value lor negative control serum) I (value for positive control serum -value 
for value for negative control serum) 
Measurement of GADss antibodies using recombinant GADs 5 
expressed in COS-cells 
The eucaryotic expression vector pMT2 (kindly donated by Dr. R. Kaufman, 
Genetics Institute, Boston, MA) was used for transient expression of rat GAD55 in 
COS-7 cells. Oligonucleotide directed mutagenesis was used to change the 
sequence surrounding the translation initiation site of GAD55 into the Kozak 
consensus sequence (31) for optimum expression in mammalian cells before 
subcloning into the pMT2 vector. A 2.4 kb eDNA fragment containing the coding 
region of rat GAD55 was released from a eDNA clone (kindly donated by Dr. A. 
Tobin, University of California Los Angeles, CA) by EcoR I restriction enzyme 
digestion and inserted into the EcoR I site of pMT2. The resulting plasmid was 
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named pMT2-rGAD65-1 0. This clone was transfected into COS-7 cells (American 
Tissue Culture Collection, ATCC) using a lipofection kit (DOTAP, Boehringer 
Mannheim, Indianapolis, IN) according to the manufacturers instructions. Cells 
were labeled 48hrs after transfection using 400 mCi of 35s methionine (Amersham 
SJ-1515) per 10 em plate for 4hrs. After labeling cells were washed 3 times in an 
ice-cold harvest buffer (150 mM NaCI, 10 mM Hepes, 10 mM benzamidine/HCI, 0.1 
mM p-chloromercuriphenyl sulfonic acid and 0.1 mM phenylmethylsulfonyl 
fluoride, pH=7.4). All following procedures were performed at 40C. The cells were 
collected by scraping into 1 ml of HEMAP buffer (1 0 mmoln Hepes, pH 7.4, 1 mmol/1 
MgCI2, 1 mmol/1 EGTA, 0.2 mmol/1 pyridoxal-5-phosphate, 1 mmol/1 
aminoethylisothiouronium bromide hydrobromide) containing 1% Triton X-114, 
followed by incubation for 10 min. and repeated pi petting through a bent pipette tip 
for 10 minutes. The solution was cleared by ultra centrifugation at 400.000 x g for 1 
hr in a Beckman TLA-1 00 ultracentrifuge with a TLA 100.3 rotor (Beckman, 
Fullerton, CA) resulting in an S-400 fraction. This supernatant was subjected to 
temperature induced phase separation (32). The detergent phase, containing the 
soluble amphiphilic GAD55, was collected and diluted in HEMAP buffer. Aliquots 
containing 200.000 cpm per immunoprecipitate were precleared ~sing normal 
human serum. Precleared aliquots were incubated with test sera for 16 hours in a 
total volume of 220 mi. I mmunecomplexes were isolated by incubation for 1 hr with 
protein-A Sepharose (Pharmacia, Linkoping, Sweden) which had been coated 
with cold COS-7-cell lysate to avoid non-specific absorpticoc. lmmunocomplexes 
bound to Protein-A Sepharose were washed 5 times in IMP-washing buffer 
(10mmoln Hepes, pH 7.4, 150mmoln NaCI, 1 Ommoln benzamidine/HCI, 0.5 mmoln 
methionine, 5mmol/l EDTA, 0.1% BSA) and once in autoclaved H20. 
lmmunocomplexes were eluted from Protein-A Sepharose, analyzed by 80S-
PAGE and processed for fluorography. Fluorograms were analysed as described 
above. In addition quantitative analyses of GAD 55 on gels was performed using a 
model 425 Phospor-lmager (Molecular Dynamics, Sunnyvale, CA ) and the same 
positive control serum for quantitative GAD55 analyses. The results of the 
Phosphor-Imager analyses and the densitometric analyses were similar except that 
the former measurement is linear over a longer range. 
Sera analyzed for GAD65 antibodies included all 7 individuals who 
developed Type 1 d·iabetes, the 4 individuals who were ICA positive, but did not 
develop diabetes, and 100 age matched controls. 
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Figure 1. Analysis of GADss autoantibodies by immunoprecipitation. 
GAD55 autoantibodies were measured in a single serum sample drawn·from 
subjects at baseline (1975-1977) (panels A,B,C) or in 1989 (panel D). Subjects 1-
8 were ICA positive, subjects 9-14 were ICA negative. Subjects 1-4 and 9-11 
developed Type 1 diabetes 1.8-7.1 years following the serum sampling. Subjects 
12 and 13 were healthy ICA negative children. 
A: Short exposure of a fluorogram of immunoprecipitates of rat islet cell GAD65 
on an X-ray film. 
B: Short exposure of a fluorogram of immunoprecipitates of COS-7 cell GAD55 
on a Phospor-lmager. 
C: Long exposure of the fluorogram in panel A 
D: Short exposure of a fluorogram of immunoprecipitates of COS-7 cell GAD65 
on an X-ray film. 
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HlA haplotyping, CF-ICA analyses, and IAA analyses 
HLA haplotyping was performed as described by Giphart and co-workers 
(33). The ICA assay was described earlier (29). The same pancreas, which gave 
an unusually low background and high specificity in the analyses of the 1975-1977 
samples (29), were used for analyses of the 1989 samples. ICA levels in samples 
were expressed in reciprocal titers. The Juvenile Diabetes Foundation world 
standard serum for ICA analyses and containing 80 JDF units, was positive on this 
pancreas up to a dilution of 1 :256. Dilution of this standard serum showed a strict 
linear titration curve, 0.625 JDF units corresponding to a titer of 1:2. This assay 
participates in the International Diabetes Workshops on ICA proficiency. IAA were 
measured in each serum using both an ELISA assay, and a 
radioimmunoprecipitation assays (11 ). Both assays participate in the International 
Diabetes Workshops on IAA proficiency. 
RESUlTS 
The GADs5 antibody assay 
The analyses of GAD55 autoantibodies in this study included i) 
immunoprecipitation of the soluble hydrophobic form of GAD65 partially purified 
from rat islets (12, 16) (Figure 1A and C), and ii) immunoprecipitation of partially 
purified membrane and soluble forms of recombinant GAD55 expressed in COS-7 
cells (Figure 1 B and D). The first assay is a derivative of the standard 
immunoprecipitation assay using GAD55 expressed in islet cells (4, 20) but uses 
only the hydrophobic soluble fraction of islets. Since very few cyfosolic proteins ·In 
rat islets, except GAD55, are hydrophobic, the use of this fraction results in very low 
background. Both methods are equally sensitive in detecting GAD 6 5 
autoantibodies in low-high titer sera. However the first method is more sensitive for 
analyses of very low titer sera, because it has a higher signal to noise ratio and 
allows specific detection of very low levels of the characteristic a and B doublet of 
GAD55 in immunoprecipitates (30) by long exposures of autoradiograms. This 
enhanced sensitivity was necessary for detection of GAD55 antibodies in the 
baseline serum from subject #11 (Figure 1 C) and the 1989 serum from subject #4 
in long exposure of fluorograms. By comparison the COS-7 cell assay did not 
detect a GAD55 signal above background in immunoprecipitates with those two 
samples after long exposures. Both assays however detected GAD55 antibodies in 
the same individuals in either earlier (subject# 4) or later (subject# 11) samples 
(Figure 1, Table 1 ). 
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Figure 2 
Longitudinal analyses of 64k0/GAD autoantibodies and ICA in 
subjects 3 and 4. 
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Prevalence ol Type 1 diabetes in the Follow-up Period 
Seven children developed Type 1 diabetes, which gave a cumulative 
incidence of Type 1 diabetes during an average follow-up period ol 11.5 years ol 
0.25% (7/2805). None of those 7 children had a first degree family member with 
Type 1 diabetes or non-insulin dependent diabetes mellitus (Type 2 diabetes). 
Prevalence of CF-ICA, GADss antibodies, and IAA in 1975-1977 
Eight ol 2,805 (0.29%) children (#1-8 table 1) were positive for CF-ICA at the 
baseline timepoint between 1975-1977. Four of these (#1-4 Table 1) were among 
the 7 who developed Type 1 diabetes during the follow-up period. Sera from the 7 
individuals who developed diabetes as well as from the other 4 ICA pos'ltive 
individuals were assayed for GAD65 autoantibodies (Figure 1A,B,C, Table 1) and 
IAA. Six of the 8 ICA positive individuals (#1-4, 5 and 8, Figure 1A,B,C, Table 1) 
were positive, including all 4 who subsequently developed Type 1 diabetes. One ol 
those individuals (#3) was the only IAA positive individual by the ELISA assay 
whereas none were positive by the radio immunoprecipitation assay. 
Among the three ICA negative children who developed Type 1 diabetes 
during the follow-up period, two (#9 and 10, Figure 1A,B,C, Table 1) were also 
negative for GAD65 antibodies in the serum sample collected between 1975-1977. 
One subject (#11 Figure 1, Table 1) was scored negative for GAD65 antibodies 
based on a short exposures of fluorograms of rat islet immunoprecipitates and 
COS-7 cell immunoprecipitates (Figure 1A). However, prolonged exposure of rat 
islet immunoprecipitates clearly revealed that this serum immunoprecipitated the 
characteristic a and b doublet ol the GAD65 autoantigen (Figure 1 C). Amongst 100 
healthy ICA negative subjects included in the GAD55 antibody analyses, one 
individual, a 16 year old female, was GAD 55 antibody positive. 
GADss Antibody status 12-13 Years Alter the Initial Sampling 
In 1989 sera were collected from all the 8 subjects who were ICA positive at 
baseline (#1-8) and from 2 of the ICA negative subjects (#1 0-1 1) who had 
developed Type 1 diabetes. Subject #9 was not available lor testing in 1989. Sera 
were assayed lor GAD55 autoantibodies and ICA (Figure 10, Table 1 ). The ICA 
and GAD55 antibody positive individuals who had developed Type 1 diabetes had 
either become antibody negative or decreased significantly in titer. The ICA 
negative, GAD65 antibody positive individual (#1 1) had a stronger GADs 5 
immunoreactivity in 1989 than in 1977 (Figure 10, Table 1). The two individuals 
who were ICA/GAD65 antibody positive at the baseline timepoint (#5 and 8) but 
who had not developed Type 1 diabetes during the observation period, were still 
Table 1: Summary of autoantibody and HLA-analyses in individuals which were either positive for islet cell cytoplasmic antibodies (ICA) at 
baseline and/or developed diabetes during an average of 11.5 year observation period. 
Subject Age at Age at Interval HLA ICA GAD65 autoantibodiesa 
Number/Sex Baseline Diagnosis (Years) DR DOw 1975-77 1989 1975-77 1989 
ICCA + => diabetes 
1M 6.1 12.4 6.3 2,3 2,6 2 Neg 2.9 Neg 
2M 7.5 12.4 4.9 3 2 32 Neg 4.0 Neg 
3F 9.2 16.3 7.1 3,4 2,8 16 8 1.8 1.6 
)> 
c: 
o-
4F 15.4 19.6 4.2 3,4 2,8 4 Neg 9.9 0.6b ~ 8' 
ICCA + => healthy ~ 
"' 5M 7.4 3,4 2,8 32 16 14.9 13.9 o-
6F 7.6 2 6 4 Neg Neg Neg I~ 
7M 14.7 1,w6 5,6 32 64 Neg Neg 
8M 18.2 1,w6 5,6 16 32 14.2 12.0 
ICCA - => diabetes 
9M 5.1 12.3 7.5 NA NA Neg NA Neg NA 
10M 12.4 14.2 1.8 4,w6 6,8 Neg Neg Neg Neg 
11M 12.7 16.2 3.5 1,5 5,7 Neg Neg o.5b 3.2 
!~ 
m 
a The quantitative values are based on Phospor-lmager analyses except for those marked by b, which are densitometric values. 
,<D 
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ICA and GAD55 positive in 1989, which was 12 and 13 years later respectively. 
Neither of those individuals has a first degree family member with Type 1 or Type 2 
diabetes. However, a niece to subject #8 had a clinical onset of Type 1 diabetes in 
1989. Subject #6 was still GAD55 antibody negative and had also become ICA 
negative in 1989. Subject #7 was still GAD55 antibody negative and ICA positive 
in 1989. Subject #1 0 was ICA and GAD55 antibody negative both at baseline and 
in 1989 which was 1.8 years before and 11.9 years after clinical onset of Type 1 
diabetes, respectively. The positive control individual had no family history of Type 
1 diabetes. She did not consent to an additional serum sampling to test whether 
the GAD55 antibodies had persisted over several years. 
longitudinal Analyses of ICA and GAD Antibodies in Two Subjects 
Two girls (subjects #3, 4) also panlicipated in a cohort study for general 
health risk factors. Each developed Type 1 diabetes during the period of this study. 
Both were re-examined every 12 months. ICA and GAD55 antibody titers were 
retrospectively analyzed and compared in the sequential sera (Figure 2). Subject 
#3 remained weakly positive for GAD55 antibodies throughout the 11 year 
observation period, which included 5 years following the clinical onset of Type 1 
diabetes. Subject 4 showed a continual decrease from a high GAD55 antibody 
immunoreactivity during the 13 year observation period. She was weakly positive 
in the last sample, which was obtained 9 years following clinical onset of Type 1 
diabetes. A similar pattern was observed for ICA. 
Sensitivity ol Individual and Combined Assays to Predict Type 1 
diabetes 
The sensitivity of a combined antibody assay positive for both ICA and 
GAD55 antibodies in a single sample to predict Type 1 diabetes in the 7 children 
who had a clinical onset during the follow-up period was 57% (4!7) or the same as 
for ICA alone. The senstlivity of a GAD55 antibody assay alone to predict Type 1 
diabetes in the 7 children was 71% (5!7). 
The sensitivity of a combined assay positive for both ICA and IAA in a single 
sample to predict Type 1 diabetes in the 7 children, who had a clinical onset during 
the follow-up period was 14% (tf7) or the same as the sensitivity of IAA antibodies 
alone and several fold lower than the sensitivity of the ICA and GAD55 antibody 
assays alone. 
Predictive Value ol ICA Combined wilh GADss Autoantibodies 
The lack of GAD55 antibody data for all but 111 of the 2.805 children 
constituting this study base excludes the calculation of a positive and a negative 
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predictive value and a specificity for GAD55 antibodies alone (35,36). However, 
these parameters can be calculated for a combined ICA and GAD55 antibody 
assay. Thus the probability of a child acquiring Type 1 diabetes within 10 years if 
both autoantibodies were positive at baseline (positive predictive value) was 67% 
(4/6) as compared to 50% (4/8) for IC.A. alone. The probability of absence of clinical 
Type 1 diabetes among subjects not positive for both ICA and GAD55 antibodies 
(negative predictive value) was 99.89% (2796/2799) or the same as for ICA alone 
(2794/2797 = 99.89%). The specificity of a test positive lor both ICCA and GAD55 
antibodies to predict Type 1 diabetes within 10 years was 99.93% (2796/2798) as 
compared to 99.86% (2794/2798) for ICA alone. 
Predictive Value of ICA Combined with IAA 
The positive predictive value lor a combined ICA and IAA assay was 100% 
(1/1), which was higher than for a combined assay for ICA and GAD55 antibodies. 
Similarly the specificity of the combined assay was 100% (2798/2798). The 
probability of absence of clinical Type 1 diabetes among subjects not positive for 
both ICA and IAA was 99.79% (2798/2804) compared to the negative predictive 
value for ICA alone and ICA combined with GAD55 antibodies of 99.89%. 
HlA-Tissue Typing 
HLA DR and DQ haplotypes are shown in Table 1. Subjects 1-5 and 10 
were HLA DR3 and/or 4 positive. All the HLA DR4 positive subjects were DQw8 
(DQB-0302) which is present in 95% of DR4 positive Type 1 diabetic patients 
versus 50% of DR4 positive controls (6,37). Subjects 7, 8 and 11 had the DR 1 
DQw5 (DQB 0501 )haplotype, which is associated with a weakly increased risk of 
Type 1 diabetes (37). Subject 6 was HLA-DR2, DQw6 (DQB0602), which is 
negatively associated with Type 1 diabetes (38). Subject #9 was not available for 
HLA-typing. The positive control individual did not consent to HLA-typing. 
DISCUSSION 
The high incidence of 64kDa GAD55 antibodies in prediabetic individuals 
and their early appearance (4, 15) suggests that these antibodies are an early 
sensitive marker of an ongoing autoimmune aggression to the insulin producing 
beta cells. The identification of GAD55 as a major humoral autoantigen in Type 1 
diabetes and the availability of this protein both from brain and from cellular 
expression systems has greatly facilitated the analyses of those antibodies. A rapid 
assay of a sensitivity and specificity smilar to that of the immunoprecipitation assay 
is needed for an accurate assessment of the predictive value of GAD55 antibodies 
in large populations. Such an assay is however still not available. 
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In the meantime, we have attempted to assess the predictive value of a 
combined assay for CF-ICA and GAD55 antibodies in a single serum sample and 
an average follow-up of 11.5 years in a low risk childhood population. With regard 
to specificity, the results demonstrate that compared to CF-ICA antibody 
measurements alone, ICA analyses supplemented with GAD55 autoantibody 
analysis are likely to have increased specificity in predicting Type 1 diabetes. Of a 
normal low risk population of 2805 children who represented the study base for 
these analyses, 4 children would be incorrectly predicted to become diabetic in a 
1 0-year follow-up by a single pos-Itive test for CF-ICA alone. This number was 
decreased to 2 subjects by requiring both CF-ICA positivity and GADs 5 
autoantibody positivity. Although analysis of GAD55 antibodies in 2805 sera was 
not possible by the current methodology, the presence of GAD55 antibodies in 
1/100 individuals randomly selected among the ICA negative subjects, who did not 
develop Type 1 diabetes, confirms earlier data on the incidence of these antibodies 
in healthy individuals (39 for review). An incidence of 1% is however 3-4 fold 
higher than the cumulative incidence of Type 1 diabetes in the Netherlands 
suggesting that a positive test for GAD55 antibodies alone, measured by current 
methods, is not sufficient to accurately predict the clinical onset of disease within a 
period of 11.5 years. 
This study has confirmed the early appearance of GAD55 autoantibodies in 
a non-familial study. The antibodies were detected in 5 individuals in a single 
serum sample obtained 31/2-7 years before clinical onset of Type 1 diabetes. 
None of these subjects had a first-degree family member with Type 1 or 2 diabetes. 
The sensitivity of GAD55 antibodies to detect individuals experiencing B-cell 
autoimmunity may be higher than for ICA. Thus amongst the 3 CF-ICA negative 
individuals who developed Type 1 diabetes, one was positive lor GADs 5 
antibodies at baseline and in 1989, which was 3.5 years before and 9.5 years alter 
clinical onset respectively. The increase in sensitivity of the single GAD 55 antibody 
test compared to the double antibody test was however counterbalanced by a 
decrease in sensitivity. It is possible however that the predictive value of a test lor 
GAD65 autoantibodies alone can be increased by introducing different GAD55 
antibody specificities. Recent studies have identified conformational epitopes 
associated with Type 1 (18), linear SMS specific epitopes (12), and a linear 
epitope associated with protection against disease ( 40) in the GAD55 molecule. 
Assays that distinguish GAD55 antibodies of different epitope specificity may 
therefore be the next candidate for predictive tests. Alternatively, a combination of a 
test for GAD55 antibodies lor high sensitivity and early detection, and a test tor 
antibodies that appear late in B-cell destruction, which be indicative ol massive loss 
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of 13-cells, may provide a better predictive value. A candidate for the latter test are 
the 37kD antibodies described by Christie et al. (41). Finally since 13-cell 
destruction in humans is likely to be T -cell mediated as in the animal models, (1) 
and antibodies may not have a direct pathogenic role, the predictive value of 
antibody tests may always have the limitations of an indirect parameter. It is 
certainly conceivable that an autoimmune response induced to an antigenic 
epitope in a particular HLA-background is dominated by cy1otoxic T-cells and 
massive 13-cell destruction whereas the response to other epitopes in the same 
molecule in the same or different HLA-haplotype is restricted to antibodies and 
compatible with an intact or only minor loss of B-cell mass. 
In the absence of a direct test for B-cell destruction, a combination of a 
positive test for CF-ICA and GAD55 autoantibodies together with HLA-typing may 
provide the most accurate predictive test currently available. In this regard it is 
notable however that subject #5, who has been positive for CF-ICA and GAD55 
antibodies lor more than 12 years, has the HLA-DR3, DQw2 and DR4,DQw8 
haplotype, which confers the highest known relative risk of Type 1 diabetes (7). 
Thus even this high risk MHC allele in conjunction with both CF-ICA and GADss 
autoantibodies is still not sufficient to rapidly induce the onset of Type 1 diabetes. 
Both CF-ICA, IAA, and GAD55 antibodies were absent at baseline in 2 
individuals who later developed Type 1 diabetes. It is not known whether 
antibodies never developed in these individuals or whether antibody positive 
periods were missed by the single sampling at baseline. Population studies 
employing regular sampling of sera over 1 or 2 decades are clearly needed to 
assess the full value of antibody testing in predicting Type 1 diabetes, and in 
particular to assess whether some individuals mount an autoimmune response 
which is restricted to T-cells, or alternatively, experience a beta cell destruction 
which is not of autoimmune etiology. 
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4.1 
Identification and Characterization ol a 38kD Pancreatic B-cell 
Antigen Which Together With Glutamic Acid DecarboxylaseMarks the 
Early Phases ol Autoimmune Responses in Type 1 Diabetes. 
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SUMMARY 
Antibodies to the enzyme glutamic acid decarboxylase (GAD55) are present 
in 70-80% of individuals experiencing both early and later phases of pancreatic B-
cell destruction and development of type 1 diabetes. A lew individuals, who are 
positive for islet cell antibodies detected by immunofluorescence of frozen sections 
of human pancreas (ICA) are GAD 55 antibody negative. Here we identify a second 
B-cell antigen, an amphiphilic membrane' protein of Mr 38kD and pi 5.6-6.1, which 
is specifically immunoprecipitated under native conditions by lgG antibodies 
present at clinical onset of diabetes in a subset of patients (12/49=24% compared 
to 37/49=76% GAD55 antibody positive) some of who (6/49=12%) are negative lor 
GAD55 antibodies. To address the question whether the 38kD protein is a target ol 
early B-cell responses in this disease, we analysed sera from 44 prediabetic 
individuals and from 37 children who developed type 1 diabetes at a very young 
age. Six (14%) prediabetic individuals were positive lor 38kD antibodies in the very 
first sample available which was 3, 9, 25, 33, 53, and 74 months before clinical 
onset of disease respectively. Four young children (11 %) were positive lor 38kD 
antibodies at clinical onset of disease at age 1.3, 1.6, 1.8, and 4.8 yrs. 33 (75%) 
and 28 (76%) patients were GAD65 antibody positive in the two groups. Taken 
together anti-38kD and/or anti-GAD65 antibody positive individuals accounted lor 
all ICA positive sera in the prediabetic group but not in the newly diagnosed groups 
consistent with the appearence of antibodies to additional antigens in later stages 
of B-cell destruction in some individuals. The diabetes associated epitopes in the 
38kD protein are conformational and do not crossreact with GAD55 autoantibodies. 
Thus GAD55 and the 38kD autoantigen represent two distinct alternative and 
sometimes coinciding targets ol early humoral autoimmunity associated with B-cell 
destruction and type 1 diabetes. 
INTRODUCTION 
Pancreatic B-cells in islets of Langerhans can be destroyed by autoimmune 
processes resulting in insulin dependent or type 1 diabetes (2). The destruction 
often proceeds over a long period of time before the clinical symptoms develop (3, 
4). The gradual loss ol B-cells is accompanied by circulating islet cell antibodies 
demonstrated by indirect immunofluorescence staining of frozen sections of human 
pancreas. Such antibodies are referred to as ICA (3, 4). Although B-cell destruction 
is believed to be mediated by T-cells (5), islet cell antibodies detected in the early 
phases of B-cell destruction are likely to be directed to the same antigen as 
pathogenic T-cells. Furthermore antigen specific B-cells may play an important role 
in presentation of rare B-cell autoantigens to maintain a chronic autoimmune 
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response that gradually depletes the B-cell pool. ICA epitopes are usually only 
detected on frozen but not on fixed pancreatic tissue consistent with their 
conformational nature. lmmunoprecipitation under native conditions has identified 
the smaller form of the neuroendocrine enzyme glutamic acid decarboxylase, 
GAD55, as a target of islet cell antibodies associated with early as well as late 
stages of B-cell destruction in 70-80% of patients (6-8). GAD55 is the synthesizing 
enzyme lor the major inhibitory neurotransmitter GABA and is expressed in 
significant amounts in B-cells and in GABA-ergic neurons (9). The diabetes 
associated epitopes in GAD 55 are predominantly conformational and only include 
a linear epitope in very rare cases (6, 10, 11 ). The non-allelic form of the enzyme, 
GAD57, which is expressed in human brain but not in human B-cells (12,13), is 
78% identical to GAD55 in the epitope areas (10,14) and yet is only rarely 
recognized by autoantibodies in type 1 diabetes (15, 16). 
A small fraction of type 1 (insulin dependent) diabetic patients have islet cell 
antibodies detected by immunofluorescence on frozen sections of human pancreas 
(ICA), but do not recognize GAD55 (17-19). Furthermore GAD does not always 
block ICA reactivity in diabetic sera suggesting that autoantibodies can be directed 
to additional antigens in this disease (20,21 ). Reactivity with denatured 
carboxypeptidase H (22), a 52kD protein (23) and a 69kD protein with homology to 
bovine serum albumin (24) on western blots has been reported in some diabetic 
sera. Those proteins are however unlikely to be targets of ICA in sera which only 
react on frozen but not fixed sections of human pancreas. We have sporadically 
detected an antigen of Mr 38kD in immunoprecipitates of rare preparations of 
human (17) and rat islets cell proteins (unpublished results) using human type 1 
diabef1c sera and native conditions. Furthermore antibodies to a 38kD rat islet 
antigen have been reported in the BB-rat, an animal model of type 1 diabetes (25). 
T-cell reactivity to a non-characterized insulinoma protein (26,27) of a similar 
relative molecular weight has also been detected in newly diagnosed diabetic 
patients. Recently the 38kD nuclear transcription factor jun-B was suggested to be 
an autoantigen in type 1 diabetes (28). Finally a 37kD tryptic fragment has been 
detected in immunoprecipitates of trypsinized but not intact islet cell membranes 
with diabetic sera (29,30). We now report that a vigorous extraction of rat islet cell 
proteins in detergent results in a consistent detection of a 38kD B-cell antigen in 
immunoprecipitates with a subgroup of type 1 diabetic sera. The difficulty in 
extracting the 38kD protein indicates that it is relatively insoluble and thus has 
escaped detection in many previous immunoprecipitation analyses with type 1 
diabetic sera. Using an improved extraction method lor solubilizing islet cell 
proteins, we have analyzed the incidence of 38kD autoantibodies in newly 
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diagnosed and prediabetic individuals and determined different characteristics of 
the 38kD antigen. 
METHODS 
Preparation of islet cell extracts and immunoprecipitation analysis 
Neonatal rat islets were isolated and labeled with 35s methionine as described 
(31). Islets were swollen on ice for 10 min in HEMAP buffer (10mM Hepes pH 7.4, 
1mM MgCI2, 1mM EGTA, 1mM aminoethyl-isothiouronium bromide hydrobromide, 
and 0.2 mM pyridoxal phosphate), followed by homogenization by 20 strokes in a 
glass homogenizer. The homogenate was centrifuged at 100,000g for 1 h to obtain 
a cytosol and a particulate membrane fraction. Preliminary experiments using 
different detergents. The particulate membrane fraction was extracted in HEMAP-
buffer with 2% Triton X-114 for 2h by repeated dispersion through a bended pipette 
tip, followed by centrifugation at 100,000g to remove debris. Amphiphilic proteins in 
both the cytosol fraction and the membrane extract were purified by temperature 
induced TX-114 phase separation (6). The detergent phase of either membrane or 
cytosol fractions were precleared with a normal human serum before 
immunoprecipitation with the indicated sera (31 ). Extracts of 250-500 rat islets was 
used per immunoprecipitate. lmmunoprecipitates were analyzed by SDS-PAGE 
using 15% gels and processed for fluorography (31). A quantitative estimate of the 
GAD55 and 38kD protein immunoreactivity of sera (antibody index) was obtained 
by densitometric scanning of bands corresponding to the proteins on 
autoradiograms using a Model 620 Video Densitometer with 1 D Analyst II and 
version 3.10 software (BioRad, Richmond, CA). Serum l15was used as an internal 
38kD antibody positive control in all analyses and its value arbitrarily set at 1 o. 
38kD antibody indexes in other sera were calculated from integrated peak areas by 
the formula: index = 10 x (value for unknown serum - value for negative control 
serum)/(value for serum 115- value lor negative control serum). Similarly GAD55 
antibody indexes are expressed in relation to a standard positive control serum 
which is a Juvenile Diabetes Foundation (JDF) world standard lor ICA analyses 
and is also used as a standard for quantitative analyses of GAD55 autoantibodies 
(18). 
The BTC3 cell line was derived from a transgenic insulinoma (32). The aTC cell 
line was similarly derived from a transgenic glucagonoma (33) and was a gift from 
Dr. D. Hanahan (University of California San Francisco, CA). The GT1 cell line was 
derived !rom a gonadotropin releasing hormone secreting tumor !rom a transgenic 
mouse (34) and was a gilt !rom Dr. R. Weiner (University of California San 
Francisco, CA). The rat hepatoma cell line HTC (35) was a gilt !rom Dr. A. Reuser, 
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University of Rotterdam. All other cell lines (table 1) were obtained from American 
Tissue Culture Collection (Rockville, MD). Cell lines were cultured according to 
established methods and labeled with 35s methionine (31 ). Membrane extracts 
were prepared, extracted and immunoprecipitated as described for neonatal rat 
islets using serum Its and serum Ct. The immunoprecipitates were analysed by 
SDS-PAGE and fluorography (31). 
Two-dimensional gelectrophoresis and determination of isoelectric 
points 
Two dimensional gel-electrophoresis using isoelectric focusing in the first 
dimension and SDS-PAGE in the second dimension was carried out as described 
(3t ,36). The isoelectric points were determined by coelectrophoresis with 
carbamylated creatin phosphokinase charge chain markers (BDH, Poole, Dorset, 
U.K.) and with total Hela cellular proteins containing several hundred marker 
proteins of known Mr. pi and location in the two dimensional pattern. The 
radioactive spots were analysed by image scanning using the Bio-lmage software 
version 4.6 (Millipore, Bedford, MA, U.S.A). 
Description of patient groups and sera 
Sera were collected following informed consent from three groups of patients, i) 49 
newly diagnosed Dutch and Swedish type 1 diabetic patients who developed 
diabetes at> 5yrs of age and 25 control individuals in the same age group; ii) 37 
Finnish and Dutch newly diagnosed type 1 diabetic patients who developed 
diabetes at:;; 5yrs of age, and 38 control individuals in the same age group ; and iii) 
44 North-American and Dutch prediabetic individuals (age 2.6-49.9). The first (and 
sometimes only) serum available from the individuals in this group was sampled 3-
85 months before clinical onset of type t diabetes. 
An antiserum to jun-B (37) was from Dr. R. Bravo (Bristol-Myers Squibb Institute for 
Pharmaceutical Research, NJ). Two patient sera which recognize a 37kD fragment 
generated by trypsin digestion of rat islet cell membranes (29,30), were a gift from 
Dr. M. Christie (Oxiord University, UK). A GAD65 antibody positive serum from a 
stiff-man syndrome patient was from Dr. R. Layzer (University of California San 
Francisco, CA). 
ICA analysis 
Islet cell cytoplasmic antibodies were analyzed by indirect immunofluorescence of 
frozen sections of human pancreas from cadaveric kidney donors of bloodgroup 0 
(38-40) Samples were titrated and end po·1nt titers were defined as the highest titer 
of detectable ICA-staining. Positive samples were expressed in Juvenile Diabetes 
The 38kD protein 185 
Foundation-units by comparing their end point dilution to a standard calibration 
curve using the international Juvenile Diabetes Foundation reference serum 
provided by the Immunology of Diabetes Workshops (41). The test laboratories are 
participiants of the ICA proficiency program conducted under the auspices of the 
Workshops (42). 
RESUlTS AND DISCUSSION 
The 38kD protein is an amphiphilic B-cell membrane protein 
of pi 5.6-6.1 
Extraction of the GAD55 antigen from islets of Langerhans is complete after 30 min 
in 1% non-ionic detergent In contrast the 38kD protein is only sporadically 
detected in such extracts by immunoprecipitation with a serum from a newly 
diagnosed type 1 diabetic patient, 115- In preliminary experiments several 
detergents (CHAPS, B-octyl-glucoside, sodium deoxycholate, Triton X-114) were 
tested lor their ability to extract the 38kD protein. A 2% concentration of each 
detergent effectively solubilized the 38kD during a vigorous 2 hour extraction of 
islet cell membranes. Triton X-114 for was selected for all further experiments to 
facilitate a partial purification of the 38kD protein by a temperature induced phase 
transition and separation of amphiphilic membrane proteins into the Triton X-114 
detergent phase. The relative insolubility of the 38kD protein suggested that it was 
membrane bound. Cytosolic and membrane proteins were subjected to a Triton X-
114 phase separation to assess the amphiphilicity of the 38kD protein (Figure 1 A). 
In contrast to the GAD55 autoantigen which is found both as a soluble hydrophilic, 
a soluble amphiphilic, and a membrane bound amphiphilic form (43,44) (Figure 1 A 
compare lanes 16 and 18), the 38kD protein was only detected in the particulate 
fraction, where it partitioned into the detergent phase (Figure 1A, lanes 15 and 16). 
Thus the 38kD protein is an amphiphilic membrane protein. The relative 
insolubility of the 38kD protein suggests that it is an integral membrane protein in 
contrast to GAD65. which is anchored to membranes via lipid residues (44). 
The 38kD protein was detected as a broad band on fluorograms of SDS-gels 
suggesting heterogeneity in size and/or charge (Figures 1 and 2). Two dimensional 
gel electrophoresis using isoelectric focusing in the first dimension and SDS-PAGE 
in the second dimension (31 ,36) revealed 7 spots of similar relative molecular 
weight and isoelectric points of 5.6-6.1 (results not shown). 
In an analysis of neuroendocrine and non-endocrine cell lines, the 38kD antigen 
was only detected in immunoprecipitates of BTC3 cells derived from a transgenic 
mouse B-cell tumor (32), whereas glucagon producing aTC cells (33) as well as 13 
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other cell lines of endocrine and non-endocrine origin were negative (Table 1 ). 
Thus expression of the 38kD protein seems to be restricted to pancreatic B-cells. 
TABLE 1: Analysis of expression of the 38kD protein in different cell lines: 
Cell Line 
~TC3 (ref. 32) 
a TC-2 (ref. 33) 
GT1 (ref. 34) 
PC12' 
CHO' 
He La· 
T47D• 
Sk-NEP-1' 
Cos~1* 
cv-1· 
HepG2' 
BHK-21' 
HTC (ref. 35) 
TERA-2' 
CCD-118Sk' 
Origin 
Mouse pancreatic insulinoma 
Mouse pancreatic glugagonoma 
GnRH neuronal tumor 
Rat adrenal pheochromocytoma 
Chinese hamster ovary 
Human ovarian adenocarcinoma 
Human ductal breast carcinoma 
Human nephroblastoma 
Monkey kidney tumor 
Precursor of Cos~ 1 
Human hepatocellular carcinoma 
Baby hamster kidney 
Rat hepatoma 
Human teratocarcinoma 
Human fibroblast 
Expression 
pos 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
neg 
*American Type Culture Collection, Bethesda MD; GnRH: gonatotropin-releasing hormone 
The 38kD protein is not a fragment of GADs5 
Christie et al., have described antibodies in sera from type 1 diabetic patients 
which recognize a 37kD trypsin fragment of an islet cell protein of similar molecular 
mass as GAD65 (29,30). Such sera do not always recognize the full length native 
GAD65 molecule, suggesting either that a sequestered epitope may become 
exposed upon trypsinization or that the 371cD fragment is derived from a different 
protein from GADes. In light of this report we have addressed the question whether 
the 38kD protein is a fragment of GAD55 or otherwise related to GADes. Islet cell 
membrane extracts were sequentially immunoprecipitated with sera that contained 
GAD 55 or 38kD antibodies. Supernatants depleted for immunoreactive GAD55 
were still positive for the 38kD protein (Figure 2). Similarly supernatants depleted 
for immunoreactive 38kD protein still contained the GAD65 molecule. Thus the 
native 38kD protein and the native GADes molecule do not display immunological 
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Figure 1A. lmmunoprecipitation ol the 38kD protein from Triton-X-114 
detergent phase purified particulate and cytosol fractions ol islet cells 
by diabetic sera. 
Fluorogram of an SDS-PAGE showing immunoprecipitation of membrane and cy-
tosol fractions of 35s methionine label•od islet cell proteins with sera from newly di-
agnosed diabetic patients I t-116 (lanes 1·18), a stiff-man syndrome serum (lane 
1 9) and sera from healthy controls C1-C3 (lanes 20-22). GAD 55 which splits into 
two bands a and B, can be seen in immunoprecipitates from both membrane and 
cytosol fractions with serum from patient I 16 (lanes 16 and 1 8) whereas the 38k0 
protein is only detected in immunoprecipitates from the membrane fraction with 
serum from patient 115 and 116 (compare lanes 15·16 with lanes 17-18). 
Membranes Cytosol 
Newly diagnosed patients Controls 
Mr(kD) 1, lz 13 14 Is 16 17 Ia !9 110 111 l12 113 114 115 116 115 116 S C1 Cz C3 
97.4-
46-
38kD-
30-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
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Figure 1 B. lmmunoprecipitation of the 38kD protein from Trilon-X-114 
detergent phase purified particulate ami cytosol fractions of islet cells 
by diabetic sera. 
lmmunoprecipitation of membrane fractions of 35s methionine labeled islet cell 
proteins with sera from newly diagnosed diabetic patiens lt5 and 162·1so (lanes 3· 
21) and healthy controls Ct and C3t-C3s- The diabetic sera recognize either the 
38kD protein alone. the GAD55 protein alone, both proteins or no specific protein. 
Mr(kD) 
97-
69-GADes//~ 
46-
38kD-
30-
21_5-
Newly diagnosed patients Controls 
1 2 3 4 56 7 8 91011121314151617181920212223242526272829 
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crossreactivity. Next we analysed whether 38kD sera recognize a 37/40kD 
fragment of GAD55, which was generated by a mild trypsin digestion of either 
protein. Although several GAD65 antibody positive sera recognized the 37/40kD 
GAD55 trypsin fragment, the sera which were only positive for 38kD antibodies did 
not recognize this fragment (results not shown). Finally two 37kD antibody positive 
sera (29,30) (kindly provided by Dr. M. Christie, Oxford University) did not 
immunoprecipitate the 38kD antigen (results not shown). In sum those results show 
that the 38kD protein is distinct from GAD55 and distinct from the 37kD fragment 
described by Christie et al. (29,30). 
The 381<0 B-cell antigen in type 1 diabetes is not jun-B 
Honeyman et al. (28) reported recently the isolation of a eDNA clone encoding jun-
B by antibody screening of an expression library from islets and placenta using a 
human antiserum from a type 1 diabetic patient. They subsequently detected 
peripheral T-cell responses to jun-B in some type 1 diabetic patients and their 
relatives and concluded that jun-B is a target autoantigen in type 1 diabetes. Jun-B 
has a Mr of 38kD. However jun-B is a soluble nuclear protein and its isoelectric 
point is significantly more basic than that of the 38kD autoantigen described here. 
Thus rat jun-B has a pi " 9 on our 2D-gels and the calculated pi for human jun-B 
based on the amino acid sequence (45) is 9.58. Furthermore antibodies to jun-B 
did not immunoprecipitate the 38kD protein (results not shown). We therefore 
conclude that the 38kD antigen described here is not jun-8. 
Autoantibodies to the 36kD antigen are present in a subgroup o I 
newly diagnosed diabetic individuals and complement GADs 5 
autoantibodies 
Using the improved method lor solubilization of the 3BkD antigen, we analysed 
38kD antibodies in 49 individuals who developed diabetes at > 5yrs and 25 
controls in the same age group (Figure 1, Table 2). Twelve patients (24%) and 
none of the controls were positive for antibodies to the 38kD protein. In comparison 
37 (76%) patients and none of the controls were positive for GAD55 antibodies. Six 
patients (12%) were positive for 38kD antibodies only. Thus the cumulative 
incidence of GAD55 and/or 38kD antibodies was 84% 
Both the 38kD antigen and GADs 5 are targets ol early B-cel! 
responses associated with B-cell destruction 
B-cell destruction can progress for several years before the first clinical symptoms 
of type 1 diabetes appear. It is conceivable that the prolonged autoimmune 
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destruction may result in secondary autoimmune responses to some molecules 
which spill out of B-cells in numbers or forms which are not tolarized during 
development. To assess whether the 38kD antigen is a target of early rather than 
late immune responses in type 1 diabetes we analysed the presence of 38kD 
antibodies in i) a group of 44 individuals (age 2.6-49.9 yrs at clinical onset) from 
whom sera were available 3-85 months prior to clinical onset of type 1 diabetes 
and ii) 37 children who developed diabetes " 5yrs of age and 38 controls in the 
same age group (Table 2). Six of the 44 prediabetic individuals (14%) were 
positive for 38kD antibodies in the first serum sample available, which was 3, 9, 25, 
33, 53, and 7 4 months respectively before clinical onset of type 1 diabetes. Two 
individuals were positive for 38kD antibodies only and 4 individuals were positive 
for both GAD55 and 38kD antibodies. GAD65 antibodies were detected in a total of 
33 (75%) of the prediabetic patients in the first sample available 3-85 mo before 
clinical onset of disease, a result consistent with our earlier studies {7,8). Thus both 
38kD and GAD65 antibodies can be detected up to several years before clinical 
onset. Follow-up samples were available lor 34 of the prediabetic individuals. 
None of the individuals changed from antibody negative to antibody positive status 
in later samples. Thus antibody negative individuals remained negative and single 
antibody positive individuals did not become double antibody positive, suggesting 
that neither the GAD 55 antibodies nor the 38kD antibodies are a consequence of 
prolonged B-cell destruction. Rather they may be determined by genetic or 
environmental factors which are either present or absent at the onset of the 
autoimmune process. 
Amongst the young newly diagnosed children, 4 of 37 patients (11 %), 1.3, 1.6, 1.8 
and 4.8 years of age respectively, were positive lor 38kD antibodies. 28 patients, 
including all of the 38kD antibody positive individuals, were positive for GADss 
antibodies (76%). None of the healthy control individuals were positive lor GAD55 
or 38kD antibodies. 
Summary ol antibody data and implications for type 1 diabetes 
Taken together amongst the 130 patients, who were analysed either in the 
prediabetic period or at the clinical onset of disease, 22 (17%) were 38kD antibody 
positive compared to 98 (75%), who were GAD55 antibody positive. Eight patients 
were positive tor 38kD antibodies only, wheras 14 had both 38kD and GAD65 
antibodies. Thus 106 (82%) were positive tor antibodies to either or both antigens. 
38kD as well as GAD55 antibodies were detected at clinical onset in children who 
developed type 1 diabetes as early as 1.3 and 0.8 years of age respectively. Since 
the duration of B-cell autoimmunity in those very young 
TABLE2: Incidence of autoantibodies to a 38kD ~-cell membrane protein in type 1 diabetes and comparison with GADasab and ICA: 
GROUP n Avg. age at Range F/M ICA Incidence 38kD Incidence GADes Incidence 38k0 
diagnosis or at years autoantibodies autoantibodies and/or GAD 55 
sampling of sera autoantibodies 
(controls) years 
Newly diagnosed 49 13.1 ±9.22 5.1 • 57.0 20/29 38./49 12*/49 37/49 41/49 
diabetic patients (0.7) 77% (24%) (76%) (84%) 
> 5 years of age 
Healthy controls 25 14.9±12.6 5.1 • 54.2 10/15 0/25 0/25 0/25 0/25 :;! 
> 5 years of age (0.7) (0%) (0%) (0%) "' 
"" 
Newly diagnosed 37 2.9 ± 1.4 0.8. 5.0 15/22 32§137 4~137 28/37 28/37 
co 
ij 
diabetic patients (0.7) (86%) (11%) (76%) (76%) a < 5 years of age (i) 
18/20 0/38 
:;· 
Healthy controls 38 2.8 ± 1.3 0.9. 5.0 0/38 0/38 0/38 
< 5 years of age (0.9) (0%) (0%) (0%) (0%) 
Prediabetic 44 19.2 ± i2.5 2.6. 49.9 14/30 28"'* /44 6>*/44 33/44 35/44 
individuals (0.5) (64%) (14%) (75%) (80%) 
3-85 mo. before 
clinical onset 
Six of whom were both GADes and 38kD antibody negative 
* 
Six of whom also had GADes autoantibodies 
§ Four of whom were both GADes and 38kD antibody negative 
~ All of whom also had GADes autoantibodies 
None of whom were both GAD 65 and 38kD antibody negative I~ H Four of whom also had GADes autoantibodies 
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Figure 2. lack of immunological cmssreactivity between GADss and 
the 38kD protein. 
Anti-38k0 antibodies and anti-GADes antibodies recognize distinct proteins. 
Fluorograms of an SDS-PAGE showing sequential immunoprecipitatiOn of 35s 
methionine-labeled rat islets membrane proteins (material from 500 islets per lane) 
with anti-38k0 antibodies and anti-GAD65 antibodies positive sera . Lanes 1 and 
S show immunoprecipitation with an anti-GAD6S antibody positive stiff-man 
syndrome serum (Lane 1 ), and a diabetic patient serum Is (lane 4). The 
supernatant after immunoprecipitation was then subjected to a second 
immunoprecipitation with anti-38kD antibody positive diabetic sera Its and l4 
(lanes 2 and S). The supernatant after immunoprecipitation in lane 2 was then 
subjected to a third immunoprecipitation with an anti- 38k0 and anti-GADes 
antibody positive serum Its (lane 3). GADes and the 38k0 prote·,n do not affect the 
immunoprecipitation of each other. 
1st!MP S S S 15 15 
2nd IMP 115 115 14 
3rd IMP 116 
Mr(kD) 
200-
97.4-
46-
38kD-
30-
21.5-
2 3 4 5 
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children must have been significantly shorter than is often the case in older 
individuals (7,8) this result suggest that both proteins may be targets of primary 
rather than secondary autoimmune processes directed to the B-cell in the human 
disease. This notion is supported by the appearance of antibodies to both antigens 
several years before the clinical onset of type 1 diabetes. Thus both 38kD and 
GAD55 antibodies mark periods of early B-cell destruction. 
The incidence of ICA detected by immunofluorescence of frozen sections of 
human pancreas was 75% (98/130). In the three groups, the 38kD and/or GAD55 
immunoprecipitation assays detected a total of 18 individuals which were negative 
for ICA by the immunofluorescence assay indicative of a lower sensitivity of the 
latter method to detect antibodies to those antigens. Blocking experiments have 
shown that the ICA response can progress from GAD-restricted to non-GAD 
restricted during the prediabetic period in some individuals which suggests a 
spreading of antigen reactivity during prolonged periods of B-cell destruction (20). 
Interestingly, all ICA positive individuals in the prediabetic group were positive for 
either 38kD antibodies, GAD55 antibodies or both. In contrast 4 and 6 ICA positive 
individuals in the young and older newly diagnosed groups respectively were 
negative for both 38kD and GAD55 antibodies, suggesting that the humoral 
autoimmune response in those individuals may include other target molecules at 
the time of clinical onset. lmmunoprecipitations did not reveal islet cell protein(s) 
that were specifically recognized by those sera (results not shown). It is 
conceivable that ICA reactivity in those 38kD and GAD55 antibody negative sera 
may be directed to non-protein molecules like gangliosides (46). Finally 8 
individuals in the prediabetic group and 2 and 3 individuals in the young and older 
newly diagnozed groups respectively were negative for antibodies by both 
immunofluorescence and immunoprecipitation assays 
The 38kD antibodies analysed in this study recognized their target under native but 
not denaturing conditions, suggesting that 38kD antibodies, much as GAD55 
antibodies, are primarily directed toward conformational epitopes. Regarding 
immune recognition, it is well established that the MHC-haplotype is influential. 
More than 90% of all individuals who develop type 1 diabetes are HLA-DR3 and/or 
DR4 positive (47). HLA-data could only be obtained for 12 of the 22 38kD antibody 
positive individuals. The DR4 haplotype was particularly abundant in those 
individuals (10/12 compared with 4/12 for DR3, and 2/12 for DR1, and DR? 
respectively). The dataset is, however, too small to analyse for statistical 
significance. 
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We have extensively analysed immunoprecipitates of detergent lysates of 35s-
methionine labelled islets with diabetic and control sera by one and two 
dimensional gel-electrophoresis in attempts to detect additional islet cell proteins 
that are specifically recognized by autoantibodies in type 1 diabetes under native 
conditions. The stringent conditions of immunoprecipitation require that antibodies 
must 1) be of the lgG isotype (for binding to Protein A-Sepharose), and 2) be of 
sufficient affinity and specificity to recognize their target protein in the midst of an 
abundance of other islet cell proteins. Using this assay, we have been unable to 
detect proteins other than GAD55 and the 3Sk0 protein that are consistently and 
specifically recognized by a significant fraction of diabetic sera. In particular, 
carboxypeptidase H, a 52k0 protein, 69k0 protein with homology to bovine serum 
albumin, and insulin, all reported to be targets of antibodies in diabetic sera (22-24, 
48) are not detected in immunoprecipitates (31 and unpublished results). Thus 
strong lgG responses to conformational protein epitopes may be limited to the 
GAD55 and 38k0 molecules in the human disease. Since high titer GAD65 and 
38kD lgG antibodies are detected in the early phases of B-cell autoimmunity, we 
predict the presence of activated C04+ T -helper cells recognizing each of those 
molecules. In fact, reactivity to both GAD (49-51) and to a 38kD B-cell protein 
(26,27) has been demonstrated using T-cell lines from newly diagnozed diabetic 
patients. The relation of the 38k0 antigen described in this report with that 38kD T-
cell stimulatory protein (26,27) remains to be clarified. An outstanding question 
now is, whether GAD and the 38k0 antigens are targets of pathogenic cos+ T-
cells which are believed to mediate B-cell destruction in type 1 diabetes (5,52), a 
result which would suggest these proteins have a potential for antigen specific 
immunotherapy aimed to prevent the disease. 
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5. General Discussion 
The work described in this thesis has resulted in the identification of the 
64kD autoantigen in type 1 diabetes mellitus as the neurotransmitter y-amino 
butyric acid (GABA) synthesizing enzyme Glutamic Acid Decarboxylase (GAD) (1 ). 
Additional immunological and biochemical analyses resulted in further 
characterization of this antigen{2, 3) The 38kD autoantigen was studied (chapter 
4) and, although not yet fully identified and characterized, the value of the 
autoantibodies against this target evaluated. Analysis of autoantibodies to both 
peptides opens new ways for disease prediction in type 1 diabetes mellitus and 
these molecules now be evaluated for studies on their role in the pathogenesis. 
The identification of the 64kD antigen has triggered further research eflorts 
on this molecule. Several laboratories started to develop antibody assays that 
would allow fast and reliable testing for antibodies to GAD. A first workshop on the 
standardization of such GAD assays was held in Orlando, Florida in April 1993. 
This meeting was held under auspices of the Juvenile Diabetes Federation (JDF), 
which also orchestrated the standardization of ICA and IAA assays. Although 
different assays were tested and the organizers had supplied the different groups 
with standard sera, the immunoprecipitation techniques proved to be the best, thus 
setting a sort of 'golden standard'. In addition to establish the predictive value of 
GAD autoantibodies, several projects were initiated to determine the role of GAD 
as a model-autoantigen in type 1 diabetes. Such studies will also help to 
determine how tolerance or absence of tolerance to such peptides is established. 
Several papers have addressed the GAD molecule since 1990. Despite of all the 
research, it is at present not known if GAD, or any other characterized antigen is a 
primary target of autoimmunity in type 1 diabetes. The next paragraphs discuss the 
work presented in this thesis and discuss directions for further research. 
5.1 The 641<0 antigen is GAD: Biochemical Function and 
Characteristics in Brain. 
As outlined in the different papers presented in this thesis, the discovery that 
the 64kD autoantigen was a neuronal enzyme was somewhat surprising. One 
isoform, GAD57, was actually cloned years before. As indicated in the introduction, 
B-cells do share several features in common with neurons and GAD is a typical 
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example. Since this enzyme has been stud·led for years by researchers in 
neurobiology and neuroscience, it is obvious that researchers studying in B-cells 
and in type 1 diabetes can learn important lessons especially on the chemical, 
functional and cell biological aspects of the protein. The next section discusses 
some of the features on GAD. The interesting links between GAD, neurons and 
diabetes are important avenues to explore in the future. 
The enzyme Glutamic Acid Decarboxylase (GAD, E.C. 4.1.1.15) catalyses 
the conversion of L-glutamate into y-amino butyric acid (GABA). GABA is the major 
inhibitory neurotransmitter in the brain and 1t has been estimated that up to 30% of 
the neurons are GABA-ergic ((4) for review). The decarboxylation of the a-COOH 
group from L-glutamate is the rate limiting step in GABA formation. In neurons, 
GAD is the major GABA synthesizing enzyme, but other mechanisms of GABA 
synthesis are present. GABA can also be formed from glutamate by an aerobic 
pathway via succinic semialdehyde. 
Figure 5.1 : GAD catalyzes the alpha decarboxylation of L-glutamic acid to form y-
amino butyric acid (GABA). GABA transaminase (GABA-T), catalyzes the transfer 
ol the amino group from GABA to a-ketoglutarate. This reversible reaction results in 
the formation of L-glutamate and succinic semi-aldehyde. Succinic semi-aldehyde 
is oxidized to succinic-acid by succinic semi-aldehyde dehydrogenase (SSADH). 
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Additional mechanisms lor GABA synthesis include production from putrescine via 
MAO (monamine oxidase), contributing about 0.5% of the GABA pool in brain., and 
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GABA synthesized from ornithine (5). Neurons do express enzymes involved in 
GABA breakdown. These are GABA transaminase (GABA-T) and Succinic semi-
aldehyde dehydrogenase (SSADH) (4) The three enzymes GAD, GABA-T and 
SSADH form together the so-called GJi.BA-shunt in which GAD is the rate limiting 
step. The GABA shunt acts as a closed loop system, that conserves the supply of 
GABA: GABA is re absorbed from the synaptic cleft by a specific GABA uptake and 
transport mechanism (GABA transporter) and is either restored in vesicles or 
transported to the mitochondria for bfeakdown. GABA breakdown produces 
glutamate (via the intermediate a-ketoglutarate). Glutamate is the precursor of 
GABA, thus closing the loop in the GABA shunt 
In the nervous system GABA is released from small synaptic vesicles and 
enters the synapse ((3, 6, 7) lor review on synaptic mechanisms see (8). The 
inhibitory effect of GABA is mediated through GABA receptors of which two types 
exist. GABAB receptor activation results in cell inhibition through closure of Ca2+ 
channels or opening of K+ channels (9, 10) GABAA receptors are made of (at least) 
6 subunits, which together form a chloride channel, that opens upon binding of 
GABA to one of the subunits. The receptor has additional binding sites lor 
benzodiazepines and steroids and can also be influenced by other chemicals (1 0-
14). Although GABA is a general neuron inhibitor, some other specific effects of 
GABA in the nervous system are known. GABA has been colocalized in cells that 
secrete other neurotransmitters or peptidergic neurotransmitters (15, 16) It may 
possess a regulatory role, particular in hypothalamic and pituitary cells (9, 17). 
Such a regulatory role in secretion was found in the pineal gland (18) 01 great 
importance is the role of GABA in development of the neuronal networks (19-25). 
Finally, GABA serves as an energy source in several cell types. 
Conflicting results existed in neurochemical literature about the molecular 
weight. Erlander and Tobin, collected and summarized these data: GAD is 
composed of two polypeptides with molecular weights between 59-67kD (4). A 
gene for GAD was cloned in 1986 (26). At that stage, it was believed that this gene 
would encode for both GAD proteins and that the different forms would be due to 
alternative splicing or post-translational modifications. In 1991 Erlander and 
coworkers showed however (27) that 2 genes existed, coding for 2 different 
proteins, now referred to as GADs? and GAD55. GAD belongs to the family of 
pyridoxal-5-phosphate (PLP) dependent decarboxylases. These enzymes have in 
general been highly conserved over evolution (28) The active form of GAD, called 
holoGAD, has PLP covalently bound to an amino group of a lysine residue in the 
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PLP binding site of the enzyme. The inactive form, apoGAD, lacks PLP. In whole 
brain homogenates, only 50% of total GAD is in the active holo form, even though 
the concentration of PLP in the brain is adequate to saturate GAD (29, 30). This 
indicates that GAD and PLP may be confined to ditterent compartments in vivo. 
Under depolarizing conditions, PLP associates with apoGAD to form holoGAD 
thereby increasing GABA production in nerve terminals with increased neuronal 
activity (4). PLP levels seem to be of major importance tor regulating GAD activity. 
GAD55 makes up most of the apoGAD reservoir in GABA-ergic neurons (30) while 
GAD57 predominantly exists in the holo-torm, is less regulated by PLP, and binds 
this coenzyme more tightly (30). Other molecules can regulate GAD activity, such 
as GABA, glutamate and aspartate which may induce apoGAD !ormation, while 
inorganic phosphate promotes holoGAD (31 ). It has been suggested, that GAD67 
is more involved in a steady state production of GABA, and that GABA formed by 
this isotorm Junctions as an energy source rather than a neurotransmitter (29). This 
is in line with observations showing that GAD57 is localized in the perikaryon, 
while GAD55 is more confined to the synaptic area. 
GAD67 activity is regulated mainly at the transcriptional level. An increase 
in neuronal activity has been strongly correlated with increased GAD57 RNA (32). 
Analysis of the 5' region of the GAD67 gene has revealed 2 ditterent promoter 
regions and several potential transcription factor binding sites (33) During 
development of the rat embryo, the translation of GAD67 is regulated by a splicing 
event. It was found that a 86 base pair exon contains a UGA-codon which is 
believed to result in a truncated form since the UGA codon represents a stop-codon 
in the genetic code (34). The UGA stop-codon, however, has recently been found 
to be overread and can result in methionine, tryptophan or selenocysteine (35) 
incorporaf1on. This addition to the genetic code has been idenf1fied in several 
species now, but a role tor this stop-codon in GAD has not been analyzed. In 
human fetal brain samples, some larger instead of truncated GAD-forms are 
present (H.J. Aanstoot, G.J. Bruining, unpublished observations). Aberrant forms of 
GAD could have ditterent activities, a possibility supported by studies showing that 
GAD in newborns is more vulnerable to heat. This observaf1on has been implicated 
in the etiology of febrile seizures (36). Other evidence for a differences in forms or 
activity of GAD in newborns comes from studies on the role of vitamin B6 (a 
precursor ol PLP) in so called pyridoxine dependent convulsions (37, 38) In 
addition, syndrome ol GAD deficiency in a newborn with convulsions has been 
described (39) although it is not clear from that study if one or both forms were 
absent. In rats, differential expression of the two forms was found during 
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development (40, 41). While GAD57 was predominantly present in the 
embryological period, GAD55 expression dramatically increased in the neonatal 
period, concomitant with a period of intense synapse formation. Alter 2 weeks, the 
expression normalized to levels found directly after birth. These observations 
indicate that our knowledge on the role of GAD and GABA in neuronal dysfunction 
and convulsive disorders, is incomplete and needs more attention. It also indicates 
that studies on brain GAD will be important to study GAD and the GABA system in 
B-cells. 
5.2 Tissue Distribution and GABA-ergic: System in the Pancreas. 
GABA-ergic neurons are w'1dely present in the central nervous system. Their 
abundance has lead to the suggestion that the brain is in a constant inhibited state. 
GABA-ergic neurons vary widely in morphology ( 42). Coexpression with other 
neurotransmitters has been found in some GABA-ergic neurons (15). In the 
peripheral nervous system, GABA and GAD containing neurons are present (43, 
44). Outside the nervous system, GAD has been found in several tissues (see (45) 
for review) including adrenal, thymus, stomach, duodenum, gall bladder, muscle 
and thyroid. However, GAD concentrations as found in B-cells and brain (46) are 
only present in fallopian tubes (oviducts) and testis. Several of the studies 
performed used enzymatic assays to measure GAD activities (see (1) for method) 
and did not directly visualize the protein by biochemical techniques such as 
Western Blotting. The enzyme assay is not specific. Other enzymes with 
decarboxylation activity can be measured. Recently, it was shown that GAD 
present in oviducts is GAD55, while in testis GAD57 was present (47). GAD57 in 
sperm probably functions as an energy source (48) while in the oviduct with 
GAD65 signaling might be the primary mle. GAD activity in the fallopian tubes in 
rats is highly dependent on the hormonal status (49, 50) with fluctuations during the 
menstrual cycle, but the exact role for GAD in these tissues is not established. 
The presence of GABA system components in the pancreas has been 
recognized since 1986 (51). However, their functional significance was not 
understood. Preliminary in vitro experiments involved the study of effects of GABA 
and GABA-inhibitors on insulin secretion, but controversial results were obtained: 
both increase as well as inhibition of insulin release was reported (52-55). More 
recently, Rorsman and co-workers suggested that inhibition of glucagon secretion 
by glucose is mediated by GABA, cosecreted with insulin (56). GABAA receptors on 
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the a-cells are present. These findings were supported by a study that showed a 
20% inhibition of glucagon secretion by GABA in mouse and rat pancreas (57). 
GABAA receptors are also present on 5-cells (58). These data support a paracrine 
role of GABA within the islets of Langerhans. 
It can be argued that GABA has no regulatory function in 13-cells. but is used 
as an energy source. 13-cells, as extremely specialized cells with high peptide 
synthesis rates, are in the need of a high energy production to keep up with the 
demands. GABA production offers an alternative fuel. The production of GABA and 
localization of GABA and GAD55 however, has many parallels to neurons that 
energy needs are not likely to be the reason for a 13-cell to express GAD. The 
specific subcellular localization of GAD55 is an additional reason to propose that 
GAD is not simply an enzyme to cover energy demands. The role of GABA in the 13-
cells can be tested in vitro by stimulating or inhibiting GABA synthesis and 
secretion. Several GABA-ergic compounds are available and have been 
extensively characterized in neurons and the brain (59-63) Interestingly, BTC3 
tumor cells have, despite the fact they are tumor cells, several features in common 
with normal B-cells. They can be induced to develop neuronal outgrowths (64). 
Such cells could be studied after stable transfection with GAD55 (to induce 
overexpression) to see if GAD behaves similar in these 13-cells as it does in 
neurons: binding to small synaptic vesicle-like microvesicles. This model would 
allow to test functional aspects of GAD, but also to do additional studies on 
subcellular localization. This could reveal to which side of vesicles GAD55 is 
localized. Moreover, the transport mechanisms involved in GAD synthesis, 
posttranslational modification and membrane binding could show if these steps are 
involved in the visualization of GAD to the immune system . 
Localization studies showed that GAD expression is limited to islets of 
Langerhans and in particular, the 13-cell (51, 65-68). Recently, Petersen and 
colleagues described the presence of GAD in a- and 6-cells (69). Human islets 
express only GAD65- In other species, such as rat, mouse, dog and pig, both 
GAD57 and GAD55 are expressed in islets (1, 70). In rats GAD expression is B-cell 
specific (69). In developing human islets the cells can express more than one 
hormone simultaneously_ This is however, never described in the adult pancreas. 
Although GAD55 expression was found in a very limited number of human adult a-
, 5-, and PP- cells, the pathophysiological importance of this observation is not 
clear. If GAD is an important antigen, autoimmunity would also include such cells, 
unless the presentation of GAD to the immune system is different. Also within the 
B-cell population, there is a striking diffe1cence in GAD expression (71 ). Using 
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confocal microscopy of whole islets, it was shown that some B-cells express 
predominantly insulin and contain low amounts of GAD, while others 
predominantly express GAD and contain little insulin. It is conceivable that different 
types 13-cells exist. These differences could fluctuate in time (i.e. the cells switch 
from one phenotype to another, perhaps under the influence of metabolic changes) 
or if they represent two more or less different populations is unknown. Aller the 
identification of the 64kD protein as GAD55, several labs cloned the human GAD 
genes It was established that the GAD65 gene is localized on chromosome 10, 
while the GAD67 gene is located on chromosome 2 (72-74). 
In proliferating neurons, GABA synthesis is needed for neurite outgrowth 
and inhibition of GABA synthesis results in underdeveloped neuronal networks (75, 
76). A similar trophic role could also be present in the islets, where the endocrine 
cells share several characteristics with neurons. We did see expression of both 
GAD and GABA in the developing human endocrine pancreas. Islet formation is a 
process that starts with endocrine cell formation in the ducts and continues through 
steps where some of the cells migrate to form an islet (77). This islet formation and 
migration may, similar to what is proposed in neurons, be dependent on 
compounds such as GABA. Other, relatively simple molecules have been 
implicated in cellular dillerentiation and proliferation processes such as sodium 
butyrate (78). In summary, analysis of GAD at the embryo-fetal level will help in our 
understanding of (non-) tolerance to GAD and will contribute to our knowledge of B-
cell and islet formation. These processes are not very well studied and the 
observations of heterogeneous 13-cell populations plus the fact that autoimmunity 
has, at least partly, to do with the levels and absolute amounts of antigen, urge for a 
more detailed look into the role of the 13-cell itself in this (B-cell specific) disease. 
In summary, the function of GABA in islets is not clear yet, but likely 
paracrine. Cells expressing GABA might represent a special subgroup. Further 
research on GAD and GABA in the pancreas, during development and later in life, 
could contribute to our understanding of the pathology of the endocrine pancreas. 
II GABA has a clear relation to insulin, studies on the GABA metabolism in the 
pancreas could offer new ways to establish and monitor B-cell function. 
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5.3 Type 1 Diabetes Mellitus: An Immunological Disturbance. 
Type 1 diabetes mellitus is considered to be an autoimmune disease. As 
described in chapter 1.5, several lines of evidence support this concept. The 
mechanism of the disease is selective B-cell destruction. This process is T -cell 
mediated and T -cell dependent. However, the reason why the immune system 
starts the attack is far from clear. A major question regarding the autoimmune 
destructive process is what causes the breakdown or lack of tolerance to a B-cell 
component. This question addresses the nature of the primary autoantigen 
involved in the autoimmune process. It must be stressed that, although the disease 
seems T-cell mediated and T-cell dependent, it is not determined if this whole 
process is actually initiated by T- or oth•er cells of the immune system. The 
selectivity of the attack by the immune system and the need for a specific B-cell 
component indicate an important role of the B-cell itself: a malfunction of B-cells 
(overexpression of non-tolerated antigens, expression of dillerent peptides than 
usual, virus infection, etc.) could initiate a primed immune system (presence of 
macrophages, dendritic cells, autoreactive T-cells, a favorable HLA haplotype). 
Thus, the immune system could be another susceptibility factor, just like the genetic 
system seems to be. Additional studies are needed to determine the role of the B-
cells in type 1 diabetes. 
Studies concentrating on the role of the B-cell in the pathogenesis must be 
based on immunological studies, which determine the antigens involved in the 
immune process. Characteristics of such antigens need to be explored in order to 
determine how and why such antigens are presented to the immune system and 
induce autoimmunity. The existence or lack of tolerance to such antigens needs to 
be explored. Experiments will include th·e study of these antigens in different 
conditions such as high glucose concentrations or the levels and forms expressed 
during viral B-cell infections. It will be clear that optimal assay systems are required 
to determine if up regulation of an antig-en actually results in triggering of the 
immune system. 
If th-e B-cell plays such an important role towards the immune system, and 
can initiate the first steps of autoimmunity, we have to assume that susceptibility for 
diabetes also include the presence of autoreactive T-cells. It is now clear from 
several experiments that autoreactive cells are actually present and can escape 
the mechanisms that exist to delete such cells. Autoreactive T-cells were found in 
control individuals in several autoimmune diseases, including multiple sclerosis 
(MS) and autoimmune thyroid disease. In IVIS, autoreactive T-cells are believed to 
be directed towards the autoantigen myelin basic protein (MBP). Other evidence 
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for the existence of autoreactive T-cells in non-disease situations comes from 
studies in normal rats, where the T-cell l'epertoire contains cells with the potential to 
cause type 1 diabetes (79) and from studies in NOD- and normal mice (80). If 
autoreactive T-cells are present, it is actually surprising how little autoimmunity is 
seen. Silencing of such T-cells is obviously an important mechanism. Special 
circumstances may activate such cells. As outlined in chapter 1.5, anergy or 
ignorance would allow the presence of such auto reactive T -cells without initiation 
of autoimmunity. Evidence for the presence of silenced autoreactive T-cells comes 
from studies where autoimmune disease could be initialed by partial T-cell 
depletion (81, 82). It has been proposed that anergy, i.e. silencing of such cells, is 
a delicate balance between different functional subtypes of CD4+ (helper) T -cells 
and that this heterogeneity in subtypes is dependent on differences in cytokine 
production by these cells (83, 84). Which cytokines are produced is partly 
determined by the nature of the antigen presenting cell and can either result in a so 
called Th1 or a Th2 response. Th2 cells produce for example, interleukin-4 (IL-4) 
which inhibits cytotoxic (Th1) responses, suggesting that Th2 cells are inhibitors of 
cellular immunity. Such data suggest that immune system exists as a dynamic and 
finely tuned balance between different immune response pathways. Autoimmune 
reactions are the result of imbalances of this system. Disturbances in ThtfTh2 
responses can be the result of environmental factors like viral infections. Thus, with 
the presence of autoreactive T-cells, disturbances of the balance between 
stimulating and inhibiting factors could determine if autoimmunity ensues. In the 
case of type 1 diabetes this involves induction of an autoreactive T-cell clone by a 
B-cell specific or a mimicking peptide. Alternatively, it is possible that the peptide 
which induces this reaction is only visible or accessible lor the immune system in 
the B-cells, and expression of the peptide in other cells is invisible or protected from 
the immune system. The absence of tolerance to this primary antigen can, upon 
presentation to the immune system, result in autoimmunity. Transgenic mouse 
models showed that in the absence of tolerance to a B-cell antigen, autoimmunity 
can be absent. However, these models showed that a triggering event, such as a 
viral infection, containing similar or mimicking antigens, could imbalance the 
system and initiate autoimmune B-cell destruction (85, 86). 
These proposed mechanisms directly pose the question what triggers the 
immune system imbalance. The activation ofT-cells takes place by an interaction 
of the T -cell receptor and an antigen presenting cell (APC). In addition, accessory 
molecules are involved, such as adhesion molecules and molecules that induce or 
transduce a so-called second signal (co-stimulatory signal), needed to initiate a 
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proliferative T -cell response and preventing the auto reactive cell from switching 
into an anergic mode. It is clear form immunological studies that the susceptibility 
for type 1 diabetes is determined by the MHC complex on chromosome 6. Until 
recently however, no conclusive evidence was presented, showing that the MHC 
molecules (i.e. the HLA molecules) are indeed involved in the immune response in 
type 1 diabetes. The association could merely be a phenomena of linkage between 
the MHC and other unidentified 'diabetogenic' genes in the same region. Recently 
it was shown in the NOD animal model of type 1 diabetes, that blocking of the 
specific NOD MHC molecule (A97) by a designed peptide resulted in a strong 
reduction of autoimmune diabetes (87). The designed peptide blocked the antigen 
presentation by the unique NOD class II molecule (A97) in vitro. It also inhibited 
responses in Ag7 specific T-cells. These effects were not seen in animals treated 
with a control peptide, which does not bind to A97, and demonstrated that antigen 
presentation by the NOD specific Ag7 has a role in the disease. A similar role of 
susceptibility HLA molecules in humans needs further studies. 
Except for MHC-peplide complex that binds toT-cells via the T-cell receptor 
(TCR) and CD4 or CDS co-receptors, a second or co-stimulatory s·lgnal is needed 
to result in T -cell activation (88). This signal is antigen independent and lack of this 
signal results in anergy. The second signal is induced by the interaction of 
receptors (such as CD28 or CTLA4) on T-cells with a molecule called 87, present 
on specialized ('professional') antigen presenting cells (APC): macrophages and 
dendritic cells (DC's). DC's are outposts of the immune system and are present in 
(non-lymphoid) several tissues including the pancreas. Although their antigen 
processing is not as good as some other APC's, they have a high density of MHC 
class II molecules and are extremely good antigen presenters, able to deliver 
second signals. Thus, these cells have an important role in the initiation of immune 
responses. Dendritic cells are present in islets (89) and may function as the cell 
type that is able to trigger autoreactive T-cells, although the !actors needed lor this 
trigger are yet unknown. It is established now however, that the outcome of an 
antigen encounter with an auto reactive T -cell is dependent on the type and abilities 
of the APC and the intensity of the stimulation. Such factors will also be dependent 
on the type ofT-cell response initiated: Th1 or Th2 (reviewed in (90)). There is still 
controversy about the role of APC's in the islets: Treatment with silica, which 
disables macrophages, was found to have no effect on the incidence of diabetes in 
animal models (91 ), thus the question remains how macrophages or Dendritic cells 
function in the first phases of type 1 diabetes . As proposed, the B-cell itself may 
have a more prominent role where differences in expression of antigens (amount, 
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peptide composition etc.) could result in a different processing by APC's in islets. 
thereby enhancing presentation of such peptides to autoreactive cells. The 
importance of APC's as antigen presenters is clear, the mechanism and position in 
the sequence of events needs to be further established. 
At present the antigen involved in this initiation of type 1 diabetas is not 
known. For such an antigen it must be shown that tolerance is lost, or never 
established. Moreover, in other experiments, it should be analyzed if immunization 
induces tolerization. Additionally, breaking of such tolerance should induce the 
disease in appropriate models. It is important to realize that such experiments can 
be performed in animal models only. In humans we do not yet know il GAD is 
tolerized or if in type 1 diabetes and SMS, tolerance to GAD is lost. Non-
establishing tolerance to GAD in the human situation may have different causes. 
GAD is a specialized molecule, only present at significant levels in few tissues. 
The expression may have started only alter completion of the immune repertoire as 
outlined above. It is striking that several enzymes, expressed in specialized tissues 
and sometimes protected by barriers lor the immune system, can become targets 
for autoimmunity, such as thyroid peroxidase and 17a-hydroxylase(92). late 
expression can result in non-tolerance. The availability of fetal human tissue to our 
lab allows to address this question in more detail and with regard to pancreatic 
GAD. Preliminary experiments do show the expression of GAD55 mRNA in islets, 
using in situ hybridization. in at least some pancreas cells of 14-18 week old 
fetuses. Detailed studies on protein expression have not yet been possible, but the 
availability to purify endocrine (precursor) cells from the human fetal pancreas (93) 
will help to establish if fetal islet do express this protein. It is possible that, although 
the adult human pancreas solely expresses GAD55, the fetal endocrine pancreatic 
cells temporarily express GAD57. 
The levels of expression will be dependent on the functional state of the B-
cell. This functional state a main topic in research in type 2 diabetes. Differential 
expression within the islet B-cell population has been observed lor key enzymes 
and proteins such as glucokinase, a B-cell specific enzyme and GLUT -2 the B-cell 
glucose transporter. all of which have important roles in the regulation of insulin 
synthesis and secretion (94, 95). Thus some cells are more involved in insulin 
synthesis and secretion, while others are likely to be primarily involved in 
regulation and paracrine signaling. Type 1 and type 2 diabetes are clearly different 
diseases , but the diseases cluster more within families than can be expected il 
they were completely unrelated. Some genetic studies indicate common 
General Discussion 212 
haplotypes in the two diseases (96, 97). The heterogeneity of the B-cells could be a 
common aspect involved in both diseases. It can be hypothesized that individuals 
with a lack ol islet regulation (role of GABA ?) or with too many GABA-containing 
regulatory B-cells starts, for example, overexpression of GAD. 
5.4 GAD and I he 38kD Molecule in Future Type I Diabetes 
Research. 
Experiments directed to unravel the questions on tolerance focus on the 
cellular immunity. For most antigens described in the context of type 1 diabetes, we 
only deal with the humoral arm of the immune system and we only know that 
antibodies are induced. The initial mechanisms of loss of tolerance are T-cell 
dependent. Secondary effects are B-cell proliferation and antigen production plus 
extension of the T- and B-cell response to other antigens that become available 
upon B-cell death. Most of the work pul8lished to date involves either B-cell 
responses (autoantibodies) or T-cell responses at clinical onset of the disease. 
The 'original' T-cell, which started the cascade of reactions, may be present at very 
low frequencies at the time of clinical onset. If autoantibodies are initiated, even 
the levels of such antibodies might have dropped by the time of diagnosis. 
Aggressive T-cell responses have a Th1 phenotype, with IL-2 and interferon 
production (83, 84). It is suggested that such T helper responses are not initiating 
strong B cell responses (which require Th2 response). th•·c antibody levels to a 
primary antigen may be low (83) Although these factors may make a humoral 
target for autoimmunity less attractive to play a key role in the onset of the disease, 
the following characteristics make GAD is an interesting molecule: 
1. GAD antibodies are the earliest detectable marker of B-cell destruction, 
suggesting them as the humoral representatives of an early autoimmune reac\ion 
towards B-cells (98, 99). 
2. Autoantibodies to GAD have an incidence of " 80% in sera from both newly 
diagnosed patients and pre-onset individuals, higher than antibodies to any other 
previously studied autoantigen including the novel antigen 'ABBOS', a fragment of 
BSA (100). 
3. Autoantibodies to GAD are present in two animal models of type 1 diabetes, 
the BB-rat and the NOD mouse( I 01, 1 02). 
4. GAD may be a target for 'molecular mimicry', a possible mechanism by 
which autoimmunity ·,s triggered by viral proteins (1 03). 
The smaller lorm of GAD (GAD55) is therefore still a candidate as primary 
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autoantigen in type 1 diabetes. This is also true for the 38kD protein, to which a 
lower incidence of autoantibodies is found. If present, they are also very early 
markers. 
GAD was characterized in islet cells, where some specific biochemical 
characteristics were studied. The importance of such studies is that the mechanism 
by which GAD becomes a target for autoimmunity is a crucial aspect in the 
pathophysiology of tolerance to such molecules. We found that the two forms of 
GAD present in brain, were identical to the two forms found in islets and that they 
differed with regard to cellular compartment and hydrophobicity. Later the eDNA for 
two pancreatic and neuronal GAD isoforms were cloned. GAD55 is the form that 
can be hydrophilic and soluble, hydrophobic and soluble or membrane bound. 
GAD57 is always hydrophilic. Using eukaryotic expression systems for both 
GAD's, we were able to extend the observations that the differences at the DNA 
level have important implications for the localization and likely for the way the 
immune system recognizes GADss. The GAD 55 molecule shows major differences 
with GAD57 at the N-terminus. We were able to show that this N-terminus is the site 
where GAD55 can become membrane bound. Several mechanisms exist for 
proteins that lack a hydrophobic stretch to become membrane bound. GADss is 
hydrophilic after its synthesis. It goes through a 2 step modification process of 
which the second step results in a firm membrane anchoring. This involves 
posttranslational, hydroxylamine sensitive, palmitoylation. More recently, it was 
documented by us and others, that GADss is the only form present in human islets 
(69, 104) in contrast to rat and mouse, where both forms can be found. It was 
proposed and shown that membrane bound GAD55 is linked to the small synaptic 
like vesicles, the endocrine cells counterpart of small synaptic vesicles. Recently, 
Soli men a and co-workers showed that in transfected cells (CHO), GAD55 becomes 
localized in the Golgi system, the area where such vesicles are formed (1 05). The 
cells used in this experiment do not posses the complete system of small vesicles 
and it will be interesting to see if expression in endocrine or neuronal cells will 
result in the localization in vesicles and transport of these vesicles through the cell 
with subsequent presentation at the cell surface. Alternatively, pharmacological 
techniques to stimulate or inhibit GAD, the transport mechanisms or stimulate 
secretion of vesicles, could help to study this. The importance of subcellular 
localization studies is both that these studies can identify how the immune system 
encounters GAD, but additionally that such studies can provide clues to the 
function of GAD and GABA in the B-cell. A localization inside vesicles opens the 
possibility of a direct presentation to the immune system. Moreover, since the 
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secretory activity oi the B-cell has been linked to induction of autoimmunity (1 06) 
and with observations that GABA secretion is linked to insulin secretion (54, 1 07) 
the effect of the functional activity of the B-cell on induction of autoimmunity may be 
studied. Recently, GAD expression in B-cells was shown to be related to the rate of 
insulin secretion (108). 
Autoantibodies to GAD were found in two diseases: type 1 diabetes and 
Stiff-man syndrome (SMS). We hypothesized that in SMS the pathophysiology is 
caused by a direct effect of the antibodies to GADss. If expressed inside the 
vesicles of GABA-ergic neurons, it could become visible at the plasmamembrane 
upon the merging of the synaptic vesicle with the plasmamembrane. Antibodies 
could have direct access to GAD and inhibit its function. Animal models of Stiff-
man syndrome could be developed to study such a mechanism. 
GAD as a target for autoimmunity in two different diseases may raise 
questions about the fact if such an antigen is interesting as a primary target. 
However, the immune response towards GAD is different in the two diseases, thus 
allowing the possibility of two different mechanisms. In Still-man syndrome, at least 
one linear epitope is present that distinguishes the antibodies from diabetes. 
Further analysis is under way to determine this epitope. Determination of this 
epitope could help to develop animal models of SMS. Immunization with this 
linear SMS epitope of GAD could result in high antibody levels as are generally 
seen in SMS. Disturbing the blood brain barrier (i.e. by pertussis toxin) could 
create a similar situation as seen in SMS patients: high titer antibodies, 
recognizing a linear epitope of GAD ·,n both serum and cerebrosp·lnal fluid. 
Specific therapy against the antibodies could result in diminishing of symptoms, 
showing if antibodies are indeed involved in the disease. Moreover, the close 
relationships between the two diseases (a.t least 30% of the patients with SMS 
develop type 1 diabetes) make them excellent models in autoimmune research. It 
should be noted that our current knowledge on SMS is limited. Sera tested so far, 
usually include patients who were diagnosed years before. We do not have 
adequate knowledge on GAD titers in earlier stages of SMS. Moreover, HLA data 
in these patients are lacking, although a recent abstract indicated that most patients 
were DR3 (DQB1 ·o201) positive, comparable to diabetes where DR3 is also 
present in many patients. 
Christie and colleagues described that trypsinization of immunoprecipitated 
GAD resulted in tryptic fragments of GAD ( 109, 1 t 0). As described in chapter 4, 
General o;scuss;on 21 5 
these 37140 kD fragments found do not have a relation to the 38kD protein 
described in this thesis. The 37/40 kD fragment seems to be either a cryptic 
fragment of GAD or a separate, co-precipitated protein. The protein is not seen in 
10% SDS-PAGE, indicating that it is probably part of a larger molecule prior to 
trypsinization. The importance of the finding by Christie is, that antibodies to the 
37140 kD fragment seem to be highly associated to onset of clinical diabetes, thus 
providing a test to distinguish individuals with latest stages of B-cell destruction 
from individuals with early onset B-cell destruction. Further studies are needed to 
study this in more detail. The 38kD protein described in this thesis has no relation 
to the 37140kD fragment as is discussed in chapter 4. 
Studies of epitope recognition of GAD are important not only lor the 
proposed SMS studies, but especially for further studies in diabetes. After induction 
of humoral autoimmunity, a polyclonal response of B-lymphocytes will be evoked. 
However, it is possible that in the beginning, the responses will be more or less 
limited to the same epitope region as which triggers the T-cells. Thus, early B-cell 
responses, may reflect T-cell epitopes. It will be of interest to analyze which 
epitopes are most common in type t diabetes, in particular in the early phases. 
Prediabetic sera, or sera from very young children with diabetes (< 5 years old, 
since the time passed between the start of autoimmunity and the disease is 
supposedly still short) can be tested to see if GAD-epitopes are more restricted. A 
recent study on epitope recognition from the lab where this thesis was prepared, 
showed that the C-terminal part of the GAD65 molecule is the predominant site of 
autoantibody recognition in type t diabetes patients (t t t ). This study was possible 
using site-directed mutagenesis of the GAD65 molecule together with the 
availability of human monoclonal antibodies (t t 2). This result can also be used in 
further designs of GAD antibody assays. The technical difficulties encountered in 
these tests could partly be due to the fact that the non-soluble phase tests hamper 
the recognition of the conformational epilopes. Interference with the molecule may 
result in loss of such epitopes and subsequent underestimation of GAD 
autoantibodies in patients as is described for ELISA's (i 13). Since theN-terminal 
is not involved in type t diabetes, this site could be modified to improve solubility or 
be used as a site for immobilization oJ the GAD molecule without interfering with 
conformational epitopes. 
As described in Chapter 2, analysis of 64kD I GAD antibodies was initially 
hampered by the difficulties in obtaining islet material. After the identification as 
GAD, recombinant expression systems were developed, but new problems arose 
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(see chapter 3). The assay system used was ·,mmunoprecipitation as described in 
the papers of this thesis. Other assays are described. Some studies use the 
enzyme activity of GAD (114). We used a similar approach to show enzyme activity 
of GAD of the 64kD antigen (1). Autoantibodies precipitate this activity and allow a 
comparison to control sera. The disadvantage is a relatively low sensitivity and the 
possibility of interference of antibodies with the active site of the molecule. Other 
groups developed RIA-like assays which compare better to the 
immunoprecipitation technique used in previous studies (115). The development 
of faster assays w·1th high sensitivity and specificity, is of importance since further 
analysis of the predictive value of GAD (and 38kD) autoantibodies will need large 
study groups. 
Antibodies to the 67kD isoform of GAD are present in a subgroup of patients. 
Three groups published data on this isoform (1 03, 113, 116) with varying results 
ranging from 9-75% of the patients positive for GAD67- Our preliminary data show 
8% of newly diagnosed patients positive for GAD67- Although it is suggested that 
GAD65 is the target for autoimmunity in type 1 diabetes and that GADs? antibodies 
only develop secondary to GAD55 autoimmunity, we identified one patient who 
only showed GADs? antibodies. However, this patient developed type 1 diabetes 
at a relatively old age (35 years). Antibodies to GADss, may have been present in 
the earlier phases of B-cell destruction. In summary, GAD57 antibodies are not 
likely to be an important parameter of autoimmune destruction in type 1 diabetes. 
T-cell responses to a partial GADs? molecule (aminoacids 208-404), expressed in 
bacteria, were found in newly diagnosed diabetes patients in one study (117) 
A second antigen of Mr 38kD was identified by the same techniques as 
originally used for the S4kD protein in islets. Both are targets for humoral 
autoimmunity in type 1 diabetes mellitus. Detection of autoantibodies to these 
targets provides a specific way of determining ongoing B-cell destruction. 
Autoantibodies to these antigens can therefore be used as markers for type 1 
diabetes risks. Since the revelation as GAD, described in chapter 3, several 
groups have embarked on further studies, both on the molecule itself and how it 
becomes a target for autoimmunity, as well as on the predictive value of GAD 
autoantibodies for diabetes as presented in chapter 4. The 38kD antigen is a new 
marker. We are currently working on the identification of its molecular structure. 
The incidence of autoantibodies to it is lower, both in the prediabetic period as well 
as at onset. However, the results in chapter 4 indicate that both proteins are not 
necessarily simultaneous targets for autoimmunity. The assays complement each 
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other and increase the predictive value for type 1 diabetes. Moreover, the 
complete correlation between GAD plus 38kD antibodies and Islet cell antibody 
(ICA) reactivity in the prediabetic period, indicate that both are major targets for the 
immune response. 
5.5 Prediction and Prevention o!l Type 1 Diabetes Mellitus 
Methods of prediction: 
No disease prevention is possible without disease prediction. This 
prediction method must be sensitive and specific. The best method in type 1 
diabetes would be to have superb susceptibility risk factors detectable before any 
attack of the B-cell takes place. This would imply that environmental factors that 
trigger the disease could be prevented. Unfortunately this is not the case. 
Prevention and prediction after an initiating event, implies that detection humoral 
or cellular autoimmunity is theoretically possible. 
Prediction of type t diabetes is based on the following items: ICA's, IAA's, 
genetic markers and functional B-cell testing. However, most studies performed 
describe family related diabetes cases. As outlined in previous chapters, most 
cases of diabetes occur without a first degree relative having the disease, thus the 
incidence studies have a 'natural' bias. Other drawbacks in those studies are the 
fact that the duration of follow up is relatively short, and the fact that only data on 
limited groups are available. It is estimated that worldwide, only 100-200 'real' 
prediabetes cases are documented. It can be concluded, that a lack of prediabetes 
samples is a severe limitation in diabetes prediction studies. This argues lor the 
establishment of national registries of new cases of diabetes. A first improvement 
could be made from here by sampling first degree relatives on a large scale, which 
will eventually result in a collection of prediabetic samples. 
The prediction assays tests usecl, have been described in previous chapters 
except lor functional B-cell tests. Although oral glucose tolerance tests are not 
helpful in detection of ongoing B-cell destruction, it was found that intravenous glu-
cose tolerance testing (IVGTT) was more precise. In particular the first phase 
insulin response (FPIR), defined as the sum of the 1 and 3 min. insulin con-
centration alter a 3 min. infusion of 25% glucose (0.5 g/l<g body weight), was found 
to be related to B-cell destruction. However, large differences in IVGTT protocols 
made comparisons of FPIR difficult. Standardization oiiVGTT was obtained (118). 
Analysis of insulin responses after partial pancreatectomies in baboons showed 
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however that relatively large percentages of the pancreas can be removed before 
B-cellfunction tests were useless. This could indicate that such tests are detecting 
B-cell mass aberrations within the first 50% of B-cell destruction, but the exact 
detection limits are not known. Analysis of repeated IVGTT's and FPIR's showed a 
significant intra-person variation, especially in children. It might be questioned 
whether the FPIR is not an early test for diagnosing diabetes instead of determining 
prediabetes. An outstanding question is, if autoimmune destruction can take place 
without appearance of autoantibodies. Palmer and coworkers showed that first 
degree relatives of patients can show abnormal insulin secretion without the 
presence of ICA's (119, 120). Such a finding could indicate to a non-linear 
decrease in B-cell function or cell mass after ·ln.ltiation of the destruction. However 
clear data on development of clinical diabetes in these individuals are not 
available. Others doubt the findings on the basis of a linear decrease in B-cell 
function observed in twins (121) 
As described in the paragraphs on ICA's and IAA's, combination of these 
tests alone or with HLA data can provide prediction. The presence of IAA's and 
ICA's increases the risk lor diabetes. In one study, more than 70% of individuals 
with both antibodies developed diabetes, compared to 42% of ICA positive alone 
and 17% for IAA positive alone in an average period of 5 years follow-up. On the 
basis of IAA's and IVGTT's, a dual parameter model was described (122) Another 
group proposed a model for prediction where the first step is based on ICA 
determinations in at risk families and on genetic markers in populations (123). At 
risk individuals in the population would be screened lor ICA, if positive for IAA and 
additional markers. In family members, ICA titer will determine further steps: If >:20 
JDF units, further screening would include HLA typing, GAD, IAA and FPIR. This 
approach is based on an important issue. Improvement of sensitivity of a given test 
will result in a decrease in specificity and vice versa(Bayes' theorem). Thus, for 
each situation (family vs. population) the requirements and approach of screening 
need to be different. The different articles describing prediction show no 
consensus yet. . This is most likely the result of the current insufficient specificity 
and sensitivity of the tests employed. 
Finally, it should be stated that prediction methods without therapeutic 
consequences can be a psychological burden for individuals who participate in 
such studies. Since most studies are performed in families, the participants are in 
general aware of the impact a positive prediction can give. Few studies are 
performed that deal with this. A study from Florida found increases anxiety levels in 
General Discussion 219 
family members who where found positive for ICA (124). The avoidance of coping 
strategies and denial of their possible future diabetes was found more frequent in 
ICA positives than in their relatives. Other family members often believed that their 
ICA+ relative would develop diabetes. In general, the psychosocial impact ol the 
prediction assay was limited, although long-term effects remain to be seen. 
Attempts to Prevent Type 1 Diabetes Mellitus: 
Several studies have been published that aimed at secondary prevention of 
type 1 diabetes. The wealth ol such strategies was the reasons lor the American 
Diabetes Association to publish a position statement on prevention of type 1 
diabetes (125). Some intervention studies on the basis of current prediction 
methods are approved in this statement, although strong recommendations are 
given to limit such studies since the cause of the disease is not known, thus 
intervention is still a risk and could induce unwanted effects. 
The earliest attempts to provide a permanent treatment for type 1 diabetes 
were pancreas transplantations. The severe medical problems connected with 
both transplantation (rejection and reinitiation of autoimmunity to the donor islets) 
together with an organ full of proteolytic enzymes, hampered this technique in 
becoming a standard treatment. Current status of pancreas transplantation is given 
in a recent review (126). One important observation was made using pancreas 
tissue from the non-diabetic discordant twin half to transplant into the diabetic twin. 
After transplantation, the autoimmune process reactivated and also destroyed the 
transplanted B-cells (127). Transplantations are still pertormed, in particular 
combined with kidney transplantations in patients with severe nephropathy with 
end-stage kidney disease. It has been tried, as in kidney transplants, to use part of 
the pancreas of a relative. The donors showed however, after hemipan-
createctomy for this purpose, a deterioration of insulin secretion and glucose toler-
ance measured one year later. If this increases the chances for clinical diabetes 
later in life, is not yet established (128). A different approach is islet or islet cell 
transplantation. Two methods are currently employed lo prevent rejection: 
immune-alteration of islets (for example by physical influences such as culture at 
low temperatures, removal of HLA class II expressing cells ) and encapsulation of 
islets to prevent attack by the immune system. Transplantation of islets is reviewed 
in (129) 
An approach that has been often applied in type 1 diabetes is 
immunomodulation. This usually implies however the modulation ol the whole 
immune system. As described before in the chapter on T-cells, several 
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immunosuppressives have been used either alone or in combinations. First 
attempts were limited to newly diagnosed diabetic patients, but currently trials are 
underway that involve ICA positive family members with aberrant FPIR's. A recent 
review summarized over 30 methods that have or are employed to influence either 
the honeymoon period or delay the (presumed) onset of the disease (130) 
The first immunotherapy studies used glucocorticoids combined with 
immunosuppressives such as azathioprine and Cyclosporine A. In newly 
diagnosed patients no persistent beneficial effect was obtained (131-133). No 
published data are available on large scale studies of this approach in predia-
betes. 
Currently nicotinamide (NA) has regained attention as an anti-diabetic 
compound after its first effects were described in 1947 (134). It is a water soluble 
vitamin (83) derived from nicotinic acid, and is also known as niacinamide or 
nicotinic acid amide. Nicotinamide is believed to restore B-cell NAD pools by 
inhibiting poly(ADP-ribose)synthetase (PARS, an enzyme involved in repair of 
DNA breaks) (135) and to function as a free radical scavenger (136). In a recent 
conference on the feasibility of a nicotinamide trial in Europe (Copenhagen, 
Denmark, December 6-7, 1992) some reports were presented showing that these 
effects were indeed described with nicotinamide, but not in the concentrations 
used. Tissue levels would not reach the required levels for such an action and 
could actually reverse the effect on PARS or lead to carcinogenic effects (M. 
Smulson, R.W. Pero, personal communication). Moreover, nicotinamide was 
reported to influence growth in young rats. NA has been used at clinical onset of 
the disease, both in animals and humans. No significant restoraf1on or sustaining 
of B-cell function was observed (137, 138). In prediabetic animal models conflicting 
results were obtained (t38-140). A preliminary report from New Zealand, where a 
nation wide trial of nicotinamide takes place, showed no convincing beneficial 
effect of NA (141). Moreover, this study enrolled ai!ICA positive individuals into the 
treatment group, so no control group is available. The taste of the drug has, 
although improvements were made by the industries, helped to reduce patient 
compliance to 60-70%. It will be difficult to conclude clear effects from such 
studies. Other studies in prediabetes have been initiated or preliminary reports are 
presented (i 42, 143). The NA treatment is claimed to be save. Hypervitaminosis 
and liver damage have been described. 
Insulin therapy is the cornerstone of therapy in type 1 diabetes. Some 
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groups however, use insulin before the clinical diagnosis, in prevention studies. 
Three different mechanisms are proposed: 
1) Hyperglycemia is toxic for B-cells. Insulin therapy would therefore help to 
improve B-cell function. In the phases just before clinical onset, short periods of 
hyperglycemia would alter the function of the B-celis. 
2) Insulin has been pinpointed as a candidate primary antigen. Insulin 
autoantibodies are present in some individuals before diagnosis and insulin is B-
cell specific Tolarization with insulin would provide a way to adapt the immune 
system. Such adaptations could be done either by subcutaneous or intravenous 
ways, but alternatively oral administration of insulin could induce tolerization. 
Similar approaches were undertaken for other autoantigens (144, 145), but the 
mechanism by which oral tolerance induction would work are unknown. Currently, 
after succesful experiments in animals (146, 147), first degree relatives are under 
treatment in the Joslin Clinic, Boston (Dr. Richard Jackson) with subcutaneous 
insulin, in an attempt to re-instruct the immune system and prevent (presumed) 
diabetes. 
3) It has been proposed that the activity of the B-cell is related to the immune 
response. Active B-cells are presenting more antigen and are therefore more 
immunogenic than resting B-cells (1 06). Insulin therapy (subcutaneous) would 
help to rest the B-cells, thereby reducing the antigen expression and the chances 
for diabetes. 
Animal models have provided evidence that direct interference in the 
immune recognition mechanism can block autoimmune diseases. Components of 
the trim eric complex can be blocked with specific monoclonal antibodies. Such 
approaches are used for the TCR (148), MHC (149), CD4(150), CDS (151) and 
cytokines (i 52). In addition, peptide-mediated immunotherapy would be a 
possibility where modified peptides bind to the MHC and TCR but do not elicit a 
proliferative response. 
Based on the assumption of loss, breakdown or non establishment of 
tolerance, other approaches have been tried with interesting results. lntrathymic 
transplantation of islets resulted in tolerance for B-cell components and prevention 
of diabetes in susceptible animals (1 53-155). These approaches have not yet 
been established for animals with overt disease, but this approach could result in 
the re-instruction of the immune system. li such treatment could be offered to 
humans in the early phases of B-cell destruction, further deterioration might be 
stopped. Several technical, medical and ethical problems will however be needed 
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to overcome before such therapies would be useful in clinical practice. At this 
moment, the are not feasible and only stress the need lor better prediction 
methods. 
In general, the immune-interventions performed at present are not specific 
and may have several side effects. For many researchers, including our group, 
such current interventions attempts are started too early and additional data on 
etiology and pathogenesis are needed. Moreover, prediction methods still suffer 
from lack on specificity and sensitivity. The scarce amounts oi prediabetic indi-
viduals lor both prediction and prevention studies is an additional problem. The 
strategy followed in the work presented here is to first obtain improved prediction 
methods accompanied by further studies to unravel the immune mechan·lsms that 
cause type 1 diabetes. Only than, intervention studies will not only prevent the 
disease in at risk relatives, but can also be applied in populations. 
GAD and 38kD autoantibodies: Better prevention? 
The antibodies to GAD and 38kD will have a role in prediction. Specific 
molecules are identified now and can be applied in prediction tests, which is a 
main improvement compared to the former assays such as islet cell antigen (ICA) 
testing. ICA's are analyzed in a 'bioassay (human donor pancreas) and no specific 
target molecules are known. Several markers for type 1 diabetes are presented in 
this thesis: MHC molecules, antibodies and T-cell analysis. A major problem is that 
technical, economical and ethical reasons do not allow to tests every available 
marker yet. It will be clear that research is needed to determine the best approach 
in prediction oi type 1 diabetes mellitus. Two main approaches are possible. 
Family studies oi first degree relatives provide a relatively large high risk group for 
the development oi type 1 diabetes. However, prediction and prevention are only 
likely to be cost-effective if applied in the population at large, since most cases 
develop in families without first degree relatives with the disease. Therefore, family 
studies are only a primer to assess predictive values of markers. In a second 
phase the results obtained in such studies can be applied in population studies. 
We are currently involved in a family related study of 80 families (1989-1992) and 
want to increase this to 300-500 families in the next few years. At this moment 
groups around the world take two main approaches in diabetes prediction. Some 
groups use ICA determination as an entry criteria for further studies (123, 156). ICA 
positive individuals are subsequently HLA typed. The risk can be established 
further by adding other markers. Others use insulin autoantibodies as an entry 
criteria for high risk (122). An approach that has been hampered by h'1gh costs 
would be to test lor susceptibility at the HLA level in the population and only study 
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lor signs of B-cell destruction (autoantibodies, T-cells) in those with a typical risk 
haplotype. HLA typing has been too costly, but new developments may change 
this rapidly. Using PCR techniques and capillary blood sampling, population size 
screening could allow the detection of at risk individuals. A major problem of this 
approach is, that not all diabetic patients will have 'a' diabetogenic haplotype. 
Furthermore, 'diabetes associated' haplotypes differ between races. Analysis of 
genetic susceptibility could be improved by the use of extended haplotypes 
(including the TAP-genes, Bcl-2 gene and other diabetes related genes as they 
have been identified in the NOD-mouse). HLA typing and extended haplotype 
analysis might provides a good way to identify susceptible individuals, but this 
method is still too expensive to apply in population based studies. 
Alternatively, fast assays for GAD could allow the analysis of large study 
groups. We propose to use this marker in conjunction with genetic screening. 
Repeated analyses might be important to detect autoantibodies as marker of B-cell 
destruction. The advantage of GAD analysis is that the identification of the target 
allows precise quantification of the assays, something that is not possible for ICA's. 
Already now, the irnmunoprecipitation method can be quantified using laser 
scanning of phosphoimager screens. Moreover, research on epitopes will allow to 
develop even more specific tests. Since large scale HLA analysis is yet expensive 
and ethically not approved, analysis of GAD autoantibodies, supplemented with 
38kD antibodies will provide a quantitative basis for type 1 diabetes prediction 
(See chapter 4.2) and will be also be feasible in large studies using new assay 
systems. 
5.6 Conclusion 
Antibodies to GAD55 and the 38kD protein are present in the early phases 
of 6-cell destruction and may represent the humoral response to a primary T -cell 
antigen in human type 1 diabetes. Additional studies are needed to evaluate why 
tolerance to GAD and the 38kD protein are lost or never established. The role oi 
the 6-cell in such events needs full attention. T-cell responses to these targets can 
help to analyze why proteins or peptides are no longer ignored and are the cause 
of a specific attack to B-cells. Analysis of the epitopes in GADss shows that specific 
parts of the molecule may be involved in type t diabetes. Further analysis may 
reveal if a restricted primary epitope is present and if prolonged 6-cell destruction 
results in broadening of the epitopes on GADss. GAD and the 38kD protein are 
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not yet identified as causative B-cell components of type i diabetes but provide 
models to explain both B-cell and immune system related mechanisms of 
autoimmunity. The further identification, characterization of these molecules is 
likely to provide information that can help to design applications lor prediction and 
prevention ol the disease. 
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LIST OF ABBREVIATIONS 
AET : Aminoethylisothiouronium bromide hydrobromide 
APC: Antigen Presenting Cell 
BB: Bio Breeding 
CMV: Cytomegalo virus 
CNS : Central nervous system 
EAE : Experimental allergic encephalomyelitis 
EDTA : Ethylenediaminetetra~acetic acid 
EGTA : Ethyleneglycol~bis~(B·aminoethyl ether) N,N,N',N'-tetra acetic acid 
ELISA : Enzyme linked immunosorbent assay 
GABA : y-amino butyric acid 
GABA-T : GABA transaminase 
GAO : Glutamic acid decarboxylase 
IAA : Insulin autoantibodies 
ICA : Islet cell cytoplasmatic autoantibodies 
lOOM : Insulin dependent diabetes mellitus 
IL-1 : lnterleukin 1 
INF-y : lnterferon-y 
HLA : Human leukocyte antigen 
HLB : Hypotonic lysis buffer 
IL:Interleukin 
LDCV: Large Dense Core Vesicle 
MBP : Myelin basic protein 
MHC : Major histocompatibility complex 
MS: Multiple sclerosis 
Mw : Molecular weight 
NEM : N~ethylmaleinimide 
NIDDM : Non insulin dependent diabetes mellitus 
NK: Natural Kiner 
NOD : Non~obese diabetic mice 
NSE: Neuron specific Enolase 
PAS : Protein A Sepharose 
PBS : Phosphate buffered saline 
PBMC : Peripheral blood mononuclear cells 
PCMPS : p·chloromercuriphenylsulfonic acid 
PLP : Pyridoxai·S'~phosphate 
PMSF: Phenyl·methyl·sulfonyl fluoride 
PVD F : Polyvinylene·diflouride 
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RlA : Radio-immuno-assay 
SDS- PAGE: Sodium-dodecylsulphate- polyacrylamide gel electrophoresis 
SG: Secretory Granule 
SLMV : Synapt'1c like microvesicle 
SMS : Stiff man syndrome 
SSV: Small Synaptic Vesicle 
SZ : Streptozotocin 
TBS : Tris buffered saline 
TCR : T-cell receptor 
TH: Tyrosine Hydroxylase 
TNF-a : Tumor-necrosis-factor-a 
Tx-100 :Triton X-100 
Tx-114: Triton X-114 
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Summary 
Diabetes Mellitus is a chronic disease, characterized by the inability of the 
body to maintain control over glucose levels. The hormone insulin is needed for 
this control. Insulin is produced in specialized cells (B-cells) in small clusters of 
endocrine cells (islets of Langerhans) in the pancreas. Two major forms of this 
disease exist: type 1 or insulin-dependent diabetes mellitus, and type 2 or non-
insulin dependent diabetes mellitus. This thesis describes work pertormed on type 
1 or insulin-dependent diabetes mellitus. 
Chapter 1 gives an overview of this disease and discussed the current 
knowledge on the pathophysiology of this disease. Type 1 diabetes is the result of 
immune destruction of the B-cells. This abolishes the possibility to produce insulin 
completely. Type 1 diabetes occurs predominantly in childhood and adolescence. 
Only about 25% of the cases occur later in life. Type 2 diabetes occurs mainly after 
the age of 35 years. The symptoms do not present because of a lack of insulin, but 
because the insulin cannot be secreted and function properly. Other diabetic 
syndromes are the result of other pancreatic diseases or problems with insulin 
usage. Type 1 diabetes can present with life-threatening complications in the 
acute phase. There is a therapy lor the disease (daily injections with insulin), but 
no cure. Most people can live a relatively normal life with this disease, but long-
term complications after 20-30 years of diabetes result in a high morbidity and 
mortality. 
The cause(s) for the B-cell destruction in type 1 diabetes is (are) not known. 
The disease has a genetic background i.e. the susceptibility can be inherited, but 
not the disease itself. Additional triggers are needed, and a role of environmental 
factors has been shown by epidemiological studies. However, which lactor(s) is 
(are) responsible is less clear. Viral infections, certain chemicals and food 
components have all been suggested, but no proof has been provided yet. 
The pathological hallmark of the disease is infiltration of the islets of 
Langerhans by cells of the immune system. These immune cells are able to 
destroy the B-cells selectively. This immune reaction is directed to a self-com-
ponent and is hence called an auto-immune reaction. All immune reactions are the 
result of an encounter of immune cells with components that they regard as non-
self: bacteria and viruses. In auto-immune reactions such responses are directed 
to self-peptides. At present it is presumed that in those individuals, who inherit the 
genetic susceptibility for type 1 diabetes, this disease can ensue. 
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The major question in type 1 diabetes research is which component of the B-
cell is responsible lor this faulty reaction. Normally, the immune system develops 
tolerance towards sell-components. It is believed that in autoimmunity, the immune 
system has lost tolerance to this self-protein or was never able to develop 
tolerance. The identification and analysis of the lack of tolerance belongs to the 
aims in this thesis : if the responsible peptide can be identified, prediction of the 
disease becomes feasible. Further unraveling of the pathophysiology could result 
in prevention. A candidate for this was identified as a 64kD protein. Chapter 2 
describes how the 64kD protein was identified as the neuroendocrine enzyme 
Glutamic Acid Decarboxylase or GAD. The rare neurological disease Still-man 
Syndrome (SMS)is associated with type 1 ·diabetes. About one third of the SMS 
patients also have type 1 diabetes. SMS patients were found to have antibodies to 
GAD, which is present in special neurons (GABA-erg·,c neurons). GAD was known 
to have a molecular weight of about 64kD. Initially, some researchers thought that 
the 64kD protein could not be identical to GAD, since 64kD antibody containing 
sera did not recognize GAD as SMS patients did. The antibodies to GAD in type 1 
diabetes were shown to be highly dependent on the three dimensional structure of 
the GAD molecule, while antibodies SMS sera recognize also the denatured 
molecule. Additional work showed that rat B-cells contained two forms of GAD, 
GAD67 and GAD55. Also the GABA-ergic neurons contain the same two forms. 
GAD65 is a molecule that can be bound to small vesicles in :• •ch neurons and in B-
cells. This binding is performed by a lipid modification of the molecule 
(palmitoylation) allowing the molecule to stay close to the place where its product 
(GABA) is needed. This subcellular and biochemical localization work helps to 
analyze how the lack of tolerance to this molecule can result in autoimmunity. In 
addition, Chapter 2 descr'lbes the dilferenc,9s between the two diseases in which 
GAD becomes a target for autoimmunity: SMS and type 1 diabetes. Except for the 
differences in immune recognition by the antibodies, the specific localization of 
neurons behind a so-called blood-brain barrier are believed to play a role. 
Moreover, it is suggested in this chapter that, while in type 1 diabetes the immune 
cells play a major role by destroying the B-cells, in SMS the antibodies are the 
cause of neuronal dysfunction. 
The antibodies to GAD in type 1 diabetes are present in 80% of the newly 
diagnosed patients, but also long before the clinical diagnosis ol type 1 diabetes. 
This allows their use as an early warning system of ongoing B-cell destruction. 
However, it will be clear that prediction is only useful once prevention is available. 
On the other hand, it is important to be able to predict diabetes, once prevention 
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methods become available. Most cases of this disease occur in individuals who 
have no first degree or second degree family member with type 1 diabetes, in other 
words, they 'pop-up' in the population without a 'warning'. Only 5% of the cases 
are family related. This implies that preventive measures, once available, are only 
useful if the population at large is screened and not if screening is limited to those 
families where type 1 diabetes is already present. This implies that sensitive and 
simple prediction methods must become available. The use of GAD 
autoantibodies in prediction of type 1 diabetes are analyzed in Chapter 3. 
Although the identification of the 64kD protein as GAD allowed the development of 
recombinant GAD systems, the assays were hampered by technical problems. An 
improved method was developed (Chapter 4.1) which allows a sensitive detection 
of GAD antibodies. The incidence of GAD autoantibodies in newly diagnosed 
diabetic children was used as a reference group. The method was compared to 
the original method using pancreatic islet cells and was found to be extremely 
sensitive. Chapter 4.2 describes the use of GAD autoantibodies in a population of 
schoolchildren in the Netherlands, showing this method as the best available 
marker of humoral autoimmunity at present. This study also clearly showed that 
further studies on diabetes prediction will need large sample sizes and that even a 
combination of several markers will not predict all cases of type 1 diabetes. A 
second target of autoimmunity in type 1 diabetes was further characterized in 
chapter 4. To this 38kD protein autoantibodies had been found in earlier studies 
but results were inconsistent. A method was developed to improve analysis of 
38kD autoantibodies. These autoantibodies were found to complement the GAD 
analysis. Individuals negative for GAD antibodies are sometimes positive for 38kD 
antibodies, although most 38kD positive patients also have GAD antibodies. In 
prediabetic samples, defined as sera obtained from the period before clinical onset 
of diabetes, the 38kD antibodies were shown to be a very early marker of auto-
immunity just like antibodies to GAD are. The 38kD autoantigen is a strongly 
membrane bound protein, likely to be glycosylated and has no cross-reactivity to 
GAD. Further analysis has started to identify the molecular structure ol this protein. 
Analysis of 38kD autoantibodies adds to the predictive value of type 1 diabetes. 
The early appearance of 38kD antibodies makes the molecule an other candidate 
of a primary antigen involved in the pathogenesis ol type 1 diabetes. Chapter 5 
discusses the results of the thesis and discussed how and why further research on 
GAD, 38kD and other antigens can be conducted. In summary, the identification 
and characterization of two targets of autoimmunity in type 1 diabetes has resulted 
in applications of this knowledge in both the prediction of diabetes and in studies 
on the pathogenesis of this disease. 
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Samenvatling 
Onder Diabetes Mellitus (suikerziekte) wordt een aantal chronische ziekten 
begrepen die als hoofdkenmerk hebben dat het lichaam niet Ianger de 
bloedsuikerspiegels, nodig voor het goed lunctioneren van aile organen, kan 
regelen. Het hormoon dat bij deze regulering betrokken is heet insuline. lnsuline 
wordt gemaakt in speciale cellen, zogenaamde B-cellen, die samen met andere 
hormoon-makende cellen in kleine groepjes (eilandjes van Langerhans) in de 
alvleesklier liggen. Twee hoofdvormen van diabetes mellitus kunnen worden 
onderscheiden alsmede een aantal bijzondere vormen. Dit proefschrift gaat over 
type 1 of insuline afhankelijke diabetes, vroeger ook wei jeugd diabetes genoemd. 
Daarnaast bestaat type 2 of niet-insuline afhankelijke diabetes, vaak ook 
ouderdoms suikerziekte genoemd. 
Hoofdstuk 1 geeft een literatuuroverzicht van de specitieke kenmerken 
van type 1 diabetes en de insuline-makende B-cel. Type 1 wordt gekenmerkt door 
een geleidelijke maar uiteindelijk volledige afbraak door het eigen afweersysteem 
van aile insuline producerende B-cellen. Deze vernietiging is een proces dat 
jarenlang kan duren. Deze periode wor•:Jt dan ook de prediabetische lase 
genoemd. Door het tekort aan B-cellen, en dus aan insuline, ontstaan de 
symptomen. Deze vorm van suikerziekte komt vooral voor bij kinderen en jong 
volwassenen. Een deel van de gevallen (± 25%) ontstaat later in het Ieven. Type 
2, of niet-insuline afhankelijke diabetes ontstaat meestal op latere leettijd. Hierbij 
wordt wei insuline gemaakt, maar de insuline komt niet goed in het llchaam en kan 
niet goed gebruikt worden door de lichaamscellen. Naast de typen 1 en 2 zijn er 
bijzondere vormen van suikerziekte, bijvoorbeeld ontstaan ten gevolge van 
medicatie, zogenaamde insuline ongevoeligheids syndromen en andere ziekten. 
Type 1 diabetes kan gepaard gaan met ernstige complicaties in de acute lase. Er 
is wei een therapie beschikbaar in de vorm van dagelijkse insuline injecties, maar 
genezing is niet mogelijk. Een redelijk normaal Ieven is mogelijk voor mensen met 
diabetes, maar de ziekte kenmerkt zich door complicaties die zich na 20-30 jaar 
openbaren, veel medische problemen geven en ook levensbedreigend kunnen 
zijn. Het betreft complicaties aan de ogen (retina), de nieren (nefropathie) en 
sommige zenuwcellen (neuropathie). 
De oorzaak van type 1 diabetes is onbekend. Bekend is wei dat de 
vatbaarheid voor de ziekte ertelijk is, de ziekte zelf niet. Andere factoren zijn nodig 
om in vatbare personen de ziekte te doen ontstaan. Epidemiologische studies 
tonen aan dat dergelijke factoren uit het milieu afkomstig kunnen zijn, zoals 
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infecties, chemische verbindingen en bepaalde componenten in de voeding. Op 
dit moment is echter geen enkele van deze factoren een bewezen oorzaak van 
type 1 diabetes. Uitsluitend zijn correlaties van deze stof!en met de ziekte 
beschreven en geen oorzaak. 
De pathologie van type 1 diabetes kenmerkt zich door een ontste-
kingsreactie in de eilandjes van Langerhans. lmmuuncellen vallen de B-cellen 
aan en vernietigen deze. Dit kan gezien worden als een afweervergissing. 
Normaal zorgt het immuunsysteemsysteem ervoor dat vreemde onderdelen van 
het lichaam worden a!geweerd. In het geval van type 1 diabetes vergist het 
afweersysteem zich en valt het een 'eigen' onderdeel van de B-cel aan. Dit proces 
wordt autoimmuniteit genoemd. Waarom het immuunsysteemsysteem deze 
vergissing maakt en tegen welke lichaamseigen stof een dergelijke reactie begin! 
is het doel van veel onderzoek en ook van dit proefschrift. Als deze lichaamseigen 
stof, die het immuunsysteemsysteem 'op hoi' doet slaan, kan worden gevonden 
word! het voorspellen van de ziekte mogelijk en komi het voork6men van de ziekte 
door middel van speciale herinstructie van het immuunsysteem binnen 
handbereik. Een kandidaat eiwit voor de rol als veroorzaker van type 1 diabetes 
was jarenlang het z.g. 64kD (kilo Dalton, een maat voor de molekuulgrootte) eiwit 
dat in B-cellen werd gevonden. Patienten met diabetes hebben al zeer lang voor 
het uitbreken van de ziekte antistof!en tegen dit eiwit (dat een antigeen word! 
genoemd omdat het een immuunreactie teweegbrengt). Wat dit 64kD eiwit precies 
was, was onbekend. Hoofdstuk 2 beschrijft hoe de identiteit van dit eiwit is uitge-
zocht. Hiervoor was niet aileen laboratoriumwerk nodig, maar bleken klinische 
gegevens van een zeldzame ziekte van groat belang. Het bleek dat in de zeer 
zeldzame neurologische ziekte 'Stiff-man syndrome' (SMS), die vaak (1/3e van de 
patienten) met type 1 diabetes gepaard gaat, antistoffen tegen zenuwcellen 
aanwezig waren. Deze antistoffen waren gericht tegen een bepaald onderdeel van 
de zenuwcellen, het enzym (oak een eiwit) Glutaminezuur decarboxylase (GAD). 
Dit is een belangrijk enzym dat een boodschapper-stof voor zenuwcellen maakt. 
Het GAD molekuul is ongeveer 64kD groat. Gekeken werd of GAD hetzelfde was 
als 64kD, omdat een aantal kenmerken van het molekuul overeenkwamen en 
omdat diabetes relatief vaak voorkomt bij SMS. Hoewel sommige onderzoekers 
eerst dachten dat er geen overeenkomsten waren, toont hoofdstuk 2 aan dat het 
64kD molekuul identiek is aan GAD. De antistoffen in patienten met diabetes 
reageerden oak met GAD. Op verschillende manieren werd vervolgens bewezen 
dat het 64kD antigen in type 1 diabetes het molekuul glutaminezuur decarboxylase 
is. Verder werk toonde aan dat de antistoffen bij diabetes aileen het GAD 
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herkennen als dit molekuul in de juiste coniormationele vorm bestaat, d.w.z. zoals 
het in de natuur voorkomt. Bij SMS kunnen de antistoiien ook door 
onderzoekstechnieken veranderd en niet meer in de juiste coniiguratie verkerend 
GAD herkennen. In dergelijke testen verandert het molekuul van driedimensionale 
structuur. Dergelijke gegevens tonen aan dat de structuur van eiwitten een 
belangrijke rol speelt bij immuunreacties en dat resultaten van methoden die 
dergelijke veranderde eiwitten opleveren, voorzichtig geinterpreteerd moeten 
worden. Sommige onderzoekers hadden door dergelijke veranderingen de 
overeenkomst tussen 64kD en GAD nooit opgemerkt. 
GAD is een bijzonder molekuul. Het enzym is van groot belang voor het 
lunctioneren van ongeveer 1/3e van onze hersencellen. Hoewel het de 
boodschapper-stol GABA maakt, is de rol van d'1t GABA in de eilandjes van 
Langerhans onbekend. Waarschijnlijk is dat het ook hier een boodschapper-
lunctie heelt tussen de verschillende celtypen in het eilandje en mogelijk er buiten. 
Er zijn twee vormen van GAD: GADss en GAD67 (genoemd naar de exacte 
molekuulmassa) en voor elke vorm bestaat een apart gen. In eilandjes van de rat 
komen beide vormen voor en deze zijn identiek aan de vormen die in zenuwcellen 
in de hersenen worden gevonden. Recentelijk is gebleken dat GAD55 echter de 
enige vorm is die bij de mens in B-cellen voorkomt. GAD55 kan op een bijzondere 
manier aan kleine blaasjes in de zenuwcellen en B-cellen worden gekoppeld (via 
een palmitoyleringsstap, dat wil zeggen, dat een vetstaart aan het molekuul wordt 
gekoppeld). De lokalisatie in de eel is van belang om te zien hoe GAD in de eel 
wordt getransporteerd en aan het immuunsysteem wordt getoond. Hooldstuk 2 
bespreekt eveneens de verschillen en overeenkomsten die gevonden werden 
tussen Still-man syndrome en type 1 diabetes. Naast verschillen in herkenning 
van GAD door de antistollen zijn er verschi:llen in de lokalisatie van het GAD: het 
immuunsysteem kan bijvoorbeeld veel moeilijker bij de hersencellen komen. Het 
grootste verschil tussen de twee ziekten is dat in type 1 d·labetes de ziekte door 
inliltrerende immuuncellen (T-Iymlocyten en macrofagen) wordt veroorzaakt, terwijl 
in Stiff-man syndrome de antistolfen (gemaakt door B-lymlocyten) waarschijnlijk 
een rol spelen bij de symptomatologie. 
Antistoffen tegen GAD worden bij zo'n 80% van de nieuw gediagnosti-
seerde patienten met type 1 diabetes aangetroflen. Van groter belang is echter het 
leit dat lang voor de diagnose (tot 15 jaar ervoor) deze antistoffen al aangetoond 
kunnen worden en dus een voorbode zijn van op handen zijnde diabetes. Het 
gebruik van GAD antistollen als merkers voor dit proces wordt beschreven in 
Hoofdstuk 3. Voorspelling van diabetes op een dergelijke manier heeft natuurlijk 
aileen nut als er een aldoende methode is om dit proces van B-cel vernietiging te 
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stoppen voordat het klinische symptomen geeft. Omgekeerd is een goede 
voorspellingsmethode nodig omdat de meeste gevallen van diabetes zich 
aandienen zonder dat de ziekte in de naaste familie voorkomt. Slechts 5% van de 
gevallen komi voor in families waar de ziekte al bij een van de familieleden 
aanwezig is. Met andere woorden, een nuttig effect van een preventieve 
behandeling kan aileen worden bereikt als aile personen met een verhoogd risico 
worden opgespoord in de populatie. Dit vereist een zeer gedegen predictietest. 
Gekeken werd of GAD antistoffen hierbij van nut kunnen zijn. Allereerst werd een 
nieuwe methode voor de bepaling van deze antistoffen ontwikkeld, gebaseerd op 
recombinant geproduceerd GAD. Vroeger waren eilandjes van Langerhans, 
verkregen uit ratten, nodig voor de bepaling. Diverse technische problemen 
werden opgelost en een zeer gevoelige methode werd ontwikkeld. In serum van 
patienten met net ontdekte diabetes werd de methode getest, vergeleken met de 
oorspronkelijke methode met eilandjes van ratten en beter gevonden. Verder on-
derzoek richtte zich op een bevolkingsstudie die eerder was uitgevoerd en waarbij 
een andere merker voor ontwikkelende diabetes werd getest (ICA's, islet cell 
antibodies). De GAD methode bleek gevoeliger voor het vaststellen van het 
proces van B-cel vernietiging, maar de methode is nag arbeidsintensief en 
verbeteringen zijn nodig. De studies toonden aan dat voor een betrouwbare 
voorspelling zeer grate groepen patienten en personen moeten worden 
geevalueerd en dus een eenvoudige methode nodig is. 
Naast GAD/64kD werd destijds een tweede interessant merkstof gevonden, 
een 38kD eiwit. Eerdere studies gaven geen duidelijkheid over de frequentie van 
antistoffen tegen 38kD in type 1 diabetes. Hooidstuk 4 beschrijft een nieuwe 
methode voor het aantonen van 38kD antistoffen. 38kD antistoffen verbeteren de 
voorspellende waarde van testen waarbij naar GAD antistoffen en ICA gekeken 
werd, doordat sommige GAD antistof negatieve patienten 38kD antistof positief 
bleken te zijn. In een relatief grate groep van prediabetische monsters werd 
gevonden dat 38kD net als GAD een zeer vroege merker is van B-cel destructie. 
Het eiwit is sterk membraangebonden en bezit suikerketens. Het heeft geen relatie 
met GAD. Verder onderzoek naar de molekulaire structuur van 38kD is gestart 
naar aanleiding van de gevonden resultaten. Hooldsluk 5 vat het onderzoek 
samen en beschrijft nieuwe recente ontwikkelingen rand type 1 diabetes en GAD. 
Hoewel veel onderzoek gericht is op de rol van het immuunsysteem, moet er in de 
toekomst meer gekeken worden naar de rol die de B-cel zelf speelt bij het op gang 
brengen van een afweerrespons. GAD en 38kD zijn eiwitten waartegen het 
immuunsysteem de normaal aanwezige tolerantie heeft verloren of misschien nooit 
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heeft opgebouwd en bieden daardoor modellen om deze tolerantie of het gebrek 
hieraan te onderzoeken. 
Samenvattend heeft de identiiicatie van het 64kD eiwit als GAD en de 
verdere karakterisering ervan een bijdrage geleverd aan het onderzoek dat de 
oorzaak van type 1 diabetes wil ontrafelen. Naast GAD is oak het 38kD antigen 
een interessante kandidaat voor de lichaamseigen stat die het immuunsysteem 
dwingt tot een afweervergissing. Seide stoffen worden toegepast in de 
ontwikkeling van voorspellingsmethoden om type 1 diabetes vroegtijdig te 
herkennen. Nader onderzoek zal de rol van GAD en 3BkD in type 1 diabetes 
verder duidelijk maken. 
Ch ter6 247 
Dankwoord 
Dit proefschrift was absoluut onmogelijk geweest zonder de hulp van velen. 
Allereerst bedank ik mijn fantastische vrouw en kinderen voor de continue steun 
die ze hebben gegeven. Het verrichten van onderzoek, plus drie verhuizingen in 
een jaar (en 6 in drie jaar), met aile drukte erbij in een ander land, is een aanslag 
op een 'normaal' gezinsleven. Desondanks hebben Aleid, lnge en Saskia ervoor 
gezorgd dat dit steeds een heerlijke tijd en een fantastische ervaring is geweest . 
Aan mijn twee promotoren, Professor Visser en Professor Galjaard ben ik 
erg veel dank verschuldigd. Van beiden leerde ik als student de beginselen van 
de medische wetenschap. De colleges, lessen, besprekingen en de geboden 
mogelijkheden om lijdens mijn studie reeds onderzoek te verrichten hebben een 
grate invloed gehad op de uiteindelijke keuze om in kindergeneeskunde en in 
onderzoek verder te willen. De interesse in de 'Scientific basis' was hiermee 
gelegd. De opleiding tot kinderarts in het Sophia Kinderziekenhuis is een 
indrukwekkende periode geweest. De steun tijdens en na ons verblijf in de VS en 
de kritiek en hulp bij het schrijven van dit proefschrift waren onmisbaar. Werken op 
de 'brug' tussen kliniek en basisvakken en 'in' de Klinische Genetica en 
Kindergeneeskunde is een ervaring en nieuwe uitdaging! Ook dank ik Professor 
Lamberts en Professor Benner voor het beoordelen van het manuscript. 
Mu Bruining dank ik voor het zeer forse aandeel dat hij in dit onderzoek 
heeft gehad en nag steeds heefl. Hij was het die, voor de aanvang van dit 
onderzoek, al vertelde dat we het 'in de neuronen' moesten zoeken. Hij is de 
absolute tegenpool van een 'Stiff-man syndroom', hetgeen een absolute vereiste is 
gebleken voor ons verblijf in de V.S. We gaan zo door! 
My special thanks go to Steinunn Baekkeskov. I will never forget the 
excitement on an April Sunday afternoon in 1990, when we both looked at the first 
gel that showed the identity of 64kD. I am very grateful for all your support and for 
the fact that you choose an unknown Dutch pediatrician with interest in diabetes as 
one of your first (post-) 'docs' in the Hormone Research Institute at UCSF. You 
have taught me what Science really is. Our (almost) 3 years stay in San Francisco 
were exciting years. Your help in the final stages of this thesis was enormous. 
It will be clear from the lists of coauthors that this work was only possible with 
an extensive network of collaborators around the world. This has been the basis 
for many fruitful discussions, collaborations and friendships. I want to thank 
everyone who has participated and hope that this will continue in the future. I am 
very grealful for all the help and friendliness from everyone at the Hormone 
Research Institute I UCSF San Francisco, but my special thanks go to Stephan, 
Cha ter6 248 
Kathi, Yuguang, Qin, Joanne, Mark and John ('Kimster'): I miss the Scandinavian 
Deli food (not). Na terugkomst in Nederland bleek dat het continueren en 
uitbreiden van het onderzoek uiteraard geen gemakkelijke zaak was. Greetje, 
Manou en Ronald wil ik dan oak bedanken voor hun hulp en geduld. Aile andere 
college's en vrienden dank ik voor de continue steun en stimulering die ze hebben 
gegeven. lk spreek mijn hartelijke dank uit aan de verschillende instanties en 
bedrijven die geholpen hebben om het fellowship in de V.S en de voortgang van 
het onderzoek in Nederland financieel mogelijk te maken. Tot slot wil ik aile 
kinderen en ouders bedanken die hebben meegewerkt, en nag steeds meewerken 
aan de diverse onderzoeken die hopelijk uiteindelijk leiden tot het verdwijnen van 
diabetes. 
Cha ter6 249 
Curriculum Vitae 
De schrijver van dit proefschrift werd of 8 februari 1957 geboren te Deventer. 
In deze plaats bezocht hij de lag ere school hetgeen gevolgd werd door de 
Rijksscholengemeenschap. De middelbare school tijd werd vanaf 1970 voortgezet 
te Zierikzee en het eindexamen Atheneum werd in 1976 behaald. Na een 
propedeutisch jaar aan de Landbouw Hogeschool Wageningen, werd in 1977 
begonnen met de studie Geneeskunde aan de Erasmus Universiteit Rotterdam. 
Het artsexamen werd in januari 1984 afgelegd. Gedurende de studie was hij, 
aansluitend aan het zogenaamde keuzepracticum (1980), werkzaam als student-
assistent op de afdeling Kindergeneeskunde (Hoofd: Prof.Dr. H.K.A. Visser). 
Voorts werkte hij in een zg. studententeam op de Intensive Care Neurochirurgie 
van het Dijkzigt ziekenhuis. In 1984 en 1985 was hij als militair arts gedetacheerd 
op de aide ling Hematologie van het Radboud ziekenhuis (hoofd destijds: Prof. Dr. 
C. Haanen) te Nijmegen alwaar gewerkt werd op de therapeutische alerese 
aldeling en een onderzoeksproject werd uitgevoerd naar de flowkaryografische 
detectie van chromosomale schade door bestraling. Aansluitend op de militaire 
diensttijd werd dit werk voortgezet als arts-assistent tot in oktober 1984 werd 
aangevangen met de opleiding tot Kinderarts in het Sophia Kinderziekenhuis te 
Rotterdam (Hoofd: Prof. Dr. H.K.A. Visser). Registratie als kinderarts vond plaats in 
oktober 1989. Na de opleiding vertrok hij naar Denemarken (Hagedorn Research 
Laboratory) en San Francisco (Hormone Research Institute University of California 
San Francisco) alwaar hij tot zomer 1992 werkte in de laboratoria van Dr. S. 
Baekkeskov. Het in dit proefschrift beschreven onderzoek werd daar uitgevoerd. 
Na terugkomst in Nederland werd met steun van de Stichting Klinische Genetica 
Rotterdam en de Sophia Stichting voor Wetenschappelijk Onderzoek h et 
onderzoek voortgezet in laboratorium en kliniek. De schrijver is getrouwd met 
Aleid Brandsm a. Ze hebben !wee dochters, I nge en Saskia. 

